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Abstract 
The purpose of this thesis is to explore the theory, practice and application of costing 
with specific reference to cancer. In part it reviews the theory and guidelines related 
to costing methods including the recent focus on the analytical techniques used with 
cost data. In addition it examines how these theories and guidelines are applied in 
practice, by reviewing the literature on costs and cancer. The empirical research in 
this thesis applies costing methods to three specific cancer sites; breast, cervix and 
lung. This analysis provides information on the total burden of these specified cancers 
in terms of cost to a typical health authority (Trent). It also explores the hypothesis 
highlighted in previous studies that the cost of cancer increases with the stage of the 
disease. The final area of contribution for the thesis is in the application of recently 
suggested analytical techniques for cost data to the breast, cervical and lung cancer 
data sets; it investigates a number of proposed techniques for the analysis of skewed 
cost data and methods for data with incomplete patient follow up. 
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Chapter 1 
Introduction 
1.1 The role of costing in the economic analysis of health care 
It is recognized that in order to ensure that the health service maximizes patients' 
benefits from the limited resources available, a systematic assessment of the costs 
and consequences of treatments or interventions in health care is required. The 
tool used for this purpose is known as economic evaluation. Such evaluations 
explore the relationship between the costs (resources used) and effects (health 
benefits) for an intervention compared with an alternative strategy. The 
incremental cost-effectiveness ratio (ICER) reports the difference in mean per 
patient cost (C) divided by the difference in benefits (E) of the alternatives being 
assessed: 
CA 
- 
CB 
<M EA 
-EB 
Where the left-hand side of the above equation is the incremental cost- 
effectiveness ratio (ICER), and M is equivalent to the maximum amount a 
decision-maker is willing and able to pay for an extra unit of effectiveness. The 
first form of economic evaluations of health care tended to be cost-of-illness 
studies undertaken on a cost-benefit framework(1-6), whereby the benefit side of 
the equation was estimated to be reduced costs of treatment and reductions in loss 
of productivity. These cost-of-illness evaluations are similar to cost-benefit 
evaluations, where the costs of the programme/intervention are compared with the 
benefits from the programme/intervention to see whether a net benefit exists. Both 
these approaches rely on the ability to value both the inputs and outputs in some 
form of monetary measure. The weakness of the approaches lies in the estimation 
of monetary values for non-monetary outcomes'''. This weakness led to the 
development of cost-effectiveness analysis, in which the effects are measured in 
physical units such as life-years gained or number of cancers detected/ prevented. 
This approach has been further refined to allow for comparisons across disparate 
diseases and medical technologies such as rheumatoid arthritis and childhood 
cancers, by `quality adjusting' the life years gained. This type of economic 
evaluation is termed a cost-utility analysis. The central theme pertaining to all 
these types of evaluations is the cost side of the equation. Thus, the definition, 
identification, measurement and valuation of costs are central to economic 
evaluations of health care. 
Although costing is central to any type of economic evaluation, until 
recently there has been little emphasis placed on the methods involved in 
identifying, measuring, valuing and analysing costs. This relative lack of interest 
is reflected in guidelines of methodology for economic evaluation in health 
care(10-12), while other researchers have been more explicit: 
"Although economists are seen as experts on costing by health professionals, the 
key issue in economic evaluation is the choice of outcome measure. " (13: 279). 
Recently there has been a resurgence of interest in the cost side of the equation. 
Although the attention has focused on the appropriate statistical analysis of cost 
data(14-19), rather than the unresolved issues of how to value the identified units 
of resource use. 
'"' Methods exist for the valuation of non-monetary outcomes in a monetary format; revealed 
preference (7) and contingent valuation (willingness-to-pay methods) (9). 
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1.2 Contribution of the thesis 
This thesis considers the theory, practice and application of costing. In part it 
reviews the theory and guidelines of costing methodology and explores the recent 
focus on the analytical techniques used with cost data. It also aims to determine 
how these guidelines are applied in practice, by reviewing a sample of published 
papers that report on cancer costs. Previous reviews of costing methods are limited 
in number and none report on how the theory and guidelines are translated into 
practice. This rgview therefore aims to provide an insight into the strengths and 
limitations of costing methods outlined in the guidelines and theory and used in 
practice. The literature review is also used to inform the main part of the thesis, 
which is devoted to applying costing methods to the disease, cancer. Cancer is an 
important disease and, for the purpose of costing, exhibits interesting properties. 
Despite progress in research providing a better understanding of cancer and 
as a result improved prognosis of cancer patients being observed over recent 
decades, malignant disease remains the number two cause of mortality in most 
industrialized countries (behind cardiovascular disease). It is responsible for 
approximately a quarter of all deaths in Europe, North America and Japan(20). In 
terms of morbidity one in three people will develop cancer in their lifetime(21). It 
is primarily a disease of the elderly, with an incidence rate for those aged 65 years 
and older being in the region of ten times greater than those aged less than 65 
years. The interest with respect to costs and cancer is that cancer imposes a drain 
on societal resources. This is made up of the medical resources such as personnel, 
equipment and materials, used in the diagnosis, staging, treatment and follow up 
care of cancer patients, plus the loss of time and production for the patients and 
their relatives while receiving or traveling to and from treatment, and any impact 
on society due to loss of productivity as a result of morbidity or premature 
mortality. In this thesis the focus is on the costs of medical resources, in particular, 
hospital costs. 
Researchers often make reference to the medical cost of cancer(22-24), for 
example: 
"Particularly in the case of cancer, the economic issue is relevant as the costs per 
case are particularly high,... " (22: S 10) 
"The economic impact of cancer is enormous, with some 5% of health care 
resources in industrialized countries devoted to its treatment and 
prevention"(23 :S 1). 
"... issues in cancer therapy, which accounts for around 7 per cent of UK health 
service spending. " (24). 
The first quote from Bonsel and colleagues is typical of many papers written about 
cost and cancer, in that there is a general acknowledgement that the costs per case 
are high, but these statements are rarely backed up by actual cost information, 
which is unsurprising given that few costing studies of cancer have been 
undertaken. Similarly, the latter quotes state that the costs of cancer is in the 
region of 5-7 per cent of most countries health service spending, but how useful is 
this rather out of date information to a health authority or policy maker and how 
were these figures calculated? More useful information would be estimates of cost 
related to specific cancer sites, such as lung and colorectal cancer, including data 
on the constituents (surgery, radiotherapy, chemotherapy, inpatient stays, 
complications etc. ) of these cost estimates. This thesis explores the hospital based 
treatment costs for three specific cancer sites; breast, cervical and lung. As well as 
providing information on the cost per case and total cost burden to a typical health 
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authority, the thesis explores a further hypothesis highlighted in previous studies of 
costs and cancer(25,26). One of the interesting properties of cancer with respect 
to costs is that cancer unless detected and treated is a progressive disease that 
develops through well-defined stages. These stages are defined according to the 
spread of the disease upon detection, if no spread is observed, the disease is 
classified as an early stage cancer, once spread to local, regional or distant parts of 
the body, the cancer is classified as a late stage disease. The hypothesis to be 
tested in this thesis is that early detection leads to a reduction in related treatment 
costs. Two studies have shown that cost is related to the stage of the cancer, and 
increases with stage of the disease(25,26), however a UK study of costs of treating 
colorectal cancer found no positive correlation between stage of cancer and cost of 
treatment(27). This thesis adds to the literature on the relationship between stage 
of the disease and treatment costs, and explores the impact in terms of early 
detection of disease. It also investigates the impact of other variables such as age 
and gender and smoking status (where applicable) on costs. 
The final area of contribution for the thesis is in the application and 
exploration of recently suggested analytic techniques for cost data. Two problems 
associated with cost data are explored. Firstly the distribution of cost data tends to 
display a positive skew. This skew poses problems for using standard statistical 
tests when comparing differences in mean cost. The second problem involves 
incomplete follow up of patients over time. This is often encountered when 
conducting economic analyses alongside trials, due to drop out (attrition), but is 
also a problem associated with the retrospective collection of resource use data 
from medical notes. The thesis explores a number of proposed techniques that take 
account of incomplete follow up. 
1.3 Structure of the thesis 
Chapter 2 is a systematic review of the literature relating to costing theory, 
methods and guidelines. The aim of the chapter is to provide a guide to the 
complexities of cost estimation by answering four key questions: 
1) What are costs? 
2) Why are we interested in costs? 
3) How are costs estimated? 
4) How should costs be analysed? 
The methods and techniques reported are examined in terms of current accepted 
conventions, current debatable issues and areas of methodological evolution 
requiring further evidence. 
Chapter 3 follows from the review of the literature on the theory, methods and 
guidelines by exploring their applications in practice. This review of costing in 
practice is restricted to cancer and its treatment. The detailed review identifies 
areas of imbalance between the methods suggested by guidelines and methods used 
in practice. Along with the review reported in chapter 2, chapter 3 provides a basis 
for the design of the empirical work conducted in the remaining chapters. 
Chapter 4 details the background and methods related to the three core costing 
chapters that follow. It provides information on the national estimates of cancer 
incidence and mortality and includes a general description of cancer, its usual 
treatment patterns and staging procedures and definitions. Details of the process of 
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data collection are reported along with information on the geographical region and 
hospitals used for this purpose. 
Chapters 5-7 report on the empirical estimation and analysis of breast, cervical 
and lung cancer costs respectively. All three chapters are identical in structure. 
They introduce the specified cancer in terms of mortality and morbidity; details 
from published sources on the diagnostic procedures and treatments are also 
discussed. The empirical section consists of information on the patient samples, 
unit costs, resource utilization and total cost estimates. Further analysis by stage, 
age, and other variables are examined. All three chapters include a comparison of 
the cost estimates with the results from other costing studies for the same cancer 
site. In addition, chapter 5 attempts a detailed evaluation of the impact of the 
national breast-screening programme using the cost results. 
Chapter 8 considers the appropriate statistical analysis of the breast, cervical and 
lung cancer cost data. Cost data are invariably skewed, which causes problems for 
using parametric statistical tests. The chapter explores a number of methods used 
by statisticians and proposed by a few health economists to overcome this problem, 
including, the removal of outliers, transformation of the data, nonparametric 
statistics and bootstrapping and re-estimates the data used in chapters 5-7. 
Chapter 9 explores the analysis of costs where data are censored. Censored cost 
data occurs where the end point of interest has not been observed for a particular 
individual/patient. Several techniques have been proposed in the literature that aim 
to adjust for any censored data when estimating the average total cost. These range 
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from ignoring the issue of censoring altogether to estimating costs based on only 
those with complete cost histories to using a combination of cost and Kaplan- 
Meier survival estimates that takes account of any censoring. The chapter reports 
on the results for the breast and cervical cancer data using the proposed techniques. 
Chapter 10 provides a discussion of the findings of the thesis in relation to: 
1) the theoretical considerations outlined in chapter 2, 
and 
2) the policy implications for the health service. 
Chapter 11 draws together the conclusions of the thesis, with particular 
consideration given to its contribution and ideas for future work. 
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Chapter 2 
Estimating Costs 
- 
Methodology Review. 
2.1 Introduction 
This chapter aims to take the reader through the complexities of cost estimation by 
answering four questions: 
1) What are costs? 
2) Why, as health economists are we interested in costs? 
3) How are costs estimated? 
4) How should costs be analysed? 
In responding to these questions the appropriate literature was searched and 
reviewed. The review has been split into two components; firstly a review of 
published guidelines to costing, and secondly a review of costing methods in 
practice. These two components of the review are necessary as the published 
guidelines to costing purely highlight the theoretical ` dos' and `do nots' of costing 
with little or no evidence of practice (discussed in this chapter). Whereas the 
published studies highlight the realities involved in costing procedures (the 
findings of which are reported and discussed in chapter 3). The first two questions 
are answered relatively simply with a description of the theoretical underpinnings 
of cost estimation. However, the last two questions provide scope for detailed and 
lengthy responses, as the estimation and analysis of cost data has limited 
standardised methodology, and can be (and is) undertaken in a number of different 
ways. In fact, the complexities of cost estimation are generally understated by 
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analysts engaged in economic evaluations. In published technical papers relating 
to methodological issues in economic evaluations, there tends to be less emphasis 
on the problems associated with cost estimation compared with those relating to 
benefits measurement. Moreover, in published economic evaluations it is usually 
difficult to determine how the final cost estimates are derived. Little explanation is 
usually given of how the resources are identified and valued, let alone any basic 
description of what resources are included in the cost estimation. 
In answering the questions on estimation and analysis of costs the chapter is 
structured so that the key costing processes and methodologies are introduced and 
discussed in the order that one would think about and undertake in practice. It is 
noticeable that some of these methods for costing have reached consensus, whereas 
others have been debated and remain unresolved and there have also been new 
areas of methodological research where ideas are still evolving and further research 
is required. The discussion part of the chapter examines the methods in terms of: 
1) Current accepted conventions 
2) Current unresolved/debatable issues 
3) Areas of methodological evolution, where further empirical research is 
required. 
2.2 Literature Search 
- 
materials and methods 
Before any analysis of the cost of cancer could be undertaken, there was a need to 
understand the costing process. This involved searching for any literature that had 
been published on the concept of cost and its estimation. The guidance to costing 
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reported in this chapter was obtained from a number of literary sources procured 
from a search of the literature conducted in the following manner: 
" 
library catalogue searches for books on economic evaluation and costing 
" Medline, BIDS, EMBASE and EconLit searches using search terms `economic 
eval*', `cost', and `cost-effect*' as key terms in the title or abstract 
" 
internet search of health economics and related sites 
http: //www. healtheconomics. com/ 
http: //www. oheschools. orý: / 
http: //www. york. ac. uk/inst/che/welcome. htm 
http: //httpl. brunel. ac. uk: 8080/departments/herg/home html 
http: //www. shef. ac. uk/uni/academic/R-Z/scharr/ 
http: //www. abdn. ac. uk/heru/ 
http: //www. ccohta. ca/ 
http: //www. york. ac. uk/inst/crd/ 
http: //www. hta. nhsweb. nhs. uk/ 
" recommendations from colleagues working in the health economics field, 
particularly for any grey literature on costing methodology or country specific 
guidelines. 
" relevant books and papers referenced in any of the previously identified 
literature. 
The only exclusion criterion used was that the text should be in English language. 
This literature search resulted in a substantial number of relevant articles, reports 
and textbooks; these are displayed in Table 1. The literature in Table 1 has been 
organised chronologically according to year of publication. All these publications 
provide information on the methods, issues and guidance related to the costing 
process. The review of this literature also provides a background to the evolution 
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of costing conventions. The costing literature in the 1960s, 1970s and early 1980s 
focused on the methods used for estimating the cost-of-illness of diseases, however 
very little was written on the methods during this period. The late 1980s and early 
1990s saw an explosion in papers and textbooks aimed at giving guidance on the 
costing process. However, this tended to be guidance on the theory of costing in 
line with economic beliefs, hence discussions about direct and indirect costs, 
opportunity costs, marginal and average costs, study perspective, discounting, how 
to cost capital and how to deal with overheads. Little information was given on the 
practical aspects involved in costing(1,2) and no information was given on how 
the costs should be analysed or reported. The list of literature in Table 2.1 shows 
that throughout the 1990's there has been an evolution of ideas and methods related 
to the practice of costing. This includes an exploration into the practical aspects of 
costing productivity losses(3-6), and whether they should be included in the total 
cost estimate for the purpose of a cost-effectiveness ratio(7,8), the methods 
involved in costing informal care(9,10), techniques to reduce the burden of data 
collection(11,12), possible methods for dealing with missing cost data(13-15), and 
issues in the analysis of cost data(16-22). These key issues are outlined below and 
are explored in greater detail throughout this chapter. 
2.2.1 Key areas in the process of cost estimation 
9 The theoretical basis of cost estimation. 
9 Process of identification of important cost-generating events to be collected; 
literature, previous studies, experts' advice etc. 
9 Process of the measurement of resource-use; questionnaires, patients' medical 
records, pre-collected database, Delphi panel, trial database, prospective or 
retrospective measurement. 
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9 Process of valuation of resource-use; source of unit cost data (finance 
department, published studies, cost estimation), adjustment of baseline price, 
currency. 
" Sample size 
9 Time-horizon 
" Discounting 
" Analysis and presentation of cost estimates 
" 
Sensitivity analysis 
9 Cost estimation with missing data 
" 
Costing alongside censored data 
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2.3 What are costs and why, as health economists are we interested in 
costs? 
"Costing healthcare services is imperative, as money is a limiting resource that 
always will be taken into account. Studies of health care costs serve as an aid to 
political and administrative decision making... " Gyldmark(23) (1995: 964). 
The concept of cost used by economists provides a definition of the term `cost' as 
used by health economists when undertaking an economic evaluation. The 
underlying concept is known as opportunity cost. This concept is the foundation 
for all economic thought, and is based on two prior principles; scarcity and choice. 
Scarcity exists in all types of society, however abundant the resources in society the 
individuals in society will always want to consume more goods and services than 
can be produced from those resources. It is therefore necessary to make a choice 
among the alternative uses to which the resources could be put. It is inevitable that 
opportunities to use resources in some activities will be foregone. The economists' 
term for costs expressed in terms of foregone alternatives is opportunity cost. 
These principles of scarcity and choice hold in the health care sector, where there 
are not enough resources to meet the needs or wants of the patients/consumers. 
Changing demographic patterns and expensive new technology (e. g. hi-tech 
medicine) provokes the scarcity of health care resources. Therefore choices 
between alternative interventions or programmes have to be made, and they should 
be measured and valued in terms of their opportunity cost. 
Johannesson (1996) uses the term cost to reflect the opportunity cost in 
terms of resource consequences of a treatment. The resource consequences are 
defined as the effect on the consumption of goods and services of a health care 
programme and the consumption of leisure(24). The estimation of costs is central 
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to all economic analyses of health care technologies. In essence, costs are the 
product of the quantification of the resources that are consumed and their 
respective unit costs. Resource use is the general term for the resources consumed 
due to a particular health care intervention and is the underlying driver of cost. 
Examples of resource-use items include outpatient visits, inpatient stays, use of 
particular equipment for example colonoscopy, medical personnel time. These 
resource use items and therefore costs can be measured on a patient-specific 
(stochastic) basis i. e. they vary from patient to patient, or a non-patient specific 
(deterministic) basis, i. e. they stay the same for each patient. Ideally, resource use 
and therefore costs should be measured on a stochastic basis (as I will argue later in 
this chapter) to allow a thorough statistical analysis to be undertaken. 
2.4 How are costs estimated? 
This section examines what influences the choice of costs to be included in a study 
and describes the various types of costs that can be measured and valued. It 
explores the process of identification of cost-generating events, the measurement of 
these events, the process of valuing cost-generating events and issues relating to 
costing such as discounting, presenting and analysing cost data. 
2.4.1 Factors influencing the choice of costs for inclusion in the study. 
Different factors affect the choice of costs to be included in a study. These are 
discussed below. 
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Perspective 
The perspective or viewpoint of an economic analysis influences the choice of 
costs to include (25-27). This perspective is partly dependent on the target 
audience. Perspectives range from the very narrow viewpoints of the patient or 
clinician, to the intermediary viewpoints of purchaser, decision-maker, health 
authority, provider unit or government, to the much wider perspective of society as 
a whole. The costs which a patient incurs when a treatment decision is made 
- 
such 
as transport costs to attend a clinic, lost earnings or child-care costs 
- 
are very 
different from those incurred by the National Health Service (NHS). Similarly 
only the societal perspective takes account of any costs associated with production 
loss. The societal approach relies on the collection and valuation of all costs, 
regardless of who incurs them. The societal approach has been recommended as 
the standard perspective for costing, as it allows the analysis to be carried out on a 
number of viewpoints (28-30). 
For economic studies of dementia the choice of perspective is particularly 
important. For example, a policy of home support for people with dementia may 
reduce hospital costs (NHS) and institutional care costs (social services and 
patients) but increase the burden of informal care provided by relatives. This 
process of cost-shifting may transfer costs from one sector/budget to another, but 
may not reduce the total cost to society as a whole. Therefore when evaluating 
these types of programmes, care has to be taken to take a broad societal perspective 
which includes the costs incurred by non-health care sectors such as social services 
and unpaid caregivers. 
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Quantitative importance 
Some authors have argued that the decision regarding which costs to include in the 
analysis will depend on their respective quantitative importance, in other words 
their impact on the total cost and cost-effectiveness result. Some studies have 
therefore omitted certain cost-generating events arguing that they have little impact 
on the final result. This is frequently seen in trials where common resource use 
exists between two arms of a clinical trial. These cost-generating events are 
excluded from the analysis with the justification that they will have no effect on the 
final decision making process. Schulman and colleagues (1996) decided to omit the 
collection of information on blood tests from their study, previous data had shown 
that even though they were frequently performed they were also of significantly 
low cost so as to only amount to 1.8% of the total cost(3 1). However, disregarding 
cost-generating events on the basis of insignificant quantitative importance or 
commonality between trial arms may lead to a biased decision-making process. 
This is because comparisons of cost and cost-effectiveness with other disparate 
health care technologies may well have to be made outside the initial comparison. 
Moreover, it is difficult to predict ex-ante which cost-generating events will have a 
significant impact on the total cost calculation. 
Time horizon 
The time horizon is defined as the period of time for which the cost-generating 
events are identified and measured. It is determined by the nature of the study; if 
prospective and alongside a trial it may be for the length of the trial, if retrospective 
it will be dependent on whether databases or medical records still exist (32). It 
may also be dependent on the period of time for which the decision-maker has an 
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interest. In most cases the decision-makers period of interest will be longer than 
the availability of the cost-generating event data. This is due to the fact that patient 
resource-use often continues long after the trial or study period has been 
terminated. An example of this is with breast cancer cases that may incur resource- 
use for follow up and recurrences for up to twenty years following initial diagnosis. 
A long-run perspective has therefore been recommended(30). This requirement for 
a long-term perspective is reinforced by the fact that a disproportionate amount of 
resource-use is consumed near death(33). Therefore by limiting the cost analysis to 
a fixed time period bias may be introduced into any comparison of costs(34). 
Although it has been recommended that the time horizon for cost analysis should 
be from a long-run perspective, financial and data-availability constraints exist. 
Thus rather than collecting data over a long period of time, modelling results 
beyond a constrained time-horizon has been suggested(14,15,35,36). 
Attributable costs 
Another area that may determine cost inclusion or exclusion is whether the cost can 
be defined as being attributable to the intervention or disease being analysed. Of 
course, it is not easy to specify whether the costs are attributable or not, and can in 
some instances be a rather arbitrary exercise. One method would be to collect 
information on all health care resource-use, including the resources used for 
treating co-morbid conditions. By including all the health care resources 
consumed, any possible exclusions of unexpected disease or intervention cost- 
generating events will be avoided, however it may upwardly bias the cost results by 
including non-related health care costs. This bias could be avoided by asking a 
panel of experts to decide what cost-generating events are attributable to the 
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disease in question. Jonsson and Weinstein (1997) when discussing the design of 
the economic evaluation for the GUSTO IIb trial stated that they opted to limit the 
scope of resource use collection to those related to coronary heart disease and its 
treatment, arguing that: 
"... the risk is that a few patients with catastrophic episodes of unrelated resource 
use (e. g. prolonged psychiatric hospitalizations) could swamp the main effect of 
the intervention. " (37: 51). 
Feasibility 
Although it has been argued that the ease of measurement should not influence 
what costs should be included(30), the final and probably the most powerful factor 
determining the choice of which costs to include in practice, is feasibility. Time 
and financial constraints have the greatest influence on what cost data are 
collected. When data collection is prospective and alongside a trial, time 
constraints can be a problem for the researchers who have been appointed the task 
of filling in the resource use questionnaires. In busy outpatient wards research 
nurses may not have time and subsequently forget to fill in such questionnaires. 
Accessing all relevant cost-generating events may also be a time-consuming task in 
cases of retrospective analysis. For direct medical resource use, hospital and GP 
medical notes have to be obtained and the appropriate information abstracted. As 
well as being a lengthy task, problems of missing data may arise when pages within 
the medical notes or the medical notes themselves cannot be traced. It might be 
thought that routinely collected databases such as cancer registries could be a cheap 
and time-efficient way to obtain resource use information. However, in practice 
such databases were initially constructed for other uses and invariably do not 
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contain all the information required. Access to patients or low response rates can 
be a problem when administering a questionnaire to assess patient costs such as 
time, travel and productivity loss. The U. S. records considerable amounts of data 
regarding health care costs. Medical and non-medical expenditures are included in 
the National Health accounts, published by the Health Care Financing 
Administration(38). Short stay hospital episodes are recorded in the National 
Hospital Discharge Survey by the National Center for Health Statistics (NCHS), and 
expenses per patient day can be obtained from the annual survey of the American 
Hospital Association. The National Ambulatory Care Survey conducted by the 
NCHS keeps records of outpatient care costs. The cost of physicians can be obtained 
from the physicians' charges documented in the American Medical Association's 
annual report on physician practice(39). Unfortunately records of data regarding 
medical resource use and cost in the UK are not so readily available, and even when 
they are, they are usually outdated or incomplete. The feasibility and practicability 
of a study therefore conflicts with the theoretical basis of cost identification, 
measurement and evaluation. However, the aim should be to get the best available 
data with the recognition of limitations such as time, financial and data constraints. 
2.4.2 Which costs? 
An overview of the types of costs to be considered for inclusion is provided below. 
It is useful to consider these costs under the headings of direct health care costs, 
direct non-health care costs, informal care costs, and productivity costs. 
Direct health care costs 
Direct health care costs are defined as the ` organizing and operating costs within 
the health care sector'(25), including the cost of diagnosis, treatment, 
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rehabilitation, therapeutic and continuing care, terminal care and prevention. They 
include variable costs such as staff time, general practitioner (GP) services, drugs 
and other medical supplies, and fixed costs such as medical equipment, building 
use and overheads such as laundry, electricity, portering etc. They also include 
number of inpatient bed days, outpatient visits, clinic visits, and general 
practitioner and nurse visits. 
These costs include the cost associated with an intervention, such as a 
course of drugs or surgical procedure, the costs of treating any adverse events, and 
the costs of complications arising from the condition, which may be reduced as a 
result of that intervention. 
Some economists have also argued that, where an intervention extends life 
expectancy, the resulting future use of health care for any reason should also be 
included. For example, Weinstein et al. argue that, 
".... if treatment results in a prolonged life because a condition has been cured or 
early disease has been avoided, then the cost of treating later disease that would 
not otherwise have arisen must be considered. " (40: 240) 
However, other analysts have countered this(41), suggesting that, 
"... if the purpose of the analysis is to determine whether the programme is a good 
investment, only the costs of the preventive program should be counted Added 
years of life involve added expenditures to foocL clothes and housing as well as 
medical care. None... is relevant to deciding whether the program is a good 
investment... " (41: 35-36). 
In the face of this lack of consensus, most studies at present include future related 
health care costs but exclude unrelated future health care costs from their 
analysis(42-44). 
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Direct non-health care costs 
Direct non-health care costs may include the costs of care to other agencies such as 
social service departments providing day care or home helps, and the out of pocket 
costs incurred by the patient, relatives and friends, for example in making home 
adaptations, buying over the counter medications, or traveling to and from 
hospitals or surgeries for treatment and incurring train, bus or taxi fares, petrol 
costs and parking fees. Patients' time costs are calculated as the opportunity cost of 
having to take time-off work or from normal activities to attend treatment. They are 
particularly important in screening programmes, where if the opportunity cost is 
perceived to be too high it may deter attendance(45-48). 
Informal care costs 
Informal care costs consist primarily of the time provided by relatives and friends 
in caring for someone whose condition impairs their independence. All evidence 
indicates that the volume of time thus provided is very substantial, but for 
economists the problem lies in trying to place a valuation on it. The approach 
typically adopted has been to assess the opportunity costs of informal care: if 
informal care was not provided in this way, what would the informal carer be doing 
instead, and what care would the patient receive instead? However, this raises 
some difficult issues: informal carers are often the elderly partners of elderly 
patients, and it may be hard to define and measure what they would otherwise be 
doing, and harder still to place a value on this; similarly, while some of the time 
provided by informal carers might otherwise be provided by formal carers, it seems 
unlikely that substitution could occur except at the margin. 
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Productivity costs 
Productivity costs of disease may occur as a result of reduced productivity at work; 
absence from work; disability, and premature mortality attributable to the disease 
of interest(49). Several studies have debated the issue surrounding the 
measurement of productivity costs (3-8,50-53). Koopmanschap and colleagues, 
(1995) argue that productivity costs are only relevant where the disease or 
intervention brings about significant changes in productivity. They have contested 
the idea that illness and absenteeism directly affects production and have put 
forward the idea of friction costs. Even if patients take time off work, actual 
production may not be affected because other workers can take on the patient's 
work in the short term, or because the patient makes up lost production on return to 
work. In the long run, if the patient is unable to return to work, another employee 
will replace them, and so the cost to society in terms of lost production is close to 
zero. However, this argument is very much dependent on the perspective of the 
analysis. When a patient perspective is taken, productivity loss to the patient due to 
absenteeism or the inability to continue working and carrying out every day 
activities may well be a cost, depending on the patient's employment conditions 
and loss of earnings during sickness absence. 
Others have argued that the measures used to value productivity costs are 
unreliable and unrealistic and therefore productivity costs should be excluded from 
the analysis. Gerard and Mooney, (1993) have proposed that, since the outcome 
measures in economic evaluations are health specific, the opportunity cost of 
resources should be defined in terms of health and therefore productivity costs 
should be excluded(54). However, Meltzer, (1997) has argued that, if the health 
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care budget has to compete with other public sector budgets to maximize utility, 
future productivity and consumption costs need to be included. 
Ethical reasons for excluding productivity costs from economic evaluations 
are also sometimes invoked: for example, it is argued that their inclusion will mean 
the allocation of resources in favour of those of productive age, biasing against the 
economically inactive and elderly. However, the ethical arguments are not clear- 
cut: resource allocation decisions do sometimes explicitly take into account the 
productive potential of individuals, both in health care treatment decisions and in 
other areas such as court settlements in personal injury cases. 
Even if the debate as to whether productivity costs should be included 
could be resolved, and a decision made as to how to value these productivity costs, 
there remains a debate as to whether they should be treated as a cost (the numerator 
in a cost-effectiveness ratio (CER)), or a health effect (the denominator of the 
CER)(7,8). Luce, Manning, Siegel and Lipscomb (1996) argue that rather than 
monetizing these productivity costs and placing them in the numerator of the 
equation they should be incorporated in the denominator in the form of a QALY 
estimate(30). The full impact of morbidity is encapsulated in the QALY measure. 
Similarly any impact on changes in life expectancy is included in the denominator of 
a cost-effectiveness ratio in the form of life years or QALY's. If the analyst feels that 
these productivity costs are important, they should present them separately. Any 
inclusion of these costs in the overall cost measure may result in double counting. 
An example of this form of double counting could easily have occurred in this thesis. 
For example, in chapter 4, the cost of the disease process of breast cancer has been 
estimated, enabling a cost-effectiveness analysis of screening for breast cancer to be 
undertaken. If the productivity costs relating to breast cancer had been included in 
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the numeraire of the cost-effectiveness analysis this would have resulted in a biased 
result due to double counting of the morbidity and mortality costs. The impact on life 
years and quality adjusted life years were included in the denominator. 
2.4.3 Identification of cost-generating events 
Although the literature has described the types of costs available for inclusion in 
the analysis and the factors influencing which costs to include, it rarely specifies 
how to identify the events that generate these costs. Detailed identification of the 
costs requires knowledge of the different care pathways for the particular disease or 
intervention under scrutiny. This can be obtained from a number of different 
sources. 
a) literature on specific diseases/illness or interventions and treatments. 
b) previous studies may highlight the parameters which are the main determinants 
of cost. 
c) clinicians and experts' advice on treatment and care for particular diseases. 
d) pilot studies using a small sample of medical notes where patients are known to 
have the disease or have had the intervention in question. 
e) trial or routinely collected databases. 
0 observations of practice. 
If the key cost generating events can be identified in advance, time and money will 
be saved by collecting data only on these events. It will also limit any burden 
placed on the patients themselves if questionnaires are required. Knapp & Beecham 
(1993) and Whynes & Walker (1995) have presented two studies identifying key 
cost-generating events in mental health care and cancer care respectively(I 1,12). 
In the study of mental health a list of 21 cost items was reduced to 5, which still 
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accounted for 94% of the total cost. Whereas in the study of colorectal cancer an 
initial list of 14 cost-generating items was reduced to four, which still accounted 
for 95% of total cost. However it remains difficult to predict these key cost 
generating events ex ante. Moreover, since the patient variation in total average 
cost was wide, simply looking at a reduced list of cost generating events conceals 
the important cost variation between patients(12). 
2.4.4 Measuring Resource Use 
When the cost-generating events have been recognised and identified they have to 
be measured and quantified in some format. 
Direct health care costs 
Direct health care resource-use is usually measured in physical units, for example, 
number of outpatient/GP/inpatient visits, number of days spent in hospital, staff 
time, dosage of drugs administered, time spent in an operating theatre, length of 
inpatient stay. The resource use can be measured at varying degrees of detail. This 
ranges from the most basic to the most detailed form of costing described by Gold 
et al., (1996) as `gross costing' and `micro costing'(30). Gross costing measures 
the resource use at an aggregated level then multiplying by the appropriate unit 
cost. For example, the cost of an inpatient stay can be estimated by measuring the 
number of inpatient days and multiplying this by the unit cost. Micro costing 
involves breaking down the hospital stay into its resource components, such as 
staff time, equipment used, ward space used, overheads such as electricity, 
portering and laundry and multiplying these measures by their corresponding unit 
costs. This requires information on staff earnings, the replacement cost of 
equipment with allowance for depreciation, the replacement cost of ward space and 
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hospital overhead costs provided by the finance department. It may also be 
necessary to consider the time spent by nursing or medical staff with specific 
patients, if the level of dependency of patients is relevant to the study. 
Luce and Elixhauser (1990) illustrate the varying levels of detail that can be 
involved in measuring cost-generating events pointing out that this process can be 
either `fairly crude' or `painstakingly detailed'(26). They cite two studies, one 
which employed very crude methods to assess the change in health care resources 
brought about by changes in use of cholesterol lowering drugs(55). The study 
involved estimating the average treatment process by asking clinicians and 
consulting the medical literature. The other study used a very detailed time and 
motion survey to assess the resource implications of changing the methods for 
administering antibiotics in secondary care(56). 
Direct non-health care costs 
The measurement of direct non-health care costs such as time and travel costs and 
out of pocket payments made by the patient and their family/carers, is usually 
achieved by administering questionnaires to patients or carers(45,47,48). The 
study by Frew and colleagues (1999) collected information from patients attending 
a screening clinic. Information supplied included modes of transport, out of pocket 
expenses (fares and car-parking), time spent travelling and in the clinic, activities 
forgone owing to attendance, details of companions and sociodemographic 
characteristics. Together these data were sufficient to estimate the time and travel 
costs incurred by individuals attending a screening clinic for colorectal cancer. 
The measurement issues relating to costs pertaining to other public sector 
budgets have been explored by researchers at the PSSRU (Personal Social Services 
Research Unit, University of Kent) and CEMH (Centre for the Economics of 
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Mental Health), leading to the development of a questionnaire to abstract cost 
information: the ` Client Service Receipt Questionnaire' (CSRI)(1,57). 
Informal care 
In collecting information on caregivers' time, techniques such as direct 
observation, retrospective estimation and diary keeping are used. Standardised 
instruments have been developed for the collection of information on the resource 
usage of informal care in studies of dementia, for example, the Caregiver Activities 
Time Survey (CATS)(58,59), the Caregiver Activity Survey (CAS)(60) and the 
Resource Utilization in Dementia (RUD)(6 1). Measurement of informal care has 
been discussed in detail elsewhere(9). 
Productivity costs 
The measurement of the impact of illness of productivity has been well 
documented(50). A questionnaire, `the Health and Labor Questionnaire' (HLQ), 
has been designed to collect data on the relationship between illness, treatment and 
performance at work(62). The HLQ consists of four modules aimed at collecting 
data on absence from work, reduced productivity, unpaid labour production and 
labour related problems. It is currently available in Dutch and English. 
2.4.5 Valuing Resource Use Measurement 
Direct health care costs 
According to economic theory, the true cost in any economic analysis is the 
opportunity cost. In practice, however, this is difficult to estimate and market 
prices are generally accepted as approximations to opportunity costs. The 
valuation of resource-use literally means multiplying the quantity of resource use 
by a unit cost. The valuation is dependent on the form of measurement, whether 
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micro or gross costing, which in turn is dependent on what question is being asked, 
data availability and time constraints. If the question is `what is the current cost to 
our region of providing cancer? ' short-run average costs can be used, this cost is 
the total cost of providing the programme divided by the total units produced. 
However, if the question is `what is the cost of extending the breast cancer 
screening programme to women aged 65-69? ' marginal costs are required. Costing 
a programme that involves a change in services requires information on marginal 
costs. The marginal cost is the cost incurred by using one unit more or one unit 
less of an intervention or programme. Neuhauser and Lewicki highlighted the 
importance of looking at the costs at the margin. In their study on the stool guaiac 
used for the screening of colonic cancer they report how the use of the average cost 
may be misleading. The average cost of detecting colonic cancer by a single stool 
test was found to be $1,175, if six tests were conducted on the same patient the 
average cost increased to only $2,451(63). However the marginal costs for the first 
and sixth test were $1,175 and $47,107,214. Other studies have shown a marked 
difference in results from calculating average and marginal costs(64-66). The 
terms marginal and incremental cost have often been used synonymously(67). 
Johnston and Brown (2000) use the term incremental cost when comparing 
different mammographic reading policies for breast cancer screening. However 
this complies with the distinction that has been made by UK researchers who state 
that: 
"... the appropriate incremental comparisons for cost-effectiveness are sometimes 
comparisons between entirely different programs and sometimes comparisons 
between different levels of intensity within the same program. Only the latter fits 
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the usual definition of marginal. In this way, incremental is a broader term, which 
includes marginal... " (68: 78-79). 
However, the argument above relates to cost-effectiveness ratios, in all the 
examples reported the authors have used marginal or incremental analysis of 
average costs. 
Micro costing involves estimating a unit cost for each level of resource use 
measured, for example, unit costs are required for staff time, capital (equipment 
and land), consumables (radiography film, chest drains, drugs, etc. ), overheads etc. 
If resource use has been measured using the gross costing approach, then the unit 
cost (per diem cost) will include all capital, overhead and staff costs(69,70). In 
practice, unit costs are obtained from a variety of sources. They can be estimated 
in every minute detail by collecting the following data and information. 
a) staff time and salaries available from personnel departments or pay review 
bodies(71,72). 
b) equipment and its useful lifetime, replacement costs and maintenance costs 
(from the supplier or hospital finance department). 
c) land, buildings, theatre and ward space from the finance department (see 
appendix 2.1 for details on costing capital) 
d) overheads for example, portering, general administration, electricity, cleaning, 
catering and laundry by assessing time, salaries, and actual market cost 
(hospital finance and accounts departments). 
For the more aggregated costing methods, costs used in previously published 
studies, or more formalized published cost information (for example, PSSRU 
estimated unit costs(73). Unit costs for drugs can be proxied using the price quoted 
in the British National Formulary (BNF) and Monthly Index of Medical 
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Specialities (MIMS)(74,75). The personnel, accounts and finance departments of 
hospitals can also offer a source of unit cost data. 
`Costing for contracts' and `reference costs' 
Since 1994, Hospital Trusts in England and Wales have been required to undertake 
a programme of costing activity(76). This came about due to government 
recognition that a lack of valid and comparable cost data in the NHS was hindering 
the contracting process in the internal market. They set up a National Steering 
Group on costing standards by the National Health Service Management 
Executive. This Group argued that costs should be analysed on a defined 
standardized sub-speciality level; the healthcare resource group (HRG), and that 
they should include all fixed, semi-fixed and variable costs. The timetable for 
implementation required all acute providers to cost HRGs in at least one of three 
specialities (gynaecology, ophthalmology and orthopaedics) for the financial year 
1994-95. The idea was to then expand this programme so that HRGs across all 
specialities would be costed by 1997-98 and beyond(77). Up to 1997 only two 
regions (Northern and Yorkshire and North West) made their cost data from all 
their trusts publicly available. 
Costing for contracts was superseded by the introduction of NHS Reference 
Costs. This idea was heralded in the White Paper, `The New NHS: Modern 
Dependable'(78) with the intention that they will provide information on the 
efficiency of the hospital sector. The costing process is analogous to that outlined 
in Costing for Contracts with costs according to HRGs, with the key difference 
being that all costs will be accessible to the public through the annual publication 
of the National Schedule of Reference Costs(79). The following quote illustrates 
the policy: 
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"The Government will develop a national schedule of `reference costs' which will 
itemise what individual treatments across the NHS cost. By requiring NHS Trusts 
to publish and benchmark their own costs on the same basis, the new 
arrangements will give Health Authorities, Primary Care Groups and the NHS 
Executive a strong lever with which to tackle inefficiency. " (79: 19) 
November 1998 saw the first schedule of reference costs for 1997/1998 published 
and provided on the internet: (http: //www. doh. gov. nhsexec/refcosts. htm). Detailed 
information was provided on 536 surgical procedures covering almost 5 million 
episodes of care across all 249 Trusts. This first publication only covered surgical 
activity, but the plan is to extend the focus to capture all NHS activity. 
Reference costs have been criticised over a number of issues(80,81). There 
are problems with the use of finished consultant episodes (FCEs) for specifying 
HRGs as they have inconsistent definitions across hospital Trusts. For example 
one Trust may count a transfer from surgery and a surgical ward to a medical ward 
for continuation of stay and observation as two separate FCEs while another 
hospital may count this as one FCE. Another problem is that atypical episodes 
(those where length of stay was above the maximum normally expected for the 
HRG) have been deleted for the purpose of comparison across Trusts as an 
indicator of efficiency. This process is known as trimming, and for the 1997/98 
National Reference Cost Index excluded 13 per cent of total surgery costs. A final 
problem of specific note to health economists who use the data for their own 
costing purposes is that the costs are reported in terms of short-run average costs 
rather than marginal costs. 
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Direct non-health care costs 
For direct non-health care costs such as patient travel, the measurement is in miles 
travelled and this can be equated with the Automobile Association mileage rate if 
private transport was used, along with the charges for car parking at the hospital. If 
bus, taxi or train were used the actual market price i. e. the fare can be used to value 
the travel cost(45,47,48). 
Informal care costs 
Two techniques have been used for valuing caregivers' time. The first is the 
opportunity cost approach which estimates the opportunity cost of foregone 
activities using the market wage rate as a proxy value for work time and leisure 
time foregone. The second approach is the replacement cost approach, which uses 
an imputed value for unpaid caregiver of the national wage for similar care 
provided in the market place. 
Productivity costs 
The most influential and widely debated approach for calculating benefits of 
improvements in health care in the form of increased production, is the human 
capital approach(82-84). The focus of the human capital approach is on the 
economic consequences of the disease and is embedded in the theory of marginal 
productivity, with the assumption that earnings reflect productivity. In practice, if 
productivity costs are included at all, the typical approach would be to attach an 
average earnings figure to the estimated time lost. 
2.4.6 Data collection 
The major determinant as to whether cost-generating events can be measured and 
valued is whether the data are available. Data collection can either be patient- 
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specific or non-patient specific, and can be collected prospectively (collected when 
the event occurs) or retrospectively (collected after the event has occurred). 
However other important areas related to data collection need to be ascertained 
before any data collection can take place. 
Sampling and sample size 
It may not be necessary to collect data from all the patients with the disease or 
those undergoing the intervention in question. Resource use data can be collected 
using a random sub-sample of patients. However, care has to be taken to weigh up 
the pros and cons of sampling. On the ` pro' side it reduces the time and financial 
burden on the researcher and does not overburden patients with data collection. On 
the ` con' side, the results might be sensitive to the chosen sample, and it is 
necessary to assess the bias in the results from a smaller sample, thus sample size 
determination is an important consideration. However, calculations of sample size 
based on detecting an economic difference e. g. cost or outcomes are not common, 
as most studies base their sample sizes on detection of differences in clinical 
outcome(85). However it has been suggested that consideration of the ability to 
detect economic differences should be made, this involves specifying the minimum 
difference in resource use, cost or cost-effectiveness which is considered 
quantitatively important(86,87). Drummond and O'Brien (1993) and Torgerson et 
al. (1995) argue that there is no consensus on defining the difference(87,88). 
There is also a problem in estimating the sample size required for cost- 
effectiveness analysis in that there are two outcomes of interest, cost and economic 
outcomes. Briggs and Gray (1998) have derived a sample size formula for cost- 
effectiveness analysis based on a combination of the confidence intervals around 
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the costs and effects(89). The power calculation is dependent on some knowledge 
of the distribution, dispersion and variability of the data(86,90). Cost or resource 
use data from previous studies or pilot studies can be used to estimate the sample 
size required(91). However, pilot studies are somewhat limited in terms of follow- 
up and the results tend not to be as variable as those reported in the final studies. 
Gray et al. (1997) found that the sample size required to detect a meaningful 
difference in cost was much larger than the sample size needed to detect a 
meaningful difference in clinical effect, and that in many published evaluations of 
community care, the trials were under powered to detect these cost differences(92). 
One reason why sample size calculations for economic data are rarely performed is 
that data on likely cost difference, distribution and variability is difficult to predict 
ex ante. Another related problem has been the lack of reporting of the variance and 
distribution of cost data. Briggs and Gray (1999) reported that out of a search of 
492 cost-effectiveness and 
-utility studies only 53 were based on patient-specific 
cost data, and out of these only 25 studies reported any measure of variance(93). 
Data collection centres 
The resource use and unit cost data can be either collected from a single centre (e. g. 
hospital, GP practice, finance department) or a number of centres. The multi- 
centre approach adds to the generalisability of the study. It has been argued 
however, that where detailed resource use data collection has taken place, 
calculations of unit costs for each centre may not be necessary(94), moreover the 
use of centre-specific unit cost data may well mask the variations in resource-use. 
However, it might be illuminating to see whether and how much unit costs vary 
from centre to centre. Drummond et al. (1992) argued that centre-specific unit cost 
40 
data should be used in cases where unit costs are a function of resource use at 
individual centres(95). Empirical research into the decision of whether to collect 
both centre-specific resource use and unit cost data has been undertaken by Raikou 
and colleagues (2000). They show that the different methods result in statistically 
different estimates of average treatment costs, however they give no indication as 
to what is the correct method(96). 
Choice of data collection tool 
The choice of data collection tool is dependent on whether resource use 
information is being collected retrospectively or prospectively and the type of 
resource use information being obtained. Although any of the tools described 
below can be used alongside retrospective or prospective study designs, response 
rate, completeness and recall of data may be an issue. One has to trade-off 
collecting resource use information when the event occurs, and perhaps 
overloading the researcher and patient with questionnaires/diaries to fill in, with 
collecting resource use information after the event, and perhaps reducing the 
response rate, completeness and recall of events. 
Interviews, questionnaires and diaries 
Interviews, questionnaires and patient diaries are three ways of eliciting patient- 
specific resource use information directly from the patients. Interviews can be 
carried out on a face-to-face basis or over the telephone(97,98). Questionnaires 
can be administered by post or handed out at the time of hospital or GP visit. They 
can be designed specifically to fit the study criteria, as with two studies by 
Scuipher and colleagues (1996) who used postal questionnaires to assess the 
resource use of women with treatment for menorrhagia(99,100), alternatively, they 
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can be a standardised instrument, for example the CSRI (Client Service Receipt 
Instrument) designed to collect retrospective information on health and social 
service resource use(57), or the resource utilisation survey (RUS) developed by 
Copley-Merriman and colleagues for prospective use alongside trials(101). Diaries 
can be given to patients to record all resource utilisation. Diaries recorded the 
resource use incurred by parents of very low birth weight infants(102), the resource 
use related to elective total hip arthroplasty(103), low back pain(104) and cochlear 
implants(105). Case record forms (CRFs) are a type of questionnaire used in 
clinical trials to collect trial data. Medical personnel and/or the patients are asked 
to complete them. For the purpose of economic evaluations alongside clinical 
trials CRFs may be adapted to capture resource utilisation(106-108). 
Questionnaires completed at the time of the patient's appointment is a cheap 
method of gaining resource use information, it also results in high response rates, 
compared with other techniques. Postal questionnaires are also a cheap method 
compared with interviews, but suffer from poor response rates. Both 
questionnaires and interviews suffer from recall bias if administered 
retrospectively, whereas patient diaries aim to overcome this bias by allowing all 
resource use to be noted down at the time of utilisation. Problems may arise if 
diaries are used over a long period of time; patient motivation for filling in the 
diaries is likely to decline over time, leading to the potential for missing data. 
Related to this aspect is the timing and frequency of the collection of resource use 
information. This is discussed in a separate section below. 
Questionnaires can also be used to assess non-patient specific resource use 
information. They have been used to collect relevant information on equipment, 
instrumentation, consumables and staff (109). 
42 
Medical notes 
All of the above examples of collecting patient specific data can be time 
consuming for the patient, especially if the disease being looked at is a chronic 
illness which incurs costs over a prolonged period of time, or involves phases of 
acute illness. It might also be the case that the study being conducted is of a 
retrospective nature and the sample of patients being analysed have already died. 
Thus medical notes, GP records and lab records may well prove to be a better (or 
only) source of data. For example Richards and colleagues (1993) used the 
medical notes of 50 patients diagnosed with advanced breast cancer to estimate the 
related costs(110) and Whynes et al, (1993) used the medical notes of colorectal 
cancer patients in order to cost their hospital treatment(111). However, medical 
records suffer their own limitations; records might be missing, stored elsewhere 
and difficult to access or destroyed (32), and when traceable they may be 
incomplete. More recently, the issue of obtaining patients' consent to access their 
medical notes has arisen(112). Accessing and abstracting data from medical notes 
can also be an extremely costly and time-consuming operation. 
Databases 
Databases provide an inexpensive and less time-consuming alternative for 
estimation of resource use but this may be at the expense of accuracy. There are 
two types of databases, administrative databases such as insurance claims or 
clinic/hospital databases that offer the opportunity to access patient-specific data 
and existing databases (e. g. cancer registry database) may be used to derive non- 
patient-specific data. Examples of use of these types of databases include studies 
by Lave et al, (1994) who discuss the strengths and weaknesses of Medicare 
databases for estimating costs(113) and Clermont and colleagues (1998) who 
43 
explored the feasibility of generating resource use data for ICU based on the 
Therapeutic Intervention Scoring System (TISS) from a database of hospital 
electronic billing data(114). Penberthy et al, (1999) used a combination of 
databases; they linked tumor registry data with Medicare administrative claims to 
determine the costs of care for breast, colorectal, lung and prostate cancers during 
the initial year subsequent o diagnosis(115). Databases, although advantageous in 
terms of large sample sizes, are limited in terms of missing data. In most cases they 
have originally been designed for another purpose and may not contain all the 
relevant data. In some cases misclassification of data can occur, for example, 
diagnosis, treatments undertaken etc. Another problem with databases is that some 
form of data abstraction has to be undertaken, this requires interpretation of the 
data by the coder, who requires training for that purpose. 
Expert opinion 
Information on resource use need not be patient specific, although this is argued to 
be the favoured technique. Estimates of resource use are sometimes obtained from 
a number of experts in the particular field of interest or Delphi panel. Expert 
panels are advantageous in terms of expense and time, as they offer a quick and 
inexpensive way of estimating resource use. However they may be limited in terms 
of accuracy, and can only provide deterministic data, which limits its use in the 
statistical analysis of costs and cost-effectiveness. A US study used clinician 
interviews using a Delphi technique validated by patient medical notes to ascertain 
the medical resource utilization when exploring the cost-effectiveness of paclitaxel 
(Taxol) + cisplatin compared to teniposide + cisplatin in advanced non-small cell 
lung cancer(116). 
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Observation 
Observational techniques such as time and motion studies also provide non-patient 
specific (deterministic) data. This method of data collection offers a way of 
measuring staff workload, casemix, patient time spent, resource-use etc. and is 
therefore very useful when estimating unit costs in a micro costing study. Walker 
and colleagues (1991) used this observational technique when estimating the 
resource use and costs involved in various diagnostic procedures for colorectal 
cancer(117). 
Piloting 
Once decisions have been made about the sample size and sampling frame 
required, what data is required, where the data collection is to be carried out and 
what format this will take, the data collection methods need to be piloted. This 
represents an important step in the design of the study. It allows for the training of 
the data collectors and assessment of the acceptability and accuracy of the data 
collection tool chosen. 
2.5 Analysis of Cost Data 
2.5.1 Estimating total cost 
Once the resource use and unit cost data have been collected the observed counts of 
separate categories of resources can be weighted by unit cost information and 
summed to provide an estimate of per patient total cost. The costs for each cost- 
generating event can be summed across the total time period of the study to provide 
total cost per patient. If the cost data is presented as average cost of detection or 
average lifetime cost or average cost by stage at diagnosis or average cost per 
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intervention it makes cost comparisons more understandable. This average total 
cost estimate is calculated by dividing the total cost by the relevant number of 
patients. These costs may be presented as life-time costs, annual costs, monthly 
costs, weekly costs or daily costs. The time period for which the costs are 
calculated depends on the time frame of the study or the duration of the trial. 
Cumulative costs can also be calculated for the given period of follow up. 
However, before these costs can be estimated, certain procedures need to be 
undertaken. 
2.5.2 Adjusting costs for a base year 
Costs are usually measured in the base year, for example, the year of disease 
diagnosis or the year of initial treatment. Therefore, if the unit costs being used 
relate to another price year they need to be adjusted for the effects of inflation 
using the Hospital and Community Health Services Pay and Price Index (HCHS 
pay and price index)(1 18). 
2.5.3 Discounting 
Discounting of costs is also required for converting future costs into present values 
thus allowing for differential timing of costs. The discount rate or factor used to 
convert a future stream of monetary amounts into its present value, accounts for time 
preference and opportunity cost. For example if an individual is indifferent between 
£1 today and £1.10 in a year's time, the implied annual rate of time preference is 
10%. This is equivalent to using a discount rate of 0.1. Discounting is achieved by 
attaching smaller weights to future events. These weights are equal to (1 + r) 
where r= the discount rate and t is the year in which the event occurs. The 
question is what this rate of discount should be. 
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If there were perfect markets, the private and public rates of return on 
investments, and the individual and social rates of time preference would all be 
equal, and a single discount rate would exist. However markets are imperfect, 
therefore the discount rate can be equivalent to either the social rate of time 
preference, or the social opportunity cost. Both have inherent problems. 
Hence Drummond and colleagues (1987: 52) suggest a criteria for selecting a 'central 
r'(25) 
1. Be consistent with economic theory (2% to 10%). 
2. Include any government recommended rates (5%, 6%, 10%). 
3. Include rates that have been used in other published studies to which you might 
wish to compare results. 
4. Be consistent with 'current practice' (for example, 5% has been used recently in 
papers published in the New England Journal of Medicine). 
In practice different rates have been applied, but are generally between 3% and 6% 
(119-124) 
2.6 Analysis and reporting resource use data 
Ideally resource-use and cost information should be reported separately(125). There 
are a number of ways for analysing and reporting utilisation data. One can present 
the percentage of patients with contacts, for example 45% of the patients received a 
chest x-ray, however for some patients there may be several contacts or provision of 
the same procedure so this may ignore valuable information. Another method is to 
present resource utilisation measured as counts or frequencies of whether a service is 
provided to a patient, for example the number of x-rays. Finally, both methods can be 
used, for example 45% of the patients received an x-ray with a mean utilisation rate 
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of 3 x-rays per patient. Use of count data allows the distribution of counts to be 
compared. 
2.7 Reporting cost data 
The reporting of cost data is dependent on its method of collection. If non-patient- 
specific (deterministic) data have been collected costs are usually presented in 
terms of total cost and a point estimate of the mean cost. However if patient- 
specific data have been collected cost data should be reported in the form of total 
cost and average cost with some indication of the variance (for example standard 
deviation and 95% confidence intervals) and distribution of the costs. Estimation 
of the mean (average) cost is important for decision makers who require this 
information to assess the total budget required to provide a particular treatment or 
intervention. An estimate of this total budget (cost) is estimated by multiplying the 
arithmetic mean (average) cost of providing the intervention by the total number of 
patients requiring the intervention. Another important area in the analysis of health 
care costs is the comparison of the cost of different interventions. It is natural to 
explore whether the average per patient cost of one specified group differs from the 
average per patient cost of another group, for example whether costs of treatment 
differ between early stage and late stage breast cancer patients. Statistical tests 
such as t tests and one-way analysis of variance (ANOVA) are used to explore 
significant cost differences. It is impossible to determine this difference solely on 
point estimates of the mean difference, information on the variance of the cost data 
and its distribution is also required. A study by Briggs and Gray (1999) found that 
out of a total of 492 cost-effectiveness and cost-utility studies (published up to 
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1996), only 11% (53) were being conducted on a patient-specific basis, and out of 
these only 25 studies presented any information on cost variance(93). 
2.7.1 Distribution and functional form of cost data 
A problem encountered when analysing cost data is its distribution. This problem 
arises when statistical analysis of the cost data is required. In most cost data sets 
there exist a relatively small number of high cost patients that result in a positively 
skewed distribution. The implication of this skewed data is that the ability to 
detect significant differences between different groups is reduced; parametric tests 
are based on the distribution of data being normal. Therefore, according to 
standard statistical textbooks, unless the data are transformed these parametric tests 
should not be used and be replaced by non-parametric tests. However, it has been 
argued that as the sample size increases, parametric tests may be useful as the 
distribution is likely to reach normality(126). 
There are inherent problems with using the three textbook methods of 
overcoming the problem of skewed data, use of the median, transformation and the 
use of non-parametric tests, when analysing cost data. 
The median rather than the mean is sometimes used in the presence of 
skewed data. However, it is inappropriate to use this measure when dealing with 
statistical analysis of cost data. As health economists, we are interested in average 
and total cost estimates. The use of the median gives us neither estimate, when 
data is positively skewed the median is lower than the mean estimate, thus when 
this median is multiplied by total number of patients treated, the estimated result 
will differ from the true total cost for that group. Furthermore, estimating the 
measures of variance around the median can prove difficult. 
49 
Transformation, by taking the logarithm, natural log, square root, reciprocal 
or some other function, is an alternative method for handling skewed data. Briggs 
and Gray (1998) have shown that back-transformation of the log transformed costs 
can be made. They argue, however, that interpretation remains problematic due to 
the inability to back-transform to the original scale(19). In multivariate analysis of 
cost data this can be overcome by re-transforming using the process (known as the 
smearing estimator) outlined by a US statistician(127). However, the problem still 
remains that any form of re-transformation results in the analysis of geometric 
rather than arithmetic means. Geometric means are not appropriate summary 
statistics for economic analyses (as with the case of median measures). Two UK 
statisticians working with cost data(128), in response to the paper by Briggs and 
Gray (1998), have argued against the analysis of any form of transformed cost data, 
stating that: 
"Analyses of costs should be based on untransformed data; any `increased power' 
obtained by transforming the data is illusory as it is at the expense of addressing 
the wrong question" (128: 255). 
Non-parametric tests such as the Mann Whitney U test and the Wilcoxon 
sum rank test are used in situations where the assumptions required for parametric 
analysis of data are violated. However, these non-parametric tests address 
differences in the ranks of the raw data and report the medians (already shown 
above to be inappropriate). Coyle and Drummond (1996) have argued that since 
the objective of most statistical analysis of cost data is to compare means, non- 
parametric data based on medians may not be appropriate(94). Briggs and Gray 
(1998) have gone further, and argued that non-parametric tests do not address 
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inferences around arithmetic means, rather they compare the whole distribution of 
costs between groups. 
Zhou and colleagues (1997) provide an alternative method of analysis for 
skewed cost data. They propose a Z-score method designed to adjust for skewness 
and compare means of log-normally distributed cost data(17). 
One non-parametric method that has been proposed as an alternative 
method for the analysis of skewed cost data is bootstrapping(19,129). 
Bootstrapping makes no assumptions about the distribution of the data, instead it 
employs the original data in a re-sampling exercise to empirically estimate the 
entire sampling distribution for the statistic of interest (in the case of cost the mean 
cost estimate). With bootstrapping the observed sample is treated as an empirical 
distribution and from this a random sample is taken from that distribution and the 
statistic of interest is calculated. This procedure is then repeated i. e. a re-sampling 
procedure is conducted. Random values are selected from the original sample (size 
n) with replacement2" to yield a bootstrap sample of size n and the statistic of 
interest is calculated. A bootstrap sample may include the costs for some patients 
more than once, while excluding the costs for other patients. The process is 
repeated many times (by convention at least 1000 times). This gives a vector of 
bootstrap estimates of the statistic of interest, which is an empirical estimate of the 
sampling distribution of the statistic of interest. 
2.1 
replacement means once a random value has been used for the bootstrap resample it is put back 
into the original sample so the same value can appear more than once in a bootstrap sample. 
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Because we are sampling with replacement, there will be variation between the 
samples. (N. B. sampling without replacement would simply yield the original 
sample and there would be no variation). 
Although, limited work has been done on the appropriate way to handle the 
analysis of cost data given its skewed distribution (16-22,92), no consensus has 
been reached as to the appropriate method. This issue of distribution of cost data is 
explored in more depth in Chapter 7, where I also look at issues of functional form 
and cost prediction. 
2.7.2 Uncertainty of results 
Once the cost analysis has been performed, it is important to recognise that the 
results are subject to uncertainties in the baseline parameters used. Uncertainty 
may arise from a number of sources; data inputs e. g. resource use data, unit cost 
data, methods used e. g. the discount rate, and assumptions made e. g. if the results 
are based on modelling or have been extrapolated. The certainty/uncertainty of the 
results needs to be quantified so that the researcher and subsequent users of the 
results know how much confidence to place on the results. There are two ways for 
analysing uncertainty relating to cost data, statistical analysis and sensitivity 
analysis. 
Statistical analysis 
The increased collection of patient-specific cost data has meant the ability to test 
for uncertainty using statistical tests to detect differences in mean costs and the 
presentation of measures of variability such as standard deviation and standard 
error. The methodology and its associated problems have already been discussed 
in section 2.6.1. 
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Sensitivity analysis 
In practice, many economic evaluations do not use patient specific data, instead 
using data from a number of sources (literature reviews, clinical judgment), where 
statistical methods cannot be used. Even in studies where statistical analysis has 
been performed, an examination of the extent of uncertainty in certain point 
estimates (e. g. discount rate or unit cost data) should be undertaken. This is done 
by a process known as sensitivity analysis and involves the systematic investigation 
of how changes in the uncertain parameters affect the overall results(130). 
Sensitivity analysis tends to be a subjective process, with the investigator 
deciding on which parameters may have an effect on the final results and selecting 
the level of variation required. The ranges across which to vary parameters is 
usually given as the highest and lowest ranges possible, or plus and minus 1 or 2 
standard deviations, or use of 95% confidence intervals. The ranges and the 
amount of change incurred in baseline results should be specified. Briggs et al. 
(1994) have specified four types of sensitivity analysis, simple, threshold, analysis 
of extremes and probabilistic sensitivity analysis. Simple sensitivity analysis can 
be univariate or multivariate. Simple univariate sensitivity analysis requires one 
parameter to be changed to see what impact this has on the final result. However, 
it has been argued to be an incomplete estimate of the uncertainty as it takes no 
account of the interaction effects brought about by simultaneously changing several 
parameters. This is the case of a simple multivariate sensitivity analysis. 
Threshold analysis identifies the critical value of the parameters above or below 
which the results of the study will change. Sensitivity analysis can also be carried 
out using the analysis of extremes approach, whereby a base case analysis is 
generated and then a further analyses is performed looking at extreme estimates. 
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Probabilistic sensitivity analysis uses Monte-Carlo analysis to simulate the 
distribution of the data. The issues surrounding handling uncertainty in economic 
evaluations have recently been reviewed by Briggs and Gray, (1999). They discuss 
in detail the different types of uncertainty arising in economic evaluations and the 
distinct forms of sensitivity analyses that can be undertaken to account for this 
uncertainty(93). 
2.8 Other issues pertaining to the analysis of cost data 
2.8.1 Missing and censored data 
Missing data is an inherent problem common to the majority of economic studies. 
Data can be missing for a number of reasons; patients may not return or complete 
data collection instruments, or it may arise due to loss to follow up where a patient 
drops out of a trial or information in the medical notes is no longer recorded. 
Missing data may therefore have implications for the analysis of the cost data and 
requires some decision to be made as to how to handle it. Non random approaches 
to handling missing data exist, one approach is to ignore it (available case 
analysis), another is to delete the cases where any data is missing and base the 
analysis on the cases with complete data (complete case analysis). An alternative 
method is to replace the missing data with imputed values. The imputed values 
may be the mean values of the non-missing data (mean imputation). Replacement 
by imputation may in fact be biased and reduce the true variability of the data(94). 
Conditional mean imputation can get around this problem of reduced variability, by 
conditioning the mean values to be imputed on certain observed characteristics 
such as age, gender, stage of disease. Moreover, data (especially trial data) are 
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seldom missing at random, and Crawford et al. (1995) suggest that regression 
imputation provides an easily implemented method of adjustment for non-random 
non-response(131). A review of these methods can be found elsewhere(132). 
Where data are missing due to loss to follow up/attrition i. e. right censored, 
several approaches have been suggested to account for this when estimating the 
mean total cost. One approach is to assign zero costs for the censored period, 
Rutten van Molken et al. (1994) have argued that this may underestimate the costs 
and suggest carrying forward the mean costs of all observations for patients with 
limited follow up(35). They argue that this is appropriate because the high level of 
resource-use at time of censoring would have been sustained or may have even 
increased. Fenn et al. (1996) have adopted techniques of survival analysis to 
extrapolate treatment costs beyond the end of the trial(14). Lin et al. (1997) (15) 
have suggested partitioning the survival curve into intervals and estimating the 
costs for each interval. This issue of missing data is discussed in more detail in 
chapter 9 with examples using the Trent cancer cost data. 
2.9 Discussion 
This chapter has documented the methods, recommendations and issues related to 
costing. From this review it is noticeable that some of the methods presented are 
current accepted conventions2.2 and undertaken by all health economists, while 
other methods are debatable with no consensus on the correct technique to be used, 
2.2 While economists by their nature are always likely to disagree, there are methods and issues 
where general consensus has been reached. 
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and finally, there are new emerging methods and techniques that require more 
empirical research. 
1. Areas of current accepted conventions in costing: 
" Measurement and valuation of direct health care costs. 
" Measurement and valuation of direct non-health care costs. 
9 Measurement of informal care. 
" Use of pilot questionnaires. 
" 
Choice of time horizon; this should cover the period in which all the main 
cost-generating events are incurred. 
" Requirements for reporting the results; average cost, with an indication of 
the variance of the cost, an estimate of the total cost of implementing the 
intervention. Where comparisons are made a statement of the statistical test 
used and results of the test. 
" Statement of any adjustments used in base year prices and how they were 
adjusted. 
" Statement of the currency in which the costs are reported. 
" 
Use of discounting. 
9 Use of sensitivity analysis to assess areas of uncertainty in cost results. 
2. Current unresolved/debatable issues 
9 The choice of perspective. Most of the existing economic evaluation 
guidelines argue that a societal perspective should be used for all analyses, 
while others have argued that the choice should be dependent on the target 
audience or the funding body who commissioned the study. For example 
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the National Institute for Clinical Excellence (NICE) has taken the 
perspective of the NHS or Social Services for its evaluations. 
9 The choice of data collection tool; in some respects the choice is 
determined by the type of study being conducted, whether it is prospective 
and alongside a trial or prospective and naturalistic or retrospective. 
However more research is required on the validity and reliability of the 
current data collection tools used, and it would be useful to be able to have 
more direct comparisons between instruments. 
The valuation of informal care costs, whether the opportunity cost or 
replacement cost approach should be used. 
9 Whether productivity costs should be included in the total cost estimate. 
This debate is dependent on the reason for costing, if it is to estimate the 
total burden of a particular disease, it is useful to include the cost due to lost 
productivity arising from the morbidity or mortality caused by the disease. 
However, if the costing process is being undertaken as part of an economic 
evaluation, whether to include indirect costs as part of the cost estimate 
(numerator of the CER) or the benefit estimate (denominator of the CER) is 
undecided. 
9 If it is decided that productivity costs should be included in the total cost 
estimate, there remains a debate as how to measure and value these costs. 
In general, lost productivity is valued using the human capital approach, 
whereby an average earnings figure is attached to the amount of productive 
time lost due to the disease or illness. However, it is the measurement of 
this time that has been the undetermined issue. 
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9 The inclusion or exclusion of future related and unrelated costs. Although 
an old topic of debate, it has been resurrected recently by Meltzer (1997) 
and Garber and Phelps (1997) (consensus on this issue is yet to be reached). 
" What rate of discount should be used? This has been widely debated, and 
varies according to which country the analysis was undertaken. However, 
the UK tends to use the rate of 6% for costs reflecting current advice from 
the Treasury to the whole of the public sector. 
" 
Type of sensitivity analysis; the type of sensitivity analysis undertaken by 
the researcher is largely dependent on the data collected, of all the types it 
has been argued that probabilistic sensitivity analysis provides the most 
useful information for the decision maker. 
3. Areas of emerging methodological techniques, where further empirical 
research is required. 
9 Choice of data collection centres. As increasing numbers of economic 
evaluations are conducted alongside multi-centre clinical trials, a debate has 
emerged as to what is the appropriate method for collecting resource use 
and unit cost data. The question is whether to collect centre specific 
resource use and centre-specific unit cost data or to use average unit cost 
data and attach this to centre specific resource use data. It is surprising to 
find that only one study has looked at this question empirically, and this is 
limited in that it uses simulated clinical trial data(96). 
" Ways of controlling for skewed cost data. Over the past four years there 
has been an emergence of published research looking at how to analyse 
costs in the presence of positively skewed data. The choice is between 
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transforming the data so as to normalise the distribution, use non- 
parametric hypothesis tests such as the Mann-Witney, use bootstrapping, 
leave the data untransformed and undertake parametric hypothesis tests. 
" Missing and censored data. In the past cost analysis has been performed 
with no account taken of any data that may have been missing. It is only in 
the past five years that health economists have been alerted to the problems 
connected with missing or censored data. Further research is required to 
understand the changes in results when using the different methods 
proposed to take account of missing or censored resource-use/cost data. 
This chapter has introduced the concept of economic costing as used by health 
economists. The purpose was to review the literature on methods, issues and 
guidelines related to costing, with the aim of informing the methods and techniques 
to be used in this thesis2 3. In reviewing the literature four questions were 
addressed, 1) What are costs? 2) Why are we interested in costs? 3) How are costs 
estimated? and 4) How should costs be analysed? This chapter therefore presents a 
descriptive outline of how the process of costing ought to be undertaken and how 
the issues related to costing be handled. The process of costing is a complex task, 
and rarely is it possible for the analyst to incorporate all relevant costs or to 
estimate the true opportunity cost of the resources used. In practice a trade-off 
must be made between the time and expense in collecting resource use information 
2.3 It should be noted that this review was initially undertaken in October-December 1994, and 
therefore a very limited set of the literature used in this chapter (published pre-1995) was used to 
inform the initial methods for this thesis. 
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and estimating costs and the integrity of the study. All studies are constrained by 
time and finance. The next chapter (chapter 3) explores the issue of the 
transferability of these costing guidelines into practice. 
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Appendix 2.1 Capital Costing 
Capital costs, for example, land, buildings and equipment are incurred at a single 
point in time, usually at the start of a programme. However, they are used over time 
and despite the initial outlay the opportunity costs are spread over time. Thus capital 
costs consist of two elements; the opportunity cost i. e. the foregone opportunity by 
investing the sum of money in that particular asset, and the depreciation factor (over 
time the value of the asset depreciatesA2-'). 
There are two ways of dealing with capital costs: 
If the market rate exists for the rental of buildings or the lease of equipment, these 
can be used to estimate the capital cost. The most widely used method advocated by 
Richardson and Gafni (1983) and Drummond et al. (1994) (25,133) incorporates 
both the depreciation and opportunity cost aspects. This involves annuitizing the 
initial capital outlay over the useful life-span of the asset, i. e. estimating the 
equivalent annual cost. This still requires knowledge of the initial value of the 
resources and the appropriate rate of interest. 
Below is the relevant equation for annuitizing an asset over its expected useful life- 
span. If the initial capital outlay is C;, one needs to find the annual sum A, which 
over a period of Y years (life of asset), at an interest rate R, will be equivalent to C;: 
A= 
Ci J(1+R)"]-1 
iP 
[=1 
Where: 
C; = Capital spent in year i 
P; = Price index for that year relative to the current year 
R= Constant discount rate 
Y= Expected years of use of the item 
This equation may have to be altered for the age of the equipment as there is 
variation between new and old equipment. The method for the annuitization of 
new equipment is straight forward, the value is taken to be the initial capital outlay 
annuitized over its useful life span. However with old equipment, one can either 
use the replacement cost and discount over its full life, or use the current market 
value of the old machine and its remaining life. The former is considered to be 
more generalizable and therefore more reliable (25). 
A2.1 The cost of land is equivalent only to its opportunity cost, there is no depreciation factor. 
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Chapter 3 
Estimating Costs In Practice 
3.1 Introduction 
In the review of methods, issues and guidelines for cost estimation in the previous 
chapter, there was a mixture of literature on guidelines and methods for costing for the 
purpose of cost of illness studies and economic evaluations. Also included in the 
review were `one-off guidelines for specialised areas of cost estimation and analysis, 
for example, sensitivity analysis(1,2), how to deal with skewed cost data in analysis(3, 
4), and censored cost data(5,6) etc. These published guidelines for cost estimation 
(the majority of which were found in texts or published papers on guidelines to 
economic evaluations) provide advice on how in principle cost estimation should be 
carried out. Economic principles (outlined in chapter 1) coupled with the requirement 
for transparency and transferability have shaped these guidelines. The aim of this 
chapter is to clarify three questions: 
1. to gauge the number and nature of studies that have estimated costs with respect to 
the disease cancer; 
2. to examine how the methods and principles of cost estimation explored in chapter 
2, transfer into practice; 
3. to highlight the methods used and problems that may arise in the estimation and 
analysis of costs of cancer. 
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In order to respond to these questions a literature review of costing and cost estimation 
with specific reference to the disease, cancer, was performed. The literature search 
was conducted using electronic bibliographic packages to identify the source of 
publications. It is however, unlikely that this search is inclusive 3.1. In the subsequent 
chapters on breast, cervical and lung cancer costs, further studies (published and 
unpublished) have been identified by utilising sources other than the bibliographic 
packages. For example, use of sources of reference in published studies, colleagues' 
advice and information on published and unpublished studies. 
3.2 Methods 
The first aim of the review was to identify any research on the subject area of cost or 
economics of cancer or cancer care. After having defined the objectives of the review, 
the next step was to identify the eligible studies. Literature on the costs and cost- 
effectiveness of cancer and cancer care were detected using electronic database 
searches. These included: 
" Embase (1980 to present) 
" 
Sci search via BIDS (1981 to present) 
Soc Sci search via BIDS (1981 to present) 
" 
Medline (1966 to present) 
NHS Economic Evaluation Database (compiled by the Centre for Reviews and 
Dissemination at York University 
- 
whole database) 
All the above database searches were conducted during August 1998. However some 
of the publications during the first eight months of 1998 may have been excluded due 
to time lags between publication and citation in the databases. 
3.1 It should be noted that it was not the purpose of this chapter to conduct a comprehensive search on 
all the published and unpublished literature on the topic of cost of cancer. 
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Studies were included if they appeared to assess the direct and/or the indirect 
cost of cancer or cancer care. Review studies were included in this initial search. The 
exclusion criteria for this initial search were purposely kept to a minimum as I required 
a comprehensive list of published studies on cost and cancer. Exclusions were made if 
the studies were clearly not anything to do with costing or cancer. In some cases when 
reading the abstract it was difficult to determine whether a cost analysis had been 
conducted or whether they were simply reporting resource use. If only resource use 
was reported these studies were excluded from the review. The searches were also 
limited to `English language' and `human' studies. Understandably a number of 
studies that appeared to meet with the inclusion criteria during the initial review were 
subsequently excluded; titles and abstracts can be misleading. Thus, once all the 
literature that appeared to satisfy the inclusion criteria were gathered, and the papers 
read in more detail, further exclusions had to be made. Table 3.1 reports the results 
from the literature search. 
From the original set of 595 papers which appeared to be of interest, a number 
of publications were found to be duplicates or triplicates (i. e. cited by more than one 
bibliographic package), or not appropriate for inclusion into the review because the 
paper gave no information on either cost or cancer or in some cases both subject terms. 
Therefore the number of papers eligible for the review was reduced to 383 
(Appendices 3.1 and 3.2). 
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Table 3.1 Results from the Literature search 
EMBASE: 
`cancer' or `neoplasms' = 29,288 
limit to `English' and `Human' = 18,619 
`cost' (include all terms) = 47,039 
limit to `English' and `Human' = 25,444 
combine = 223 
01, intcrc"t 
Sci Search BIDS: 
search in the title, keywords/abstract field 
`cancer and cost' = 2,672 
Of interest 21«) 
SocSci Search BIDS: 
search in the title, keywords/abstract field 
`cancer and cost' = 394 
Of interest K(, 
Medline: 
`cancer' (include all terms) = 95,713 
limit to `English' and `Human' = 66,802 
`cost': `cost & cost analysis' 
`direct service costs' 
`drug costs' 
`employer health costs' 
`hospital costs' = 29,208 
limit to `English' and `Human' = 18,532 
`economics': `medical' = 17,338 
`hospital' 
`nursing' 
`pharmaceutical' 
limit to `English' and `Human' = 5,919 
`cost-benefit analysis' = 15,803 
limit to `English' and `Human' = 12,290 
`cost of illness' = 1,630 
limit to `English' and `Human' = 1,449 
combine 
`cancer' and `cost' = 325 
`cancer' and `economics' = 47 
`cancer' and ` CBA' = 224 
`cancer' and `cost of illness' = 49 
0f interest - 92 
NHS Economic Evaluation Databa se 
- 
CRD 
`cancer' = 126 
`cancer' + `cost' = 123 
of interest -115 
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3.2.1 Categorization of study type: 
Not all the studies in the review were reports of costs or economic research, although 
all had some element of cost in them. I therefore decided to categorize them according 
to study type: 
1) Economic evaluation: 
Cost-effectiveness analysis (CEA) 
Cost-utility analysis (CUA) 
Cost-benefit analysis (CBA) 
Cost-minimisation analysis (CMA) 
2) Other cost study, e. g. cost of illness or cost of disease/ process/ treatment. 
3) Review studies of economic aspects of cancer care or economic evaluations of care. 
4) Guidelines/description of methods used for cost estimation of cancer and cancer 
care. 
5) Other 
- 
e. g. conference proceedings, editorials, letters. 
Further exclusions to the 383 publications were made; review or guideline papers, 
letters, conference proceedings and editorials were excluded from any detailed 
analyses. The reason for these exclusions was that primary research studies were 
required for such a review of the practical elements of costing. The remaining 262 
papers were classified according to disease/cancer site or treatment type, year of 
publication, country from which the study originates (see section 3.3). 
As the main aim of this review was to ascertain whether the practical and 
applied costing adhered to the theory set out in the guidelines outlined in Chapter 2. A 
detailed review of a single paper took three hours on average. To attempt a detailed 
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examination of all papers that met with the inclusion criteria would have therefore 
taken a considerable amount of time. It was therefore felt to be impractical to review 
all 262 papers in detail. The number of papers for detailed review needed to be 
reduced. A 15% random sub-sample of the 262 papers that met with the inclusion 
criteria was selected for intensive detailed review of the costing methodology used. 
The detailed review required a decision on a number of study criteria to which 
an assessment of adherence could be made. The choice of criteria was based on the 
methods, guidelines and issues discussed in Chapter 2. These criteria along with the 
background information required for the review are set out in Table 3.2. 
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Table 3.2 Background information and criteria for the review of published 
studies of costing and cancer. 
" Author 
" Year 
" Type of economic study: 
-CCA 
-CBA 
-CMA 
- 
CEA 
-CUA 
" Type of health care strategy: 
- 
treatment 
- 
prevention 
- 
diagnostic 
" 
Type of cancer 
" 
Type of intervention 
" 
Viewpoint/ perspective: 
- 
patient 
- 
health service 
- 
society 
Type of cost: 
- 
direct health care 
- 
direct non-health care 
- 
informal 
- 
productivity 
" 
Study design: retrospective or prospective analysis 
" 
Stochastic or deterministic analysis 
" Time horizon 
" 
Relevant costs included 
" Data collection centre 
-single centre or multi-centre 
" Sample size calculation 
" 
Quantification of resource use: 
- 
previous studies 
- 
medical records 
- 
RCT 
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- 
literature search 
- 
clinical advice/ Delphi panels 
- 
interviews/patient diaries 
- 
observation 
" 
Valuation of cost estimation: 
- 
cost of resources from estimation 
- 
unit costs of resources from finance 
- 
prices: billing data, tariffs 
- 
published studies 
" 
Costs and resource use information stated separately 
" 
Price base: 
- 
use of Hospital and Community Health Services pay and price index or RPI 
to change price base 
" Currency: 
- 
use of exchange rate or Purchasing Power Parity to convert currencies 
" 
Discounting 
" 
Analysis of cost data: 
- 
statistical analysis and reporting of costs 
9 Costs varied in sensitivity analysis: 
- 
one way 
- 
multiway 
- 
probabilistic 
- 
analysis of extremes 
-threshold 
" 
Handling of missing data 
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3.3 Results from the review 
From the 383 studies identified in the electronic databases, 262 were eligible for 
further analysis (see Appendix 3.1). 121 of the papers were excluded for the following 
reasons; 17 were conference proceedings, 6 were editorials, 4 were guidelines to 
costing, 21 were letters, 64 were review articles, 2 were a mix of guidelines and 
reviews, 6 were found to have no English translation available and I could not be 
traced by inter-library loans (Appendix 3.2). The 262 left for further analysis, have 
been categorized according to; economic study type (Figure 3.1), country where the 
study was carried out (Figure 3.2), cancer site or specific therapy (Table 3.3), 
publication year (Figure 3.3) and author of study (Table 3.4). 
Figure 3.1 Type of economic study 
EA 
34% 
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Figure 3.2 Country where study was undertaken 
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Table 3.3 Cancer site or specific therapy 
Site Multiple sites ]I: 
Breast 66 Breast, Lung, Colorectal, Prostate, 
Colorectal 41 Stomach 
Cervical 22 Breast, Lung, Colorectal, Prostate, 
Prostate 22 Bladder 
Lung 19 Breast, Lung, Colorectal 
Ovarian 10 Breast, Lung, Ovarian 
Cancer 7 Breast, Lung, Stomach, Uterus 
Stomach 6 Breast, Lung 
Testicular 3 Breast, Cervical, Colorectal 
Endometrial 3 Breast, Cervical 
Melanoma 3 Breast, Colorectal, Prostate 
Brain 2 All neoplasms (2) 
Childhood 2 
Hodgkins 2 Therapy 
Leukemia 2 Terminal care 11 
Bladder I Chemotherapy 10 
Head and neck I Radiotherapy 4 
Non-Hodgkins I Anti-emetics 3 
Oesophagus I Radiology 3 
Oral 1 Pain 3 
Pancreas 
Upper aerodigestive tract I 
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Figure 3.3 Year of publication 
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Table 3.4 Authors of publications concerned with `cancer' and `costing' 
where numbers of publications are >1 
Hillner BE 13 van der Maas PJ 3 
Smith T 11 Virgo KS 3 
Whynes DK 8 Waugh N 3 
Evans WK 7 Baker MS 2 
Walker A 7 Bastin K 2 
Koopmanschap MA 6 Bennett CL 2 
Brown ML 4 Butler JRG 2 
de Koning HJ 4 Goodwin PJ 2 
Gyrd-Hansen D 4 Hall J 2 
Messori A 4 Hodgson T 2 
Norum J 4 Hutton J 2 
Salkeld G 4 Jonsson B 2 
van Ballegoijen M 4 Launois R 2 
van Inveld BM 4 Leese B 2 
Arveux P 3 Lieberman D 2 
Carlsson P 3 Lokich JC 2 
Fahs MC 3 Neilson A 2 
Hurley SF 3 Simon MS 2 
Lindfors KK 3 Tsuji 1 2 
Littrup PJ 3 Weeks J 2 
Mandelblatt JS 3 Wodinsky HB 2 
Rosenquist CJ 3 
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Fifty per cent of the studies are categorised as cost studies, thirty-four per cent are 
cost-effectiveness studies. Between five and ten studies have been undertaken in each 
of the following countries; Norway, France, Japan, Sweden, Italy and the Netherlands. 
Sixteen studies were undertaken in Australia, twenty-three in Canada, thirty-two in the 
UK and one hundred and twenty five in the USA. Of course, since the literature 
search was restricted to publications in the English language, studies from Europe and 
other non-English speaking countries may be underrepresented. However, given that 
the majority of international studies do get published in English language journals, this 
under-representation may not be as great as expected, (as supported by the various 
countries included in the review (Figure 3.2)). The under-representation is more likely 
to be concentrated on specific countries such as studies from China and Russia. 
Unsurprisingly, most of the studies reported in the literature examine the most 
common cancers. Sixty-five per cent of the 262 studies considered breast, cervical, 
prostate, lung or colorectal cancer. Breast cancer alone accounted for twenty five per 
cent of all the studies in the review. The majority of the studies (86%) on cost and 
cancer were published in the 1990's, with fifty published in 1996 alone. It must be 
remembered that the figures for 1998 are only for 8 months of the year as this literature 
search was carried out in August of that year, moreover there are time lags between 
publication and being entered into the electronic databases. Therefore the figure of 18 
for 1998 is likely in reality to be much higher. The final categorisation of the 262 
studies was by author of the paper. Fifty-eight per cent of the total number of studies 
were by first authors who had published more than 1 study out of the 262. 
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3.4 Detailed Review 
A 15% random sample of the 262 papers that met with the inclusion criteria resulted in 
a detailed review of 40 publications. The papers in this review are documented in 
Appendix 3.3. 
3.4.1 Background information of publications in the detailed review 
Tables 3.5 and 3.6 give background information such as study type and year of 
publication. This information closely matches that of the 262 published papers found 
in the literature review (see Figures 3.1 and 3.3), with 50 per cent of the studies being 
cost studies and the majority being published in 1994-1997. 
Table 3.5 Study type (detailed review) 
Study type Number % of total 
Cost 19 47.5 
CEA 13 32.5 
CUA 5 12.5 
CMA 25 
CBA 1 2.5 
Table 3.6 Year of publication (detailed review 
Year of 
publication 
Number % of total 
1979 1 2.5 
1980 1 2.5 
1983 1 2.5 
1986 1 2.5 
1987 2 5 
1988 1 2.5 
1989 1 2.5 
1990 1 2.5 
1991 2 5 
1992 1 2.5 
1993 4 10 
1994 7 17.5 
1995 5 12.5 
1996 5 12.5 
1997 5 12.5 
1998 2 5 
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Type of health care strategy 
Of the 40 studies, 29 (73%) are categorized as treatment studies, while 8 (20%) are 
prevention studies and 3 (8%) investigate diagnostic procedures. 
Type of intervention 
Exploring the type of interventions looked at in the papers, screening contributed to 8 
of the papers (20 %), as did chemotherapy. Other interventions included diagnostic 
procedures such as biopsy(7) or radiology(8), or the entire disease management of 
specific cancer sites(9-13). 
Type of cancer 
Costs were estimated in the studies for a range of cancer sites (Table 3.7). Breast 
cancer accounted for 5 papers (12.5 per cent of the total), while colorectal cancer made 
up 15 per cent of the total (6 papers), lung cancer accounted for 10 per cent of the total 
(4 papers), cervical cancer, prostate cancer and chemotherapy accounting for 3 papers 
each (7.5 per cent each). 
Table 3.7 Cancer site or specific thera py (detailed review) 
Cancer site Number of pap ers % of total 
Colorectal 6 15 
Breast 5 12.5 
Lung 4 10 
Cervical 3 7.5 
Chemotherapy 3 7.5 
Prostate 3 7.5 
Cancer 2 5 
Endometrial 2 5 
Terminal 2 5 
Other 10 25 
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The above, all represent background information to the papers reviewed. However the 
main purpose of the detailed part of the review was to look at the costing 
methodologies used. 
3.4.2 Costing methods used in publications in the detailed review 
Viewpoint/perspective of the study 
The first area of interest in any costing study is what is the viewpoint or perspective of 
the study. Out of the 40 studies looked at, 31 were from the perspective of the health 
service, 6 were based on a societal perspective, and 2 from the USA were from the 
`payors' perspective. 
The type of perspective chosen governs the type of cost to be estimated. For 
all cases, the direct health care cost was ascertained (Table 3.8), four of these studies 
also estimated the direct non-health care costs, i. e. the patients' and families' travel 
costs or any other direct payments made by the patient or family as a result of 
receiving the medical care(12,14-16). Three studies estimated the productivity costs 
related to the disease(] 0-12). Informal care costs were estimated by Lan sky and 
colleagues (1979) when estimating the non-medical costs of childhood cancer (15). 
Table 3.8 Type of cost 
Type of cost Number of studies Percentage of studies 
Direct health care costs 40 100% 
Direct non-health care costs 4 10% 
Informal care costs 1 3% 
Productivity costs 3 8% 
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Prospective, Retrospective or Model 
The studies differ in the type of design. The design is an important factor to consider 
as it impacts on how the resources are identified, measured and valued, and whether 
the information collected is stochastic or deterministic, and whether statistical analysis 
and/or sensitivity analysis of the cost data is undertaken. 
Figure 3.4 Proportion of articles by study type 
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Figure 3.4 summarises the various designs used in the 40 published studies. Forty- 
three percent of the studies had been carried out on a retrospective basis, usually using 
a retrospective case series of patients. A secondary analysis of trial data had been 
conducted in 19% of the studies, and in 5% they were conducted prospectively 
alongside an RCT. Eight per cent of the studies had also been conducted 
prospectively, but not alongside a trial. Finally 25% of the studies used some form of 
modelling based approach. Fahs et al. (1992), Shimbo et al. (1991) and Smith et al. 
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(1993) all use Markov models. Others used decision-analytic models to estimate the 
cost-effectiveness of treatments(7,17-19), or other forms of mathematical 
simulation(20-23). 
Deterministic versus Stochastic analysis 
Figure 3.5 displays the nature of the study in terms of patient-specific (stochastic) data 
or non-patient-specific (deterministic) data, by publication year. Whether patient- 
specific data collection and analysis has increased over time; no clear inference can be 
made from this review of 40 publications. 
Figure 3.5 Deterministic or stochastic analysis by year of publication 
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Time horizon 
Another important area in costing is the time period over which the costs/resource use 
is related. This time horizon can indicate whether all the relevant costs are included. 
In order to make the costing methodology transparent, published papers should state 
the time period used for costing. However, in this review, 10 of the papers gave no 
indication of the time period used. Twenty-three appeared to have adequate follow up 
time and included relevant costs for the cancer type. For example, 7 studies looked at 
the cost of the whole disease process(9,13,14,18,20,24,25). Others simply looked 
at the costs from the diagnosis of the event to death e. g. from diagnosis of advanced 
disease to death(8,26), from time of randomization in the trial until death(27), or with 
the case of terminal cancer, from the onset of terminal cancer until death(28,29). Two 
studies specified time periods of 42 and 24 months or until death, however this time 
period was justified as it was likely that all the cost-generating events would be 
included in studies estimating the costs of palliative interventions for end-stage 
cancer(30,31). Some of the papers looked at the costs of the screening process(21,23, 
32-34). 
Two papers looked at the annual expenditure of cancer using a prevalence 
approach to costing(10,11). Lansky et al. (1979) estimated weekly non-medical costs 
related to childhood cancer. Jones et al. (1994) chose an eight-year follow up approach 
following brachytherapy for cervical cancer. Similarly the study conducted by 
Layfield et al. (1993) encompassed all the costs by following up the patients diagnosed 
with breast cancer for ten years. 
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Are the relevant costs included? 
Seven papers appeared to have inadequate time periods, and hence did not reflect the 
true costs of the disease or intervention being looked at. Smith et at (1997), when 
evaluating the treatment costs of Hodgkins and non-Hodgkins disease, considered the 
resource use and cost solely for the trial period. No statement was made in the paper 
as to the length of the trial period, however it was clear that no follow up time was 
costed. 
Messori and colleagues, (1997), assessing the cost of treatment for melanoma 
used a follow up time of one year and then made the assumption that follow up costs 
after this period were the same for both trial arms. 
"After the first year, the follow-up costs for those two patient groups were assumed to 
be identical (e. g. number and length of hospitalizations, laboratory tests, expenditure 
for treating drug-related side-effects, costs of terminal illness etc. ) " (37: 1374-1375). 
Whynes et al. (1993) may well have missed out on important costs of 
recurrences and complications by restricting the time period to three years following 
diagnosis of colorectal cancer. However one must weigh up the feasibility of follow 
up. If carried out prospectively, this can be an expensive process, yet if carried out 
retrospectively, with cancer there can be a problem of accessing relevant data. 
Whynes and colleagues actually qualify their choice of three years by stating: 
"To assess the economic impact of the disease more fully, treatment costs for each 
patient were calculated over a3 year period (or until death, if occurring within this 
period), starting from the date of diagnosis in each case. The choice of three years as 
a cut-offpoint was dictated by (i) the need to generate a sample of sufficiently large 
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size to permit statistical inference, (ii) clinical findings, which suggest that the 
majority of complications and cancer recurrences are likely to occur within 1-2 years 
of the initial intervention. " (38: 965). 
Jones and colleagues (1994), when comparing the cost of two types of 
brachytherapy for the treatment of cervical cancer, state that they have used an eight- 
year time horizon as this is the potential useful life of the caesium implant used in this 
type of therapy. However, they fail to include any of the costs incurred over the time 
period of the follow up and complications related to the therapy. 
Ortega et al. (1997) based their costing on a model developed from the 
literature using an evidence based approach. 
"The analytic time period consisted of 4 months of first line combination 
chemotherapy, subsequent cycles of secondary treatment for primary non-responders, 
and the progression free survival interval. "(17: 456). 
However, they did not state the time period involved in the programme free survival, 
and therefore it was difficult to tell whether all relevant costs had been included in the 
analysis. 
Licht et al. (1994) evaluated the impact on cost of early discharge following 
surgery for prostate cancer. One could argue that the follow up period of thirty days 
after surgery would not capture all complications or inpatient hospital stays etc. 
Vetto et al. (1998) when looking at the cost-effectiveness of the diagnosis of breast 
cancer in males only looked at the costs of diagnostic procedures, and excluded any 
forms of follow up costs. 
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The above seven studies rely upon inadequate time spans for their costing procedures, 
and therefore significant areas of resource use and cost have been excluded from the 
estimation. This leads the reader to question the reliability of the results. 
Quantification of resource use 
Another area of importance when costing is the measurement of the resources used i. e. 
an assessment of the resources involved in the treatment, care or detection of the 
disease in question. It can be seen from Table 3.9 that the source of resource use 
information varies from study to study. 
Table 3.9 Quantification of resource use 
How resource use information was Published study 
obtained 
Multi-centre RCT (14,25,36,37) 
Multi-centre non-randomised trial (39) 
Single centre RCT (21,30) 
National and regional dataset (9,13) 
Government database (10,11) 
Case series of patients (12,29,31,33,40,41) 
Medical records of a sample of patients (8,24,26,42-44) 
Published literature (7,34,45,46) 
Current practice (16,22) 
Questionnaire (15) 
Mix of methods (17-20,23,27,28,32,35,38) 
The majority of studies looked at in the review based their resource use collection on 
single sites/centres, although a number were based on multi-centre randomised control 
trials(14,25,36,37), or multi-centre non-randomised trials(39). Glimelius et al. 
(1995) and Gyrd-Hansen et al. (1998) obtained their resource use information from 
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randomised control trials, based on the experience of a single centre. Others used 
national or regional datasets, such as hospital discharge databases(32) or hospital 
admissions databases(13), the continuous Medicare history sample file(9). Other 
sources of resource-use are government databases such as the government annual 
spending from the US health care financing administration(10) or the Japanese 
ministry of health and welfare(11). Some studies used a case series of patients(12,29, 
31,33,40,41), while others used medical records of a sample of patients(8,24,26, 
42-44). Benoit et al. (1994), Konski et al. (1997), Layfield et al. (1993) and Shimbo et 
al. (1994) all took their resource use information from published literature(7,34,45, 
46), while others used `current practice' as a basis for resource use, although in all 
cases no information was given on what this current practice actually constituted(16, 
22,32). Lansky et al. (1979) used a questionnaire to ascertain resource use. A number 
of studies used a mixture of sources of information; Sculpher et al. (1995) based their 
resource use on the RCT and published literature, while data from a single centre RCT 
and medical records were used by Whynes et al. (1993). The cancer registry, hospital 
admissions database and medical records were used by Gray and colleagues (1987). 
Ortega et al. (1997) used RCT based studies and hospital charts and had the resource 
use verified by a panel of experts. Others used NCI patient data query, cancer registry, 
literature, backed up by expert advice(20), official Japanese government statistics, 
medical charts and expert opinion(23), trial data, literature and expert opinion(19), or 
trial data and hospital dossiers(27). Jones et al. (1994) obtained their resource use 
information from the Hamilton Regional Cancer Centre, Canada, using the medical 
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records and observation of staff and operating time by conducting interviews with 
staff. 
Valuation of resource use information 
The valuation of this resource use information should also be stated as transparently as 
possible. The valuation of the costs differs in respect to the source of unit cost data. 
For some the cost data is estimated, others used charges for procedures, while others 
use costs that have been published in the literature. In the review of the 40 studies, 
valuation of resource use was carried out in a number of ways, although two 
predominant methods were used; estimation (use of information on staff time, salary, 
capital, equipment, overheads etc. ) and the use of charges (see Table 3.10). 
Table 3.10 Valuation of resource use 
How the resources were Published study 
valued 
Estimation (8,14-18,20,24,26,28,30,33,35,37,39,41) 
Prices/Charges (9,19,22,25,29,31,32,36,40,42,44-46) 
Government expenditure (10,11) 
Mixture of methods (7,12,13,23,34,38,43) 
96 
The valuation of costs was carried out using estimation in 40 per cent of the studies. 
Out of these studies, very detailed and transparent estimations were carried out by 
Richards et at (1993), Sculpher et at (1995) and Wodinsky et at (1987). 
An example of the estimation by Sculpher et al. (1995) is given below: 
" resource use was valued using a set of unit costs based on supplier prices or derived 
from the financial accounts of UCLH... The unit costs of endoscopic procedures 
include the costs of staf, consumables such as gloves and tubes, drugs such as 
sedation and reverse sedation and an allocation of hospital overheads. The cost of 
equipment was also included, such as the cost of the laser and of the endoscopes 
which has been amortised to an equivalent annual cost using a 6% discount rate, and 
estimates of expected useful life and annual utilisation" (18: 1642). 
Richards et al. (1993) gave a transparent and detailed account of their costing 
methodology (this allowed a comparison of the breast cancer cost results in this thesis 
with theirs, see chapter 5). The costs were split into inpatient costs, medical and 
surgical outpatient costs, radiotherapy costs, chemotherapy costs, surgery costs and 
radiology and laboratory investigation costs. 
When estimating inpatient costs.... 
"... the cost of an overnight stay was estimated by calculating the total cost of running 
the ward and dividing this by the total number of overnight stays for the year 
1988/89.... Salaries including employers National Insurance Contributions and 
London weighting for staff employed on the ward (e. g. nurses) was calculated at a 
March 1991 pay and price base. The proportion of the working week attributable to 
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the management of Breast Unit in-patients was calculated for other staff (e. g. doctors, 
physiotherapists, dietitians) and costs were calculated accordingly... In addition both 
direct (e. g. portering and domestic services) and indirect overheads (e. g. hospital 
administration) were included in the calculation of costs. A fu' rther 19% was added to 
the calculated cost to cover the capital charges applicable to Guys and Lewisham 
NHS trust in the year 1991-2. " (26: 857). 
Outpatient costs were estimated in a similar fashion where they were valued as the 
total cost of running the clinic/ward divided by the throughput, including salary costs, 
consumables, portering, domestic services, administration and capital charges. 
Radiotherapy costs were based on published literature, chemotherapy costs and 
endocrine therapy costs were based on the market price of the drugs. Surgery costs 
were estimated by the product of length of operation and staff costs with additions for 
anaesthetic consumables and surgical and medical equipment, with indirect and direct 
overheads for running costs and capital charges. Radiology and laboratory costs 
included the cost of consumables, staff and direct overheads. 
Wodinsky et al. (1987) estimated the costs using the wholesale price of the 
drugs, administration costs, nurses' salaries and employees benefits, consumables, 
dispensing fees and allocated overheads. They also considered nonmedical costs to 
the patients and their families, taken from published literature. 
A number of studies (33 % of the total) relied on price or charges for the 
valuation of resource use e. g. Medicare charges, other reimbursement schedules and 
hospital charges (needless to say the majority of these were U. S. studies). Studies by 
Hodgson (1983) and Maeda (1983) used government expenditure as a proxy for cost 
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data. Other studies used a mixture of sources for their valuation of costs. van 
Ballegooijen et at (1995) used a combination of Dutch hospital charges for diagnosis 
and treatment of cervical intraepithelial neoplasia (CIN 
- 
pre-invasive cervical cancer), 
and then estimated the cost of colposcopy using staff time, equipment and clinic unit 
costs. Norum et at (1996) used a mixture of charges and national database 
information. Ross et al. (1996) produced a very comprehensive and transparent 
valuation of resource use using a variety of sources such as the literature, hospital 
finance departments, estimation using salary costs and equipment costs with 
amortisation over its useful lifespan. Shimbo and colleagues (1991) report use of a 
combination charges, literature and expert opinion. The cost of a faecal occult blood 
test (FOB) was taken from the Japanese national reimbursement tables, flexible 
sigmoidoscopy cost was taken from the literature as was the treatment cost, cost of 
colonoscopy and terminal illness from "expert reports", cost of follow up was based 
on the hospital cost of outpatient visits. 
Whynes et al. (1993) used a mixture of estimation and previously published 
literature. Okubo and colleagues (1991) used the literature combined with expert 
opinion. Layfield et al. (1993 used the literature and charge data. In two of the studies 
reviewed it was impossible to determine the methods used for valuing the 
resources(21,27). 
Costs and resource-use stated separately 
Out of the forty studies, thirteen (28 per cent) outlined the costs and quantities 
separately. These were displayed as either as actual numbers and percentages or 
average frequency counts (e. g. average number of outpatient visits) and average length 
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of stay. Only one paper, Gray et al. (1987), provide a separate analysis of the resource 
use data. They explore the differences in inpatient stays and survival between the 
intervention and control groups using a one-way analysis of variance and report F 
statistics and p values for these differences. 
Price base 
Figure 3.6 shows how the price base ranged from 1977 to 1996. Sixteen studies (40 
per cent) gave no details of the price base used. 
Figure 3.6 Year of price base 
Number of 
6 studies 
51 
4 
3 
2 
1 
0 
Index used to adjust prices 
Only one study used any index to inflate the price base. Evans et al. (1995) used the 
Canadian Consumer Price Index. 
Currency 
The currency utilised tends to be governed by the country in which the study was 
carried out. Figure 3.7 reports on the currencies used. 
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1977 1980 1984 1988 1989 1990 1990-1 1991-2 1992 1993 1994 1995 1996 
Year of price base 
Five studies converted their baseline currency into another currency. All five 
studies used exchange rates, van Ballegooijen et al. (1995) present the results in Dutch 
Guilders, but quote the exchange rate for the British pound. Two Japanese studies 
used exchange rates to convert yen into U. S. dollars(23,34). Norum et al. (1996) 
converted their costs from Norwegian kroner to British pounds. Messori et al. (1997) 
report all their costs in US dollars after having converted Italian lira to U. S. dollars. 
Figure 3.7 Currency used in studies 
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Discounting 
Ten studies discounted their costs. Baker et al. (1991) when estimating the costs of 
lung and breast cancer, only discount the costs of terminal care and give no details of 
the discount rate used. Eight of the studies used a rate of discount of 5 per cent and 
one used a range of rates(12). For twelve of the studies discounting was not necessary 
as all the costs were incurred within one year. 
Statistical analysis 
Table 3.11 displays the statistical analysis and reporting of cost data undertaken for the 
40 papers reviewed. All papers report, either total cost (12.5%), average cost (72.5%) 
or both (15%). A proportion also report median costs (15%). Ortega and colleagues 
(1997) use median cost and cost-effectiveness estimates with 95% confidence intervals 
around these point estimates, calculated using a method suggested by statisticians for 
use with such nonparametric analysis(47). The use of median cost estimates has been 
discussed in chapter 2. According to standard statistical theory medians should be 
used in place of means when the data being analysed are non-normal or skewed. Ross 
et al, (1996) discussed how they dealt with the problem of outliers in estimating costs 
of treating advanced colorectal cancer. 
"It is not uncommon for cost data to be non-normally distributed. Therefore mean 
treatment costs were calculated for each treatment group, as the mean accounts for 
the small number of patient (outliers) who generate the greatest costs. " (43: S 14) 
Norum and colleagues (1996) used a slightly different approach when 
estimating the costs of Hodgkins disease, they noted one patient outlier who because 
s/he received autologous bone marrow transplantation displayed significantly higher 
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treatment costs than other patients in their sample. They accordingly investigated the 
impact on the average cost estimate of removing this patient from the analysis, the 
result was to reduce the average cost of stage IV patients from £29,837 to £19,943. 
From the 40 published studies, 53% (21 papers) were identified as reporting 
patient specific resource use and /or cost data (Table 3.11). Three of the papers under 
the heading `Model' also used patient-specific resource use data for their analyses (17- 
19). However out of a total of 24 papers using stochastic methods, only 12 (50%) of 
these report any measures of variation in their cost estimates. No papers in the review 
report confidence intervals around cost-effectiveness ratios. From the 19 papers that 
used stochastic data and who performed a comparison of estimated costs, only 7 used 
standard statistical tests to report differences in cost estimates. Two studies used one- 
way analysis of variance (ANOVA), 3 used the students t-test, one used the non- 
parametric Mann- Whitney test, and one graphically displayed average costs with 95% 
confidence intervals. 
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Table 3.11 Statistical analysis and reporting of cost data 
Study TC AC Per LYG Median Range SD 95% P Cost 
CI value comparison and 
comments 
Patient specific data 
Norum, 1996 Comparison of 
cost according 
 
 (QALY) ý/  to 
four stages of 
Hodgkins 
disease using 
ANOVA 
Smith, 1997 Reports actual 
 
and % cost 
difference 
- 
no 
statistical test 
Lansky, 1979 Reports 
average medical 
./    and non- 
medical costs of 
childhood 
cancer 
Glimelius, Incremental 
1995 CEA between 
 
 (QALY)  chemotherapy 
and best 
su ortive care 
Raikar, 1996 Comparison of 
costs of surgical 
versus 
 
endoscopic 
interventions 
for cancer of 
pancreas using 
t-test 
Gray, 1987 Used ANOVA 
to compare 
home based 
hospice service 
ce. normal 
hos ice care 
Hoffman, 1989 Reports total 
cost savings to a 
hospital of 
 
implementing a 
colorectal 
cancer 
screening 
programme 
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Study TC AC Per LYG Median Range SD 95% P Cost 
CI value comparison and 
comments 
Mayr, 1994 Reports cost 
savings 
involved with 
implementing 
 
 
 MRI scans for 
treatment 
planning of 
brain 
metastasis 
Schapira, 1994 West of cost 
difference of 
 
hospice cc no 
hospice care 
and reported 
SE 
Agboola, 1997 Cost per cancer 
detected and 
incremental 
 
 
CEA of adding 
chest x-ray and 
smear to 
physical 
examination 
Ross, 1996 Comparison of 
cats of 4 
chemotherapy 
 
 
./ regimens for 
treating 
colorectal 
cancer 
Whynes, 1993 West used to 
compare 
 
 
treatment costs 
for 4 stages of 
colorectal 
cancer 
Rae, 1994 Comparison of 
costs and cost 
per cancer 
 detected for 
four types of 
faecal occult 
blood tests 
Goodwin, 1988 Incremental 
CEA of two 
different 
 
(QALY) chemotherapy 
regimens for 
small cell lung 
cancer 
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Study TC AC Per LYG Median Range SD 95% P Cost 
CI value comparison and 
comments 
Licht, 1994 Comparison of 
costs of early 
versus late 
J hospital discharge 
following 
surgery for 
prostate cancer 
Jaakkimainen, Incremental 
1990 CEA of two 
different 
chemotherapy 
J J regimens and 
best supportive 
care for non 
small cell lung 
cancer 
Hanks, 1986 Cost 
comparison of 
treating 
J J J prostate cancer 
with surgery, 
lymph node 
dissection or 
radiotherapy 
Kennedy, 1995 Incremental 
CEA of 
chemotherapy 
versus best 
supportive care 
J J(QALY) J J J for non small 
(IQR) cell lung cancer Comparison of 
costs using non- 
parametric 
Mann-W itney 
test 
Richards, 1993 Average cost of 
J diagnosis and 
treatment of 
breast cancer 
Messort, 1997 Incremental 
CEA of 
J J J J adjuvant 
therapy for 
melanoma 
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Study TC AC Per LYG Median Range SD 95% P Cost 
Cl value comparison and 
comments 
Vetto, 1998 Reports 
reduction in 
average charges 
J from different 
diagnostic 
procedures for 
breast cancer in 
males 
Model 
Fahs, 1992 Incremental 
CEA of one-off, 
annual, 3- and 
J J J 5-year cervical 
screen 
compared to 
no-screen 
Sculpher, 1995 Cost 
comparison of 
J two palliative 
interventions 
for oesophageal 
cancer 
Shimbo, 1991 Incremental 
cost and CEA 
of various 
J J screening 
strategies for 
colorectal 
cancer 
Gyrd-Flansen, Incremental 
1998 CEA of various 
screening 
strategies for 
colorectal 
cancer 
Ortega, 1997 Incremental 
CEA of 
combination 
J /(QALN) J ý/ J versus single 
agent 
chemotherapy 
for ovarian 
cancer 
Evans, 1995 Average cost of 
diagnosis, 
J treatment and 
follow up of 
lung cancer 
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Study TC AC Per Ll'G Median Range SD 95% P Cost 
Cl value comparison and 
comments 
Okubo, 1991 Incremental 
CEA of various 
 
 
screening 
strategies for 
breast cancer 
Smith, 1993 Incremental 
CEA of 
tamoxifen, 
J J (QALV) chemotherapy 
or combined 
therapy for 
early stage 
breast cancer 
Layfield, 1993 Incremental 
CEA of various 
 
 diagnostic 
strategies for 
breast cancer 
Lokich, 1996 Reports 
 monthly 
char es 
Othcr- 
Jones, 1994 Incremental 
cost of high 
J dose versus low 
dose 
brachytherapy 
Benoit, 1994 Reports 
average cost per 
person screened 
for prostate 
cancer by age 
group 
van Reports 
Ballegooijen, average care 
1995 cost of CINI-111 
Konski, 1997 Comparison of 
costs for six 
different 
treatment 
options for 
endometrial 
cancer 
Baker, 1991 Reports 
average initial, 
continuing and 
terminal care 
costs for breast 
and luncancer 
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Study TC AC Per LYG Median Range SD 95% P Cost 
CI value comparison and 
comments 
Wodinsky, Cost of 
1987 outpatient 
versus inpatient 
chemotherapy 
Lowenthal, 10, Cost of home- 
1996 versus hospital- 
based 
chemotherapy 
Hodgson, 1983 COI study 
- 
cost of cancer in 
US 
Maeda, 1983 COI study 
- 
cost of cancer in 
Japan 
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Sensitivity analysis 
In 48% of the studies no sensitivity analysis was undertaken. In the remainder of cases 
the sensitivity analysis varied in procedure. The various parameters altered include; 
clinical parameters, such as the natural history of the disease, progression rates, 
regression rates, sensitivity and specificity; the resource use parameters; cost 
parameters such as staff cost, equipment cost etc.; outcomes such as estimated life 
years, QALY, survival time and value weighting. All used one-way sensitivity 
analysis. Ortega et al. (1997) used one-way sensitivity analysis using 95% confidence 
intervals for given parameters, as did Sculpher et al. (1995). In some cases `realistic 
ranges' for parameters were chosen, but very little information was given (35). In 
general very little information was given on why the parameters were chosen for the 
sensitivity analysis and where the ranges around these parameters come from. For 
example, Fahs et al. (1992) used data based on a review of the available literature, but 
gave no reference to the sources. Shimbo et al. (1991) carried out a large sensitivity 
analysis although again, no reference was made as to the sources of variation. 
Handling missing data 
Only two papers included any information on missing data, one explicitly (31). Raikar 
and colleagues, (1996) reported loss to follow up of 34 patients in the trial from which 
the resource use data for their study were obtained. However, no account was taken of 
this attrition in their analysis. Whynes and Walker (1993) truncate their cost data to a 
three-year period, so that the treatment costs were calculated for patients over a 3-year 
period or until death. They argue that this time period can be justified by clinical 
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evidence that all complications and recurrences are likely to occur within the first two 
years. 
3.5 Conclusions 
This chapter reports on the results of an initial search of the literature on cost and 
cancer and a detailed review of a random sample of forty of the papers detected in the 
search. The aim was to respond to three questions: 
1. to gauge the number and nature of studies that have estimated costs with respect to 
the disease cancer; 
2. to examine how the methods and principles of cost estimation explored in Chapter 
2, transfer into practice, and; 
3. to highlight the methods used and problems that may arise in the estimation and 
analysis of costs of cancer. 
The principle findings in response to these questions are detailed below: 
1. The literature search was useful in highlighting the number and type of studies 
undertaken by researchers when estimating the cost of different cancers and 
interventions for cancer. The search involves a lengthy process of scrutinizing, 
first, the abstracts and then the papers to determine eligibility for inclusion into the 
review. It was interesting to find that many of the papers detected by the search 
using the key search terms were of no relevance to either costing or cancer. 
2. The detailed review of the forty published papers indicated that variation in the 
methodology used exists. For example, the design, perspective, collection of 
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resource use data, time horizon, source of unit cost data, analysis and reporting of 
results. 
In the previous chapter (2), it was noted that there were some areas of current accepted 
conventions in costing methodology. However, when reviewing the forty costing 
studies, this consensus of theoretical costing conventions did not appear to be borne 
out in practice. 
. 
The methods used for the measurement and valuation of resource use varied 
from study to study. Methods used were dependent on the nature of (in terms 
of retrospective or prospective, stochastic or deterministic, study perspective) 
and country of origin of the study. 
. 
Where questionnaires or proformas were used to abstract resource use 
information, there was no indication that they had previously been piloted. 
. 
From the review, 57.5% of the studies used a time horizon that encompassed 
all significant cost-generating events, 17.5% of the studies appeared to have 
inadequate time horizons and 25% of the studies failed to indicate the time 
horizon chosen for their study. 
9 Sixteen studies gave no details of the reference year for the cost data. 
. 
All studies reported the currency in which the cost estimates were reported, and 
where currencies were converted, exchange rates were used rather than 
purchasing power parities. 
" 
Twenty five per cent of the studies discounted, for the remainder, thirty per 
cent reported costs incurred within one year and therefore had a legitimate 
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reason for not discounting, while forty five per cent gave no indication of 
whether their costs had been discounted or not. 
" Average cost estimates were reported in 88% of the studies. The remainder 
reported total cost estimates. Only a few of the studies explored the total 
budgetary impact of implementing the intervention, this was done either on a 
hospital or a national basis. Only 12 studies report any measures of variation 
in their cost estimates. No papers in the review reported confidence intervals 
around cost-effectiveness ratios. From the 19 papers that used stochastic data 
and made some comparison of estimated costs, only 7 used a formal hypothesis 
test using standard statistical techniques to report differences in cost estimates. 
" Accounting for uncertainty and generalisability of the study in the form of a 
sensitivity analysis was undertaken by twenty-one of the studies, and all used 
one-way sensitivity analysis. 
This review has therefore highlighted the fact that even where there is supposed 
consensus on theoretical issues involved in costing, there remains variation in 
practice. It is therefore unsurprising to find that new emerging techniques in 
costing, discussed in Chapter 2, have rarely been undertaken in practice. Most 
notable are the lack of reporting of the distributional form of the cost data, and the 
completeness of the data collected and analysed. No account was taken on the cost 
side for censored data in trials, and with patient-specific studies there was no 
mention of missing values and what was done (if anything) in these cases. 
3. The review has provided a basis for the design of and methods used in the costing 
chapters (Chapters 5,6 and 7) in this thesis. It has also highlighted areas of 
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weakness in current costing studies where further practical research is required, 
such as analytic methods of cost data, and issues of missing data. These areas are 
explored in Chapters 8 and 9 respectively. 
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Chapter 4 
Background and Methods Related to the Costing 
Chapters 
4.1 Introduction 
Cancer represents both a key public health issue and a major area of economic 
concern. Not only is there a high cost associated with the treatment and care needs 
of cancer patients but a wider social and economic loss due to premature illness 
and death and a cost to the patient and family in terms of time, travel and other out- 
of-pocket expenses. Some data are available to demonstrate this at the national 
level (see section 4.3). There is, however, a lack of adequate information on the 
cost burden at a regional and patient-specific level. This is surprising given that 
cancer is one of the diseases in the UK that has been relatively well documented by 
regional and national Cancer Registries. However UK registries have never 
collected data of economic consequence, for example, number and type of 
consultations, inpatient length of stay. UK cancer registration is discussed in more 
detail in section 4.6. The purpose of this thesis is to first explore the cost burden of 
selected cancers in the Trent region and by doing this investigate the methods used 
for costing these cancers. 
This chapter outlines the background to the thesis, including clinical 
terminology, national estimates of cancer incidence, mortality and cost, and the 
process involved in obtaining the data. Sections 4.2 to 4.4 provide the reader with 
some background information essential for the thesis. This includes a description 
of cancer in general, the usual treatment patterns and what is meant by disease 
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stage. This is followed by nationally provided statistics on the current incidence, 
mortality and cost burdens of cancer in the UK. 
Sections 4.4-4.11 outline the processes involved in obtaining the data, 
including the decisions made on what cancers to study, how the data were 
obtained, the design of the proformas for data collection and data entry. This 
section also provides the reader with information on the geographical region used 
for data collection (Trent) and the Trent Cancer Registry. 
4.2 What is cancer? 
The human body is made up of millions cells. Cancer occurs when one or more of 
the cells breaks free from the normal restraints it is under and starts to multiply in 
an abnormal, uncontrolled way. This can happen to more or less any type of cell 
(bone, blood, skin etc. ) so there are as many types of cancers as there are different 
cells in the body- approximately 200. Unfortunately, all these cancers have 
different causes, symptoms and rates of progression and often respond differently 
to treatment. 
The management of all cancers tends to be by one or a combination of four 
modalities. These are surgery, radiotherapy, chemotherapy and hormone therapy, 
all of which can either be radical or palliative depending on the disease stage. 
. 
Surgery is often the first step in the treatment of cancer. The objective of 
surgery varies. Sometimes it is used to remove as much of the evident tumour 
as possible, or it may be to remove the major bulk of the tumour so that there is 
less that needs to be treated by other means. Depending on the cancer type and 
location, surgery may also provide some symptomatic relief to the patient. 
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Radiotherapy involves the use of high-energy radiation, primarily 
electronically generated x-rays, to kill cancer cells. Radiation therapy works by 
damaging the cancer cells' DNA. Once the DNA has been damaged, the cancer 
cells are not able to divide and grow, causing the tumour to shrink. Equipment 
is used to aim high-energy x-rays or other electromagnetic radiation precisely 
at tumours or parts of the body where cancer cells are present. Its two main 
goals are to cure cancer and relieve symptoms. For many patients, radiation is 
the only treatment needed. However, radiation treatment may also be given in 
combination with chemotherapy and/ or surgery. Radiation can be used before 
surgery to shrink a tumour, and during or after surgery to kill any cancer cells 
that may still be present. Doctors sometimes use radiation along with 
anticancer drugs to destroy the cancer, instead of performing surgery. 
Radiation can also be used as a palliative therapy. 
Radiation treatment can be given in one of two forms: external or internal. 
Most cancer patients receive external radiation therapy where the radiation 
provided by a machine called a linear accelerator. This treatment is generally 
administered on an outpatient basis, the patient lies on a table and the beam is 
directed around him/her. This only takes a couple minutes, but is done five 
days per week for 3-6 weeks, usually at a total dose of 25-35 fractions. 
After the initial consultation, the radiation oncologist may need to do some 
special planning to pinpoint the treatment area, a process known as 
"simulation. " Alignment is critical during this planning process, so the patient 
will be asked to lie very still on a table while the radiotherapist (a specially 
trained technologist), under the supervision of the radiation oncologist, uses a 
special x-ray machine to define the patient's treatment area, sometimes called 
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the treatment portal or field. This is the exact place in the body where the 
radiation will be aimed. Ink lines are usually drawn on the skin to identify the 
area to be treated. Several other treatment-planning steps occur after simulation 
and before treatment, but the patient is not required to be present for these. The 
information from simulation, other tests, and the patient's medical background 
will be used by the doctor, radiation physicist (who monitors the equipment), 
and dosimetrist (who calculates the correct dose) to create a customized 
treatment plan. The doctor then decides how much radiation is needed, how it 
will be delivered, and how many treatments the patient will need. 
Internal radiation therapy places the source of the high-energy rays inside the 
body, as close as possible to the cancer cells. Internal radiation therapy allows 
the doctor to give a higher total dose of radiation in a shorter time than is 
possible with external treatments. The radioactive substances used typically 
include radium, caesium, iodine, and phosphorus, and they may be implanted 
for only a short time or left in place permanently. The high doses of radiation 
that damage or destroy cancer cells also cause side effects such as skin 
reactions, hair loss, nutritional problems and fatigue. 
. 
Chemotherapy or the use of chemical agents to destroy cancer cells is another 
intervention used in the treatment of malignancies. The goal of treatment with 
chemotherapy has evolved from relief of symptoms to cure. A major advantage 
of chemotherapy is its ability to treat widespread or metastatic cancer, whereas 
surgery and radiation therapies are limited to treating cancers that are confined 
to specific areas. Almost all chemotherapy agents currently available kill 
cancer cells by affecting DNA synthesis or function, a process that occurs 
through the cell cycle. Because many chemotherapeutic agents also effect 
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healthy cells and organs, the patient's laboratory data should be checked before 
chemotherapy administration, including white blood cell count, platelet count, 
renal function tests, liver function tests. Abnormalities in any of these values 
may require dose adjustments or the delay of therapy. Additionally, 
pretreatment actions, such as increased fluids or administration of anti-nausea 
medicines may be needed to decrease side effects. The most common routes of 
administration for chemotherapy are by mouth, through a vein, and into a 
muscle. 
Chemotherapy is generally spaced out over an extended period of time. Many 
patients receive their chemotherapy over a4 to 12 month period of time. 
Additionally, the interval between doses of chemotherapy is based on 
achieving the greatest effect on the cancer cells, while also allowing the healing 
of the normal healthy cells. Most often, patients receive their chemotherapy 
every 3 to 4 weeks. 
Combination Chemotherapy combines agents that differ in both the way 
they act and their side effects. This is done to achieve maximum tumour effect 
with minimal side effects. Because tumour cells have different biological 
characteristics, combining drugs may effectively eliminate cancer cells' 
resistance to a single agent. 
Adjuvant chemotherapy may be given when no clear evidence of cancer can be 
found, but certain factors (e. g. metastasis to the lymph nodes) predict an 
increased risk of cancer recurrence. 
" 
Hormone therapy aims to induce tumour shrinkage by manipulating the 
normal hormonal level. A number of cancer types have been found to be 
hormone dependent for example, breast and prostate cancers. Hormonal 
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therapy may consist of surgical resection to remove the source of hormone, 
the administration of hormonal substances or the administration of anti- 
hormone drugs. 
4.2.1 Cancer stage 
Cancers progress through well-defined stages of disease, dependent on the size and 
spread of the tumour. Stage generally refers to the degree to which the cancer has 
spread beyond its original location. Lower stages of cancer (stages I and II) are 
generally more confined to their site or region of origin than more advanced stages 
(III or IV). 
Different cancer types are staged in different ways, according to a complex 
series of rules. While there are subtle differences in the staging rules for different 
cancer types, a physician generally needs to look at three things: 
"T stage (tumour stage), defined according to the size of the tumour itself; 
"N stage (nodal stage), defined according to the number of lymph nodes 
which contain cancer; and 
"M stage (stage of metastatic disease), defined according to the presence (or 
absence) of cancer that has spread into other organs or parts of the body. 
The TNM (tumour-node-metastases) classification is the most widely used system 
for classifying the extent of tumour spread(l). The T, N, and M stages have many 
nuances within them, and each is subdivided (Ti, 72, T3, etc. ) Different 
combinations of T, N, and M combine under the staging rules to determine whether 
a patient is stage I, II, III, or IV. Other staging systems exist; for example, the 
Dukes classification system uses stages A through to D to classify colorectal 
cancers. The stages A to D correspond to the stages Ito IV from the TNM system. 
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For the purpose of this thesis all cancers are reported by stage according to 
this TNM classification. The ability to stage cancer accurately is of vital 
importance as a guide to prognosis and forms the basis upon which the initial 
management of the patient is decided and therefore a good indicator of the 
resources used and the cost of care. For all cancers the prognosis is inversely 
proportional to the extent of the tumour, with early stage I and 11 cancers having 
higher survival probabilities than late stage cancers III and IV. Appendix 4.1 
displays the staging used for the purpose of this thesis for breast, cervical and lung 
cancers. 
4.2.2 Grade 
Cancerous cells can be ` graded' according to their degree of `differentiation'. 
Differentiation refers to how closely the cancerous cells resemble their cells of 
origin. The more differentiated a cancer cell looks, the closer it resembles cells 
belonging to its organ of origin. The more undifferentiated a cell is, the less normal 
it looks under a microscope. In some cancers, grade can affect the cancer stage 
and/or impact on treatment decisions. A pathologist makes the assessment of 
tumour type and grade. 
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4.2.3 UK cancer incidence4' (2-4) 
With approximately 255,000 new cases registered in the UK in 1996, it is predicted 
that one in three people in the UK will suffer from cancer at some stage in their 
lifetime. However, it is more likely to occur later in life, over 65 per cent of 
cancers develop in those aged over 65 years old. Lung, breast, large bowel 
(colorectal') and prostate account for half of all new cases (Figure 4.1). The term 
`other cancers' include those that contribute less than 1 percent to the total number 
of cancers. They include cancers of the testis, eye and gall bladder, and amount to 
14% of the total UK cancer incidence. 
The commonest cancer for men is lung cancer (Figure 4.2). Although the 
incidence has fallen as a result of a reduction in smoking in men it is still 
responsible for 20 per cent of all new cases. In women the most common cancer 
with 35,000 registrations in the UK in 1996 and accounting for a quarter of all 
female cancers is breast cancer (Figure 4.3). The lifetime risk of breast cancer is 
one in ten women. Breast cancer incidence increased throughout the 1980's, 
mostly occurring in screen-detected women aged 50-64 (see Chapter 5 for more 
detail). Similarly the number of invasive cervical cancer registrations have 
reduced over the past thirty years due to the National cervical screening 
programme, however, the number of pre-invasive cervical cancer registrations 
have increased over this time, with screening detecting the pre-invasive lesions 
(see Chapter 6). 
4.1 The incidence figures reported in this thesis are not true numbers of incident cases as there are 
problems with coding and misclassification of cancers by the Cancer Registries. Therefore the 
figures reported are often an indication of the number of registrations documented by the Cancer 
Registries and sent to the Office for National Statistics. This is discussed in more detail in section 
4.6. 
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4.2.4 Cancer Mortality 
Cancer is the cause of a quarter of all deaths in the UK(5). In 1998 there were a 
total of 155,000 deaths from cancer (see figure 4.4), 23 per cent of these were 
attributable to lung cancer alone. Approximately half of all cancer deaths in men 
are caused by a combination of lung, prostate and bowel cancers (Figure 4.5). 
Lung cancer mortality accounts for 27 per cent of all male cancers. In women, 
breast and lung cancer each account for 18 per cent of all female cancer deaths 
(Figure 4.6). This has been due to a fall in the number of breast cancer deaths and 
a rise in the number of lung cancer deaths in females over the past decade. This is 
due to the earlier detection and better treatment of breast cancer(6,7), combined 
with a rise over the past three decades in the number of female cigarette smokers. 
Cigarette smoking has been identified as one of the single most important causes of 
preventable diseases and premature death in the UK. One third of all cancer deaths 
are due to smoking, with 90 per cent of lung cancer deaths directly attributable to 
cigarette smoking(8). 
4.2.4 Mortality to Incidence Ratios 
Lung cancer has a high mortality to incidence ratio (0.91)(9); this is due to the poor 
survival rates for lung cancers. Cancers with better prognosis due to early 
detection or effective treatment display lower mortality to incidence ratios; 
colorectal 0.56, prostate 0.50, cervical 0.45, breast 0.43 and skin 0.01. 
4.3 National estimates of the cost of cancer 
Information on the cost of cancer is limited to estimates based on national 
expenditure statistics. The estimates that are often quoted are outlined below. 
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" 
Based on the bed occupancy rate by disease classification data derived from the 
Hospital Inpatient Enquiries of the 1980's, an estimate of the inpatient cost of 
cancer treatment in England and Wales was estimated to be £850 million in 
1991 prices. This represents approximately 5 per cent of NHS expenditure(10) 
(Office of Health Economics 1992: 79). 
" 
The total costs of cancer treatment and prevention to the NHS have officially 
been estimated at approximately 7 per cent of health service spending(11), this 
represents a 1999 expenditure of approximately £3,377 million per annum 
However, these estimates give no indication of cancer-specific costs, for example, 
lung cancer versus breast cancer. Nor do they inform decision-makers where the 
burden of cost lies within the treatment of specific cancers, for example, 
chemotherapy versus radiotherapy, or even, what costs are incurred within a 
specific treatment, for example, within surgery the cost of equipment, staff, 
consumables etc. 
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Figure 4.1 UK Incidence 1996: Cancers, which contribute I% or more to 
total burden 
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Figure 4.2 UK Incidence 1996: Males 
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Figure 4.3 UK Incidence 1996: Females 
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Sources: Office for National Statistics, Cancer registrations. England and Wales 1996 (personal 
communication); Scottish Cancer Registry, Cancer registrations, Scotland 1996 (personal 
communication); Northern Ireland Cancer Registry, Annual Report 1998 (personal 
communication). 
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Figure 4.4 UK Mortality 1998: Cancers, which contribute 1% or more to 
total mortality 
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Figure 4.5 UK Mortality 1998: Males 
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Figure 4.6 UK Mortality 1998: Females 
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4.4 Choice of Methods 
The primary research for this thesis in terms of the estimation of resource-use and 
cost of cancer was undertaken in conjunction with an epidemiological examination 
of reasons for the variation in survival of selected cancers. Both research topics 
were funded by Trent Health Authority to inform decision-makers about current 
practices in cancer in their region and to inform future changes in service 
provision. The project was also useful for Trent Cancer Registry to highlight the 
data needs of researchers of different academic disciplines. The methods used for 
the data collection were based on a joint approach between the economic and 
epidemiological studies. When it was discovered that Trent Cancer Registry lacked 
the appropriate data for our research purposes (section 4.6), a collaborative 
decision was made to access patients' medical notes (section 4.7). Although this 
joint approach led to economies of scale in terms of time and cost in obtaining 
ethics committee approval and accessing the patients' notes, the economic study 
required different information from the epidemiological study. It was therefore 
decided to use separate forms for the abstraction of data, although a lot of the data 
collected for the two studies overlapped and were used as a check for the reliability 
of the abstraction process. 
4.4.1 Choice of Cancer Sites 
The three cancers chosen for the analysis of survival variation and resource-use 
came about due to a consensus decision between the two research projects and the 
funding body (Trent Health Authority). The decision was based on the following: 
" 
The epidemiological study had identified key cancer sites displaying significant 
variation in survival across the region; cervix, lung, stomach and bladder. 
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The health authority expressed a preference for cancers where 1) burden in 
terms of incidence and mortality were large, 2) the government had already set 
targets(11). 
9 For the purpose of the economic study, the requirement was 1) that no previous 
detailed patient specific costing had been carried out in the UK (for example, 
colorectal cancer was ruled out as previous patient specific costing had been 
undertaken(12,13)), 2) that the cost analysis undertaken could provide useful 
information for future cost-effectiveness analyses of current programmes or 
new interventions. For example the cost analysis of breast cancer could be used 
in future research on the cost-effectiveness of changes to the current screening 
policy. 
The cancers were chosen on an iterative basis, with the first site being breast 
cancer. Once the data collection for breast cancer was nearing an end the second 
site, cervical cancer was decided. Finally the third cancer (lung) was chosen when 
half the data collection for cervical cancer had been undertaken. 
4.5 Trent Region 
The setting for the research was Trent region (Figure 4.7). Trent covers the East 
Midlands area of England, UK. It stretches from South Yorkshire and North 
Lincolnshire in the north, down through Derbyshire, Nottinghamshire and the rest 
of Lincolnshire to Leicestershire in the south. Approximately 5 million people live 
in Trent, which contains both rural and urban areas, the main cities being Sheffield, 
Nottingham, Leicester, Derby and Lincoln (Figure 4.8). 
In December 1993 the Government announced a restructuring exercise: `Managing 
the new NHS in England'. Regional Health Authorities were to be reduced from 
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fifteen to eight and abolished altogether in 1996, the regional tier being replaced by 
eight regional offices of the NHS Executive. Except for the inclusion of South 
Humberside, Trent region has remained unchanged geographically as a result of 
the 1994 re-organisation (Figure 4.9). The region has 11 health authorities 
responsible for assessing the health needs of their population, commissioning 
health services to meet those needs and working with other organisations to build 
healthy local communities. 
Figure 4.7 Trent in relation to other Health Authorities 
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Figure 4.8 Trent region 1990-1994 
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4.6 Trent Cancer Registry Data 
Given that cancer registrations in the UK have long been documented by the 
cancer registries, one might believe that the collection of patient-specific resource 
use information for particular cancers be easily undertaken using this pre-collected 
data. However, when the Trent Cancer Registry was contacted, it became clear that 
their core data set was rather limited in scope and lacked completeness and 
accuracy. For example, information on all treatment procedures, whether 
preventive, curative, diagnostic, investigative or palliative was essential. During 
the research period for this thesis, only the primary treatment procedure was 
documented by the Registry. The stage and grade of the cancer was unavailable, 
as was any information on follow-up, disease recurrence or metastatic spread. This 
lack of scope in the data is a problem with all Cancer Registries. Moreover, Trent 
Cancer Registry was trying to clear their three-year backlog of registrations. When 
approached in 1995 for breast cancer registration information, their most recent 
complete annual data were for 1991. 
4.6.1 What is cancer registration? 
As cancer is a major cause of illness and death in the population, it was felt to be 
necessary and useful to have comprehensive information about the numbers of 
cases of different cancers. This enables the long-term health of the population to be 
monitored, and aids the planning of services and care for the people affected. In 
order to do this effectively the cancer registration system was set up by the NHS 
over a 20-year period (1945-1965). In 1950 there were 74 centres registering 
cancer in England and Wales, by 1958 the system had been simplified and ten 
regional cancer registries had been set up. Full coverage of England and Wales 
was achieved in 1962. 
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4.6.2 Organisation of cancer registries 
Each health region in the UK is served by a cancer registry, so that every area in 
the UK is covered by a cancer registry. A common set of information is collected 
on every case of cancer by the regional cancer registries. This is then sent into the 
national cancer registry, which is run by the Office for National Statistics, who 
conduct national monitoring of incidence, mortality and survival from cancer. 
4.6.3 How is a tumour is registered 
The Registry receives notifications of new tumours in a variety of ways: 
Currently the most important of these is through the hospital patient administration 
system (PAS/HISS). A patient's records are updated on the hospital PAS/HISS 
when they have completed an inpatient stay or attended as a day case. If the reason 
for the in-patient stay is a notifiable neoplastic disease a special screen appears 
prompting the operator to make a cancer registration notification. 
The second major source of registrations is death notifications that are routinely 
received for all patients for whom cancer is mentioned as a cause of death. The 
patient details on the death notifications are checked against the database to see 
whether a registration already exists for that patient. If no match is found a 
provisional registration is made whilst a query is sent to the patient's GP or hospital 
to find out whether the tumour was ever formally diagnosed and treated. If no 
further details about the tumour can be found other than those on the death 
notification then the registration for that tumour is labeled a "death certificate only" 
(DCO) registration. 
Apart from information on registration and death, the registries collect 
other patient specific information (see section 4.6.5). They differ in their methods 
166 
of data collection, some employ peripatetic staff while others use hospital record 
staff to extract data for the registry. 
4.6.4 What data are available? 
Information is available on the three main areas of cancer statistics; 
" 
incidence (how many new cases of cancer develop), 
" mortality (how many people are dying from their cancer), and 
" survival (how long people are living with their cancer). 
The basic function of the Registry is to keep a record of every new cancer 
diagnosed in the population it covers. From these raw numbers of cancers the 
Registry calculates crude, age specific and age standardised registration rates. They 
are termed registration rather than incidence rates as they can never be sure that 
every cancer that develops is diagnosed or registered. The rates are calculated for 
Trent, but also for smaller areas such as the constituent district health authorities. 
Numbers of cancers can also be reported by hospital of initial registration or 
electoral ward. In addition to registration information, the Registry maintains a 
record of deaths from different cancers by age and sex, which it receives from the 
Office for National Statistics (ONS). Mortality rates are calculated from these 
figures. Observed and relative survival rates are calculated using survival 
information from the Registry database. In addition to summary numbers and rates 
the Registry is able to provide lists of patient specific information to authorised 
clients. 
4.6.5 Problems with Cancer Registry data 
Section 4.6 has introduced some of the problems found with using Trent Cancer 
Registry data for the purpose of this thesis. This section furthers this discussion, 
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by looking in detail at problems associated with data from all UK Cancer 
Registries. 
" 
Information on completeness and accuracy of Cancer Registry data is available 
from specific studies(14-18). Tables 4.4-4.6 provide information on the 
accuracy and completeness (in terms of misclassification of cancers, 
differences in recorded date of diagnosis) of Trent Cancer Registry data used 
for the purpose of this thesis, the errors are incurred in the transition from the 
medical notes or hospital databases to the Registry records. However, because 
the selection of medical notes used for the data collection was based on 
registrations of patients documented by the cancer registry, the issue of 
whether the registry was picking up all the cancers arising in the population 
could not be investigated. A more recent publication has investigated this 
specific area of completeness(19). The researchers found that the Cancer 
Registry had a shortfall of 134 patients that had been listed as having cancer on 
a particular hospital database in 1997. The reason for this was due to the 
source of notifications coming from the hospital PAS system, which only 
documents inpatient and day case episodes 
, 
therefore excluding any patients 
solely managed as outpatients (such as those only treated with tamoxifen). 
They also found that any patient diagnosed and treated privately was missed by 
the registry. 
" 
Duplication of registrations occurs between regions when a patient is resident 
in one region but treated in another, they can also occur due to coding error. 
" 
For the purpose of research there are problems with the scope of the data 
collected by the Cancer Registry. Each Registry is required to collect a 
minimum set of data, however, this does not include data of economic 
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consequence, for example, number and type of consultations and 
investigations, inpatient length of stay, medication, information on recurrence, 
or metastases. Table 4.1 displays the data collected by Trent Cancer Registry in 
1994. The lack of information required for a thorough costing exercise is 
clear4'2. In 1996, Trent Cancer Registry introduced their new minimum data 
set (Table 4.2 (changes highlighted in red)). Noticeable additions are the stage 
and grade of tumour, information on screening history and treatment indicators. 
Trent Cancer Registry was responding to national minimum standards and 
targets for registration services introduced by the NHS Executive in 1996 and 
the Calman report `A Policy Framework for Commissioning Cancer Services' 
that stressed the need for more stringent evaluation of cancer services(20). 
Hence the requirement for current practices to be documented to provide a 
baseline so that future services could be compared and evaluated. However, 
even this extended data set would be considered inadequate to provide an 
estimate of the cost of care for specified cancer sites. 
4.2 During the process of this thesis I was consulted by Trent Cancer Registry to find out what I felt 
should be included in their minimum 
data set and what other information would be useful for the 
purpose of this type of costing exercise. 
Appendix 4.2 outlines my suggestions for a necessary 
minimum data set and useful extra 
information. 
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Table 4.1 Trent Cancer Registry Minimum Data Set (1994) 
HOSPITAL DETAILS 
" 
District Health Authority 
" 
Hospital 
" 
Consultant 
" 
Patient Unit Number 
" 
Radiotherapy Treatment Number 
PERSONAL DETAILS 
" 
NHS Number 
" 
Forenames 
" 
Surname 
" 
Address at time of diagnosis 
" 
Post Code 
" 
Sex 
" 
Marital status 
" 
Date of birth 
DIAGNOSTIC DETAILS 
" 
Site of primary neoplasm (or main presenting secondary when 
primary site is not known) 
Morphology (type of neoplasm) 
Date of diagnosis (Anniversary date) 
First treatment procedure 
Date of Death 
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Table 4.2 Trent Cancer Registry Minimum Data Set (2000) 
HOSPITAL DETAILS 
" 
District Health Authority 
" 
Hospital 
" 
Consultant 
" 
Patient Unit Number 
" 
Radiotherapy Treatment Number 
PERSONAL DETAILS 
" 
NHS Number 
" 
Forenames 
" 
Surname 
" 
Name at birth (previous surname) 
" 
Address at time of diagnosis 
" 
Post Code 
" 
Sex 
" 
Marital status 
" 
Ethnic origin 
" 
Date of birth 
" 
Country of birth 
OCCUPATION DETAILS 
" 
Patient's occupation 
" 
Patient's employment status 
" 
Patient's industry 
(for females and children aged 16 and under, head of household's 
occupation and industry is also recorded) 
DIAGNOSTIC DETAILS 
" 
Site of primary neoplasm (or main presenting secondary when 
primary site is not known) 
" 
Morphology (type of neoplasm) 
" 
Laterality (side) for paired organs 
" 
Stage (for breast and cervix from 1993, colon and rectum 1995, 
others sites to be phased in later) 
Grade of tumour (degree of differentiation) 
Basis of diagnosis (Histology, Cytology, Haematology, Clinical 
Opinion, Other Tests) 
Date of diagnosis (Anniversary date) 
Treatment indicators (Surgery, Radiotherapy, Chemotherapy, 
Hormone Therapy. Other) 
" 
Alive/dead 
Date of Death 
" 
Cause and place of death (from 1996) 
" 
Post Mortem 
" 
Registration at Screening (breast and cervix at present) 
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4.7 Data collection from patient medical notes 
Given the limitations with the Trent Cancer Registry data it was decided that 
information on resource-use and patient characteristics would have to be obtained 
by accessing information held in patient's medical notes. This process required 
local ethics committee approval for all possible districts where primary treatment 
was undertaken. This was sought and approved by the following local ethics 
committees under the proviso that the patients' consultants should be contacted to 
ask for permission to access their medical notes, and that they would have the final 
say on whether their patients' case notes could be accessed. All the consultants 
contacted gave their consent. 
" 
North Lincolnshire 
" South Lincolnshire 
" Leicestershire 
" 
Central Nottinghamshire 
" 
North Nottinghamshire 
" 
Doncaster 
" 
Rotherham 
" 
Barnsley 
" 
North Sheffield 
" 
South Sheffield 
" 
North Derbyshire 
" 
South Derbyshire 
Patient information in the form of patient name, hospital and District Health 
Authority of primary treatment, consultant, patient unit number, NHS number and 
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radiotherapy treatment number were supplied by Trent Cancer Registry. Once 
consultant approval had been obtained, a corresponding list of these patient 
identifiers were sent to the medical records centre of the various hospitals where 
primary treatment had been undertaken to enable the correct case notes to be 
identified and `pulled'. Each of the hospitals that had been identified as a site of 
primary treatment for a patient in the sample had to be visited. Over the course of 
the research this amounted to 24 different hospitals. Some hospitals were the site 
of primary treatment for all three cancer sites and had to be visited on three 
separate occasions (see Table 4.3). A considerable amount of time was spent in 
the medical records centre abstracting the resource-use information from the 
medical records (see Table 4.4). For some hospitals (approximately 25%) the staff 
refused to identify and pull the medical notes. This meant that an extra amount of 
my time was spent searching for the notes (approximately 3 minutes per case note). 
For every patient who received radiotherapy, radiotherapy centres (not necessarily 
based at the same hospital as diagnosis or primary treatment) kept their own 
medical records of radiotherapy treatment received. Thus all the appropriate 
radiotherapy centres (6 hospitals) had to be visited to obtain these patients' 
radiotherapy records. Similarly, for those patients who received chemotherapy at 
chemotherapy units, chemotherapy medical records were kept on site (9 sites). 
The hospitals where diagnosis, treatment and follow up of the patient 
sample were undertaken are a mix of teaching and non-teaching hospitals. Most of 
the care takes place at a small number of the large providers such as Louth County, 
St Georges, Nottingham City and University Hospitals, Doncaster Royal Infirmary, 
Leicester General Hospital, Leicester Royal Infirmary, Rotherham District 
General, Chesterfield & North Derbyshire Royal, Derby City and Derby Royal 
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Infirmary, Northern General Hospital and Weston Park Hospital. A number of 
these have since been designated specialist cancer hospitals; St Georges, 
Nottingham City and Weston Park Hospitals. 
4.8 Patient sample 
As the data collection for this thesis was undertaken alongside the data collection 
for an epidemiological study, the sample size was determined by results from 
previous work on survival variation for the epidemiological study. For the breast 
cancer patients, the original sample consisted of a random sample of 100 patients 
in each of the four districts displaying the highest and lowest survival rates in the 
region (North and South Derbyshire, North Lincolnshire and Rotherham) 
diagnosed during the period 1979-81. Similarly, a random sample of 50 breast 
cancer patients diagnosed in each of these four districts in 1991 were also taken. 
The former period was chosen to allow for an adequate follow up period, during 
which all resource generating events including side-effects, complications and 
recurrences would have occurred. The latter sample was chosen to determine 
whether practices in the care of patients had changed since 1979-81. 
The collection of the 1979-81 case notes proved to be difficult(18). The 
main problem was the inaccessibility of case notes. Data collection was therefore 
only carried out for the first two districts. Only an average of 37 per cent of case 
notes could be obtained for these two districts. For both districts, a large 
proportion of case notes had been destroyed. This is a direct result of the policy 
issued by the Department of Health that case notes can be destroyed after eight 
years after the last contact with a patient (circular HC (89)20). The case notes of 
patients who had died or were last seen within the last eight years were either held 
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in storage off-site or kept on-site at the hospital. In North Derbyshire, 28 per cent 
of the records were held in off-site storage, and the ability to access these involved 
a cost of £3.75 per patient record. There were five sets of case notes that could not 
be traced, even though four of these were apparently still alive according to Cancer 
Registry records. The collection of the 1979-81 data for the remaining two 
districts was not attempted due to the poor retrieval rates for the first two districts. 
The retrieval of 1991 case notes was easier. A much higher rate of retrieval was 
achieved. Table 4.5 displays the collection of the breast cancer data for the four 
districts over the two time periods. 
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Table 4.3 Hospital sites of primary therapy, surgery, radiotherapy and 
chemotherapy 
District Hospital Breast" Cervical Lung 
Diagnosis and referring 
hospital 
North Lincolnshire Lincoln County Hospital 0.8% 3.6% 
Louth County Hospital 1.7% 4.0% 
St Georges Hospital, Lincoln 0.6% 12.6% 
South Lincolnshire Pilgrim Hospital, Boston 2.5% 2.5% 
Grantham Hospital 2.2% 0.0% 
John Coupland, Gainsborough 0.3% 0.4% 
Skegness District Hospital 0.3% 0.7% 
South Humber Grimsby District Hospital 0.0% 0.4% 
Scunthorpe General Hospital 0.0% 0.4% 
Leicestershire Glenfield General Hospital 0.0% 0.4% 
Leicester Royal Infirmary 7.5% 0.0% 
Groby Rd Hospital, Leicester 0.0% 0.4% 
Leicester General Hospital 5.0% 0.0% 
Hinckley & District Hospital 0.3% 0.0% 
Nottingham Nottingham City Hospital 9.7% 12.6% 
University Hospital, Nottingham 9.4% 13.0% 
Newark General Hospital 0.3% 0.0% 
Park Hospital (private) 0.6% 0.0% 
Central Nottinghamshire Kings Mill Hospital 6.1% 0.4% 
Bassetlaw District General 3.3% 0.7% 
Hospital 
Doncaster Doncaster Royal Infirmary 12.2% 0.0% 
Montagu Hospital 0.0% 4.0% 
Rotherham Rotherham District General 5.5% 16.2% 
Hospital 
Barnsley Barnsley District General Hospital 6.9% 0.4% 
Sheffield Northern General Hospital, 5.5% 17.3% Sheffield 
Royal Hallamshire Hospital, 0.3% 8.7% 
Sheffield 
Weston Park Hospital, Sheffield 0.0% 0.4% 
Nether Edge Hospital, Sheffield 0.3% 1.1% 
Jessop Hospital for Women 4.4% 0.0% 
North Derbyshire Chesterfield & North Derbyshire 5.8% 0.0% 
Royal hospital 
South Derbyshire Derby County Hospital 8.6% 0.0% 
Heanor District Hospital 0.3% 0.0% 
Surgery 
North Lincolnshire Lincoln County Hospital 4.5% 1.3% 0.0% 
Louth County Hospital 8.4% 1.9% 0.0% 
St Georges Hospital, Lincoln 5.1% 0.6% 0.0% 
South Lincolnshire Pilgrim Hospital, Boston 0.0% 2.5% 0.0% 
South Humber Grimsby District Hospital 1.1% 0.0% 0.0% 
Leicestershire Glenfield General Hospital 0.0% 0.0% 3.3% 
Leicester Royal Infirmary 0.0% 4.4% 0.0% 
Leicester General Hospital 0.0% 7.5% 0.0% 
Nottingham Nottingham City Hospital 0.0% 13.1% 60.0% 
University Hospital, Nottingham 0.0% 9.4% 3.3% 
Park Hospital (private) 0.0% 0.6% 0.0% 
Central Nottinghamshire Kings Mill Hospital 0.0% 1.9% 0.0% Bassetlaw District General 0.0% 3.8% 0.0% 
Hospital 
Doncaster Doncaster Royal Infirmary 0.0% 11.3% 0.0% 
Rotherham Rotherham District General 26.4% 5.6% 0.0% 
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Hospital 
Barnsley Barnsley District General Hospital 0.0% 1.3% 0.0% 
Sheffield Northern General Hospital, 0.0% 21.3% 26.7% 
Sheffield 
Royal Hallamshire Hospital, 0.0% 0.0% 6.7% 
Sheffield 
Parkfield Hospital (private) 0.6% 0.0% 0.0% 
Jessop Hospital for Women 0.0% 6.3% 0.0% 
North Derbyshire Chesterfield & North Derbyshire 26.4% 2.5% 0.0% 
Royal hospital 
South Derbyshire Derby City Hospital 6.7% 5.0% 0.0% 
Derby Royal Infirmary 20.8% 0.0% 0.0% 
Radiotherapy 
St Georges Hospital, Lincoln 25.3% 8.5% 20.9% 
Leicester Royal Infirmary 0.0% 11.7% 0.8% 
Nottingham City Hospital 0.0% 3.1% 28.7% 
Nottingham General Hospital 0.0% 25.6% 0.0% 
Weston Park Hospital, Sheffield 45.8% 40.4% 49.6% 
Derby Royal Infirmary 28.9% 10.8% 0.0% 
Chemotherapy 
St Georges Hospital, Lincoln 38.5% 26.3% 5.9% 
Pilgrim Hospital, Boston 0.0% 0.0% 11.8% 
Nottingham City Hospital 0.0% 21.1% 5.9% 
Nottingham General Hospital 0.0% 10.5% 0.0% 
Rotherham District General 7.7% 0.0% 0.0% 
Hospital 
Weston Park Hospital, Sheffield 7.7% 31.6% 58.8% 
Northern General Hospital, 0.0% 0.0% 17.6% 
Sheffield 
Chesterfield & North Derbyshire 15.4% 0.0% 0.0% 
Royal hospital 
Derby Royal Infirmary 30.8% 10.5% 0.0% 
# Diagnosis and referring hospital is not applicable to breast cancer patients, as the only 
information given by Trent Cancer Registry was hospital of primary surgical treatment. This was 
amended for cervical and lung cancer as this was 
felt to be important information. 
Table 4 
.4 
Time spent abstracting information from medical notes 
Breast Cervical Lung 
Dates of data collection 27/2/95- 9/11/95- 2/11/96- 12/10/95 22/7/96 16/11/97 
Number of visits to 26 67 55 
medical records 
(average visit =6 hours) 
Average number of 7 6 5 
medical notes per visit 
177 
Table 4.5 Retrieval of case notes 
- 
Breast cancer 
North South North Rotherham 
Derbyshire Derbyshire Lincolnshire 
1979-91 
Total sample size 100 100 
- 
Case notes retrieved 39 35 
-- 
Case notes destroyed 29 63 
-- Case notes stored off 28 0-- 
site 
Untraced case notes 4 2-- 
1991 
Total sample size 50 50 50 50 
Case notes retrieved 48 49 49 49 
Untraced case notes 2111 
The patient sample for cervical cancer consisted of all the patients 
diagnosed in the Trent region in 1990, a total of 378 patients with invasive cervical 
cancer. Of this original sample, 42 patients had to be excluded on the grounds of 
missing notes, no information in the notes, incorrect diagnosis, duplication or 
being diagnosed outside the chosen year of diagnosis, 1990. Table 4.6 outlines the 
case note retrieval for the cervical cancer patients. 
For the lung cancer patients a 10% random sample of those diagnosed in 
the Trent region in 1993 was taken. This amounted to 290 lung cancer patients, 
252 being classified as non-small cell lung cancers (NSCLC) and 38 being 
classified as small cell lung cancers (SCLC) by Trent Cancer Registry. It was later 
found at the time of data abstraction that some of the patients had been 
misclassified by cell type. One patient was reported to be a non-small cell type, 
when in fact according to their medical notes the cell type was small cell. In 
addition, 9 patients were reported by the Registry as being small-cell lung cancer 
patients, but their medical notes stated that they were non-small cell cancer 
patients. This resulted in a sample with 260 non-small cell lung cancers and small- 
cell cancers. Four districts corresponding to the best and worst lung cancer 
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survival rates were chosen, North Lincolnshire, Nottinghamshire, Rotherham and 
Sheffield. Of this original sample 37 patients had to be excluded on the grounds of 
missing notes, no information in the notes, incorrect diagnosis or being diagnosed 
outside the chosen year of diagnosis, 1993. Table 4.7 displays the results of the 
medical note retrieval for the lung cancer sample. 
Table 4.6 Retrieval of case notes 
- 
Cervical cancer 
Excluded: 
District No of case Not Duplicate Recurrence No Not Not 
notes found information cancer diagnosed 
retrieved in 1990 
North 21 332 
Derbyshire 
South 31 212 
Derbyshire 
Leicester 47 4---41 
N Lincs 15 1_--_ 
S Lincs 15 1-1- 
Bassetlaw 12 
Central 23 
Notts 
Notts 71 2---I2 
Barnsley 24 
Doncaster 44 
----1- 
Rotherham 20 
---23- 
Sheffield 38 311 
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Table 4.7 Retrieval of case notes 
- 
Lung cancer 
North Nottinghamshire Rotherham Sheffield 
Lincolnshire 
SCLC 
Total sample size 535 17 
No diagnosis of lung 
---1 
cancer 
Missing notes 
---2 
Diagnosed outside 1993 
---1 
NSCLC 
--- 
Total sample size 66 71 60 63 
No diagnosis of lung 2-11 
cancer 
Missing notes 5172 
No information in notes 2 
Diagnosed outside 1993 4242 
4.9 Limitations 
- 
Generalisability of patient sample 
For cervical cancer, one can assume that this group of patients is representative of 
other areas in the UK due to the fact that the data for this group consist of all 
patients diagnosed with cervical cancer in Trent in 1990. For the breast and lung 
cancer patients, where a sample of those diagnosed was taken, it is probable that 
there are limits to the generalisability. For the breast cancer patients, once 
exclusions are made for misdiagnosis, patients diagnosed outside 1991 and failure 
to stage the cancer, there are a total of 137 patients on which to base the cost 
analysis. This is more worrying when costs are analysed by stage because only 6 
patients are diagnosed at stage IV disease. Clearly one may question whether the 
costs estimated from these patients are truly representative of the population of 
stage IV breast cancers. Similarly, with the 10% lung cancer sample, the Cancer 
Registry provided the data on registrations for small-cell and non-small cell lung 
cancer in 1993. However, as described in section 4.8, the Cancer Registry had 
misclassified the cell types for a proportion of the sample. Incidence of small cell 
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lung cancer is expected to be 20-25% of all lung cancers(21,22), whereas in the 
sample provided by Trent Cancer Registry the proportion of SCLC amounted to 
10%. This represents an underestimate of the expected proportion of SCL cancers 
in a typical population. 
It should be recalled that the cost data reported in this thesis relates to the 
resource-use incurred by the hospital. No information was collected on the costs 
incurred in the community, for example costs of care while at home, visits to and 
from the general practitioner or community/oncology nurse or costs of community 
based palliative or hospice care (only inpatient hospital based palliative care has 
been included in this analysis). However, with cancer care, it is the secondary care 
costs that dominate, GP care of cancer patients is minimal: 
"... the GP's involvement with cancer diagnosis and treatment is frequently 
limited" Royal College of General Practitioners (1986: 25). 
Even follow up care is organised through the hospitals(24,25). In 
addition, there is an argument against including the costs of community hospice 
care, the resources used are not condition specific and therefore there is enormous 
variation between patients. This variability arises due to the nature of care 
received at hospices; some patients will simply require respite care, while others 
will be in need of long-term care. Although no information was collected on the 
cost to the patient and their family in terms of time and travel costs as a direct 
result of receiving hospital based care, estimates of these types of costs from 
previous studies have been included in the analysis. This is described in more 
detail in each of the costing chapters (Chapters 5,6 & 7). 
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4.10 Questionnaire (abstract form) design 
Data were collected from the hospital case notes using a data abstract form. This 
was designed for all three cancer sites using reviews of the literature on the 
epidemiology of the cancer and its diagnostic, treatment and follow up procedures. 
Advice from a consultant breast cancer surgeon, a consultant radiotherapist, a 
consultant oncologist, a consultant thoracic surgeon and a consultant gynaecologist 
was also extremely useful. It permitted details of diagnostic procedures, treatment, 
stage of disease, and other prognostic factors, follow up and outcome to be 
recorded for each patient. Each of the questionnaires was piloted on a total of 30 
case notes per cancer site, which allowed for improvements to be made before 
commencing the actual data abstraction. The abstract forms used can be found in 
Appendices 5.1,6.1, and 7.1 in the relevant chapters on breast, cervical and lung 
cancer. 
4.11 Valuing the resources 
This thesis makes use of two main sources for the unit cost data: published unit 
costs used in other UK based studies and cost data from the hospital finance 
departments. An example of the unit cost data collected from the finance 
departments for cervical cancer is displayed in Appendix 4.3. This was performed 
for all three cancers. A letter was sent to each of the finance directors of the 
hospitals where diagnosis or treatment for patients in the sample had taken place. 
This letter explained the nature of the research and the unit cost data required (see 
Appendix 4.4). The letter was followed up a week later by a telephone call to 
confirm that the letter had been received and the information requirements 
understood. Eight of the twenty finance departments contacted asked to arrange a 
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meeting so that I could explain my unit cost data requirements in more detail. 
Since 1993, all NHS providers have been required to follow a uniform accounting 
protocol, requiring that their services be costed at full cost, i. e. all service-specific 
variable costs, with the inclusion of the relevant components of fixed and overhead 
cost(26). The unit cost data collected from the hospital finance departments were 
pooled to provide average unit cost data across the region. Although, disagreement 
exists about the extent to which both centre-specific resource-use and centre- 
specific unit cost data need to be collected from all centres in a multi-centre study, 
many commentators have argued that calculation of centre-specific unit costs may 
not be necessary if detailed resource-use data have been collected, and may in fact 
conceal differences in resources utilized(27-29). 
All costs were reported in the year in which diagnosis occurred, 1991 for 
breast cancer costs, 1990 for cervical cancer costs and 1993 for lung cancer costs. 
The Hospital and Community Health Services Pay and Price Index was used to 
inflate or deflate the cost data according to the year required(30). All costs 
incurred beyond the initial year of diagnosis were discounted at a rate of 6 per cent 
in line with current recommendations(3 1). 
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4.12 Data entry and analysis 
The data from the medical notes were entered into a database using Dbase IV 
software, this can be exported directly into Excel, which was accordingly used for 
data manipulation and attaching unit costs to the resource-use data. All statistical 
analyses were carried out using SPSS for Windows versions 6,8 and 9. The 
resource use and cost data are reported separately. The resource use data are 
presented by way of the number and percentage of investigations undertaken by 
stage and year incurred. The cost data are reported as total cost and mean cost by 
stage at diagnosis for the three cancer sites. Standard deviations and 95% 
confidence intervals are used to represent the variance of the data. The differences 
between the stage-specific costs are explored using a one-way analysis of variance 
(ANOVA). Although resource use data for the breast and cervical cancer sample 
are collected for up to a maximum of 60 months and 77 months (respectively) 
following diagnosis, the analysis is restricted to 4- and 5-year cost estimates. 
These time frames were chosen to reflect clinical advice on the period from 
diagnosis in which the majority of recurrences would be likely to occur. However, 
for a proportion of the breast and cervical cancer patient samples the resource-use 
data for the complete period of analysis were missing. This was handled using the 
method used by Rutten van Molken et al. (1994), where resources utilized in the 
previous months are carried forward and used for those individuals where data are 
missing, the patient year approach '(32). This was not an issue for the lung 
cancer sample as all patients have complete cost histories, either from diagnosis to 
death or to the 48th month of follow up. 
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4.13 Conclusions 
This chapter has provided the background information necessary for the 
understanding of the following three chapters on breast, cervical and lung cancer 
costs. Descriptions of the disease cancer, including stage of the disease and 
treatment options have been discussed, backed up by information on nationally 
reported statistics on cancer incidence, mortality and cost. The chapter also 
provides a detailed account of the processes involved in obtaining the data 
necessary for the research purpose of this thesis, and reports the advantages and 
disadvantages related to this process. 
The following three chapters report the hospital-based resource use and 
cost data related to diagnosis, treatment and follow up of breast, cervical and lung 
cancer in Trent region. 
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Appendix 4.1 
The TNM system 
The TNM system for describing the anatomical extent of disease is based on the 
assessment of three components: 
T- The extent of the primary tumour 
N- The absence or presence and extent of regional lymph node metastasis 
M- The absence or presence of distant metastasis 
The addition of numbers to these three components indicates the extent of the 
malignant disease; TO, Ti, T2, T3, T4 
NO, Ni, N2 
MO, Ml 
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Breast 
- 
Clinical TNM staging 
T- PRIMARY TUMOUR 
TO No evidence of primary tumour 
Ti Tumour 5 2cm in greatest dimension 
T2 Tumour > 2cm but :5 5cm in greatest dimension 
T3 Tumour > 5cm in greatest dimension 
T4 Tumour of any size with direct extension to chest wall or skin 
N- REGIONAL LYMPH NODES (same side) 
NO No regional lymph node metastasis 
NI Metastasis to palpable and mobile axillary nodes 
N2 Metastasis to palpable and fixed axillary nodes 
N3 Metastasis to internal mammary lymph nodes (oedema of the arm) 
M- OTHER METASTASES 
MO None found 
MI Present 
Stage Grouping 
Stage I 
Ti, NO, MO 
T2, NO, MO 
Stage II 
Ti, Ni, MO 
T2, Ni, MO 
Stage III 
Any T, N2, MO 
Any T, N3, MO 
T3, NO, MO 
T3, Ni, MO 
T4, NO, MO 
T4, Ni, MO 
Stage IV 
Any T, any N, M1 
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Cervical 
- 
Clinical TNM staging 
T- PRIMARY TUMOUR 
TO No evidence of primary tumour 
Ti Cervical carcinoma confined to the uterus 
Tla Preclinical invasive carcinoma, diagnosed by microscopy only 
Tib Tumour with invasive component >5mm in depth taken from the base of 
the epithelium and >7mm in horizontal spread 
T2 Cervical carcinoma invades beyond the uterus but not to the pelvic wall or 
to the lower third of vagina 
T2a Without parametrial invasion 
T2b With parametrial invasion 
T3 Cervical carcinoma extends to the pelvic wall and/or involves the lower 
third of the vagina and/or causes hydronephrosis or nonfunctioning of the 
kidney 
T3a Tumour involves the lower third of the vagina, no extension to the pelvic 
wall 
T3b Tumour extends to the pelvic wall and/or causes hydronephrosis or 
nonfunctioning of the kidney 
T4 Tumour invades mucosa of bladder or rectum and/or extends beyond true 
pelvis 
N- REGIONAL LYMPH NODES (paracervical, parametrial, obturator, 
internal and external iliac, presacral and sacral) 
NO No regional lymph node metastasis 
NI Metastasis to regional lymph nodes 
M- OTHER METASTASES 
MO None found 
Ml Distant metastasis 
Stage Grouping 
Stage IA 
Tla, NO, MO 
Stage IB 
Tlb, NO, MO 
Stage IIA 
T2a, NO, MO 
Stage IIB 
T2b, NO, MO 
Stage IIIA 
T3a, NO, MO 
Stage IIIB 
Ti, Ni, MO 
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T2, N 1, MO 
T3a, Ni, MO 
T3b, Ni, MO 
Stage NA 
T4, any N, MO 
Stage NB 
Any T, any N, M1 
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Lung 
Lung cancer is split into two main types of disease according to the cell type: 
Non-small cell lung cancer (NSCLC) 
Small-cell lung cancer (SCLC) 
NSCLC can be staged using TNM staging (outlined below) 
SCLC can be divided into limited disease and extensive disease. 
For the purpose of this thesis, lung cancer is divided simply into SCLC and 
NSCLC, due to the fact that no information was reported in the patient medical 
notes on stage of the cancer. 
Clinical TNM staging 
T- PRIMARY TUMOUR 
TO No evidence of primary tumour 
Ti Tumour :5 3cm (not in main bronchus) 
T2 Tumour > 3cm, involving main bronchus, 2cm or more from the carina or 
invading pleura or with atelectasis 
T3 Tumour of any size with direct extension to chest wall, diaphragm, 
mediastinal pleura or tumour in main bronchus < 2cm from carina 
T4 Tumour of any size invading mediastinum, heart, bones, canna or tumour 
with malignant pleural effusion 
N- REGIONAL LYMPH NODES 
NO No regional lymph node metastasis 
Ni Metastasis to ipsilateral peribronchial and/or hilar lymph nodes 
N2 Metastasis to ipsilateral mediastinal and/or subcarinai lymph nodes 
N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or 
contralateral scalen or supraclavicular lymph nodes 
M- OTHER METASTASES 
MO None found 
M1 Distant metastasis beyond supraclavicular lymph nodes 
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Stage Grouping 
Stage I 
Ti, NO, MO 
T2, NO, MO 
Stage II 
Ti, Ni, MO 
T2, Ni, MO 
Stage lila 
Ti, N2, MO 
T2, N2, MO 
T3, NO, MO 
T3, Ni, MO 
T3, N2, MO 
Stage IIIb 
Any T, N3, MO 
T4, any N, MO 
Stage IV 
Any T, any N, M1 
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Appendix 4.2 
uired and desired patient information for Trent Cancer Re 
Required minimum database Desired extra information 
Already collected 
- 
District Health Authority 
Hospital 
Consultant 
Patient Unit Number 
Radiotherapy Treatment Number 
NHS Number 
Forenames 
Surname 
Address at time of diagnosis 
Post Code 
Sex 
Marital status 
Date of birth 
Date of diagnosis 
Date of death 
Clinical Information 
- 
Clinical Information 
- Cancer type Grade 
Stage at diagnosis 
Screen detected 
Metastases 
Recurrence 
Resource use 
- 
For each inpatient, outpatient and day case episode 
- Number and length of inpatient stay Dates in which incurred 
Number of outpatient visits Medication 
Number of day visits Consultations 
Diagnostic procedures 
Investigative procedures 
Treatment 
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Appendix 4.3 
Letter to the finance offices to obtain cost information for cervical cancer 
5 December 1996 
Name 
Director of Finance, 
Finance Department, 
Hospital NHS Trust address, 
Dear Name, 
I am currently working on a research project estimating the costs of selected cancers 
in the Trent region. This research, funded by Trent Health Authority, involves 
identifying the diagnostic, treatment and follow up procedures typically used in the 
management of selected cancers by way of a retrospective audit of a sample of 
medical notes. Unit cost data is subsequently combined with this resource-use 
information to ascertain a total procedural cost for that particular cancer type. 
I am writing to you to ask for some help and advice on the unit costs of treatments 
and procedures for cervical cancer. 
Enclosed are details of the treatments and procedures that I require cost information 
on: 
The first set of information gives a description of the treatments and procedures of 
interest to me. 
The second set outlines the information I require. 
On the final group of pages I have constructed a table of the treatments and 
procedures where you can put the corresponding cost information. 
For your convenience you will find a pre-paid envelope addressed to me at the Trent 
Institute for Health Services Research. 
I hope this does not cause too much inconvenience. If you have any questions about 
what I have asked for, please do not hesitate to contact me on the above telephone 
number. 
I thank you in advance for your assistance. 
Yours Sincerely, 
Jane Wolstenholme. (Research Assistant) 
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Description of Treatment and Procedures for Cervical Cancer. 
Diagnostic and Staging Techniques: 
Cytological smear 
Colposcopy 
" Examination of the cervix by means of an endoscope. 
Punch biopsy 
" 
Removal of a small cylindrical specimen for biopsy by means of a special 
instrument that pierces the organ. An outpatient procedure. 
Cone biopsy (conization) 
" Removal of a cone-shaped part of the cervix by knife or cautery. An inpatient 
procedure. 
Loop excision (loop diathermy) 
" 
Passage of a high frequency electrical current through the tissue so heat is 
produced. This is used to cut through the malignancy. An outpatient 
procedure. 
Dilation and curettage 
Examination under anaesthesia 
" 
Use of speculum for rectovaginal and pelvic examination. 
Cystoscopy 
" 
Use of cystoscope (type of endoscope) to view the internal surface of urinary 
bladder. 
Chest X-ray 
Intravenous pyelogram / urography 
" 
Radiographic visualization of the renal pelvis and ureter by injection of a 
radioopaque liquid. 
Proctoscopy 
" 
Use of proctoscope (type of endoscope) to examine the rectum. 
Sigmoidoscopy 
" 
Use of sigmoidoscope to visualize he rectum and sigmoid flexure of the colon. 
Ultrasound 
CT scan 
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" 
Computed tomography scanning. 
Abdominal x-ray 
Kidney x-ray 
Pelvic x-ray 
Bone scan 
Sureerv: 
Total conservative abdominal hysterectomy (no pelvic node dissection). 
Radical/ Wertheims hysterectomy (pelvic lymphadanectomy) 
Colostomy 
Radiotherapy 
Intracavity radiotherapy 
External beam radiation 
Chemotherapy: 
Bleomycin, ifosfamide & cisplatinum (BIP) 
Doxorubicin & methotrexate 
Cisplatinum & bleomycin 
Carboplatin 
Oophorectomy 
" 
Either excision of an ovary, or ovarian ablation by a dose of radiotherapy. 
Hormone replacement therapy 
Palliative care 
" Inpatient care on ward, pain relief. 
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Follow ua and Surveillance: 
Outpatient visit 
Radiotherapy clinic visit 
Clinical examination 
Cytological smear 
Bimanual palpation 
Chest x-ray 
Spine x-ray 
Head x-ray 
Abdominal x-ray 
Ultrasound 
CT scan 
Liver scan 
Bone scan 
MRI scan 
Intravenous pyelogram (urography) 
Cystoscopy 
Sigmoidoscopy 
Colposcopy 
Histooathology laboratory: 
Cost of preparing and screening slide of cervical smear. 
Biochemistry 
ßaematoloev 
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Appendix 4.4 Unit costs for cervical cancer procdures from finance departments 
npstic and Si T*chn! gLm OP Prkas DC Pride IP PrIces 
mean min Max median mean min max median mean min max median 
OA*Wml smear 5.60 4.79 6.29 5.63 
46.35 25.56 60.35 44.99 
48.25 39.63 60.35 46.51 173.95 97.98 326.60 163.30 239.98 206.90 308.14 206.90 
40.00 16.33 80.35 43.31 198.06 152.65 273.34 176.44 257.02 206.90 308.14 257.02 
oonizaypn 23.53 10.95 43.31 16.33 238.73 152.65 432.39 209.45 269.45 233.24 306.66 269.45 
axebipn diatherm 43.31 43.31 43.31 43.31 239.75 152.65 432.39 175.37 255.78 205.90 305.66 255.78 M 
go qu 199.27 130.64 298.20 176.37 221.47 176.79 306.30 182.33 
39.13 16.33 61.93 39.13 178.78 124.25 289.40 152.65 194.97 157.05 232.88 194.97 
9.23 5.96 13.49 9.16 
kftvsnou@ pym4gTm /u rah 81.15 31.24 122.12 81.17 122.12 122.12 122.12 122.12 
, 43.31 43.31 43.31 43.31 170.08 134.90 251.50 146.97 186.73 186.73 186.73 186.73 
29.82 16.33 43.31 29.82 177.02 96.56 251.50 162.66 280.77 186.73 358.42 249.96 
LWInound 21.10 12.87 32.05 19.17 
63.50 35.50 106.50 65.68 
AbdomMW X 10.26 5.96 17.88 9.16 
X4 27.36 6.39 73.26 19.53 
X 10.63 6.39 14.24 10.37 52.66 13.46 115.03 48.28 
Po1tl 
cpnervalhve abdominal 
188.85 142.71 264.77 192.27 
no poMC reds dissedi0n 
pk1oW h 195.25 142.71 278.44 195.32 
nacWM) w 
196.26 108.54 316.43 173.95 
pr. 
kýaca m 
beam ºadistlon 
xobamlda a 
m RIP 
a msu+oasxats 
222.49 169.90 365.00 201.70 
HonlgM t Theta 
163.30 163.30 163.30 163.30 206.90 205.90 206.90 206.90 
pý0yy and Kwvo anc' 37.27 19.88 49.70 38.2 
AM 37.63 30.63 49.70 36.15 
27.84 18.33 36.92 27.44 
pnpý 6.80 4.79 8.29 5.63 9.23 6.96 13.49 9.15 
10.26 5.98 17.86 9.15 
x, A 27.36 6.39 
7328 19.63 
10.63 6.39 14.24 10.37 
tX 15.70 7.10 25.58 14.89 
52.56 13.46 115.03 48.28 
02 38 13.26 109.76 26.86 
. 63.60 35.50 106.50 65.88 
123.72 85.20 187.76 117.15 
21.10 12.87 32.05 1117 
h 61.15 31.24 122.12 81.17 
39.13 18.33 81.93 39.13 178.78 124.25 269.40 152.66 194.97 157.05 232.88 194.97 
29.82 16.33 43.31 29-82 177.02 96.56 251.60 162.86 260.77 166.73 356.42 249.96 
48.25 39.63 60.35 46.51 173.96 97.98 326.60 163.30 239.98 205.90 308.14 205.90 
13.66 7.81 26.56 9.89 
8.87 4.97 20.72 5.57 
4.73 1.24 8.30 4.47 
4.97 2.49 6.41 5.04 
5.99 3.55 8.68 5.91 
ran 
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Chapter 5 
Breast Cancer 
5.1 Introduction 
Female breast cancer is a disease of national importance and is a major contributor to 
the overall level of the economic burden of cancer. It is the most common cancer in 
women, representing 27% of all female UK cancers. It is also the leading cause of 
cancer death in UK women(I ). The incidence of breast cancer increased throughout 
the 1980's peaking in 1992. As a result an estimated I in 11 women will develop it in 
their lifetime(2). 
breast cancer represents: 
" 
31,843 new registrations in England and Wales in 1992(3). 
" 
2,530 new registrations in the Trent region in 1997. 
" 
Upward trends in incidence have been noted in England and Wales over the pas 
decade (see Figure 5.1), although this is thought to have peaked in 1992. Sinc 
1988 this increase mainly occurred in women aged 50-64 and is associated wit 
the national screening programme. 
" 
11,980 deaths from breast cancer in England and Wales in 1997; 18% of al 
female deaths from cancer(4). 
" 
1,155 deaths from breast cancer in Trent. 
" 
internationally, with respect to breast cancer mortality, England and Wales ar 
ranked fourth worst (lying behind Belgium, Scotland and Ireland) wit 
approximately 50 deaths per 100,000 female population (aged 35-64 years 
compared with Japan which has a death rate of 15 per 100,000 femal 
population(s). 
The 5-year relative survival rate for breast cancer in England and Wales is 64%, 
and for early stage breast cancer this rises to 85%, while for those with 
metastatic disease the 5-year survival rate is 21 % These rates again compares 
poorly with other European countries(6). 
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Figure 5.1 Female breast cancer registrations 1974-1994 Trent (rate per 1000 
female population) 
Rate per 1000 
female population 
1.4 
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0.8 
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0 
1974 1976 1978 1980 1982 1984 1986 1988 1990 1992 1994 
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Breast cancer strikes in the prime of life. In Trent, forty-five per cent of those 
diagnosed with breast cancer in 1994 were aged between 20 and 60 years of age (see 
Figure 5.2). Very few cases of breast cancer occur in women in their teens or early 
twenties, but by the age of 35-39 years over 1,000 women are diagnosed with breast 
cancer annually in England and Wales. The rate increases with age until it peaks with 
over 4,000 women aged 60-64 being diagnosed each year(3). In fact age is the most 
important risk factor for breast cancer. Apart from screening (secondary prevention), 
there is no known (primary) preventive action, as the known (hormonal) causes are not 
amenable to modification. Breast cancer has an unpredictable course, and although 
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the 5-year survival rates compared with the survival rates for other cancers are good5.1, 
the risk of recurrence and metastases remains for twenty years or more after the initial 
diagnosis(7,8). The majority of recurrences however do occur within the first 5 years 
after initial treatment(9). 
Since breast cancer represents such a major health problem for the UK, it is 
important and useful to determine the resource impact and costs of the components of 
breast cancer care. To enable this, a comprehensive understanding of the diagnostic 
work up, therapeutic options, management of recurrent or metastatic disease and of 
terminal care is required. This chapter explores the resource use and costs involved in 
breast cancer care for a sample of patients diagnosed with breast cancer in Trent 1991. 
It goes on to investigate how these costs can be used to assess the impact of treatment 
or prevention policies/interventions for breast cancer. 
5.2 Methods 
The assessment of the resource use and cost implications of breast cancer care requires 
data on all cost-generating events in the diagnosis, treatment and follow up of breast 
cancer patients. The first step was to undertake a literature search of diagnosis and 
treatments for breast cancer. This information was used to construct stage specific 
treatment algorithms (Appendix 5.1). The literature based treatment algorithms were 
useful in the development of an abstract form to be used for obtaining information on 
breast cancer resource use from the medical notes. 
5.1 Approximately 64% of women diagnosed with breast cancer in 1983-85 were alive five years later 
(6). 
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Figure 5.2 
Number of 
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5.2.1 Treatments for breast cancer 
- 
Literature 
Diagnosis: Given the suspicion of breast cancer, a confirmatory clinical diagnosis may 
be reached in a variety of ways. These include physical examination, mammography, 
fine needle aspiration, ultrasound, or any combination of these methods(] 0). In some 
circumstances the diagnostic techniques may not yield appropriate samples and 
therefore requires some form of excisional/tru-cut biopsy. The staging of the disease 
on diagnosis thereafter dictates treatment modality. 
Treatment 
- 
stages I& II: For stages I and 11, where the preponderance of cases are 
deemed potentially curable, surgery is typically employed. Such surgery might be 
radical (mastectomy) or conservative (lumpectomy or wide-local excision). 
Registrations 
per 1000 female 
population 
3 
2.5 
2 
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Thereafter, regimens of adjuvant therapy in the form of endocrine therapy, 
radiotherapy or chemotherapy generally follow, either singly or in combination. Many 
patients who present with early stage breast cancer in fact have micro-metastatic 
disease. It is the aim of adjuvant systemic therapy to eradicate this. A meta-analysis 
of 133 randomized control trials(11) has informed the basis for the management of 
patients with adjuvant therapy. In the pre-menopausal age group a statistically 
significant survival benefit was demonstrated for those treated with combination 
chemotherapy. It was clear that combination chemotherapy was more effective than 
single agents, and although there is no standard chemotherapy regimen, CMF 
(cyclophosphamide, methotrexate, fluorouracil) is the most widely used. Similar 
effects on mortality and recurrence were found in pre-menopausal women who had 
undergone ovarian ablation or oophorectomy. In postmenopausal women, tamoxifen 
was found to be beneficial, with a highly significant reduction in the annual 
probability of death and recurrence. Moreover, it generates fewer side-effects 
compared with chemotherapy. A proportion of patients will require further surgery for 
local or regional recurrence(12,13). 
Treatment 
- 
stage III: In comparison with cancers at stages I and II, a higher 
proportion of those at stage III (locally advanced) prove inoperable, requiring greater 
reliance upon the non-surgical therapies. The mainstay of treatment for inoperable 
tumours has been radiotherapy and/or tamoxifen for postmenopausal women and 
combination chemotherapy or ovarian ablation/oophorectomy for premenopusal 
women(14,15) 
. 
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Treatment 
- 
stage IV: For stage IV patients (metastatic cancer), the principal aim of 
treatment is palliation of symptoms rather than cure. Treatment consists of 
chemotherapy and tamoxifen, with single fractions of radiotherapy given for pain 
relief from bone metastases(13). 
Follow u: Patients with cancers at any stage risk recurrence, requiring the further 
employment of any or all of the modalities noted above. Due to the recurrence risk, 
all patients are the subjects of outpatient follow-up, entailing physical examinations, 
X-rays, scans, and so forth. Terminal cases from all stages may require palliative 
care(16,17). 
5.2.2 Estimation of treatment costs 
The ideal method for costing any disease process is to have resource use and cost 
information on a patient specific basis. Given that the epidemiology of cancer in the 
UK has long been documented by the Cancer Registries on such a patient specific 
basis, it might be thought that a population-based resource use audit could be easily 
accomplished using pre-collected data. However, the Registry databases do not 
usually include details of either resource use or cancer stage at diagnosis. The 
treatment cost analysis was accordingly based on a detailed examination of the case 
notes of 137 breast cancer patients treated in the Trent region (central England). This 
was facilitated by the use of an abstract form developed with the aid of information 
obtained from the initial literature review on treatment (see Appendix 5.2). It was 
verified by a breast cancer consultant surgeon based at the City hospital, Nottingham, 
and piloted on 30 medical notes of breast cancer patients treated at the same hospital. 
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The 137 breast cancer patients used for the cost analysis were taken from an 
initial sample of 200 drawn at random from 4 districts covered by the Trent Cancer 
Registry. Of this original sample, 36 patients had to be excluded on the grounds of 
missing notes, incorrect diagnosis or being diagnosed outside the chosen year of 1991 
(Table 5.1). Of the 164 patients who met with the inclusion criteria, for 27 (16%) 
there was insufficient information to enable the staging of their cancers (Table 5.2). 
The patient numbers were 102,13,16 and 6 for stages I through IV, respectively. 
Table 5.1 Breast cancer sample: retrieval of medical notes and 
exclusion of patients (by district of primary treatment) 
District I District 2 District 4 District 11 
N Derbysh ire S Derbyshire N Lincolnshire Rotherham 
Number of case notes 48 49 49 49 
retrieved 
Number not found 2 11 1 
Excluded: 
Not able to stage 7 11 6 3 
No information on 4 31 3 
breast cancer 
Not diagnosed in 1991 1 3 11 3 
Table 5.2 Total sample size used for cost estimation (by district of primary 
treatment) 
All District I 
N Derbyshire 
District 2 
S Derbyshire 
District 4 
N Lincolnshire 
District II 
Rotherham 
Total sample 164 33 32 31 41 
Stage I 102 25 21 21 35 
Stage lI 13 4 4 3 2 
Stage III 16 4 2 6 4 
Stage IV 6 
- 
5 1 
- 
All the patients in the sample had been diagnosed with breast cancer in 1991. This 
particular year was selected on the grounds that it permitted the construction of a 
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resource audit for each patient over a minimum of 46 months and a maximum of 60 
months follow up from diagnosis, a period following diagnosis during which the 
majority of cancer recurrences would be likely to occur(9). The sample demographic 
and resource use data were entered into SPSS for Windows version 6 on a patient 
specific and anonymous basis. From the individual patient records, stage-specific 
algorithms of diagnostic and therapeutic events entailing costs were developed. 
The unit costs of each event during diagnosis, treatment and follow-up were 
obtained from two sources. First, for events which had previously been the subject of 
detailed costing by other investigators (18-25), published estimates were employed, 
converted to 1991 prices using the National Health Service (NHS) pay and prices 
index. Second, for events where such data were unavailable, I requested the 
appropriate cost information from the finance departments of the eight service 
providers in the region and used the mean values obtained, again converted to 1991 
prices (see Table 5.3). All costs were discounted at 6 per cent. 
By combining the unit cost estimates with the resource use information, the 
mean costs of diagnosis, treatment and follow-up by stage at diagnosis for the sample 
over the follow up period were obtained. For comparative purposes costs were also 
split into three distinct disease phases; initial care, continuing care and terminal care 
costs. Initial treatment costs included all the costs initiated within the first 3 months 
from diagnosis and also calculated again using a longer phase of the first 6 months of 
treatment. Terminal care costs were calculated using the last 3 months of costs for 
patients who had died during the follow up period. These were also calculated again 
using a longer phase of the last 6 months of treatment and care. Continuing care costs 
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were obtained by calculating the average monthly cost incurred after the initial 3 
months following diagnosis, and in cases where death occurred, prior to the final 3 
months of care used for estimating the terminal care costs. Again, continuing care 
costs were also calculated taking account of the 6-month initial costs and 6-month 
terminal costs. The three month and six month periods were chosen in order to make 
comparisons with other studies using these time horizons(26,27). 
It is important to appreciate that, for some patients, cost over the follow up 
period used for this analysis will necessarily represent an under-estimate of total 
treatments costs arising from the condition. For those surviving, certain therapies 
(essentially those which are non-surgical) are likely to continue into the fifth/sixth 
years and beyond, and all patients will be the subjects of follow-up, usually until 
death. Based upon the sample data, the effects of this additional resource use can be 
assessed by extrapolating costs for the remaining years of life expected by patients at 
each disease stage. 
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Table 5.3 Unit Costs 
Origin Year of Investigation/Treatment unit cost in 1991 prices 5,2 
cost 
calculation 
Finance departments 1994/95 mammography £22.06 
fine needle aspiration £43.57 
tru-cut biopsy £ 19.46 
frozen section biopsy £ 19.47 
mastectomy £267.97 per inpatient day 
conservative surgery £296.02 per inpatient day 
inpatient stay £216.58 per bed day 
out-patient visit £74.07 
oophorectomy/ovarian £229.39 
ablation 
Robertson J. F. R. 1994 biochemistry £6.10 
Whynes DK. et haematology £3.09 
al. (25) ultrasound £ 12.74 
chest x-ray £ 10.10 
bone scan £72.07 
CT scan £63.25 
chemotherapy 
CMF £18.13 per month 
MMM £236.47 per month 
epirubicin £292.46 per month 
anti-emetics £27.66 per month 
endocrine therapy: 
tamoxifen (86%) £ 1.34 per month 
megace (14%) £27.57 per month 
Gravelle H. et al. (21) 1980 brain scan £ 16.68 
liver scan £22.29 
marker biopsy £45.52 
Goddard M. Maher E. 1988 palliative radiotherapy £46.99 per fraction 
et al. (20) 
Hill F. & Oliver C. 1984 palliative care £107.85 per inpatient day 
(23) 
5.2 Converted to 1991 prices using the HCIIS pay and price index. 
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Radiotherapy costs from finance departments 
Radiotherapy Type Cost per episode 
(£) 
Low energy: 
1-4 fractions £ 249.92 
5-10 fractions £ 624.80 
Simple: 
1-4 fractions £ 702.90 
5-10 fractions £2,093.08 
11-15 fractions £3,764.42 
16-25 fractions £5,716.92 
Simple with simulation: 
1-4 fractions £ 702.90 
5-10 fractions £2,108.70 
11-15 fractions £3,803.47 
16-25 fractions £5,763.78 
Complex with simulation: 
16-25 fractions £4,169.88 
25+ fractions £7,169.58 
Complex with technical 
support: 
16-25 fractions £5,873.12 
25+ fractions £7,357.02 
Brachytherapy £ 1,187.12 
5.2.3 Survival estimates 
Of the sample, 68 per cent were still alive at the time of data recording, with the result 
that an accurate assessment of the sample's life expectancies by stage following 
treatment will only be possible many years hence. However, in order to obtain life- 
year estimates for modelling purposes, two methods were used. The first method was 
to fit a trend though the survival data of the sample, to obtain mean life expectancy 
following treatment. Experimentation with functional forms revealed that the 
goodness-of-fit of complex formulations was not demonstrably superior to simple 
linear trends, and the latter were accordingly employed (see Appendix 5.3). For stages 
I and II, the survival estimates were 10.79 and 6.07 years, respectively. Owing to a 
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small sample size, I estimated life expectancy for those with cancers at stage III and 
IV on a pooled basis, resulting in an estimate of 2.53 years. 
The second method used the declining exponential approximation of life 
expectancy (DEALE) method(28,29). Using age and sex adjusted life expectancy 
figures(30) and the sample 5-year survival figures resulted in survival estimates of 
10.66 years for stage I cancers, 7.49 years for stage 2 cancers and 2.03 for those with 
cancers at stages III and IV (see Appendix 5.3). This method was replicated using 5- 
year survival rates reported by the CRC in place of the sample survival rates(3 1). The 
resulting survival estimates were 12.65 years for stage I cancers, 9.59 years for stage II 
cancers and 5.15 years for stage III cancers and 2.45 years for those with cancers at 
stage IV. 
Comparison of these results with national estimates of post-diagnosis survival 
by stage is problematic. National estimates are deemed unreliable owing to known 
variations in stage classification by trial centre(32). However, this estimate for early 
stage and later-stage cancers corresponds closely to that observed in other studies(27, 
33). 
Given that mean life expectancies for stage III and IV patients are less than the 
minimum time horizon for the data collection period (48 months), it was assumed that 
no additional costs would be incurred by such patients. However, patients with stage I 
and stage II cancers would expect to survive, and receive additional treatments, for a 
further 6.66 and 3.49 years on average, respectively (using the most conservative 
survival estimates from the DEALE method using 5-year survival data from the 
sample). For modelling purposes, using the method proposed by Rutten van Molken 
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and colleagues(34), I assumed that, for each remaining year of life, each stage I and 
stage II patient would consume the same quantity of therapeutic resources as she 
consumed, on average, in the previous 12 months. Resource use arising from 
diagnosis, primary surgery and radical radiotherapy was excluded from this imputed 
additional cost, on the grounds that these procedures are largely confined to the first 
two years following diagnosis. Costs of such resource use were discounted at the 
same rate as for the four-year calculation. 
5,3 Results 
5.3.1 Sample characteristics 
The sample characteristics by stage at diagnosis are displayed in Table 5.4. 
Approximately three-quarters of the sample present with stage I disease, while less 
than 5 per cent present with stage IV disease. The mean age at diagnosis for the 
sample of patients diagnosed with breast cancer in 1991 was 62 years. A one-way 
analysis of variance indicates that mean age at diagnosis does not differ significantly 
between stage of disease (F = 0.8301, P=0.4797). Sixty-seven per cent of the sample 
were still alive at the time of data collection from the medical notes, this corresponds 
with nationally reported 4- and 5-year survival rates(6). It can be seen from Figure 5.3 
that the sample used for the cost estimation is generally representative of the Trent 
population of breast cancer patients in terms of age at diagnosis. 
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Table 5.4 Sample Characteristics 
Stage No. (%) Mean age at 
diagnosis (sd) 
No. deceased at 
abstraction (%) 
No. alive at 
abstraction (%) 
102(74%) 61 (13.07) 21 (21%) 8](79%) 
II 13 (10%) 63 (12.47) 5 (38%) 8 (62%) 
111 16(12%) 63 (11.34) 14(88%) 2(13%) 
IV 6(4%) 69 (15.07) 5 (83%) 1 (17%) 
Total 137 (100%) 62 (12.89) 45 (33%) 92(67%) 
Figure 5.3 Comparison of age at diagnosis of breast cancer for sample 
patients (diagnosed 1991) and Trent breast cancer patients (diagnosed 1991,1992 
& 1993) 
% of patients 
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The following table (Table 5.5) depicts the mode of presentation of patients in the 
sample. Of the cancers in our sample 32 per cent had been detected as a result of 
screening, 46 per cent were self-detected, whilst the remainder were discovered 
primarily through examinations by general practitioners. 
Table 5.5 Mode of presentation of breast cancer patients by stage at 
diagnosis 
Stage Self detected Partner GP Screen Other 
43(43%) (1%) 14(14%) 37 (38%) 5 (5%) 
II 8(61%) 
- 
1 (8%) 3 (23%) 1(8%) 
III 8 (53%) 
- 
4(27%) 1 (7%) 2(13%) 
IV 2(33%) 
- 
1 (17%) 1 (17%) 2(33%) 
Total 61(46%) 1 (1%) 19(14%) 42 (32%) 10(7%) 
5.3.2 Resource use 
Appendix 5.4 presents the treatment resource use by tumour stage for the breast cancer 
patient sample. This includes information on the mode of presentation, type of 
investigations used for screening, diagnosis and follow up, type of surgery, 
radiotherapy and endocrine therapy, and the number and proportion of patients by 
stage receiving chemotherapy, palliative care, post-surgery/treatment inpatient 
investigations and oophorectomy/ovarian ablation. None of the patients in the sample 
underwent breast reconstruction. 
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From the sample; 
" 
90%, 92%, 57% and 0% of stage I-IV patients respectively received a primary 
surgical procedure. 
" 40%, 62%, 38% and 33% of stage I-IV patients respectively received radical 
radiotherapy. 
" 3%, 15%, 13% and 17% of stage I-IV patients respectively received 
chemotherapy. 
" 92%, 100%, 94% and 100% of stage I-IV patients respectively received 
endocrine therapy. 
" 1%, 8%, 13% and 17% of stage I-IV patients respectively received palliative 
radiotherapy. 
To enable detailed costing and allow for discounting, this resource-use was estimated 
by the year in which it was incurred (see Appendix 5.5). 
One of the most significant factors contributing to the cost of cancer care is the cost of 
hospitalization. Table 5.6 outlines the average length of stay for stages Ito IV by 
therapeutic procedure. 
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Figure 5.4 shows the length of stay by stage for the two surgical procedures 
performed on the sample of breast cancer patients. For all three stages the 
average length of stay for those patients treated by mastectomy exceed those who 
underwent conservative surgery. When observing all patients who underwent 
some form of surgery, the mean length of stay for mastectomy patients (7 days) 
was longer than the mean length of inpatient stay for conservative patients (4 
days) (P = 0.001). 
Following initial treatment for the cancer significant burdens of care are 
again incurred when a patient suffers a recurrence or disease progression (regional 
recurrence or metastasis). Table 5.7 displays the recurrence and disease 
progression by stage of the disease at diagnosis. 
Figure 5.4 Average length of stay by primary surgical procedure 
Mean length of 
stay (days) 
9.00 
8.00 6 55 
7.00 9 
6.00 
5.00 3 
4.00 
3.00 
2.00 
1.00 
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0.00 
Stage I Stage II Stage III 
Stage at diagnosis 
"Conservative surgey (Wide local 
excision) 
  Mastectomy 
70 
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Table 5.7 Recurrence and disease progression by stage at 
diagnosis for the breast cancer sample 
All Stage I Stage 11 Stage III Stage IV 
Local recurrence 5 (4%) 2 (2%) 1 (8%) 2 (13%) 
- 
Contralateral 2(1%) 1 (1%) 1 8%) 
- - 
recurrence 
Regional 5 (4%) 5 (5%) 
- - - 
recurrence 
Metastasis 37(27%) 19(19%) 3 (23%) 10(63%) 6(100%) 
Site of Liver (4) Bone (1) Lung (3) CNS (1) 
metastasis Lung (2) Brain (1) CNS (1) Bone (3) 
CNS (1) Missing info (I) Bone (5) Pleura (1) 
Bone (8) Missing info (1) Brain (1) 
Pleura (1) 
Ascites (1) 
Missing info (2) 
5.3.3 Treatment costs 
Table 5.8 presents the results of the cost analysis. For the sample data, one-way 
analysis of variance (Duncan multiple range test at 5 per cent) suggests that the 
mean total cost of diagnosis, treatment and follow up for stage IV cancers is 
significantly higher than that for cancers at the other three stages. It should be 
noted that the confidence intervals for stage IV cancers are particularly wide, 
reflecting both the possibilities of short life expectancy, on the one hand, and 
intensive and costly treatment, on the other, for metastatic breast cancer. 
The sample size for the stage IV cancer cost calculation is small (n=6). 
Combining stage IV cancers with stage Ill into a composite group of "advanced 
cancer" yields a mean total four-year cost of £4,953 (sd 3930). In this case, the 
Duncan test reveals no significant differences between mean cost for cancers in 
stage I, stage 11 and the advanced cancer group. It is worth noting that although 
the stage IV cancer cost sample is small and displays a large standard deviation, 
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the difference in costs between this group of patients and the patients in other 
stages is still significant. Palliative radiotherapy and palliative care are the largest 
contributors to the overall cost of stage IV patients (table 5.8), this is unsurprising 
given the average length of stays for these procedures are 50 and 37 days 
respectively (see table 5.6). 
Analysis of the costs was also carried out for the 27 cancers that could not 
be staged. These unstaged cancers yield an average cost of £3,066 (sd 1425), the 
Duncan test reveals no significant differences between mean cost of unstaged and 
stage I, II, and III cancers. 
Treatment costs may also vary according to factors other than stage of the 
cancer. Other well-documented factors affecting treatment decisions in breast 
cancer include age and menopausal status. Table 5.9 shows that for stage I 
cancers both pre-menopausal women and women aged <50 years result in 
significantly higher costs than post-menopausal women and 2: 50 year olds 
respectively. Moreover, for the cost information to be useful to other researchers, 
exploration of the costs associated with recurrence and disease progression is 
necessary. Table 5.10 displays such costs. These were calculated from the 
diagnosis of the recurrence or metastasis to the time of death or last seen at the 
hospital. Another way cancer costs have been analysed by other researchers is to 
split them according to three disease phases, initial care costs, continuing care 
costs and terminal care costs(26,27). These initial, continuing and terminal care 
costs for the breast cancer sample have been estimated according to stage of 
disease and are displayed in Table 5.11. 
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It is useful to observe when the costs of breast cancer treatment are incurred. 
Figure 5.5 explores these treatment costs by year from diagnosis. In the first two 
years following diagnosis the average cost incurred by stage IV patients are 
significantly higher than those incurred by stage I-III patients. These stage IV 
costs fall in years 3-4, the reason being that only one stage IV patient remains 
alive throughout this period, and she only incurs costs associated with a normal 
follow up regime. Table 5.12 presents the estimates of lifetime costs, at various 
discount rates. Using either of the above formulations for late-stage cancers 
(stage III and IV separately or combined), the addition of the imputed extra costs 
of treatment following the initial audit period makes the differences between the 
mean total costs for each cancer stage statistically insignificant (Duncan test). As 
costs for early-stage cancer depend upon estimated life expectancies, table 5.12 
also illustrates the sensitivity of early-stage cancer costs to the assumption of life 
expectancies one year shorter than the initial estimate and changes in the discount 
rate. 
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Table 5.10 Costs of recurrence and disease progression 
Stage I 
N Mean SD 
Local recurrence 2 £ 1,625 184.68 
Regional recurrence 5 £1,731 1064.16 
Metastasis 19 £ 1,764 2098.42 
Stage 11 
N Mean SD 
Local recurrence I £ 141 
- 
Regional recurrence 0 
- - 
Metastasis 3 £786 785.8 
Stage III 
N Mean SD 
Local recurrence 2 £1,960 1958.4 
Regional recurrence 
- 
- 
- 
Metastasis 10 £3,105 2894.03 
Stage IV 
N Mean SD 
Local recurrence 0 
- 
- 
Regional recurrence 0 
- - 
Metastasis 6 £6,613 4919.88 
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Figure 5.5 Treatment cost by year 
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5.4 Comparison with other breast cancer costing studies (Table 5.13) 
Of existing costing studies, that which appears methodologically closest to this 
one was conducted on a sample of 50 advanced cancer (stages III and IV) patients 
at Guy's Hospital, London, audited until death(33). The results of this study 
indicate an average diagnosis and treatment cost per patient of £7,620. The 
distribution of patients between the two stages was not delineated in the Guy's 
study and their estimate is slightly higher than the stage III and stage IV estimates 
(Table 5.8). Such a result might be taken to suggest a degree of consistency 
between the two sets of findings. This having been said, it appears that the 
patients in the Guy's sample were treated primarily with the prospect of cure, 
whilst palliation was the objective for a proportion of the Trent patients. In 
consequence, the treatment modalities of the two samples might have differed. 
Other costing studies examining breast cancer cost by stage of the disease have 
found that costs increase with stage of the disease(26,27,35,36). 
Analyses based on models of screening programmes in Australia(37), the 
Netherlands(38), the USA(39) and France(40,41) have also all concluded that 
treatment costs increase with disease advancement. In consequence, screening is 
seen to offer sizeable discounts on overall treatment costs, by facilitating the 
treatment of more cases at the earlier, cheaper, stages. 
Without access to the other researchers' primary data it is difficult to 
account for the divergence between my findings and theirs, although the 
following are the most probable causes. First, preferred treatment modalities are 
likely to differ between countries: the regular use of more aggressive 
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interventions at the terminal illness phase, for example, would further increase the 
average costs of stage IV cancers. Second, the relative unit costs of resources will 
differ between countries, depending upon resource endowment and payment 
systems. The US studies(26,39), for example, based its assessment on charges 
(claims through Health Maintenance Organisations) rather than costs, and the 
correspondence between the costs and charges is inevitably uncertain(42). A 
direct cost audit of an Australian hospital that examined costs over five years also 
concluded that costs increased with stage(43). However, the audit contained, on 
the authors' admission, certain biases. For example, the authors limited their 
analysis to the cost of treatments provided within the hospital chosen for study, 
with the result that certain resource usage will have been omitted. Moreover, 
owing to the costs and complexity of data collection, the authors assumed that 
treatment costs were distributed evenly over time. Given that "the most expensive 
therapies 
- 
surgery with chemotherapy and/or radiotherapy 
- 
are usually provided 
early in the course of treatment" then it follows that the assumption will lead to 
an "underestimate of treatment costs if a positive discount rate is used" (43: 371). 
The assumption is accordingly likely to entail the relative underestimate of costs 
of early cancers, where the greatest resource use occurs early in the treatment 
path, and the relative overestimate of the costs of late-stage cancer costs, where 
the preponderance of resource use occurs later. Without this bias, in other words, 
it is reasonable to assume the Australian cost profile by stage would be likely to 
differ less from that which we have identified for the Trent sample. Indeed, it has 
been discovered that for breast cancer treatment and screening evaluations 
229 
generally, a perceived variation in findings between studies can typically be 
attributed to differences in method and measurement. 
"When comparably defined programmes are evaluated using similar assumptions 
about consequences, very similar results are obtained" (44: 117). 
For the purpose of comparison with studies by Taplin et al. (1995)(26) and 
Will et al. (Forthcoming)(27), the costs have been split into three disease phases, 
initial care costs, continuing care costs and terminal care costs (see Table 5.11). 
Will et al. estimated initial care costs based on the initial 3 months of treatment 
costs to be between £3,022 - £4,041 (UK 1991), similar to my estimates of £2,371 
- 
£3,274, average monthly continuing care costs are higher than the estimates for 
Trent; £186 compared to £44. Their estimated terminal care costs are twice that 
of my estimates; £5,713 compared with £1,694. Taplin et al. (1995) used a six- 
month period to estimate the costs associated, with initial, continuing and terminal 
care. Their estimates are approximately five times that of my estimates. 
However, these differences are to be expected given that their study was based in 
the United States and used Health Maintenance Organization (HMO) charge data. 
Hurley and colleagues (1992) report on the treatment costs of breast cancer 
recurrence in Australia. Their median cost estimate for non-fatal recurrences 
(inclusive of local, regional and metastatic recurrences) of £2,526 are similar to 
the cost estimates based on the Trent patient sample, £1,534 (1991 prices). 
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5.5 The Effect of Screening 
5.5.1 Background 
Whilst the effectiveness of breast cancer screening appears beyond 
dispute, discussion continues over the extent to which effectiveness 
translates into cost-effectiveness. The evaluation that supported the 
introduction of mass screening into the United Kingdom 
- 
the Forrest 
Report(47) 
- 
produced a minimum estimate of cost per life-year gained of 
approximately £3,000 at 1984 prices. Although the Forrest estimates, 
revised for inflation, appear to have subsequently occupied a permanent 
place in the "cost-effectiveness league table", it is important to appreciate 
that they have been the subject of criticism, especially with respect to the 
quality of data employed(48-50). For example, given that mass screening 
had yet to be implemented at the time of the evaluation, the values of 
many of the parameters within the overall cost-effectiveness calculations, 
such as the unit cost of screening, compliance and rates of recall, had to be 
modelled from trial data. Whilst the use of such methods was by no means 
illegitimate at the time of the original evaluation, the fact that the UK 
screening programme has now been in operation for some time means that 
we currently possess realistic data for these parameters. 
At the time of the Forrest evaluation, no attempt was made to 
estimate possible changes in overall cancer treatment costs occasioned by 
the introduction of screening. Were they to exist, however, differential 
treatment costs between a screened and non-screened population would 
represent a point of substance. If early-stage cancers are actually cheaper 
to treat than cancers at later stages, the screening programme could be 
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expected to produce economies in direct health care costs in addition to the 
survival benefits accruing to patients. On the other hand, if the treatment 
of late-stage disease proves to be the cheaper, then the cost-effectiveness 
estimates suggested by the original evaluation were over-optimistic. Stage 
specific cost estimates have been used in a number of studies evaluating 
the cost-effectiveness of breast cancer screening(37-40), and have 
suggested that the former possibility is the more likely. However, 
resolution of this issue in the UK context requires an estimate of the 
diagnosis, treatment and follow-up costs of breast cancer by stage. 
5.5.2 Methods 
Based on these models of evaluation(37-40), I decided to incorporate the 
treatment cost information into a comparison of the costs and outcomes of 
the screening programme in the Trent region with that of a hypothetical 
scenario, one that assumes that screening had not been introduced and that 
all cancers had been detected in other ways. For consistency, I have 
attempted to follow an approach similar to that employed in the original 
Forrest evaluation(47). The analysis requires the following data and 
assumptions. 
The UK screening programme was introduced gradually between 
1987 and 1990. Trent Cancer Registry data indicate that the annual 
registration rate of new cases of breast cancer prior to the introduction of 
screening was roughly constant: the registration rates for 1986 through 
1988 were 969,974 and 962 per million women, respectively. As would 
be expected, the introduction of screening very quickly raised this rate to 
1,147 in 1992, although the rate thereafter fell to 956 per million in 1994. 
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It therefore appears reasonable to assume that the sensitivity of, and 
compliance with, mammography have been sufficiently high for the 
earliest screening rounds to have been successful in identifying the 
preponderance of prevalent cancers. In the future, therefore, incidence 
screens will be detecting essentially the same number of cancers as that 
resulting from symptomatic presentation prior to screening. I have 
therefore assumed that the effect of incidence screening is to improve the 
staging distribution at diagnosis, with no effect on cancer yield. 
5.6 Using the cost and staging data to inform the cost-effectiveness 
of breast cancer screening 
In the Trent region and in the reference year (1991), 106,172 women were 
invited for screening, 81,694 attended and 5,825 were recalled for further 
investigation(51). The unit costs of screening this cohort were assumed to 
be the average cost of mammography as employed in the earlier unit cost 
estimates (£22). The assessment of suspected cancers following recall 
varied with both condition and practitioner and I employed average figures 
based on stage-specific mean costs derived from the cost audit of screened 
patients in Trent. The costs were £49, £37, £22 and £22 for stages 1 
through 4, respectively, yielding a weighted average of £47. 
The Forrest evaluation was conducted prior to the introduction of 
mass screening, with the result that programme administration costs were 
not included in that cost per life-year estimate. Administration of the 
programme, however, is a current reality although no formal accounts 
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appear to be available. I have employed an estimate of £7 per woman 
invited, provided by the Nottingham screening unit(52). 
In 1991, there were 2,687 new breast cancer registrations in the 
Trent region. Of the cancers in the Trent sample, 32 per cent had been 
detected as a result of screening, 46 per cent were self-detected, whilst the 
remainder were discovered primarily through examinations by general 
practitioners. The distribution of cancers by stage was 74,10,12 and 4 per 
cent for stages I through IV, respectively. For the screening scenario, I 
assumed that the 2,687 cancers presented or were detected according to 
this stage distribution. For the no-screening scenario, I assumed that these 
cancers would have presented according to the staging distribution of the 
sub-sample of those cancers not detected by screening. This was 68,11, 
16 and 5 per cent for stages I through IV, respectively. As expected, this 
latter distribution was comparatively inferior from the prognostic point of 
view. 
As a measure of life-year gains by stage in both scenarios, I used 
the sample survival data described earlier. Although there exists a debate 
over whether and how survival gains should be discounted in economic 
evaluations(53-55), I have discounted life-year gains at the same rate as for 
costs, to ensure consistency with the Forrest methodology. In summary, 
therefore, the approach was to estimate the cost and survival impact of a 
screening programme whose sole effect would be to improve the staging 
distribution at diagnosis. Appendix 5.6 summarises these assumptions 
used in the screening model. 
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5.7 Results from the screening model 
- 
Cost-effectiveness of 
screening 
The results of comparing the screening scenario with the no-screening 
scenario appear in Table 5.14. As may be seen, the shift in stage 
distribution occasioned by screening entails higher total treatment costs for 
stage I cancers, although these are almost completely offset by lower 
treatment costs for cancers at stages II through IV. Overall, the diagnosis, 
treatment and follow-up costs of screened patients are higher than those 
under the no-screening scenario, although by only 0.5 per cent. 
Table 5.15 presents the results of a sensitivity analysis, allowing 
for variations in treatment costs by stage within the estimated confidence 
intervals and changes in the discount rate. I have also relaxed the 
assumption that early-stage cancers incur additional treatment costs 
beyond the fourth year, i. e. such patients are deemed to return to the 
-normal" population. As may be seen, lower discount rates contribute 
significantly to improving the cost-effectiveness ratio. The effect of 
reduced life expectancy for early-stage cancer is also investigated. 
In the model, the change in the distribution of cancer stages occasioned by 
screening was inferred from data collected at a particular point in time, 
whilst a screening programme was actually in progress. However, studies 
conducted in Southampton, UK(13), and in Texas, USA(56), have reported 
on the staging distributions actually observed both before and after the 
introduction of mass screening programmes. Their observed distributional 
changes are at variance with those inferred from our Trent data in one 
important respect. The observational studies both suggest that screening 
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increases the proportion of cancers detected at early stages (I and II 
combined) by around 5 percentage points, a figure only marginally lower 
than my assumed increase of around 7 points. However, the findings of 
both studies suggest that the assumption of 68 per cent of cancers in an 
unscreened population being detected at stage I may be unrealistic or 
atypical. Each reports a proportion of unscreened stage I detections of 
around a much lower 23 per cent, with a correspondingly higher 
proportion of stage Its (55-60 per cent). Screening then shifts the 
distribution, such that stage I detection rises to 45-50 per cent of the total, 
with stage II detection falling to 30-40 per cent. 
Re-estimating the model, using the Southampton and Texas pre- 
and post-screening distributions in place of our assumed Trent 
distributions, produces broadly similar estimates of the treatment cost 
increase occasioned by screening, namely, 0.3 and 0.5 per cent, 
respectively. Whilst the changes in the stage distribution assumptions 
have no impact on the costs of the screening programme, expected survival 
gains increase considerably relative to the base-line estimate. This is due 
to the large rise in stage I detections, where potential life gains are the 
highest, being only partially offset by the losses from a smaller proportion 
of stage II detections. In consequence, the estimate of the cost per life- 
year gained from screening falls to £1,636 and £1,244 for the Southampton 
and Texas stage distributions, respectively. These figures represent a fall 
of 51 and 63 per cent, respectively, from the base estimate. Impressive as 
they are, however, the previously noted caveat relating to the known 
variability of staging by study site should be borne in mind(32). 
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Although the Forrest Working Group produced estimates of the 
time and travel costs of screening these do not appear to have been 
included in the final cost per life-year calculation. However, using more 
recent estimates of time and travel costs(57), it is now possible to include 
such factors. Revised to 1991 values, the mean costs per visit were £1.7 
for travel and £5.0 for time, these amounts were added to each element of 
activity where such costs might be expected to be incurred, e. g. attendance 
for screening, in-patient and out-patient visits and follow-up5.3. The 
inclusion of such time and travel costs increases the estimated expected 
lifetime treatments costs by 5.3,5.2,3.9 and 1.7 per cent for cancers at 
stages Ito IV, respectively. The expected gross (health service plus time 
and travel) cost of implementing the screening programme as originally 
modelled rises from around £2.8 million to around £3.4 million, an 
increase of around 21 per cent. In consequence, the estimate of cost per 
life-year gained from screening rises to £4,086. 
5.3 It should be borne in mind that of course these costs are going to under represent the 
time costs involved in inpatient stays. 
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5.8 Breast cancer screening 
- 
comparisons with other studies 
Tables 5.16 and 5.17 display the results from cost-effectiveness and cost-utility 
analyses of breast cancer screening. They differ in respect to the country of 
evaluation, screening intervention, screen interval and target age group. They 
also differ in respect to how the analyses were conducted, some are directly 
based on data from pilot studies or actual screening programmes(21,58-61), 
while others(47,62-68) are secondary analyses of previous case-control studies 
and trials, such as the Nijmegan study(69), the Health Insurance Plan 
Study(70), the Swedish two-counties study(71), the Malmo trial(72,73), and 
the Utrecht study(74). However, the results, for those with a similar 
intervention; mammography, screen interval; biennial, and target age group; 
50-64 years, are comparable with the Trent data results. The results range from 
£3,135 to £4,994 (£, UK 1991X47,62,63,75). The results for those studies 
that evaluated biennial breast cancer screening by mammography for the 50-69 
age group display greater variation, £2,769-£9,573(59-61,65-67,75). 
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5.9 Conclusions 
As a result of a detailed, patient-specific resource audit, the conclusion is that 
screening is unlikely to offer the prospect of significant treatment cost 
economies. Although late-stage patients consume relatively large amounts of 
palliation resources, their high costs are counter-balanced by early-stage 
patients consuming more surgical and follow-up resources. It is interesting to 
note that these reservations about the potential for treatment cost reduction by 
screening are shared by the authors of a systematic review of the literature, 
who conclude that the assumption of a wide differential between lifetime 
treatment costs for early- and late-stage cancer "is almost surely 
fallacious"(44: 115). 
This having been said, there appear grounds for believing that the 
original Forrest estimate may have under-stated the cost-effectiveness of 
breast cancer screening in the UK. Translated into 1991 values, the basic cost 
per life-year estimate from the Forest Report becomes approximately £4,500. 
Employing a Forrest-type cost-effectiveness methodology with the Trent data, 
we have obtained a base-line figure some 25 per cent lower. This figure, it 
should be recalled, includes invitation costs. Experiments with other observed 
changes in staging distributions suggest that even this base-line figure might 
be an over-estimate, whilst the inclusion of private costs still yields a base-line 
cost-effectiveness ratio superior to the original Forrest estimate without 
private costs. 
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It is perhaps necessary to make explicit that the intention of the latter part of 
the analysis has been to enhance the understanding of the technical efficiency 
of breast cancer screening. The fact that an intervention's cost-effectiveness 
ratio might be more favourable than had originally been thought does not, of 
course, mean that the intervention is necessarily worthwhile per se. 
Moreover, in reaching decisions about the management of screening 
programmes, "... technical efficiency is simply one argument in a complex 
function which also includes ethical, medico-legal, and emotional 
considerations. " (83: 31). 
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Appendix 5.1 Diagnosis/staging algorithm for breast cancer from the 
literature 
Diagnosis 
Mammography Suspicious 
FNA Biopsy: Malignant 
Presentation Ultrasound 
Fozen section 
-ý 
I-Clinical examination Tru-cut Benign 
Benign 
repeat FNA 
Malignant 
ography 
.. Benign 
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Treatment algorithm for breast cancer by stage from the literature. 
Mastectomy 
+ axillary sampling 
Stage I& tl 
post-menopausal 
Conservative surgery 
Stage I& 11 
Malignant sample 
Mastectomy 
+ axillary sampling 
Conservative surgery 
axiallary nodes radical radiotherapy 
sitive + endocrine therapy 
axillary nodes 
negative endocrine therapy 
radical radiotherapy 
lumpectomy 
anillary nodes positive 
i 
+ endocrine therapy, 
` 
+ axillary sampling 
/ \exillary 
nodes negative 
radical radiotherapy 
+ endocrine therapy, 
radical radiotherapy 
WLE \ 
axillary nodes positive + endocrine therapy, 
+ exillary sampling radical radiotherapy 
exillary nodes negative + endocrine therapy, 
axiallary nodes radical radiotherapy 
positive + chemotherapy 
ýaxillary 
nodes 
negative chemotherapy 
radical radiotherapy 
axillary nodes positive + endocrine therapy lumpectomy 
+ axillary sampling i radical radiotherapy \axillary 
nodes negative + endocrine therapy 
radical radiotherapy 
axillary nodes positive + endocrine therapy, WILE 
+ axillary sampling < radical radiotherapy \axillary 
nodes negative + endocrine therapy 
endocnne therapy 
endocrine therapy + 
radiotherapy 
palliative mastectomy 
III Chemotherapy + 
-oophorectomy 
\ Chemothaapy + 
IV 
ti 
ti 
Palliative radiotherapy + 
palliative chemotherapy+ 
endocrine therapy 
Palliative chemotherapy + 
Endocrine therapy 
Palliative radiotherapy + \Endocnne 
therapy 
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BASIC INFO Current Date: 
Study No: 
Disrict Code: m TIHSR ID: 
Pat's Name: D. o. b. 
1i 
clinical Trial: Yes / No El 
Trial Number: 
t Hospitals: Consultants: Hospital Number: 
1) primary Treatment: (ie. surgery) 
2) Radiotherapy: 
3) Syssemic Therapy: 
(Horjnone/Chemotherapy) 
4) Regular follow-up: 
HISTORY 
Duration of history of 
rfmptoms (weeks): 
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Menopausal status: 
Oophorectomy in past: 
Hysterectomy in past: 
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5 Other 
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Mode of first diagnosis: 
Date of first diagnosis: 
Date admitted 
Date discharged 
DIAGNOSIS (continued) 
Further diagnosis: 
Date: 
Date admitted 
Date discharged 
1 FNA 
2 Core biopsy 
3 Operation 
4 Other 
(IP/DC/OP) 
I2 
Yes / No 
(IP/DC/OP) 
Mme: 1 FNA 2 Core biopsy 
3 Operation 
4 Other 
Clinical staging at primary diagnosis 
TNM as recorded in notes 
TREATMENT OF PRIMARY 
Surgical treatment of primary: 
Date of first surgery: 
IP/DC/OP 
Date admitted 
Date discharged 
Type of surgery: 
1 Breast procedure: 
TO NQ MQ 
0 
El 
El 
12 
Yes / No Q 
(d/m/y) 
1 None Q 
2 Incision biopsy 
3 Excision biopsy/lumpectomy 
4 Wide local excision 5 Segmentectomy/quadrantectomy 
6 Subcutaneous mastectomy (No skin removed. 
Nipple preserved. ) 
7 Simple mastectomy/total mastectomy (No muscle removed) 8 Modified radical mastectomy 9 Radical mastectomy 
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DIAGNOSIS FORM Abstracter: 
SURGERY (continued) 
2 Axillary procedure: 1 None Q 2 Sampling 
3 Clearance 
12 
Second surgical procedure: Yes / No 
Q 
Date: (d/m/y) 
IP/DC/OP 
Date admitted 
ýFT-1 
Date discharged M 
Type of surgery: BP 
AP 
Radiotherapy: 1 Not given 2 Breast/chest wall 
3 Axilla/gland fields 
4 Combined (eg breast & axilla) 
9 Not specified 
Date started: 
Date finished: 
IP/OP/DC 
ADjUVANT SYSTEMIC THERAPY 
1 Chemotherapy 
(d/m/y) 
(d/m/y) 
1 None 
2 Chemotherapy 
3 Endocrine therapy 
4CT&ET 
9 Not specified 
1 CMF 
2 Others 
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specify 
a 
F-1 
0 
r-l 
2 Endocrine therapy 
Drugs: 
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IP/OP/DC 
1 Tamoxifen 
2 Aminoglutethimide 
3 Other 
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Date finished: 
IP/OP/DC 
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Oophorectomy: 
Palliative care 
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Yes / No 
Date started: 
Date finished: 
IP/OP/DC 
12 
Yes / No 
Date started: 
Date finished: 
IP/OP/DC 
0 
EIIET= 
oI I-T-o 
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FOLLOW UP/OUTCOME 
Local recurrence, distant metastases, vital status 
12 
Local r Yes / No EJ (Breast/chest 
wall) 
Date of first local recurrence: (d/m/y) 
12 
Regional recurrence: Yes / No Q (Axilla/SCF) 
Date of first regional recurrence: (d/m/y) T-F 
12 
Contralateral breast recurrence: Yes / No Q 
Date of first contralateral breast 
recurrence: (d/m/y) Q 
12 
Distant metastasis: Yes / No Q 
Date of first distant metastasis: (d/m/y) 
Site of first distant metastasis: 1 Liver Q 2 Lung 
3 CNS 
4 Bone 
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7 Other 
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specify 
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Radiothprapy clinic check up 
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Other: 
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Dead / Alive 
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CLINICAL TNM STAGING 
SKIN 
- 
BREAST AREA ONLY 
(Ti) 1 Normal 
('1'2) 2 Incomplete fixation (tethered or dimpled) 
(T3) 3 Complete fixation within tumour area (infiltrated or ulcerated) ('j'3) 4 Peau d'orange within tumour area 
(T4) 5 Peau d'orange or skin involvement wide of tumour area (but not wide of breast) 
NIPPLE 
1 Normal 
(T2) 2 Retracted 
3 Paget's disease (confined to nipple) 
(T2) 4 Paget's disease (wide of nipple) 
pEC'FORAL MUSCLE 
CHEST WALL 
AXILLARY LYMPH NODES 
(same side) 
(T2) 1 No fixation 
(T3) 2 Fixed 
(T2/T3) 1 No fixation 
(T4) 2 Fixed 
(NO) 1 None palpable (Ni) 2 Palpable and mobile (N2) 3 Palpable and fixed (N3) 4 Oedema of arm 
SUPRACLAVICULAR and (NO) 1 None palpable 
INFRACLAVICULAR NODES (N3) 2 Palpable 
(same side) 
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OTHER METASTASES (MO) 1 None found 
(including skin wide of breast NO 2 Present 
other breast 
contralateral lymph nodes, etc) 
'T QNQMQ Stage I II III IV Q 
Appendix 5.3 Estimating life expectancy 
Linear trend 
camnh- survival rates by stage 
Year 0 Year 1 Year 3 Year 5 
Stage I 1.00 0.96 0.84 0.78 
Stage II 1.00 1.00 0.64 0.64 
Stage III & IV 1.00 0.73 0.25 0.12 
Trends for sample survival rates 
Survival estimates are obtained using information from the stage specific linear trend- 
lines: 
Stage I= (1/0.0463)/2 =10.79 years 
Stage 11 = (1/0-0823)/2 = 6.07 years 
Stage III = (1/0.977)/2 = 2.53 years 
  
9 y=0.0463x +1 R2 = 0.9804 
90% 
70% 
Y=-0.0623x+1 
f Siegel 
R2 =0 8286   stage 2 
SD% f stage 3&4 
-Linear (stage 3& 4)1 
40% { -Linear (stage 2) 
Linear (stagel) 
30% 
A 
20% 
y=-01977x+1 
R2=0.918 
10% 
0% 
1 
0 12345 6 
Year 
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DEALE method 
1) Take the reciprocal of the age-sex-adjusted life expectancy to obtain the age-sex- 
adjusted average mortality rate gas. 
2) Obtain the disease specific mortality rates. For this single point survival data (e. g. 
5-year, 10-year) can be used. They are converted into mortality rates by 
logarithmic transformation. The average annual rate can be calculated using the 
following equation: 
1 
yd =-- in(S) 
t 
Where t= time 
S= survival proabaility 
e. g. if 5-year survival rate = 0.81 t=5 and s=0.81 
3) Take the recipricol of the sum of gas and µd to obtain the life expectancy. 
1) Calculation of the average mortality rate µas. 
Stage Mean age at Age and sex adjusted Conversion to Average 
diagnosis (from life expectancy from average mortality rate: 
sample) life tables mortality rate gas 
61 22.6 1/22.6 0.04425 
-II-- 63 22.6 1/22.6 0.04425 ýI 63 22.6 1/22.6 0.04425 
IV 69 14.7 1/14.7 0.06803 
2) Calculation of the average annual disease specific mortality rate µd. 
i using sample survival rates: 
Stage 5-year survival Conversion to Average disease 
average disease specific mortality 
specific mortality rate: 
rate d 
0.78 
- 
lnO. 78/5 0.0496 
0.64 
- 
ln0.64/5 0.0893 
nI 1V 0.12 410.12/5 0.4241 
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ii) using Cancer Research Campaign reported survival rates[Cancer Research 
Campaign, 1991 #1065]: 
Stage 5-year survival Conversion to 
average disease 
specific mortality 
rate 
Average disease 
specific mortality 
rate: 
d 
0.84 
- 
lnO. 84/5 0.0348 
II 0.71 
- 
lnO. 71/5 0.06 
ýI 0.48 
- 
lnO. 48/5 0.15 
IV 0.18 
- 
lnO. 18/5 0.34 
3) Take the recipricol of the sum of as and µd to obtain the life expectancy: 
P, for sample stage survival data: 
Se Converion to life expectancy Life expectancy (years) 
1/(0.04425+0.0496) 10.66 
ti 1/(0.04425+0.0893) 7.49 
III & TV 1/(0.06803+0.4241) 2.03 
ii' for CRC survival data: 
Se Converion to life expectancy Life expectancy (years) 
I 1/(0.04425+0.0348) 12.65 
1/(0.04425+0.06) 9.59 
III 1/(0.04425+0.15) 5.15 
N 1/(0.06803+0.34) 2.45 
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Appendix 5.4 Total Resource Use by Stage 
- 
Breast cancer 
Stage 1 (a-102) State II a-13 Stage 1110-16) State IV a-6 
Mode of Presentation 
Self 43 (43%) 8(62%) 8 (53%) 2 (33%) 
Partner 1(1%) 
GP 14 (14%) 1(85010) 4 (27%) 1(170/*) 
screw 37 (37%) 3 (23%) 1(70/o) l(17%) 
other 5(50/6) 1(80/0) 2 (13%) 2 (33%) 
Screening 
mammography 15 (15%) 2(15%) 1(6%) 1(170/6) 
mammography/tru-cut 2(20/o) 
biopsy 
mammography/fna 13 (13%) 1 (8%) 
mammography/fna/ 7(7%) 
Ultrasound 
Diagnosis 
Primary diagnosis 89 (87%) 12 (92%) 16 (100%) 6(100%) 
mammography 11(11%) 1 (7%) 2(13%) 
Tru-cut biopsy 16 (16%) 2(13%) 3 (19%) 1(170/9) 
Fna 35 (34%) 4(31%) 9(50%) 2 (33%) 
ultrasound 2(20/*) 
mammography/fna 9(90/0) 
fna/tru-cut biopsy 2(2%) 
mammography/fna/ 1(70/6) 
ultrasound 
Frozen section biopsy 2(20/o) 1 (7%) 
Marker biopsy 10 (9%) 1(70/o) 
physical examination 2(20/6) 2 (13%) 3 (19%) 3 (50%) 
Secondary diagnosis 24 (24%) 4 (31%) 2(13%) 
mammography/foal 1(1%) 
ultrasound 
Tru-cut biopsy 5(501e) 4(31%) 1(6%) 
Fna 6 (6%) 
ultrasound 100/0) 
Tru-cut biopsy/ultrasound 1(6%) 
Frozen section biopsy 8(80/0) 
Marker biopsy 3(30/o) 
Tertairy Diagnosis 2 (2%) 1 (8%) 
Tru-cut biopsy 1(19'0) 
Frozen section biopsy 1(8%) 
Marker biopsy 1(1%) 
Treatment 
Primary Surgery 
Conservative surgery 37(36%) 3 (23%) 3 (19%) 
Mastectomy 56(55%) 9(69%) 6(38%) 
Secondary surgery 2 (15%) 1(6%) 
Conservative 2 (2%) l(6%) 
mastectonly 6 (6%) 2(15%) 
Endoffne therapy 94 (92%) 13 (100%) 15(94%) 6 (100%) 
tainoxifen 84(92%) 11(85%) 9(56%) 4 (67%) 
tamoxifcn/megestrol 10(10%) 2(15%) 6 (38%) 2 (33%) 
Radical radiotherapy 41 (40%) 8(62%) 6(39%) 2 (33%) 
ChenwdmVy 8 (8%) 2(150/9) 3(190/9) 2(33%) 
palliative radiotherapy 6 (6%) 1(8%) 4 (25%) 2(33%) 
Palliative care 12 (12%) 5 (39%) 8 (50%) 3 (50%) 
Inpatient investigation 13 (13%) 1(8%) 4(25%) 
inpatient stay for 2(21/o) 2(15%) 1 (17%) 
complications 
Oophorectomy 3 (3%) - - - 
Follow up 
breast clinic 97 (95%) 12 (92%) 10 (63%) 2 (33%) 
radiotherapy clinic 43 (42%) 9(69%) 10 (63%) 3(50%) 
maamography 53 (52%) 5(39%) 3 (19%) - 
chest x-ray 36 (35%) 8(62%) 10 (63%) 2 (33%) 
spine x-ray 6 (6%) 1 (8%) 2 (13%) 1 (17%) 
bone scan 27 (27%) 5 (39%) 7(44%) 1 (17%) 
ultrasound 20 (20%) 2(15%) 2(13%) 1 (17%) 
CT scan 3 (3%) - 2(13%) 1(17%) 
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Appendix 5.5: Resource use by stage years 1-5 
- 
Breast cancer 
YEAR 1 State I n-102 Stage II (n-13) Stage III a-16 Stage IV n-6 
Mode of Presentation 
Self 43 (43%) 8 (62%) 8 (53%) 2 (33%) 
Partner 1(10/0) 
OP 14 (14%) 1(851/6) 4 (27%) 1(170/o) 
screen 37(37%) 3(23%) 1(70/o) 1(170/o) 
other 5(50/o) 1 (8%) 2(13%) 2(33%) 
Screening 
mammography 15(159/6) 2(15%) 1(60/o) 1 (17%) 
mammography/tru-cut 2(20/o) - - - 
biopsy 
ography/fna 13 (13%) 1(80/o) - - 
memnography/fna/ 7(70/o) - - - 
Ultrasound 
Diagnosis 
Primary diagnosis 89 (87%) 12 (92%) 16(1000/9) 6(100%) 
mammography 11010/0) 1(7%) 2(13%) 
Tru-cut biopsy 16(16%) 2(13%) 3 (199/0) l(17%) 
Fna 35 (34%) 4(31%) 8(50%) 2(33%) 
ultrasound 2(20/o) - - - 
mammography/fna 9 (9%) - - - 
fna/tru-cut biopsy 2(2%) 
- - - 
mammography/fna/ 1 (7%) - - 
ultrasound 
Frozen section biopsy 2 (2%) i (7%) 
Marker biopsy 10(90/. ) 1(70/*) 
- - 
Physical examination 2(20/o) 2 (13%) 3 (19%) 3(500/*) 
Secondary diagnosis 24(240/9) 4 (31%) 2(13%) - 
mammography/fna/ 1(1%) - - 
ultrasound 
Tru-cut biopsy 5(5%) 4(31%) 1(65/6) 
Fna 6(60/o) - - - 
ultrasound 
Tru-cut biopsy/ultrasound 
- - 
1(60/o) 
Frozen section biopsy 8(80/0) - - - 
Marker biopsy 3(30/o) - 
Tertairy Diagnosis 2 (2%) 10%) - - 
Tru-cut biopsy 1(1%) - - - 
Frozen section biopsy 1 (8%) - - 
Marker biopsy 1(1%) - - - 
Treatment 
Primary Surgery 
Conservative surgery 37(360/*) 3 (23%) 3 (19%) - 
Mastectomy 55(54%) 9 (69%) 6(39%) 
Secondary surgery 1 (8%) 
conservative 1 (1%) - - - 
Mastectomy 4 (4%) 1(9%) - - 
Endocrine therapy 94 (92%) 13 (100%) 15(94%) 6(100%) 
tamoxifen 94(92%) 11(850/0) 9 (60%) 4 (67%) 
temoxifen/megestrol 10(100/0) 2(15%) 6(400/*) 2 (33%) 
Radical radiotherapy 41(40%) 9(620/*) 6(39%) 2 (33%) 
Chemotherapy 3 (3%) 2(15%) 2(13%) l(17%) 
Palliative radiotherapy 1 (1%) 1(8%) 2 (13%) 1 (17%) 
palliative care 2 (10%) 1(8%) 2 (13%) 3 (50%) 
Inpatient investigation 11(11%) 1(80/0) 3(19%) 
Inpatient stay for 2(15%) - 1 (17%) 
complications 
Oop my 3 (3%) - - - 
Follow up N (% of sample) N (% of sample) N (% of sample) N (% of sample) 
mean no of visits mean no of visits mean no of visits mean no of visits 
breast clinic 96 (94%) 3 12(92%)3 9(560/9)3 2 (33%) 4 
radiotherapy clinic 43 (42%) 4 7(54%)5 10 (63%) 4 3 (50%) 3 
manwuWVhy 13 (13%) 1 1 (8%) I 1(6%)l - 
chest x-ray 25 (25%) 2 5 (38%)1 9(56%)l 2 (33%) 2 
spine X-my 2 (2%) I - 1(6%) 1 1(17%)l 
bone sm 19 (19%) 1 3(23%)l 7(44%) 1(17%)l 
ultrasound 13 (13%) 1 1 (8%)1 1(6%) 1 l(17%) 1 
CT scan 1 (1%) 2 1(6%)l 1(17%) 1 
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YEAR 2 
Tmt e. t 
Malty Swpery 
Camuvadve surgery 
MAY 
Secondary surgery 
Camervative 
mastecumny 
Endocrine dicraff 
hmcxifen 
twoldhohnerstrol 
Radical ndiodwapy 
Chdabodlers" 
Fdliitive radiotherapy 
Palliative we 
IupitiaK investiguion 
Inpatient stay for complications 
OophorectomY 
Follow up 
brad clinic 
rsdiothaapy clinic 
MOMMOFSPhy 
dust x-ray 
- x-ray 
bone acne 
okouound 
CT scan 
YEAR 3 
Treatment 
F $WVWY 
Camervative wrgery 
MutectomY 
Secondary sue' 
Conservative 
Mastectomy 
Endocrine 6012PY 
tomwtiCt 
mnoxifamegewol 
Radical ra dY 
Chemotherapy 
Palliative radiotl-r-PY 
PaUis ve core 
Inpatient investigation 
loped" stay for complications 
0 
Fellow up 
beast clinic 
radiotherapy clinic 
MMVAWVVbY 
chat x-ray 
spine x-ray 
bone acne 
Wtraound 
CT scan 
YEAR 4 
Treatmest 
Primary SWIPY 
Conservative wrwY 
Mastectomy 
Secondary MBA 
Coosavsü e 
Y 
Endocrine thmap 
tonoxifen 
ttawdf x9mcgekrol 
Ra6od ndiodwsp- 
Cbemodw"w 
palliative radio hapY 
Palliative cue 
loped" investigation 
lopedw stay for complications 
ocvbawcta"Y 
Fellow up 
brow t clinic 
radiollim, PY clinic 
aoY 
chest x-ray 
pipe x-ray 
bone acan 
dtrxsou d 
Cr scan 
I (l%) 1 (8SG) 1(8%) 
- 
. 
1(8%) 
1(1%) 1(8%) 
- - 
86(90%) 12 (92%) 12(100%) 3(1000/*) 
77(81%) 10(77%) 6(50%) ](33%) 
9(9%) 2(15%) 6(500/e) 2 (66%) 
2 (2%) 
- 
1(8%) 1(33%) 
2 (2%) 
- 
1(8%) 1(33%) 
4 (4%) 1(8%) 4(33%) 
- 
N (% of sample) mean N (% of sample) mean N (% of sample) mean N (% of sample) mean 
no of visits no of visits no of visits no of visits 
72 (76%) 2 9(69%)2 5(42%)2 1(33%)l 
35 (37%) 3 9(69%)3 7 (58%) 3 2(66%)3 
24 (25%) I 1(8%)l 
6 (6%) 1 3(23%)l 2(17%)4 1 (33Yo) 1 
2 (2%) 1 1(8%)l 
3 (3%) 1 1(8%)1 2(17%)1 
- 
3(3%) 1 
- 
1(8%)l 
- 
1(8%)2 
- 
Stage I (u-86) Salle II (n-11) Stage III (a-7) Stage IV (a-2) 
1(1%) 
- - - 
I(l%) 
- - - 
78 (91%) 9(92%) 7(100%) 2(100%) 
70(91%) 8(73%) 4(57%) 1 (50Y. ) 
9(9%) 1(9%) 3(43%) 1(50%) 
2 (2%) 
2 (2%) 
- 
1(14%) 
- 
3 (3%) 3 (27%) 2(29%) 
- 
- 
1(14%) 
1(1%) 
- - - 
64 (74%) 2 6(55%)] 3(43%)2 
36 (42%) 4 6(55%)3 4(37%)4 2 (100%) 3 
26 (30%) 1 1(9%)1 2(29%)2 
5 (6%) 1 2(18%)1 1(14%)1 
- 
1 (1%) 1 
- -- 
7 (9%)l 3(27%)l 
-- 
4(5%) 1 1(9%)] 
-- 
1 (l%)1 
- -- Stage 1 (a--76) Slap 11 (a-7) Stop III (ar4) Slap IV (a-I) 
i fix) 
1 (1%) 
--- 
1 (1%) 
--- 
68(39%) 7(100%) 4(100%) 1(100%) 
62(91%) 7(100%) 2(50%) 
- 
6(9%) 
- 
2(50%) 1(100%) 
1 (1%) 
--- 
3 (4%) 
--- 
1(1%) 
--- 
1(1%) 
--- 
51 (67%) 2 4(57%)l 1(23%)1 
- 31 (41%) 2 4(57%)2 3(73%)2 1(100%)3 
17 (63%) 1 2(29%)2 
-- 3 (4%) 1 2(29%)l 
-- I (I%) 1 
--- 
3 (4%) 1 
- 
5 (7%) 1 
- 
I (1%) 1 
--- 
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YEAR 5 Stage I (a-31) Stage !I (r3) Stage III (a-I) Stage IV (n-l) 
Treatment 
S i 
- urgery mary Pr 
Conservative surgery 
Mastectomy 
--- 
-- 
Secondary surgery 
Conservative 
- 
- 
- 
-- 
--- 
Ma tectomy 
Endocrine therapy 
--- 
tamoxifen 31(100%) 3(1004/o) 1000%) - 
pmoxifamogestrol 1 (IOD%) 
Radical radiotherapy 
& 
-- 
Cbemo mff 
Palliative radiotherapy --- 
Palliative care -" 
Inpatient investigation 
-- 
Ipp stay for complications 
Oophorectonly 
- --- 
FONOW up 
treat clinic 5(16%)1 l(33%)2 
ndiot6eropy clinic 15(49%)2 2(67%)2 1(100%)1 1 (I 00%/i) 2 
y 5(16%) --- 
cbest x-ra 1(3%) . 
spine x 
sow bone 1(3%) 1(33%) 
ultrasound 1(3%) 
CT scan 
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Appendix 5.6 Assumptions for the breast cancer screening model 
" 
The assumption was made that the effect of incidence screening is to improve the 
staging distribution at diagnosis, with no effect on cancer yield 
. 
In 1991 (reference year), 106,172 women were invited for screening, 
" 
81,694 attended, 
" 
5,825 were recalled for further investigation[Trent Breast Screening Quality 
Assurance Reference Centre, 1996 #325]. 
" 
The unit cost of screening was taken to be the average cost of mammography as 
employed in our earlier estimate (£22). 
" 
An estimate of £7 per woman invited for administration costs, was provided by the 
Nottingham screening unit[Nottingham City Hospital Breast Screening Unit, 1996 
#326]. 
" 
Assessment costs were calculated from the audit of the medical notes of screened 
patients. The costs were £49, £37, £22 and £22 for stages I through IV. 
" 
In 1991 (reference year) there were 2,687 new breast cancer registrations in the Trent 
region. Of the cancers in the sample, 32 per cent had been detected as a result of 
screening, 46 per cent were self detected, whilst the remainder were discovered 
primarily through examinations by general practitioners. The distribution of cancers 
by stage was 74,10 12 and 4 per cent for stages I through 4, respectively. 
" 
For the screening scenario it was assumed that the 2,687 cancers presented or were 
detected according to the above stage distribution. 
" 
For the no-screening scenario, it was assumed that these cancers would have 
presented according to the staging distribution of those cancers not detected by 
screening. This was 68,11,16 and 5 per cent for stages I through IV, respectively. As 
expected this latter distribution for the no-screen scenario was comparatively inferior 
from the prognostic point of view. 
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Chapter 6 
Cervical Cancer 
6.1 Introduction 
In the UK invasive carcinoma of the cervix uteri (otherwise known as cervical 
cancer) accounts for two per cent of all cancer registrations in women. It is 
the eighth most common cancer in women. The disease is rare below the age 
of twenty, but increases rapidly to peak in the 35-39 year age group. There 
then follows a slight decline in rates followed by another rise, peaking at a 
slightly higher rate in the 65-69 age groups, then declines once again (Figures 
6.1 & 6.2). With respect to this bimodal distribution in age-specific incidence, 
cervical cancer is unusual. The age-specific incidence rates demonstrate the 
cohort effect of those women born in the 1920's having higher rates of 
cervical cancer throughout their lives(1). There has been an increase in the 
number of registrations in the under 35 age group, it represents the most 
common cancer for women aged 20-35 years, with 25 per cent of all cancer 
registrations in this age group being attributable to cervical cancer. 
Registrations of these invasive cancers represent a combination of 
symptomatic and screen-detected cases, screening has the effect of advancing 
the age at diagnosis. Therefore, it may be that the trend in age-specific 
incidence in young women is an artefact of the screening programme. 
However, it is believed that a true increase in this age group has occurred and 
that the reason for it is the disease's associated risk factor. It is thought that 
the genital wart virus, human papilloma virus (HPV), may be a causal factor 
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for cervical cancer in young women. Recently there has been increased 
research into screening for HPV and developing diagnostic tests(2,3). 
Before becoming invasive, cervical cancer progresses through a pre- 
malignant stage of the disease, cervical intraepithelial carcinoma (C1N), 
segregated into grades 1 to 3, (CIN I-III). CIN III is coded as carcinoma-in- 
situ (CIS). The Cancer Registries and therefore the Office for National 
Statistics only record cases of CIN III/CIS. As for invasive carcinoma, there 
has been an increase in the age-specific registration rates for the 15-44 age 
groups. The rate per 1000 female population in Trent has increased from 0.39 
in 1979 to 1.26 in 1994, peaking at 1.49 in 1990. These registration figures 
are an underestimate of the true incidence of CIS as the disease is 
asymptomatic and can only be detected by screening. In fact these figures are 
actually a mixture of the prevalence, in women being screened for the first 
time, and incidence of the disease. Only where women are screened every 
year are these figures a true representation of the actual incidence. 
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From the most recent registration and mortality figures, invasive cancer of the cervix 
uteri accounts for: 
" 
3,400 new registrations in England and Wales in 1992 (Figure 6.1)(4). 
" 
229 new registrations in the Trent region in 1997 (Figure 6.2)(5). 
" 
There has been a significant increase in the number of registrations for 
invasive cervical cancer and carcinoma-in-situ in young women (Figures 6.3 
& 6.4). 
" 
1,339 deaths in England and Wales in 1997(6) (Figure 6.5) 
" 
133 deaths in Trent in 1997. 
" 
The 5-year relative survival rate is 60% in England and Wales, and 65% in 
Trent. However, survival is directly related to stage at the time of diagnosis. 
For those diagnosed at an early stage the survival rate is much higher at 
nearly 80%, while those diagnosed at a very advanced stage fare less well 
with survival rates of less than 10%(7,8). 
. 
18,409 registrations of carcinoma in situ (CIS) of the cervix in 1992(4), this 
figure includes those with cervical intraepithelial carcinoma grade 3 (CIN 
III) (Figure 6.6). 
. 
1,868 registrations in Trent in 1997. 
. 
85% of all CIN III registrations are incurred by women aged 20-44 years of 
age (Figure 6.7). 
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Figure 6.1 Number and age-specific cervical cancer 
registrations, England and Wales 1992 
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Figure 6.2 Number and age-specific cervical cancer 
registrations, Trent 1994 
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Figure 6.3 Cancer of the cervix uteri 
- 
registration rate per 
1000 female population by age, Trent 1971-1994 
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Figure 6.4 Carcinoma-in-situ of the cervix 
- 
registration rate 
per 1000 female population by age, Trent 1979-1994 
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Figure 6.5 Number and age-specific cervical cancer mortality rates per 
1000 Female Population, England and Wales, 1992 
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Figure 6.6 Number and age specific registration rates for CINIII/CIS 
per 1000 female population, England & Wales 1992 
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Figure 6.7 Number and age specific registration rates for CINIII/CIS 
per 1000 female population, Trent 1994 
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As with breast cancer, a tumour staging classification has been established for 
cervical cancer(9) and five-year survival rates appear to be closely associated 
with cancer stage at initial diagnosis and treatment. For cervical cancer in 
particular, expected five-year survival rates following primary treatment range 
from virtually 100 per cent for the pre-invasive cervical intraepithelial 
neoplasia (CIN) phases, to around 80 per cent for stage I invasive cancers, 
falling to below 10 per cent for cancers at stage IV(7). In consequence, an 
improvement in the stage distribution on detection can be expected to yield 
benefits in survival gains, and such is the logic behind the mass population 
screening programmes introduced into many industrialised countries following 
the development of the Papanicolaou (Pap) smear test in the 1940s. In the 
United Kingdom, the screening programme is thought to have relieved the 
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burden of incidence of invasive cancers that might otherwise have occurred, 
especially amongst younger-to-middle-aged women(10). 
This chapter attempts to shed further light on the issue of the cost of treatment 
for cervical cancer, by estimating the stage-specific costs of cervical cancer 
diagnosis, treatment and follow up for a large sample of UK patients. The 
results from this analysis are then compared with other published cost 
estimates. 
6.2 Methods 
The assessment of the resource use and cost implications of cervical cancer 
care requires data on all cost-generating events in the diagnosis, treatment and 
follow up of cervical cancer patients. The first step was to undertake a 
literature search of diagnosis and treatments for invasive and pre-invasive 
cervical cancer. Details were primarily taken from Chomet et al. (1989) for 
pre-invasive cancer(11) and Dickson (1980), Brenner (1982), Coulter and 
Mason (1990), Sproston (1994) and Kingston (1985) for invasive carcinoma 
of the cervix(12-16). 
This information was used to construct stage specific treatment 
algorithms (basic algorithms are presented in Appendix 6.1). These literature 
based treatment algorithms were useful in the development of a proforma to be 
used for obtaining information on cervical cancer resource use from the 
medical notes of all patients diagnosed with cervical cancer in Trent in 1990 
(Appendix 6.2). 
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6.2.1 Treatment for pre-invasive and invasive cervical cancer 
- 
Literature 
Diagnosis: All pre-invasive and most of invasive cervical carcinomas will 
usually be detected by the Pap smear. These patients along with those 
presenting symptomatically will require further investigations to assess the 
extent and spread of the disease and to aid in the staging of the disease. 
All patients will be referred for clinical examination and the majority 
will require colposcopic investigation. This involves a stereoscopic 
microscope providing a brightly illuminated magnified dimensional image and 
requires a skilled operator. A smear may be taken from the cervix for cytology 
and a punch biopsy taken if there is an obvious lesion present. A cone biopsy 
may be performed if the lesion is small enough to excise completely, this 
involves the surgical excision of a wedge-shaped circular section of the cervix. 
Rectovaginal examination must be performed in all patients to assess 
the possible parametrial and posterior tumour spread. If the cancer proves to 
be invasive there is a need to exclude any spread of the tumour beyond the 
confines of the cervix. Pyelography (IVP) is essential, particularly in cases 
where the tumour has spread beyond the cervix. Obstruction of the ureter is a 
clear sign of infiltration of the parametrial tissue. This is of particular 
importance prior to surgery. Other investigations involve lymph. angiography; 
to assess spread to the lymph nodes and aid the planning of radiotherapy, 
scanning and ultrasound, for example CT scanning. 
Mandatory investigations include a full blood count, urea and 
electrolytes, liver function tests, intravenous urogram and chest radiography. 
An examination under anaesthesia should then be performed. Rectovaginal 
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examination should be repeated in order to clinically stage the tumour. If 
there is any suspicion of rectal spread, proctoscopy and sigmoidoscopy are 
performed. Cystoscopy is not considered essential in patients who have early 
stage disease but must be performed if the disease appears to be locally 
advanced. For example, at the time of the examination under anaesthesia 
when the biopsy is being taken it might be convenient to examine the bladder 
by way of a cystoscope to check for bladder involvement. 
Treatment 
- 
CIN: Before treatment, there is a need to rule out the existence of 
invasive carcinoma. The Pap smear is repeated, then colposcopic 
investigation, endo-cervical curettage, and colposcopically directed cervical 
biopsy for the more advanced cases. 
Treatment usually consists of either a full cone biopsy, laser ablation or 
cryosurgery to remove any abnormal epithelium, after which no further 
treatment is usually necessary. In some cases simple hysterectomy might be 
recommended. In all cases, follow up smears are mandatory. 
Treatment 
- 
Earl Ystage invasive carcinoma (stage I& II4): The mainstay of 
treatment is surgery and/or radiotherapy. Wertheim hysterectomy is the most 
common form of hysterectomy carried out in current practice, it consists of an 
en bloc dissection of the uterus, vagina and parametria. In addition the pelvic 
lymph nodes are dissected. Post-operative complications do exist, the most 
frequent being uretero-vaginal fistulae in approximately 3% of patients. 
Radiation therapy tends to be a combination of intracavity implants and 
external therapy. External therapy is given by high energy X-rays from a 
linear accelerator administered at a dose of approximately 160-200 rads per 
day, total dose of approximately 4000/5000 rads in 4-6 weeks. It is given to 
295 
control the spread within the pelvis and treat the pelvic lymph nodes, and can 
also contribute to tumour control. Therefore it is usually given prior to intra- 
cavity radiotherapy (ICT). Complications from radiotherapy involve the 
bladder, rectal ulceration, fistula formation, colitis, fractures, vaginal necrosis, 
etc. These occur in 5-10% of patients. 
Neither surgeons nor radiotherapists can claim any statistical 
superiority of either treatment, the 5 year survival rate in the UK whatever the 
modality is 80% for stage I, and 60% for stage IIA (17). 
Treatment 
--Advanced carcinoma of the cervix (stage IIb. III and IVI: 
Radiotherapy is generally the treatment of choice. If the patient is fit this 
should be radical and not necessarily palliative. 
Involvement of the bladder or rectum is not necessarily a death 
sentence and unless clinical examination reveals evidence of blood or bone 
metastasis or lymphatic involvement, radical radiotherapy should be indicated. 
If the disease has metastasised then palliative care is required. 
To date no chemotherapeutic regimen has had significant impact on 
this type of cancer, although short remissions have been induced by a 
combination of vincristine, bleomycin and mitomycin-C. 
EQIWw u: Careful follow up of all patients for cancer of the cervix is 
essential. This includes clinical examination and regular smears to check for 
early signs of recurrence. 
Recurrence: For local recurrence, further radiotherapy may be justified, 
although there is a risk of necrosis and fistula formation. Chemotherapy may 
be given to those patients who have already received surgery and radiation 
therapy, this treatment is mostly palliative. The most common sites of 
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recurrence are the pelvis (83% of cases), cervix (29%), bladder (23%), 
parametria (10%), pelvic wall (10%). The risk of recurrence diminishes each 
year after treatment and by the fifth year the mortality of the patients treated 
for cervical cancer is the same as for the normal population(12). 
6.2.2 Estimation of treatment costs 
The ideal method for costing any disease process is to have resource use and 
cost information on a patient specific basis. Given that the epidemiology of 
cancer in the UK has long been documented by the Cancer Registries on such 
a patient specific basis, it might be thought that a population-based resource 
use audit could be easily accomplished using pre-collected data. However, the 
Registry databases do not usually include details of either resource use or 
cancer stage at diagnosis. The treatment cost analysis was accordingly based 
on a detailed examination of the case notes of 336 invasive cervical cancer 
patients treated in the Trent region (central England). This was facilitated by 
the use of a proforma developed with the aid of information obtained from the 
initial literature review on diagnosis and treatment (see Appendix 6.2). It was 
verified by a consultant in obstetrics and gynaecology based at the City 
Centre, Nottingham, and piloted on 50 medical notes of cervical cancer 
patients treated at the same hospital. 
The 336 cervical cancer patients used for the cost analysis were 
obtained from the population of 378 individulas in the 12 districts covered by 
the Trent Cancer Registry. Of this original sample, 42 patients had to be 
excluded on the grounds of missing notes, no information in the notes, 
incorrect diagnosis, duplication or being diagnosed outside the chosen year of 
1991 (Table 6.1). 
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Table 6.1 Cervical cancer sample: retrieval of medical notes and 
exclusion of patients (by district of primary treatment) 
Excluded: 
District No of case Not found Duplicate Recurrence No Not Not 
notes information cancer diagnosed 
retrieved in 1990 
N 21 3- 
--3 2 
Derbyshire 
S 31 2- 
--1 2 
Derbyshire 
Leicester 47 4- 
--4 1 
N Lincs 15 
-1 --- 
- 
S Lincs 15 1- 1-- 
- 
Bassetlaw 12 
-- --- 
- 
Central 23 
-- --- 
- 
Notts 
Notts 71 2- 
--1 2 
Barnsley 24 
-- --- 
- 
Doncaster 44 
-- --I 
- 
Rotherham 20 
-- -23 
- Sheffield 38 31 1-- 
- 
Of the 336 patients who met with the inclusion criteria, for 76 (23%) there was 
insufficient information to enable the staging of their cancers. The patient 
numbers were 128,76,41 and 15 for stages I through IV, respectively (Table 
6.2). 
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Table 6.2 Total sample size used for cost estimation by stage 
Stage Number Percentage Stage Number Percentage 
of staged 
cancers 
la 20 6% I 128 49% 
Ib 81 24% 
1 28 8% 
IIa 24 7% II 76 29% 
Jib 40 12% 
II 12 4% 
IIIa 4 1% III 41 16% 
tub 22 7% 
III 15 4% 
IVa 1 0% IV 15 6% 
IVb 1 0% 
IV 13 4% 
Unstaged 76 23% 
Total 336 
All the patients in the sample had been diagnosed with cervical cancer in 
1990. This particular year was selected on the grounds that it permitted me to 
construct a resource audit for each patient over a minimum of 59 months and a 
maximum of 77 months follow up from diagnosis. The analysis of the cost 
data was based on a five-year follow up time horizon, a period following 
diagnosis during which the majority of cancer recurrences would be likely to 
occur(12). Imputation of cost data was undertaken for those patients who did 
not have full cost histories for this period (excluding those who had died or 
been discharged) using monthly averages based on the previous 12 months 
data. The sample demographic and resource use data were entered into SPSS 
for Windows version 6 on a patient specific and anonymous basis. From the 
individual patient records, stage-specific algorithms of diagnostic and 
therapeutic events entailing costs were developed. 
The unit costs of these events were obtained from a survey of eleven of 
the region's principal service providers, each of whom was sent a form 
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requesting the cost of the various activities, as performed at their site (Table 
6.3) (a 100% response rate was achieved following persistent contacts with 
key finance personnel). Since 1993, all National Health Service (NHS) 
providers have been required to follow a uniform accounting protocol, 
requiring that their services be costed at full cost, i. e. all service-specific 
variable costs, with the inclusion of the relevant components of fixed and 
overhead costs (NHS Management Executive, 1993). The mean of the 
reported costs was employed for each event, converted back to 1990 prices 
using the NHS pay and price index. Given that management events were 
occurring across time, the cost of events occurring in year 2 onwards, 
following diagnosis were discounted at 6 per cent. In other words, mean five- 
year costs were expressed as a 1990 present value, to represent the prospective 
cost implications from the perspective of the baseline year. 
By combining the unit cost estimates with the resource use 
information, the mean costs of diagnosis, treatment and follow-up by stage at 
diagnosis for the sample over the follow up period were obtained. For 
comparative purposes costs were also split into three distinct disease phases; 
initial care, continuing care and terminal care costs. Initial treatment costs 
included all the costs initiated within the first 3 months from diagnosis and 
also calculated again using a longer phase of the first 6 months of treatment. 
Terminal care costs were calculated using the last 3 months of costs for 
patients who had died during the follow up period. These were also calculated 
again using a longer phase of the last 6 months of treatment and care. 
Continuing care costs were obtained by calculating the average monthly cost 
incurred after the initial 3 months following diagnosis and in cases where 
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death occurred prior to the final 3 months of care used in estimating the 
terminal care costs. Again, continuing care costs were also calculated taking 
account of the 6-month initial costs and 6-month terminal costs. 
Table 6.3 Unit costs of diagnosis, treatment and follow-up events (£ 
sterling 1990 prices) 
Event Outpatient cost (£) Day-case cost (£) Inpatient cost (£) 
Smear 43.35 
Colposcopy 48.25 173.95 239.98 
Punch biopsy 40.00 198.06 257.02 
Cone biopsy 23.53 238.73 269.44 
Loop excision 43.31 239.75 255.78 
Laser ablation 250.00 250.00 
D&C 45.00 199.27 221.47 
Cystoscopy 39.13 178.78 194.97 
Chest x-ray 9.23 
IVP 61.79 122.12 122.12 
Proctoscopy 43.31 170.08 166.73 
Sigmoidoscopy 43.31 177.02 260.77 
Ultrasound 21.10 
CT scan 57.36 
MRI scan 123.72 
Liver scan 38.01 
Abdominal x-ray 10.50 
Kidney x-ray 27.38 
Pelvic x-ray 10.63 
Bone scan 57.07 
Liver function test 38.01 
Laparotomy 43.31 177.02 260.77 
Polypectomy 43.31 177.02 260.77 
Total conservative hysterectomy 188.85 
Radical wertheims hysterectomy 195.25 
Colostomy 196.26 
Inpatient stay (per day) 180.96 
Outpatient visit 37.27 
Inpatient palliative care (per day) 145.50 
Hormone replacement therapy (per month) 3.49 
Hi stopathology 13.66 
Cytology 8.87 
Biochemistry 4.73 
Haematology 4.95 
Microbiology 5.99 
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Table 6.3 (continued) 
Radiotherapy costs 1990 prices (£ sterling) 
Radiotherapy Type Cost per attendance (£) Cost per episode (£) 
Low energy: 60.35 
1-4 fractions 227.20 
5-10 fractions 568.00 
Simple: 63.90 
1-4 fractions 639.00 
5-10 fractions 1902.80 
11-15 fractions 3422.20 
16-25 fractions 5197.20 
Simple with simulation: 67.45 
1-4 fractions 639.00 
5-10 fractions 1917.00 
11-15 fractions 3457.70 
16-25 fractions 5239.80 
Complex with simulation: 74.55 
16-25 fractions 3790.80 
25+ fractions 6517.80 
Complex with technical support: 
16-25 fractions 5339.20 
25+ fractions 6688.20 
Brachytherapy 1079.20 
Chemotherapy costs 1990 prices (£ sterling) 
Cytotoxic Drug Dosage Cost (£) 
Bleomycin 15 units/15mg 12.71 
Ifosfamide 500mg 6.05 
Ig 10.53 
2g 19.44 
Cisplatin 10m1/l0mg 4.02 
50ml 20.07 
100ml 40.13 
Doxorubicin 10mg 14.60 
50mg 73.01 
Methotrexate Iml 1.51 
2m1 2.10 
4ml 4.01 
8mI 8.02 
20ml 20.05 
40m1 35.65 
200m] 160.45 
Carboplatin 5ml 17.83 
15m1 53.48 
45m1 160.45 
Mitomycin 2mg 4.93 
10mg 16.22 
20mg 30.94 
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Unfortunately the sample of 336 patients only included those diagnosed with 
invasive carcinoma of the cervix. In order to ascertain any cost savings 
brought about by a shift in the stage distribution of the cancers due to the 
national screening programme, some idea of the resource use and cost of pre- 
invasive carcinoma was required. The regional cancer registry holds records 
only for CIN III cases, although details of management are not included. Thus 
the information was obtained from a consultant gynaecologist who has kept a 
record of all women seen at his colposcopy clinic at Queens Medical Centre, 
Nottingham, since June 1990. Notes were kept of all diagnostic, management 
and follow up information. All women seen at the colposcopy clinic had been 
referred as a result of an abnormal smear, and following further colposcopic 
investigation could be deemed either to have no abnormality, CIN I, CIN II or 
CIN III. 
Information for all patients seen at the colposcopy clinic from June 
1990 to June 1991 was abstracted. 221 women were seen at the colposcopy 
clinic during this period, although not all of these were diagnosed as having 
pre-invasive cancer (see Table 6.4). Women found to have no abnormality or 
diagnosed with invasive cancer were excluded from further analysis. 114 pre- 
invasive cancers were detected. The total costs of pre-invasive disease were 
estimated in the same way as for invasive cervical cancer, using the resource- 
use of all CIN I-III patients and the unit costs from the finance departments. 
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Table 6.4 Results of case note retrieval 
- 
pre-invasive cancer 
Findings n % of total sample 
No abnormality 57 25 
CIN I 15 7 
CIN II 31 14 
CIN III 95 43 
Invasive 6 3 
Missing information 17 8 
Total 221 
- 
6.3 Results 
6.3.1 Sample characteristics 
The sample characteristics by stage at diagnosis are displayed in Table 6.5. 
Approximately fifty per cent of the sample present with stage I disease, while 
six per cent present with stage IV disease. The mean age at diagnosis for the 
sample of patients diagnosed with invasive cervical cancer was 54 years. A 
one-way analysis of variance indicates that mean age at diagnosis differs 
significantly according to the stage of the disease (F = 8.930, P=0.000), with 
late stage cancers diagnosed in older women. Sixty-one percent of the sample 
was still alive at the time of data collection. This corresponds with the national 
5-year survival rate of 60%(7). 
Table 6.5 Sample characteristics 
Stage No (%) Mean age at 
diagnosis (sd) 
No. deceased at 
abstraction (%) 
No alive at 
abstraction (%) 
I 128 (490%) 50 (14.18) 17(13%) 111(87%) 
II 76 (29%) 54 (16.42) 41(54%) 35 (46%) 
III 41 (16%) 60 (15.20) 29 (70%) 12 (30%) 
IV 15(6%) 67 (15.45) 13 (87%) 2(13%) 
Total 260 54 (15.74) 100(39%) 160(61%) 
Table 6.6 depicts the mode of presentation of patients in the sample. Of the 
cancers in the patient sample the majority had been self detected (49 %), 35 
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per cent had been screen detected, 9 per cent had been detected by GPs or in 
the genito-urinary (GU) clinic. The remainder (7 %) were detected through 
other means, mostly by being admitted to accident and emergency 
departments with abdominal pains. 
Table 6.6 Mode of presentation of cervical cancer patients by stage at 
diagnosis 
Stage Self detected GP Screen GU clinic Other 
I 42 (33%) 9 (7%) 72 (56 2 (2%) 3(2%) 
II 50 (66%) 2 (3%) 19 (25%) 1 (1%) 4 (5%) 
III 30 (73%) 5 (12%) 0 1 (2%) 5 (12%) 
IV 5 (33%) 2 (13%) 1 (7%) 0 7 (47%) 
Total 127 (49%) 18 (7%) 92 (35%) 4 (2%) 19 (7%) 
6.3.2 Resource Use 
Invasive cancer: Considerable diversity with respect to cost-events was 
evident on a patient-by-patient basis. For example, a total of 22 distinct 
diagnostic events were found to have occurred amongst the 261 cases, 
including cytology, colposcopy and various X-rays and scans. In some cases, 
many or all of the diagnostic events were undertaken on an inpatient basis 
whilst, in others, some or many of the tests were administered on an outpatient 
or day-case basis, with differential consequences for costs. Surgery was of 
two types, namely, Wertheim's and conservative hysterectomy, whilst 
radiotherapy was palliative or radical, external beam, intracavity or 
combination. Patient-specific radiotherapy costs varied with type (e. g. low 
energy, simple, complex), number of fractions and setting (e. g. inpatient or 
outpatient). Post-primary treatment, each patient received one or more of up 
to 18 forms of immediate procedure or further investigation, for example, 
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investigation for fistulae, blood transfusion or emergency inpatient admission. 
Within the sample, 7 different chemotherapy drugs were employed, in 
combinations, dosages and settings specific to each of the patients so treated. 
Appendix 6.3 presents the treatment resource-use by tumour stage for the 
invasive cervical cancer patient sample. To enable detailed costing and allow 
for discounting, this resource-use was estimated by the year in which it was 
incurred (see Appendix 6.4). 
One of the most significant factors contributing to the cost of cancer 
care is the cost of hospitalization. Table 6.7 outlines the average length of stay 
for stages Ito IV by therapeutic procedure. No difference in the proportion of 
patients by stage undergoing inpatient diagnosis exists, although the mean 
length of stay increases according to stage progression. This can be explained 
by the requirement of more investigations performed to assess the spread of 
the disease in late stage cancers. In-patient stays for surgery are more 
prevalent for stage I cancers compared with stage II and III cancers, however 
this is an effect of a greater proportion of stage I patients having surgery. No 
major difference in inpatient stay or length of stay exists between cancer 
stages for chemotherapy or investigations. Stage I, II and III cancers show 
higher rates of inpatient episodes for primary radical radiotherapy than for 
stage IV cancers, again explained by the treatment specification for these 
patients. This is also the case with inpatient palliative care and palliative 
radiotherapy where the prevalence of inpatient episodes and average length of 
stay increase with stage severity. 
Following initial treatment for the cancer significant burdens of care 
are again incurred when a patient suffers a recurrence or disease progression 
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(regional recurrence or metastasis). Table 6.8 displays the recurrence and 
disease progression by stage of the disease at diagnosis. 
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Table 6.8 Recurrence and disease progression by stage at diagnosis 
for the cervical cancer sample 
All Stage I Stage 11 Stage III Stage IV 
Local recurrence 52(20%) 10 (8%) 28 (37%) 14 (34%) 
- 
Metastasis 26 (10%) 4 (3%) 12 (16%) 5 (12%) 5 (33%) 
Site of metastasis Lung (3) Bone (4) Liver (2) Lung (1) 
Pelvis (1) Lung (6) Kidney (I) Liver (2) 
Liver (2) Brain (1) CNS (2) 
Spine (1) 
Pre-invasive cervical cancer: Appendix 6.5 presents the treatment resource-use by 
tumour stage for the pre-invasive cervical cancer patient sample. Understandably, the 
range of diagnostic, management and follow-up events for the pre-invasive cancers 
was comparatively narrow, being confined to smears, colposcopy and biopsies (1 1 
distinct events in total). No inpatient episodes were required for any of the patients 
and all were discharged within one year of treatment. 
6.3.3 Treatment costs 
Table 6.9 presents the results of the cost analysis for the invasive cancer patients. For 
the sample data, one-way analysis of variance (Duncan multiple range test at 5 per 
cent) suggests that the mean total cost of diagnosis, treatment and follow up for stage I 
cancers is significantly lower than that for cancers at the other three stages. The 
proportions of the total costs incurred in the first year following diagnosis were 78,76, 
88 and 98 per cent, for stages I through IV, respectively. With such high proportions, 
the impact of discounting on mean historic costs is small, undiscounted costs are 
£6,716, £1 1,127, £10,980 and £l 1,548 for stages Ito IV respectively. 
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Within the sample, stage I costs for diagnosis, radiotherapy, chemotherapy, 
investigations and inpatient palliative care were significantly lower than those for 
stages II through IV. Grouping the two principal palliative cost categories (palliative 
radiotherapy and inpatient palliative care) together, stage IV palliative costs were 
significantly higher than those for stages II and III, and all three were higher than 
those for stage I. Grouping the primary treatment cost categories (surgery, radical 
radiotherapy, investigations, hormone replacement and chemotherapy), stage IV 
primary treatment costs were significantly lower than those of stages II and III, whilst 
I costs were lower than those of stage II. A further analysis of cost by therapeutic 
regimen (surgery vs. non-surgery) was conducted on the 126 stage I and 68 stage II 
patients where interventions were intended to be curative rather than palliative. For 
these stage I cancers, 57% received surgery, with a mean five-year cost of £5,839 (all 
palliative treatments excluded). The corresponding mean cost for those treated non- 
surgically was significantly higher at £7,967 (t-test, P=0.01). For stage II cancers, 
32% proceeded via surgery, at a mean cost of £10,478. The mean cost for those 
treated non-surgically, £ 12,261, was not significantly higher (t-test, pß. 45). Sample 
sizes for the remaining stages were too small to enable comparisons to be made. 
The pre-invasive cancer sample comprised 15,31 and 95 cases at C1N 1 
through CIN3, respectively. The differences between mean costs for the management 
of pre-invasive carcinomas at each of these grades were insubstantial (< 1%). 
Averaged across all the CIN grades the mean cost of management was estimated at 
£386 (SD 66) (Table 6.10). This comprised costs of diagnosis (19% of the total mean 
cost) 
- 
including initial smear, colposcopy (13%) and punch biopsy 
- 
costs of 
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treatment (62%) 
-including loop cone (44%), knife cone (10%) and laser biopsies - 
and costs of follow-up (19%), entailing further smears, colposcopy and biopsies. 
Analysis of variance revealed that the mean total cost of pre-invasive carcinoma of the 
cervix was significantly lower than that for all stages of invasive cancer (F = 90.06 P 
= 0.000). 
In clinical management terms, the significant cost differential between stage I 
cervical cancer and that at more advanced stages may be explained as follows. Stage I 
cervical cancer requires fewer staging investigations to assess the extent of tumour 
spread at the time of diagnosis. The treatment of choice tends to be hysterectomy with 
adjuvant radical radiotherapy. In turn, such radiotherapy is less complex and is more 
regularly carried out on an outpatient basis. Due to superior prognosis, fewer post- 
primary treatment investigations are undertaken and less palliative radiotherapy and 
palliative inpatient care is necessary. 
As is evident from the standard deviations presented in table 6.9, cost 
variations about the mean for particular classes of events are high, with standard 
deviations often exceeding the means. Such a pattern is commonly observed when 
cohorts are costed and arises because of wide variations in treatment patterns between 
patients, even amongst those ostensibly exhibiting the same pattern of disease. Spread 
is inevitably enhanced when, as is often the case, a proportion of the cohort receives 
no treatment under a particular cost heading, i. e. zero costs are included in the range. 
It will be observed in tables 6.9 and 6.10 that, whilst certain individual items of 
therapy display large variances, the variance in the total is substantially smaller. This 
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is accounted for by negative correlations between costs in the different categories, 
principally, the palliativelprimary sub-divisions as noted above. 
The costs reported exclude the time and travel costs incurred by the patient and 
their family when undergoing any of the treatment. When these costs, based on 
estimates reported by Sculpher and colleagues(18) updated to 1990 costs, are included, 
the estimated management costs for cervical cancer increase by 4.7%, 3.0%, 2.3%, 
1.9% and 1.3% for pre-invasive to stage IV cancers respectively. 
For the purpose of comparison with the breast cancer data and with other cervical 
cancer cost estimates(19) it is useful to observe costs according to three distinct 
disease phases, initial, continuing and terminal disease. Table 6.11 displays these cost 
data. The initial care costs have been calculated using the first three and six months of 
care. The terminal care costs have been taken to be the costs incurred three months 
and six months prior to death. Continuing care costs are based on average monthly 
costs of continuing care. For the sample as a whole, mean initial, continuing and 
terminal care costs estimated over a 3-month period amount to £5,831, £82 and £4,089 
respectively, over a 6-month period they amount to £6,169, £81 and £5,809 
respectively. 
302 
44 
liz 
Ln 
eia 
aA 
wrw 
oý 
''- 
o 
N 
N 
O 
O 
N 
x M N 
OO OO MM [ý O p 
ý 
O 
c 
N 
- 
V) 
N 
- 
p0 
CO 
M 
Cý 
Cl) 
N N 
O 
oc 
41 
CI 
L N 
r4 
N 
- 
M 
cq 
00 
O 
Ö 
N 
N 
O, 
O 
C) 
M 
vl 
ýO 
'IT 
N 
O 
O 
14; 
N 
'C M 
M 
O 
S 
NQ 
N 
x 
IO 
C14 
x 
N 
x 
CA 
- 
lzr 
M 
M 
r- 
10 
n 
cq 
l- 00 
M 
"t 
[ý 
c" 
N 
O O 
00 
r 
p 
O N M M M 
x 
x (ON V% Oý 
Ö 
O 
N 
M 
rý M 
Oý 
-: 
et M 
O M 
,' 
N 
vl 
Ö 
M 
- 
vii 
N 
p 
- 
N 
V1 
O 
M Q1 00 
Q 
pý 
O 
N 
pip 
N 
co C> 
N 
a` 
1- 
oo 
4 
Ö 
N M 
ii 
v 
- 
10 ýs 
v) 
O 
O' 
O 
r- 
a0 
t-I 
rIq 
Ö 
ry 
Ir N N ýD Q: M V'1 
Op 
'o It 
r- 
[\ Iýt O 't 
Vl 
C 
v% 
- F- ON 
N 
en 
M [- 
N ^ 
N 
ýO 
N 
a cad v 
x I 
v 
Oý 
N 
Oý 
N 
ýn 
N 
O 
M 
Oý 
- 
O ýC (N 
M 
N 
'O 
C 
00 
00 
ý, 
n 
z: 
^ 4 
_j Ü ö 
L C «S cÖ Ö 'p d (1 C = Oi 
c 
a 
: 
N ä 2 ro 
v = 
,a 
i c 
b L a r 
M 
O 
M 
Table 6.10 Cost of pre-invasive carcinoma of the cervix 
CIN 1 (15) CIN 11 (3 1) CIN 111 (95) 
Mean SD % of Mean SD % of Mean SD % of 
total total total 
Diagnosis Smear 2 4 0.5 1 2 0.5 1 3 0.5 
Colposcopy 52 13 13 48 
- 
13 48 
- 
12 
Punch 32 27 8 34 21 9 19 20 5 
biopsy 
Management Loop cone 128 124 33 178 107 47 174 108 45 
biopsy 
Knife cone 
- - - 
15 60 4 53 100 14 
biopsy 
Laser 83 122 21 40 94 11 23 66 6 
biopsy 
Follow up Smear 42 12 11 31 22 8 30 19 7 
Second 3 11 0.5 1 8 0.5 5 15 1 
smear 
Third 
- - - - - - 
1 5 0.5 
smear 
Colposcopy 42 17 11 23 25 6 31 23 8 
Biopsy 8 17 2 3 10 1 3 10 1 
TOTAL 392 89 375 59 388 64 
COST 
95% Cl 343-441 353-396 375-402 
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Table 6.11 Cost of initial, terminal and continuing care 
Cost £ All Stage I Stage II Stage III Stage IV 
Mean SD Mean SD Mean SD Mean SD Mean SD 
Initial 3 month* 5,831 4,062 4,644 2,951 6,635 4,406 7,697 3,959 8,672 7,653 
Terminal 3 4,089 5,674 2,094 2,987 3,599 4,727 5,184 6,777 5,703 7,695 
month** 
Continuing 3 82 302 50 163 123 387 39 51 478 1,082 
month*** 
Initial 6 month+ 6,169 3,877 5,030 3,081 7,531 4,559 7,449 3,179 9,682 5,862 
Terminal 6 5,809 7,527 3,192 4,320 4,401 6,405 7,571 8,302 9,313 10,157 
month++ 
Continuing 6 81 477 79 555 98 392 44 59 18 16 
month+++ 
*Initial treatment costs include all the costs initiated within the first 3 months from diagnosis 
**Continuing care costs are calculated using the average monthly cost incurred after the initial 3 
months following diagnosis and in cases where death occurred prior to the final 3 months of care used 
in estimating the terminal care costs 
***Terminal care costs were calculated using the last 3 months of costs for patients who had died 
during the follow up period 
+Initial treatment costs include all the costs initiated within the first 6 months from diagnosis 
++Continuing care costs are calculated using the average monthly cost incurred after the initial 6 
months following diagnosis and in cases where death occurred prior to the final 6 months of care used 
in estimating the terminal care costs 
+++Terminal care costs were calculated using the last 6 months of costs for patients who had died 
during the follow 
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6.4 Impact of costs with respect to Trent region 
In addition to the 376 invasive cancers identified in the Cancer Registry data, 1,867 
cases of pre-invasive cancer were detected in 1990, as a result of the screening 
programme. Assuming that the full population of invasive cancers was staged 
according to the sample stage distribution, the gross 1990 discounted five-year costs of 
the management of cervical cancer in Trent would amount to approximately $4.1 
million, equivalent to slightly less than £1 per head of population (see Table 6.12). 
For cervical cancers as a whole, the invasive cases comprised just 16 per cent of the 
total, yet were responsible for 83 per cent of the costs of diagnosis, treatment and 
follow-up. Sizeable cost economies in the management of cervical cancer may 
evidently be realised by detection at earlier stages; for example, had all the invasive 
cancers been detected at stage I then the total diagnosis and treatment costs for Trent 
would have been around 21 per cent lower. Perhaps more improbably, had all the 
cancers been detected by screening at the pre-invasive stage, then the total diagnosis 
and treatment costs for Trent would have amounted to only around £0.9m, 
representing a saving of £3.3 million or 79 per cent of cervical cancer management 
costs. Naturally, these potential treatment cost savings would have to be offset against 
the costs of the screening programme. 
Table 6.12 Impact of cost of cervical cancer in Trent 
Stage Stage distribution Number of Average cost Total cost 
-- - 
cancers 
- 
estimate £ 1990 £ 1990 
---- CIN III/CIS - 82% ---- 1,867 --- 338 631,046 
Stage I 8% 195 6,621 1,291,095 
Stage II 5% 115 10,910 1,254,650 
Stage III 3% 64 10,838 693,632 
Stage IV 1% 24 11,535 276,840 
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6.5 Comparison with other cervical cancer costing studies. 
The results of this analysis of cervical cancer management costs can be compared with 
those of other studies (Table 6.13). One undertaken in the USA (20) produced figures 
for stage I cancer of around £6,000 (converted into £ 1990 using exchange rates and 
up-rating using the Hospital and Community Health Services Pay and Price Index) 
and, for stage IV, of around £10,000. However, unlike my results, stage II and III 
costs were closer to those of stage I than they were to those of stage IV. Another US 
study produced significantly lower cost estimates for invasive cervical cancer ranging 
from £3600-£7,100(21). A later US study (22) cited results with a closer similarity to 
the Trent estimates 
- 
stage I at around £7,000 with stages II through IV at £ 11-12,000 
- 
whilst another (23) produced translated estimates of around £5,500 for early-stage, and 
of around £8,000 for late-stage, cancer. The study by Mandelblatt and colleagues 
produced similar cost estimates to the Trent estimates, with estimates converted to 
1990 £ sterling of £930 for carcinoma-in-situ, £5,500 for early stage cancer and 
£10,400 for advanced stage cancer(24). Unfortunately the methods used for costing 
were not described in detail and limited any thorough comparisons. A more recent US 
study exploring the costs and cost-effectiveness of screening for cervical cancer in 
HIV-infected women used significantly higher cost estimates for pre-invasive (£900- 
£3,800) and invasive (£13,200-£19,100) cancer(25). Significantly higher cost 
estimates were also used by two more US studies when estimating the cost- 
effectiveness of PAPNET testing(26) and interactive neural network assisted 
screening(27). In a New Zealand study(28) the average treatment costs for all 
invasive cancers across all stages was estimated at around £6,500. A French study 
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estimated the costs of pre-invasive cancer at £480, early stage cancer ranging from 
£1,500-£5,900 and late stage cancer at £14,000(29). A Dutch study resulted in similar 
cost estimates to those reported in this thesis for invasive disease, stage I was 
estimated to range from £5,100 toil 1,052, and £10,500 for stages I1-IV(30). Similar 
results were also reported in a US study where costs were estimated according to 
initial and terminal care costs (based on a six month basis)(19). The reported initial 
and terminal costs were, for local disease £6,600 (compared with the Trent cost 
estimate of £5,000), for regional disease £8,500 and £5,700 (compared with Trent cost 
estimates of £7,500 and £6,000), and for distant disease £9,300 and £10,800 
(compared with the Trent cost estimates of £9,700 and £9,300). 
Suggestive as these findings are, it must be borne in mind that the comparison 
of cost results across health care systems is intrinsically problematic. Currency 
conversions are essentially arbitrary and, especially in the USA, charges and prices are 
frequently used in place of resource costs. Perhaps most importantly, none of the 
above studies provide either sufficient detail of the methods of cost-accounting 
employed, or information at a disaggregated level, to enable the reader to identify the 
sources of similarities and differences between their estimates and those reported in 
this thesis. The following studies however, are more transparent: 
One early UK study(3 1) employed a case record approach to costing and 
examined 80 pre-invasive and invasive cases. Converted into 1990 prices, the 
estimates were £376 and £1,969 per case, respectively, and the pre-invasive estimate 
corresponds closely with the Trent figures. The invasive estimate, however, is 
considerably lower, and this is accounted for by the use of a one-year, rather than five- 
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year, time frame, the omission of many chemotherapy and radiotherapy costs and the 
use of, in my view, an unrealistically-low estimate of inpatient hospital stay (less than 
10 per cent of the values observed in the Trent data, even after allowance for 
inflation). A more recent study (32), which used only length of stay as an indicator of 
resource usage for invasive cancer, produced an order-of-magnitude estimate of 
£3,000 per case per annum (1990 prices), i. e. £15,000 over five years. Cuzick and 
colleagues (1999) (33) in a review of the role of HPV testing, estimated the costs of 
CIN and invasive cancer, the cost estimates for stage I and advanced disease closely 
approximate the Trent cost estimates, however the costs for pre-invasive (£900) and 
stages II and III cancers (£6,000) differ. 
Of the existing studies, the two that come closest to those reported in this 
thesis, in terms of methodology, were based in Holland. That which assessed the cost 
of management of invasive cancer at stages III and IV (34) produced an estimate in 
local currency that translates to £9,034, proximate to the Trent estimate of around 
£10,500. However, that which assessed the cost of CIN III pre-invasive carcinomas 
(35) produced an estimate of £1,153 in 1990 prices. This figure is considerably higher 
than my estimate, yet the transparency of the Dutch study permits an explanation of 
the difference, which derives essentially from variations in patient management 
between the samples. In the Dutch study, 33 per cent of women had conservative 
treatment (laser ablation, cryotherapy and loop diathermy), 56 per cent had conization 
with an average length of inpatient stay of 2.7 days and 11 per cent underwent 
hysterectomy, with an average length of stay of 1.3 days. In the Trent sample, 
however, no CIN3 case underwent hysterectomy, 95 per cent had conization and only 
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5 per cent had conservative treatment. Neither of these last two procedures required 
inpatient stays as all were carried out on either an outpatient or day-case basis. This 
comparison clearly indicates that, whilst costs inevitably differ within a health care 
system on a patient-by-patient basis, systematic cost differences can be observed 
across health care systems, owing to the acceptance of different management 
protocols. 
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6.6 Conclusions 
At the time of planning the analysis of the costs for cervical cancer in the Trent region, 
only one rather out-dated UK cost study existed(3 1). Cost estimates from other 
countries were available, however, again the majority were from studies conducted in 
the 1970s and 1980s(20-22,28). Even where cost estimates were available for current 
years of analysis(23,34), variations in treatment protocols and ways of estimating 
costs through the use of charges make it problematic to transfer the results to a UK 
setting. It was surprising to find that no formal cost-effectiveness analysis of the 
screening programme has ever been undertaken in the UK. However, this lack of 
analysis is due to the lack of available data from the UK cervical screening 
programme. The screening programme was introduced in the mid 1960's based on the 
prior hypothesis that screening would reduce the incidence and mortality of invasive 
cervical cancer. A hypothesis based on little evidence let alone any randomised 
control trial. The UK programme led a haphazard existence until the mid 1980's (see 
Appendix 6.6 for explanation of the UK cervical cancer screening service since 1984), 
and is blamed for the continually high rates of invasive cancer incidence and mortality 
in the UK compared with other countries where screening has been in place. As 
Draper (1982) states: 
"When compared with the performance of services in some other countries, and with 
computed expectations in this country, the UK screening service appears to be a 
relative failure. " (38: 39). 
Due to the length of time the screening programme has existed in the UK, no 
data exist on incidence rates or stage distribution prior to the implementation of the 
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programme. It was therefore felt impossible to use the cost estimates reported in the 
chapter to analyse the cost-effectiveness of the UK cervical screening programme. 
However, analysis of the cost-savings relating to altering the current distribution of 
stage at diagnosis was undertaken. 
This cost analysis has therefore provided current estimates of cost for cervical 
cancer by stage of disease. It suggests that the mean total cost of diagnosis, treatment 
and follow up for stage I cancers is significantly lower than that for cancers at the 
other three stages, and that cost of pre-invasive cancer is significantly lower than that 
for invasive cancer. For cervical cancers as a whole, the invasive cases comprised just 
16 per cent of the total, yet were responsible for 83 per cent of the costs of diagnosis, 
treatment and follow-up. Sizeable cost economies in the management of cervical 
cancer may evidently be realised by detection at earlier stages; for example, had all the 
invasive cancers been detected at stage I then the total diagnosis and treatment costs 
for Trent would have been around 21 per cent lower. Perhaps more improbably, had 
all the cancers been detected by screening at the pre-invasive stage, then the total 
diagnosis and treatment costs for Trent would have amounted to only around £O. 9m, 
representing a saving of £3.3 million or 79 per cent of cervical cancer management 
costs. Naturally, these potential treatment cost savings would have to be offset against 
the costs of the screening programme. 
The estimation of these costs is extremely pertinent to the current research into 
HPV testing. Before such a programme can be introduced, the National Health 
Service requires evidence of its effectiveness and cost-effectiveness. Modeling work 
has already been undertaken using Dutch cost estimates(30,33). However two new 
317 
trials have recently been funded using the cost estimates reported in this chapter to 
explain the potential cost savings involved in implementing HPV testing. 
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References 
1. Cancer Research Campaign. Cancer of the Cervix Uteri: Cancer Research 
Campaign; 1994. Report No.: Factsheet 12.1. 
2. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, et al. A systematic 
review of the role of human papilloma virus (HPV) testing within a cervical 
screening programme: summary and conclusions. British Journal of Cancer 
2000; 83(5): 561-5. 
3. Wise J. UK pilot scheme for HPV testing announced. British Medical Journal 
2000; 320(7235): 600. 
4. Office for National Statistics. 1992 Cancer Statistics, registrations. London: 
HMSO; 1998. 
5. Trent Cancer Registry. Trent Cancer Registry 
- 
Third Report. Sheffield; 1999. 
6. Office for National Statistics. 1997 Mortality Statistics, Cause. London: HMSO; 
1998. 
7. Austoker J, Ann MP. Cervical Screening. 2 ed. Oxford: Oxford University Press; 
1992. 
8. OPCS. 1989 Cancer Statistics: registrations England & Wales. London: HMSO; 
1994. 
9. Shephard JH. Revised FIGO staging for gynecological cancer. British Journal of 
Obstetrics and Gynaecology 1989; 96(8): 889-892. 
10. Parkin DM, Nguyen-Dinh X, Day' NE. The impact of screening on the incidence 
of cervical cancer in England and Wales. British Journal of Obstetrics and 
Gynaecology 1985; 92: 150-157. 
11. Chomet J, Chomet J. Cervical Cancer: Its Prevention and Treatment: Thorsons; 
1989. 
12. Dickson RJ. Management of Carcinoma of the Cervix. The Practioner 
1980; 224: 899-904. 
13. Brenner DE. Carcinoma of the Cervix -A Review. The American Journal of The 
Medical Sciences 1982; 284(1): 31-48. 
319 
14. Coulter C, Mason P. Cervix and endometrium. In: Sikora K, Halnan KE, editors. 
Treatment of Cancer. London: Land, Chapman Hall Medical; 1990. 
15. Sproston ARM. Non-surgical treatment of cervical carcinoma. British Journal of 
Hospital Medicine 1994; 52(1): 30-34. 
16. Kingston R. Primary surgical management of cervical cancer. British Journal of 
Hospital Medicine 1995; 53(9): 447-451. 
17. Hopkins M, Morley G. Radical hysterectomy versus radiation therapy for stage lb 
squamous cell carcinoma of the cervix. Cancer 1991; 68: 272-273. 
18. Sculpher MJ, Buxton MJ. The private costs incurred when patients attend 
screening clinics: the cases of screening for breast cancer and for diabetic 
retinopathy. Uxbridge: Brunel University; 1993 1993. Report No.: HERG 
Discussion Paper No. 10. 
19. Helms LJ, Melnikow J. Determining costs of health care services for cost- 
effectiveness analyses: the case of cervical cancer prevention and treatment. 
Medical Care 1999; 37(7): 652-61. 
20. Schneider J, Twiggs LB. The Costs of Carcinoma of the Cervix. Obstetrics and 
Gynecology 1972; 40(6): 851-859. 
21. Smucker CM, Swint JM, Stovall M, Guinee VF. The model of economic benefits 
of early stage detection and treatment of cancers and its application to cervical 
cancer. Cancer Detction and Prevention 1979; 2(3): 399-409. 
22. Baker MG, Kessler LG, Smucker RC. Analysis of the continuous Medicare history 
sample file: the cost of treating cancer. In: Procedings of Cancer Care and Costs; a 
meeting of American Cancer Society; 1987 1989; San Diego, California; 1987. 
23. Fates MC, Mandleblatt J, Schechter C, Muller C. Cost effectivenss of Cervical 
Cancer Screening for the Elderly. Annals of Internal Medicine 1992; 117(6): 520- 
527. 
24. Mandelblatt J, Freeman H, Winczewski D, Cagney K, Williams S, Trowers R, et 
al. The costs and effects of cervical and breast cancer screening in a public hospital 
emergency room. The Cancer Control Center of Harlem. American Journal of 
Public Health 1997; 87(7): 1182-1189. 
320 
25. Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits, 
and cost-effectiveness of screening for cervical cancer in HIV-infected women. 
Annals of Internal Medicine 1999; 130(2): 97-107. 
26. Schechter CB. Cost-effectiveness of rescreening conventionally prepared cervical 
smears by PAPNET testing. Acta Cytologica 1996; 40(6): 1272-82. 
27. Radensky PW, Mango U. Interactive neural-network-assisted screening. An 
economic assessment. Acta Cytologica 1998; 42(1): 246-52. 
28. Bethwaite J, Rayner T, Bethwaite P. Economic aspects of screening for cervical 
cancer in New Zealand. New Zealand Medical Journal 1986; 99(811): 747-751. 
29. el M'Rini T, Arveux P, Gay C, Woronoff Lemsi MC, Gautier C, Gaillard A, et al. 
Estimation of the treatment cost of cervical cancer. Rev Epidemiol Sante Publique 
1997; 45(6): 508-15. 
30. van Ballegooijen M, van den Akker van Marle ME, Warmerdam PG, Meijer CJ, 
Walboomers JM, Habbema JD. Present evidence on the value of HPV testing for 
cervical cancer screening: a model-based exploration of the (cost-)effectiveness. 
British Journal of Cancer 1997; 76(5): 651-7. 
31. Thorn JB, Macgregor JE, Russell EM, Swanson K. Costs of detecting and treating 
cancer of the uterine cervix in North-East Scotland. Lancet 1975: 674-676. 
32. Waugh N, Robertson A. Costs and benefits of cervical screening. H. Is it 
worthwhile reducing the screening interval from 5 to 3 years? Cytopathology 
1996; 7: 241-248. 
33. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, et al. A systematic 
review of the role of human papillomavirus testing within a cervical screening 
programme. London: NHS R&D HTA Programme; 1999. Report No.: Vol 3 No 
14. 
34. van Ballegooijen M, Koopmanschap MA, Subandono Tjokrowardojo AJ, van 
Oortmarssen GJ. Care and Costs for Advanced Cervical Cancer. European Journal 
of Cancer 1992; 28A(10): 1703-1708. 
35. van Ballegooijen M, A. KM, J. D. F. H. The Management of Cervical Intra- 
epithelial Neoplasia (CIN): Extensiveness and Costs in The Netherlands. European 
Journal of Cancer 1995; 31 A(10): 1672-1676. 
321 
36. Muller C, Mandelblatt J, Schecter CB, al. e. The costs and effectiveness of 
screening for cervical cancer in elderly women: Series on Preventive Health 
Services Under Medicare. Washington: Office of Technology Assessment, US 
Congress; 1990. Report No.: Paper No. 4. 
37. Eddy DM. Screening for Cervical Cancer. American College of Physicians 
1990; 113(3): 214-226. 
38. Draper GJ. Screening for cervical cancer: revised policy. The recommendations of 
the DHSS Committee on Gynecological Cytology. Health Trends 1982; 14: 37-40. 
322 
Appendix 6.1 Diagnosis/staging algorithm for cervical cancer from the 
literature 
Repeat smear 
ti 
BENIGN 
Presentation Cytological smear 
Repeat smear BENIGN 
Colposcopy 
/ 
Biopsy Pyelography 
\Rectovaginal examination CT scan Lymphagiogram SUSPICIOUS Full blood count, electrolytes, etc. Sigmoidoscopy 
Liver fucntion test 7Cvstoscopv 
hest X-mv 
A DISTANT SPREAD 
MALIGNANT 
ti 
NO SPREAD 
Treatment algorithm for breast cancer by stage from the literature. 
Conservative hysterectomy 
Surgery 
I and Ili 
ýNo 
surgery 
No radiotherapy 
/Intrt 
cavity radiotherapy OCT) 
"External beam radiotherapy (EBRT) ti 
Combination radiotherapy ICT + EBRT 
ti 
No radiotherapy 
//Intraavity radiotherapy (iCT) 
External beam radiotherapy (EBRT) 
ti 
Combination radiotherapy ICT + EBRT 
ti 
Intracavity radiotherapy (ICT) 
External beam radiotherapy (EBRT) 
Combination radiotherapy ICT + EBRT 
ti 
Malignant sample Surgery 
- 
Wertheim hysteretomy 
ICT 
I ti 
Stage lib & 11I 
EBRT 
ti 
palliative radiotherapy 
ti 
palliative radiotherapy 
ti Stage IV <inpatient 
palliative care 
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Appendix 6.3 Resource use by stage 
- 
invasive cervical cancer 
Event All Stage 1 (128) Stage 11 (76) Stage 111 (41) Stage IV (15) 
n % of n % of n % of n % of 
stage I stage stage stage 
11 111 IV 
Wertheims 78 57 45 19 25 2 5 0 0 
hysterectomy 
Total hysterectomy 17 14 11 3 4 0 0 0 0 
Chemotherapy 26 5 4 16 21 5 12 0 0 
Primary radical 161 67 53 59 78 30 71 2 13 
radiotherapy 
Primary Palliative 18 1 1 3 4 6 14 8 53 
radiotherapy 
Hormone 56 34 27 21 28 1 2 0 0 
replacement 
therapy 
Investigation 68 23 18 30 40 11 26 4 27 
Palliative care 20 3 2 10 13 4 10 3 20 
Inpatient palliative 56 8 6 25 33 15 36 8 53 
care 
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Appendix 6.4 Resource use by cancer stage years 1-7 
- 
Invasive cervical 
cancer 
Patients using resources by stage (%) 
YEAR 1 I (n=128) II (n-16) 111(u-41) 
Diagnosis cytology 39 30 21 
Colposcopy 78 47 31 
Punch Biopsy 50 70 67 
Cone biopsy 52 22 17 
Loop excision 2 3 0 
D&C 54 51 50 
Cystoscopy 39 62 67 
Chest x-ray 52 53 55 
IVP 38 40 43 
Proctoscopy 0 0 5 
Lymphangiogram 17 12 5 
Ultrasound 7 11 31 
CT scan 24 28 26 
Chest x-ray 2 3 2 
Sigmoidoscopy 1 0 2 
Abdominal x-ray 1 1 0 
Kidney x-ray 1 0 0 
Pelvic x-ray 2 0 0 
Bone scan 0 1 2 
MRI 6 8 5 
Laparotomy 2 0 2 
Polypectomy 1 0 0 
Surgery Wertheims 44 24 5 
hysterectomy 
Conservative 11 3 0 
hysterectomy 
Radiotherapy Radical 11 5 1 
Intracavity 
Radical External 4 13 14 
beam 
Radical Internal + 41 64 55 
External 
Palliative 0 1 0 
Intracavity 
Palliative 1 4 10 
External beam 
Palliative Internal 0 1 5 
+ External 
Chemotherapy 0 8 5 
Hormone 17 11 0 
replacement 
therapy 
Investigations 
Inpatient 
palliative care 
Palliative care 
IV (n=15) 
13 
27 
53 
0 
0 
27 
60 
80 
40 
0 
7 
47 
20 
13 
13 
0 
0 
7 
0 
0 
7 
0 
0 
0 
0 
0 
13 
0 
27 
27 
0 
0 
6 13 17 13 
2 9 26 53 
0 5 5 20 
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YEAR 1 I (n=128) U (n-76) 111(u-41) IV (n=1S) 
Follow-up Outpatient visit 56 41 14 27 
Radiotherapy 40 49 57 40 
clinic 
Bimanual 10 16 10 7 
palpation 
Bone scan 0 0 0 0 
Clinical 43 33 29 20 
examination 
Colposcopy 0 0 0 0 
CT scan 4 3 14 0 
Chest x-ray 7 3 17 33 
Cystoscopy 2 3 2 0 
IVP 2 0 0 7 
Liver function 0 0 2 0 
test 
MRI scan 2 4 5 0 
Sigmoidoscopy 0 1 2 0 
Cervical smear 27 5 2 7 
Spine x-ray 2 0 2 0 
Ultrasound 2 7 7 7 
YEAR 2 
Radiotherapy Radical 1 0 2 0 
Intracavity 
Radical External 0 0 2 0 
beam 
Radical Internal + 0 0 0 0 
External 
Palliative 0 0 0 0 
Intracavity 
Palliative 0 1 0 13 
External beam 
Palliative Internal 0 0 0 0 
+ External 
Chemotherapy 0 11 2 0 
Hormone 21 21 0 0 
replacement 
therapy 
Investigations 9 11 10 0 
Inpatient 2 17 2 0 
palliative care 
Palliative care 0 4 5 0 
Follow-up Outpatient visit 57 47 19 7 
Radiotherapy 46 66 50 27 
clinic 
Bimanual 20 20 12 13 
palpation 
Bone scan 3 4 7 0 
Clinical 64 54 29 13 
examination 
Colposcopy 2 0 0 0 
CT scan 6 16 12 7 
Chest x-ray 9 22 14 7 
Cystoscopy 2 1 10 0 
IVP 2 0 5 7 
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YEAR 2 I II III IV 
Follow up Liver function 1 1 0 0 
test 
MRI scan 1 3 2 0 
Sigmoidoscopy 1 3 0 0 
Cervical smear 47 21 10 7 
Spine x-ray 2 11 0 0 
Ultrasound 4 16 7 0 
YEAR 3 
Surgery Wertheims 0 1 0 0 
hysterectomy 
Conservative 0 1 0 0 
hysterectomy 
Radiotherapy Radical 0 0 0 0 
Intracavity 
Radical External 2 2 0 0 
beam 
Radical Internal + 0 0 0 0 
External 
Palliative 0 0 2 0 
Intracavity 
Palliative 2 0 0 0 
External beam 
Palliative Internal 0 0 0 0 
+ External 
Chemotherapy 2 2 2 0 
Hormone 23 21 2 0 
replacement 
therapy 
Investigations 3 7 5 0 
Inpatient 1 3 0 0 
palliative care 
Palliative care 1 0 0 0 
Follow-up Outpatient visit 56 37 14 7 
Radiotherapy 47 45 29 20 
clinic 
Bimanual 13 12 7 7 
palpation 
Bone scan 0 4 0 0 
Clinical 50 29 12 7 
examination 
Colposcopy 2 0 0 0 
CT scan 5 4 7 7 
Chest x-ray 6 11 2 0 
cystoscoPy 2 1 0 0 
IVP 2 3 2 0 
Liver function 0 0 0 0 
test 
MRI scan 1 1 0 0 
Sigmoidoscopy 1 0 2 0 
Cervical smear 45 21 7 7 
Spine x-ray 1 3 2 0 
Ultrasound 3 8 0 0 
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YEAR 4 I II III IV 
Radiotherapy Radical 0 0 0 0 
Intracavity 
Radical External 0 0 0 0 
beam 
Radical internal + 0 0 0 0 
External 
Palliative 0 0 0 0 
Intracavity 
Palliative 0 1 0 0 
External beam 
Palliative Internal 0 0 0 0 
+ External 
Chemotherapy 1 3 2 0 
Hormone 22 22 2 0 
replacement 
therapy 
Investigations 5 4 5 13 
Inpatient 1 0 7 0 
palliative care 
Palliative care 1 0 0 0 
Follow-up Outpatient visit 46 28 12 7 
Radiotherapy 41 36 14 20 
clinic 
Bimanual 15 12 2 13 
palpation 
Bone scan 1 1 5 0 
Clinical 33 25 2 13 
examination 
Colposcopy 1 1 0 0 
CT scan 3 7 5 7 
Chest x-ray 7 7 5 0 
Cystoscopy 1 0 2 7 
IVP 1 0 0 0 
Liver function 0 0 0 0 
test 
MR! scan 1 0 0 0 
Sigmoidoscopy 2 3 2 0 
Cervical smear 34 18 5 0 
Spine x-ray 0 0 0 0 
Ultrasound 2 3 7 7 
YEAR S 
Radiotherapy Radical 0 0 0 0 
Intracavity 
Radical External 0 1 0 0 
beam 
Radical Internal + 0 0 0 0 
External 
Palliative 0 4 0 0 
Intracavity 
Palliative 1 3 0 0 
External beam 
Palliative Internal 0 0 0 0 
+ External 
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YEARS I II III IV 
Chemotherapy 1 0 0 0 
Hormone 20 22 2 0 
replacement 
therapy 
Investigations 2 H 0 7 
Inpatient 1 3 0 0 
palliative care 
Palliative care 1 4 0 0 
Follow-up Outpatient visit 41 22 10 7 
Radiotherapy 39 34 14 20 
clinic 
Bimanual 9 7 5 7 
palpation 
Bone scan 1 3 0 0 
Clinical 36 24 5 7 
examination 
Colposcopy 1 0 0 0 
CT scan 5 4 0 0 
Chest x-ray 4 3 2 0 
Cystoscopy 2 0 0 0 
IVP 0 0 0 0 
Liver function 0 0 0 0 
test 
MRI scan 1 0 0 0 Sigmoidoscopy 0 0 0 0 Cervical smear 30 11 5 0 Spine x-ray 0 1 0 0 Ultrasound 2 1 0 0 
YEAR 6 
Radiotherapy Radical 0 0 0 0 Intracavity 
Radical External 0 0 0 0 
beam 
Radical Internal + 0 0 0 0 
External 
Palliative 0 0 0 0 
Intracavity 
Palliative 0 1 0 0 
External beam 
Palliative Internal 0 0 0 0 
+ External 
Chemotherapy 0 0 0 0 
Hormone 0 0 0 0 
replacement 
therapy 
Investigations 0 1 0 0 
Inpatient 1 0 0 0 
palliative care 
Palliative care 0 0 0 0 
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YEAR 6 I II in IV 
Follow-up Outpatient visit 38 20 5 7 
Radiotherapy 31 27 15 20 
clinic 
Bimanual 6 7 2 0 
palpation 
Bone scan 1 0 0 0 
Clinical 19 11 2 7 
examination 
Colposcopy 0 0 0 0 
CT scan 1 4 0 7 
Chest x-ray 2 1 0 0 
Cystoscopy 0 1 0 0 
IVP 1 3 0 0 
Liver function 0 0 0 0 
test 
MRI scan 0 1 0 0 
Sigmoidoscopy 0 0 0 0 Cervical smear 18 8 0 0 
Spine x-ray 1 1 0 0 
Ultrasound 2 3 2 0 
YEAR 7 
Radiotherapy Radical 0 0 0 0 
Intracavity 
Radical External 0 0 0 0 
beam 
Radical Internal + 0 0 0 0 
External 
Palliative 0 0 0 0 
Intracavity 
Palliative 0 0 0 0 
External beam 
Palliative Internal 0 0 0 0 
+ External 
Chemotherapy 0 0 0 0 
Hormone 0 0 0 0 
replacement 
therapy 
Investigations 0 0 0 0 
Inpatient 0 0 0 0 
palliative care 
Palliative care 0 0 0 0 
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YEAR 7 I II III IV 
Follow-up Outpatient visit 1 0 0 0 
Radiotherapy 3 2 0 0 
clinic 
Bimanual 0 0 0 0 
palpation 
Bone scan 0 0 0 0 
Clinical 0 0 0 0 
examination 
Colposcopy 0 0 0 0 
CT scan 0 0 0 0 
Chest x-ray 0 0 0 0 
Cystoscopy 0 0 0 0 
IVP 0 0 0 0 
Liver function 0 0 0 0 
test 
MRl scan 0 0 0 0 
Sigmoidoscopy 0 0 0 0 
Cervical smear 0 0 0 0 
Spine x-ray 0 0 0 0 
Ultrasound 0 0 0 0 
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Appendix 6.6 
Explanation of UK cervical cancer screening programme since the 1980s 
In 1984 the DHSS produced guidelines based on the recommendations made 
by the Committee on Gynecological Cytology [Department of Health and 
Social Security: Committee on Gynecological Cytology, 1981 #200; 
Department of Health and Social Security: Health Services Development, 
1984 #201], this stated that all sexually active women aged 20 to 65 years 
should be screened at five yearly intervals. In 1988 a Department circular 
marked the introduction of the current programme, which extended screening 
to all women aged between 20 and 65, with recall at least every 5 years. 
Some health authorities follow this process although the majority now follow 
the recommendations made by the Intercollegiate Working Party on Cervical 
Cytology Screening to screen every 3 years. The Committee on 
Gynecological Cytology also called for the nationally based call and recall 
scheme to be replaced by local schemes, using computer facilities wherever 
possible. In fact it is FPC's who now perform the role of call and recall with 
computerised systems. The potential for primary care to influence and 
improve coverage of target populations was recognised. Hence, the 1990 
general practitioner contract set target payments for cervical cancer screening. 
Payments are triggered on reaching 50% or 80% coverage of the target 
population (women aged between 25 and 64) over the preceding 5.5 years. 
The 50% coverage target rate is met with a lower target payment. This has led 
to a considerable increase in screening activity. Coverage of the target 
population has increased, as can be seen in the table below [Government 
Statistical Service, 1989-1995 #202]. 
Year England Trent Lowest Highest 
(% coverage in (% coverage in coverage coverage 
last 5 years) last 5 years) 
1989-1990 62% 72% 34% 79% 
1990-1991 74% 83% 61% 86% 
1991-1992 80% 88% 64% 88% 
1992-1993 83% 89% 70% 89% 
1993-1994 84% 90% 75% 90% 
1994-1995 86% 91% 76% 91% 
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Chapter 7 
Lung Cancer 
7.1 Introduction 
As is the case for most industrialised countries, lung cancer is the most prevalent form 
of cancer in the United Kingdom. Along with ischaemic heart disease, 
cerebrovascular disease and pneumonia, it has ranked amongst the top four causes of 
mortality over the past three decades[1]. The risk of lung cancer, as with most 
cancers, increases with age (Figure 7.1). Lung cancer is uncommon before the age of 
forty-five and then increases rapidly with age, peaking at the age of 70-74 years. Lung 
cancer is primarily a disease of the elderly with approximately 73% of lung cancer 
registrations in Trent occurring amongst the over 65's. It is also predominantly a male 
disease with the ratio of male to female lung cancer patients at approximately 2: 1. 
Recently, there has been a decline in the incidence in men, but the numbers of women 
with lung cancer are still rising. These trends are shown for the Trent data in Figure 
7.2. The increasing incidence and mortality in women is believed to reflect the uptake 
of cigarette smoking in women a couple of decades later than men. The vast majority 
of lung cancer cases (about 9 out of 10) are caused by tobacco smoking[2]. Although 
smoking is by far the major cause of lung cancer, it is not the only cause. Exposure to 
certain carcinogens in the workplace or at home, such as asbestos and radon, also 
increase the risk of lung cancer. 
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Along with great morbidity, lung cancer is also associated with high mortality 
rates, in fact with the 5-year survival rates being so poor (7% survival at 5 years[2]) 
and there being a short clinical course and poor prognosis it is unsurprising to find that 
mortality rates are a good approximation for the incidence of the disease and vice 
versa. 
Although it is generally believed that lung cancer treatment places a substantial 
burden on national health care resources, few data are available to substantiate this 
beliefj3]. This chapter presents estimates of the direct economic costs of the hospital 
treatment of lung cancer, based on the records of a sample of patients drawn from the 
Trent region. 
the most recent registration and mortality figures, lung cancer is 
ible for: 
" 
37,312 new registrations in England and Wales in 1992, of which male 
registrations accounted for 24,985, and female registrations accounted for 
12,327[4]. 
" 
3,177 new registrations in the Trent region in 1997, (males 2,114, females 
1,063)[5]. 
" 
The incidence of male lung cancer in England and Wales over the past 
decade is declining, while the incidence of female lung cancer is increasing. 
These trends are similar in the Trent region (see Figure 7.2). 
" 
30,199 deaths from lung cancer in England and Wales in 1998, (males 
19,036, females 11,1 63)[6]. 
" 
2,893 deaths in Trent in 1997 (males 1,915, females 978)[5]. 
" 
Internationally England and Wales is ranked twelfth worst out of 22 
countries for lung cancer mortality rates. Scotland has the highest death rate 
from lung cancer, 63 per 100,000 population, England and Wales has a death 
rate of 43 per 100,000 population, and Japan has the lowest at 21 per 
100,000 population[7]. 
" 
The 5-year relative survival rate for lung cancer in England and Wales is 
poor at approximately 7%[8]. 
" 
57 million years of life were lost due to lung cancer in 1992[7]. 
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Figure 7.1 Number and age- and gender-specific lung cancer registrations, 
Trent 1994 
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Figure 7.2 Male and female lung cancer registrations, 1971-1994 Trent (rate 
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7.2.1 Methods 
The assessment of the resource use and cost implications of lung cancer care requires 
data on all cost-generating events in the diagnosis, treatment and follow up of lung 
cancer patients. The first step was to undertake a literature search of diagnosis and 
treatments for lung cancer. Details were primarily taken from guidelines for the 
diagnosis, treatment and follow-up of lung cancer patients developed by a Department 
of Health working group[9]. 
7.2.1 Diagnosis, treatment and follow-up of lung cancer patients - Literature 
This information was used to construct stage specific treatment algorithms (Appendix 
7.1). These literature based treatment algorithms were useful in the development of a 
proforma to be used for obtaining information on lung cancer resource use from the 
medical notes of a ten per cent sample of those patients diagnosed with lung cancer in 
Trent in 1993 (Appendix 7.2). 
' sis: The majority of patients will present symptomatically to their GP. The 
GP's diagnosis will be based on physical examination and chest x-ray. The suspicious 
patient will be referred ideally to a chest physician, thoracic surgeon or oncologist for 
further diagnostic investigations. Diagnosis takes the form of clinical examination, 
chest x-ray and bronchoscopy. Bronchoscopy is a method of obtaining biopsies for 
the histological diagnosis of lung cancer, and should be performed whenever active 
treatment is required. There are two types of bronchoscopy; flexible bronchoscopy is 
a day case procedure performed under local anaesthetic, rigid bronchoscopy is a more 
complicated operation and is required if there are difficulties with the former 
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procedure or if larger specimens are required. Percutaneous needle biopsy is 
necessary if a sample is taken from the periphery of the lung. 
Other procedures commonly performed at this stage include lung function tests 
to assess the patients' ventilatory capacity and radioisotope scanning, e. g. bone, liver 
and brain scans which are useful in confirming clinical suspicion and improving the 
detection of stage. CT scanning is particularly beneficial in identifying peripheral 
tumours and can aid percutaneous needle biopsy. The CT scan has generally 
superseded older invasive surgical investigations such as mediastinoscopy and 
mediastinotomy which allowed sampling and visualisation of the mediastinal lymph 
nodes. 
For decisions about clinical management and for the purpose of constructing 
the treatment algorithm, lung cancer patients are differentiated according to cell type. 
The major histologic distinction is between non-small cell lung cancer (NSCLC) and 
small cell lung cancer (SCLC). SCLC can be split further into limited and extensive 
disease. 
Ircatlluent NCLC_ The majority of lung cancer patients (typically around 75-80 per 
cent) are diagnosed with non-small cell lung cancer (NSCLC)[10]. For them, surgical 
techniques may prove appropriate, whilst inoperable patients will be treated with 
radiotherapy[ 11] and, rarely in the UK at present, chemotherapy. The major chance of 
cure for this group of patients is provided by surgery, although only 20% of patients 
are deemed to be acceptable for surgical treatment. If there are no contraindications to 
surgery in the initial patient assessment these patients are then subjected to thoracic 
CT scanning to assess the spread to the mediastinum. If there is no tumour spread 
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then the patient should be considered for thoracotomy without any further 
investigations. If there are signs of spread to the mediastinum then the patient will 
have to undergo fu ther preoperative investigations in the form of mediastinoscopy 
and/or mediastinotomy. Surgical resection of the lung is in the form of either 
pneumonectomy (removal of the whole lung) or lobectomy (removal of part or a 
wedge of the lung). 5% of the patients who undergo thoracotomy will subsequently be 
found to be unsuitable for resection, and will therefore follow the treatment pathway 
of the inoperable patients. 
Inoperable patients are either treated with radiotherapy or palliatively with a 
mixture of symptom control, palliative radiotherapy and/or palliative chemotherapy. 
Radiotherapy with the intention of cure is given to those patients who are unsuitable 
for surgery but whose disease is confined to the chest. The total dose of radiotherapy 
ranges from 50-60 Gy delivered with megavoltage equipment (linear accelerator or 
cobalt-60) over 3-6 weeks. 5-year survival is approximately 28%. 
ft tment SCLC: Chemotherapy is the preferred treatment for the small cell lung 
(SCLC) cancer cases, on occasions in combination with radiotherapy[9]. Median 
survival for untreated limited SCLC is only 14 weeks, 7 weeks for extensive disease. 
Chemotherapy improves this median survival significantly to 12-18 months for limited 
disease and 9 months for extensive disease. Radiotherapy may be given in some cases 
after chemotherapy to enhance tumour control. For those patients with poor 
performance status the main aim of treatment is palliation using the minimum of 
cytotoxic drugs to control the disease and maintain a reasonable quality of life. 
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ollow u: Patients will usually receive post-treatment follow-up involving x-rays 
and/or scanning, although practices and policies appear to vary widely between 
clinics[12,13]. The most common investigations include chest x-ray, bone and brain 
scans and CT scanning. 
The majority of patients will eventually require palliative chemotherapy, 
palliative radiotherapy and/or symptom control. This having been said, it is probable 
that many patients never receive any treatment for lung cancer. 
7.2.2 Estimation of treatment costs 
The ideal method for costing any disease process is to have resource use and cost 
information on a patient specific basis. Given that the epidemiology of cancer in the 
UK has long been documented by the Cancer Registries on such a patient specific 
basis, it might be thought that a population-based resource use audit could be easily 
accomplished using pre-collected data. However, the Registry databases do not 
usually include details of either resource use or cancer stage at diagnosis. The cost 
estimates were therefore based on an analysis of treatment records of a sample of 
individual patients. Individual patient costing provides far more realistic overall cost 
estimates than does average costing or simulated costing. However, by auditing cost 
events for each single patient, the procedure is particularly time-consuming[ 14]. With 
2,900 lung cancer cases being diagnosed annually in Trent in 1993, a complete cost 
analysis of a full year's cohort was deemed to be prohibitively expensive. 
Accordingly, a 10 per cent random sample, amounting to 290 cancer patients from the 
Trent register was identified for four districts where primary treatment was undertaken 
(North Lincolnshire, Nottinghamshire, Rotherham and Sheffield). All had been 
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nominally diagnosed with lung cancer in 1993. This particular year was selected as a 
baseline on the grounds that it would permit the construction of a resource audit for 
each patient for up to four years, a period following diagnosis during which the 
majority of cancer recurrences and treatment complications would be likely to occur. 
If the patient was still alive after four years s/he was assumed to be cured and return to 
the life expectancy of the normal population[9]. The costing exercise was based on a 
retrospective examination of the medical case notes of the patient sample. This was 
facilitated by the use of a proforma developed with the aid of information obtained 
from the initial literature review on diagnosis and treatment and designed to collect 
both the epidemiological and economic data (see Appendix 7.2). It was verified by a 
consultant thoracic surgeon based at the Queen's Medical Centre, Nottingham, and 
piloted on 30 medical notes of lung cancer patients treated at the same hospital. 
An attempt to retrieve the full treatment records for all 290 cases revealed that, 
for 47, notes were untraceable, or cancers had been misclassified, either by diagnosis 
or by year. The initial sample according to the cancer registry had 252 patients 
classified as having NSCLC and 38 classified as having SCLC, however it was found 
that some of the patients had been misclassified by cell type. One patient was reported 
as being of non-small cell type, when in fact according to their medical notes the cell 
type was small-cell. Nine patients were reported by the registry as being small-cell 
lung cancer patients, where according to their medical notes they were reported as 
having non-small cell lung cancer. This resulted in a sample with 260 NSCLC 
patients and 30 SCLC patients. From this sample, further exclusions had to be made 
on the grounds of records being untraceable or containing no information, and cases 
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being misclassified by year of diagnosis (see Table 7.1). After these exclusions, 253 
records were available for analysis with 227 NSCLC patients and 26 SCLC patients. 
For the NSCLC patients it is possible to stage the disease according to the standard 
TNM classification ranging from stage Ito IV[ 15], however there was no information 
in the medical notes to enable this to be undertaken. For the SCLC patients, 17 were 
classified as having limited disease, 6 as having extensive disease and 3 patients could 
not be classified. 
A full audit of resource-using hospital events was compiled for each of these 
patients, for four years following initial diagnosis or until death, if occurring earlier. 
The unit costs of these events were obtained from a survey of eleven of the region's 
principal service providers, each of whom was sent a form requesting the cost of the 
various activities, as performed at their site (Table 7.2). Since 1993, all National 
Health Service (NHS) providers have been required to follow a uniform accounting 
protocol, requiring that their services be costed at full cost, i. e. all service-specific 
variable costs, with the inclusion of the relevant components of fixed and overhead 
costs[ 16]. I employed the mean of the reported costs of each event in the estimates, 
converted back to 1993 prices using the NHS pay and price index[17]. By combining 
the unit cost estimates with the resource use information, the mean costs of diagnosis, 
treatment and follow up by cell type at diagnosis for the sample over the follow up 
period were obtained. Given that management events were occurring across time, the 
costs of events occurring in years 2 through 4 following diagnosis were discounted at 
6 per cent. In other words, mean four-year costs were expressed as a 1993 present 
value, to represent the prospective cost implications from the perspective of the 
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baseline year. The discount rate chosen was that conventionally employed in 
evaluations of UK public sector projects[] 8]. 
Table 7.1 Lung cancer sample: retrieval of case notes and exclusion of 
patients (by district of primary treatment) 
North Nottinghamshire Rotherham Sheffield 
Lincolnshire 
SCLC 
Total sample size 
No diagnosis of lung cancer 
Missing notes 
Diagnosed outside 1993 
NSCLC 
Total sample size 
No diagnosis of lung cancer 
Missing notes 
No information in notes 
Diagnosed outside 1993 
5 3 5 17 
2 
66 71 60 63 
2 
_ 
1 1 
5 1 7 2 
2 
_ 
4 2 4 2 
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Table 7.2 Unit costs of diagnosis, treatment and follow up events (£ UK 1993) 
Investigation/Treatment Unit cost in 1993 
prices 
Chest x-ray 11.51 
Ultrasound 27.91 
CT scan 94.33 
Other x-ray 21.38 
Bone scan 77.01 
Bronchoscopy 308.36 
Percutaneous needle biopsy 67.93 
Mediastinoscopy (per day) 239.46 
Sputum cytology 13.67 
FNA 43.11 
Lung function test 79.82 
Biopsy 42.29 
Liver function test 6.57 
MRI scan 163.64 
Blood count 3.31 
ECG 2.84 
Outpatient visit 52.40 
biochemistry 6.25 
haemotology 6.57 
microbiology 7.91 
Surgery/Thoracotomy (per day) 382.13 
Inpatient palliative care (per 231.54 
day) 
Inpatient stay (general-per day) 186.17 
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Table 7.2 continued. 
Radiotherapy Costs 1993 Prices (£ UK) 
Radiotherapy Type Cost per attendance (£) Cost per episode (£) 
Low energy: 77.22 
1-4 fractions 290.70 
5-10 fractions 726.76 
Simple: 81.76 
1-4 fractions 817.60 
5-10 fractions 2434.64 
11-15 fractions 4378.72 
16-25 fractions 6649.85 
Chemotherapy Costs 1993 Prices (£ UK) 
Cytotoxic Drug Dosage Cost (£) 
Etoposide 50 mg (20 tablets) 113.95 
100 mg (10 tablets) 99.57 
Cyclophosphamide 50 mg (20 tablets) 1.91 
Vincristine I ml 9.80 
2m l 19.00 
5 ml 39.60 
Cisplatin IOmI/10mg 5.15 
50ml 25.73 
l 00ml 51.54 
Ifosfamide 500mg 7.75 
Ig 13.50 
Methotrexate I ml 1.94 
2ml 2.69 
4m1 5.14 
8m l 10.28 
20ml 25.71 
40m1 45.71 
200ml 205.71 
Mitomycin 2mg 6.32 
10mg 20.80 
20mg 39.67 
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7.3 Results 
7.3.1 Sample characteristics 
The sample characteristics by cell type are displayed in Tables 7.3 and 7.4. Ninety per 
cent of the sample are classified as NSCLC with the remaining ten per cent as SCLC. 
Seventy-one per cent of the NSCLC are cancers found in the male population sample, 
while sixty-nine per cent of the SCLC are found in men. The mean/median age at 
diagnosis of the samples of patients was 71/72 years (SD 9 and range 35 years) for 
NSCLC and 66/67 years (SD 9 and range 47 years) for SCLC. Only six per cent of 
the NSCLC and four per cent of the SCLC patients were alive at the time of data 
collection. This corresponds with national 5-year survival rate of 7%[2]. Given that 
the greatest risk factor for lung cancer is cigarette smoking. It is interesting to note 
that ninety and ninety-two per cent of the NSCLC and SCLC sample respectively are 
smokers or ex-smokers. 
Table 7.3 Sample characteristics 
Cell Type No (%) Mean age at No. deceased at No. alive at 
diagnosis (s. d. ) abstraction (%) abstraction (%) 
NSCLC 227 (90%) 71 (9.34) 214 (94%) 13 (6%) 
SCLC 26(10%) 66 (9.21) 25 (96%) 1 (4%) 
Table 7.4 Gender and smoking history by cell type 
Cell Type Gender No. (%) Smoking history No. (%) 
Male Female Smoker Non- Ex- Not 
smoker smoker recorded 
NSCLC 162 (71%) 65 (29%) 97(43%) 11 (5%) 106 (47%) 12 (5%) 
SCLC 18 (69%) 8(31%) 12 (46%) 2 (8%) 12 (46%) 
- 
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Table 7.5 explores the mode of presentation of the patients in the sample. The 
majority (61%) presented at a GP surgery due to symptoms, such as coughing up 
blood or difficulty breathing. The remainder was detected by routine chest x-ray or 
investigations for other diseases, or by other routes such as presenting in accident and 
emergency departments. 
Table 7.5 Mode of presentation of lung cancer patients by cell type 
Cell Type GP due to Routine Investigation for other Other 
Symptoms CXR disease 
NSCLC 141 (62%) 10(4%) 12(5%) 64(28%) 
SCLC 13 (50%) 2(8%) 4(15%) 7 (27%) 
7.3.2 Resource use 
Considerable diversity with respect to cost-events was evident on a patient-by-patient 
basis. For example, a total of 19 distinct diagnostic events were found to have 
occurred amongst the sample as a whole, and in a wide variety of combinations. In 
most cases, many or all of the diagnostic events were undertaken on an in-patient basis 
although, in others, some of the tests were administered on an out-patient or day-case 
basis, with differential consequences for costs. Appendix 7.3 displays data on the 
frequency of use of investigations and treatments by year in which it was incurred. 
Surgery included thoracotomy, lobectomy, segmentectomy and pneumonectomy. 
Patient-specific radiotherapy costs varied with type (palliative or radical, low energy 
or simple), number of fractions and setting (e. g. in-patient or out-patient). Within the 
sample, 7 different chemotherapy 
drugs were employed, in combinations, dosages and 
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settings specific to each of the patients so treated. Post-primary treatment, each patient 
received one or more of up to 13 forms of immediate procedure or follow-up 
investigation, largely the same as those used as initial investigations. Twenty per cent 
of NSCLC, and 23% of SCLC, patients required further inpatient stays, including 
emergency admission, surveillance for metastases, spinal cord compression, pleural 
effusion and blood transfusion. One of the most significant factors contributing to the 
cost of cancer care is the cost of hospitalisation. Table 7.6 displays data pertaining to 
usage of inpatient care over the entire four-year period. Costs associated with in- 
patient episodes accounted for 80 and 76 per cent of total mean costs, for NSCLC and 
SCLC, respectively. 
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7.3.2 Treatment costs 
Table 7.7 displays the mean four-year costs by broad management category. Only 14 
patients (6 per cent) survived the full four years following diagnosis and, on average, 
96 and 97 per cent of all costs were incurred in the first year in the two sub-samples, 
respectively. In consequence, the cost estimates were extremely insensitive to 
variations in the discount rate (table 7.8). It is evident from Table 7.7 that differences 
in the mean costs of the two lung cancer types were insignificant (mean difference in 
cost = £481.94, t-test; t=0.328, P=0.743). The costs associated with diagnosis and 
inpatient palliative care accounted for the greatest proportion of total care costs 
(approximately 50 per cent and 18-26 per cent respectively across the two cell types). 
Exploring the cost data in detail the reported skew for the non-small cell cancer 
type was high at 4.86, a histogram plot of the data verified the skew and highlighted 
one patient outlier whose total cost of care exceeded £75,000, excluding this patient 
from the sample resulted in a reduced mean cost for non-small cell lung cancer care of 
£5,832 (SD 5,559), the skew in the data was also reduced to 1.66. 
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Table 7.7 Four-year costs of diagnosis, treatment and follow-up by cell type, 
(£. 1993) 
Non-small cell lung cancer Small-cell lung cancer 
Mean cost SD % of total Mean cost SD % of total 
cost cost 
Diagnosis 2,940 3,468 47.8% 2,746 2,352 48.4% 
Surgery 369 1477 6.0% - - 
Radical 191 1297 3.1% 41 192 0.7% 
radiotherapy 
Palliative 250 814 4.1% 171 249 3.0% 
radiotherapy 
Chemotherapy 17 156 0.3% 899 1,828 15.9% 
Investigations 573 1639 9.3% 523 1,442 9.2% 
Inpatient 1623 5519 26.4% 1,019 1,854 
palliative care 
Follow up 187 332 3.0% 271 360 
Total cost 6,150 7,333 5,668 4,426 
95% Cl 5,191-7,110 3,881-7,456 
Table 7.8 Impact of different rates of discount on the results 
NSCLC SCLC 
Mean 95% Cl Mean 95% Cl 
Discount rate 6% 6,150 
(baseline) 
0% 6,185 
5,191 
- 
7,110 5,669 3,881 
- 
7,456 
5,221 
- 
7,149 5,689 3,890 
- 
7,488 
3% 6,167 
9% 6,135 
5,206 
- 
7,128 5,679 3,885 
- 
7,472 
5,278 
- 
7,092 5,659 3,876 
- 
7,442 
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7.4 Impact of costs with respect to Trent region 
A total of 3,482 cancers of the lung were registered as being diagnosed in the Trent 
region in 1993, male cancers accounted for 2,435 of this total, with the remainder, 
1,047, being diagnosed in the female population. Assuming the full population of 
lung cancers in Trent were to present according to the proportions of each cell type 
identified in the Trent sample (90% NSCLC, 10% SCLC), the total discounted four- 
year cost of the management of lung cancer in Trent in 1993 would amount to 
approximately £21.3 million (£19.3 million for NSCLC and £2 million for SCLC). 
7.5 Comparisons with other lung cancer costing studies 
The results of this analysis on the costs of lung cancer can be compared with those of 
other studies (Table 7.9). To date, the most ambitious attempt to cost lung cancer 
management has taken place in Canada[3,19-22]. This research produced five-year 
cost estimates of £10-16,000 for NSCLC and of £16-20,000 for SCLC (converted to 
UK £, sterling 1993, using the exchange rate and the NHS pay and price index). 
These estimates are considerably higher than those identified for the Trent sample, 
although the transparency of the Canadian research allows the identification of the 
sources of the discrepancies. First, the assumed per diem cost of in-patient stay was 
almost twice as high in the Canadian study as it was in the Trent analysis. This 
presumably reflects on the differential financial structures of the two health care 
systems and, as noted above, in-patient costs are a major component of overall 
management costs. Second, the methodology of the studies differs. The Canadian 
estimates have not been obtained solely from direct observation of patient experiences. 
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They are based on simulations or models of events, derived both from agreed clinical 
protocols and from specialist opinion on the nature of "proper practice". In particular, 
the Canadian protocols appeared to have allowed for more radical treatments than was 
observed in my sample and the authors accepted that such an assumption might have 
been unrealistic in the case of elderly, frail patients. For example, over 85 per cent of 
Canadian NSCLC patients were deemed eligible for surgical resection, with an 
average hospital stay of 20 days. In the Trent sample, only 8 per cent of NSCLC 
patients received resection, with an average stay of 14 days. Third, the Canadian 
study reported five-year survival following diagnosis of all forms of lung cancer at 13 
per cent, superior to the observed four-year rate for Trent. The proportion of cost 
incurred by the Canadian patients in the first year was 82% and 83% for NSCLC and 
SCLC, respectively. These results are consistent with the view that the Trent patients 
received less aggressive therapy than was assumed to be the case for the Canadian 
patients. 
Studies conducted in the US using Medicare charges result in significantly 
higher cost estimates than those reported in this thesis[23,24]. Similar differences 
were found when comparing cost estimates for the breast and cervical sample based on 
the Trent data in chapters 5 and 6 with estimates from US studies. A German study 
also reported higher cost estimates for SCLC (£9,700) and NSCLC (£9,100)[25], 
however these results were based on a review of the medical notes for only 26 
patients. Significantly higher cost estimates for small-cell-lung cancer were also 
reported by both an Australian (£7,900 (1993 prices)[26] and a UK based study 
(£10,252 (1993 prices)[27]. The major contributing cost for SCLC in both studies 
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were found to be due to inpatient stays and chemotherapy, accounting for 49 per cent 
of the total cost in the UK based study. Unfortunately, the transparency of the 
methods reported in each paper preclude a full investigation of why the Trent cost 
estimates for SCLC were significantly lower than their cost estimates7'. 
The closest estimate to the Trent sample is based on a retrospective review of 
196 patients treated for lung cancer in Southampton in 1990. Sanderson and 
colleagues (1992) report an average cost per lung cancer patient of £5,228 (updated to 
1993 prices), however the lack of transparency in the reported methods makes a direct 
comparison impossible. 
7.1 The UK based study was a published conference abstract. I was unable to access their data as their 
work was undertaken as part of a consultancy project. 
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7.6 Conclusions related to lung cancer costs 
Detailed information on the costs of a disease such as cancer is generally not 
available. This is because of the enormity of the task involved in collecting and 
analysing the data. Cancer is a disease that occurs over extended periods of time 
and costs should ideally be monitored from the date of diagnosis to the date of 
death. Due to the poor survival rates associated with lung cancer this makes the 
task of estimating the costs of lung cancer management somewhat easier than 
those of breast cancer, which has a better prognosis and a higher chance of 
recurrence up to 20 years following diagnosis. Therefore, surprisingly, compared 
with breast cancer, relatively few costing studies in the field of lung cancer have 
been published. Lung cancer is always blamed for its huge burden on the public 
purse, but as to what these cost burdens actually are and where the major 
components of these costs lie have been relatively unknown and usually guessed at 
using `back-of-the-envelope' calculations. The aim of this chapter was to estimate 
the lung cancer treatment costs and to find out for what treatment regimes the 
major burden of these costs lie. A detailed patient-by-patient costing analysis, 
based on case records for 253 patients diagnosed in 1993, revealed that the mean 
four-year diagnosis and management costs amounted to £6,150 and £5,668 for 
non-small cell and small cell lung cancer, respectively. These costs are lower than 
those identified in Canadian studies, the difference being explained by the use of a 
simulated costing methodology in these studies, lower unit costs and less 
aggressive interventions. But how might this information be of help to any 
decision maker or planner? Apart from being able to estimate the total burden of 
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lung cancer in cost terms for a region or Nation, the results could be used by 
analysts wanting to explore the cost-effectiveness of possible smoking cessation 
programmes or even the impact of introducing a screening programme for lung 
cancer. At the start of this cost analysis, it was apparent from the literature that 
screening for lung cancer was unlikely to be ever introduced, however this 
assumption was not based on any evidence. Recently there has been a revived 
interest in lung cancer screening, and a recent `News' article in the British Medical 
Journal has highlighted a plan for a proposed screening trial for lung cancer using 
low radiation dose computer tomography in smokers and ex-smokers[34]. The 
cost analysis reported in this chapter could accordingly be used to in a pre-trial 
modelling exercise of the cost-effectiveness of such a screening programme to 
inform the trial of the important parameters in the trial, i. e. those in the model 
having the greatest impact on the cost-effectiveness results. 
7.7 Cost comparison between the three cancer sites 
Chapters 5-7 have reported on the results from the empirical estimation of the 
cost of breast, cervical and lung cancer in Trent region. The comparison of the 
cervical cancer management costs with those of breast cancer clearly indicates not 
only that the former are significantly higher but that the implications of stage 
progression for management costs differ between cancer sites. Broadly speaking, 
for cervical cancer, a cost plateau is reached after stage I and inter-stage cost 
variations thereafter are insubstantial (F = 90.06, P<0.000, Duncans post hoc test 
at 5% suggests stage I costs significantly differ from stages II-IV) (see figure 7.3). 
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For breast cancer, the cost plateau occurs across the first three stages and costs 
subsequently rise at stage IV (F = 2.3, P=0.077, Duncans post hoc test at 5% 
suggests stage IV costs significantly differ from stages I-III) (see figure 7.4). In 
consequence, shifting detection of disease to the earliest invasive stage exerts a 
greater relative impact on overall management costs for cervical cancer than it 
does on those for breast cancer. For cervical cancer the treatment cost economies 
for stage I cancers are as a result of a higher proportion of stage II-IV patients 
undergoing high cost inpatient radiotherapy and palliative care compared with the 
stage I patients. Whereas the cost driver for breast cancer patients is in terms of 
the significantly higher inpatient length of stay for stage IV cancer patients 
compared to stage I-III cancers. 
An additional comparison can be made with results from a study of the cost of 
treating colorectal cancer, conducted in the context of the UK colorectal screening 
trial using faecal occult blood tests[35]. This analysis audited 360 patients over 3 
years. In common with breast and cervical cancer, colorectal cancer possesses a
defined staging structure, A through D, which might be considered analogous to 
the four stages of breast and cervical cancer. In the colorectal study, stage A 
cancer was found to be significantly cheaper to treat than stages B and C and, in 
this respect, the cost profile by stage of colorectal cancer differs from that 
discovered for breast and cervical cancer. In the case of colorectal cancer, 
however, the lower cost of stage A was largely accounted for by the potential for 
using low-cost surgical techniques entailing reduced lengths of hospital stay. 
Stage D colorectal cancer was found to be significantly cheaper to treat than the 
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intermediate stages, owing to shorter survival times (requiring less follow-up) and 
the more frequent use of relatively cheap palliative therapies (see figure 7.5). 
Possibly of greatest significance, however, is the colorectal study's conclusion that 
no sizeable treatment cost economies could be anticipated as a result of an early 
detection programme, a finding consistent with the breast cancer results, yet 
inconsistent with the cervical cancer results. 
The 4-year lung cancer cost results (£6,500 
- 
£7,100 UK, 2000 prices) 
(figure 7.6) can be compared directly with the 4-year breast cancer (£4,700 
- 
£8,400 UK, 2000 prices) and the 5-year cervical cancer cost results (£9,200 
- 
E16,100 UK, 2000 prices). For all three cancer sites the preponderance of resource 
use occurred in the year immediately following diagnosis. 
In all four cancer sites the standard deviations of the mean costs emerged 
as particularly high, indicating the wide variation in patient-specific resource use 
even within a given stage at diagnosis. 
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Figure 7.3 Cost by stage for cervical cancer patients (UK £, 2000) 
Cost per patient £18,000 
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Figure 7.4 Cost by stage for breast cancer patients (UK £, 2000) 
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Figure 7.5 Cost by stage for colorectal cancer patients (UK £, 2000) 
(source: [35]) 
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Figure 7.6 Cost by cell type for lung cancer patients (UK £, 2000) 
Cost per patient £8,000 
(£, 2000) 
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Table 7.10 displays the structure of the total cost estimates in more detail 
within each cancer site. Significant cost drivers for the breast cancer sample are 
those related to surgery and follow up, accounting for 60 per cent of the total cost. 
For cervical cancer the costs of diagnosis and radical radiotherapy account for 55 
per cent of the total cost, and for lung cancer diagnosis and inpatient palliative care 
costs account for 73 per cent of the total cost. However, the costs for breast cancer 
are significantly lower than those for cervical and lung cancer. The principal 
cause of the difference lies in the diagnosis, radical radiotherapy and inpatient 
palliative care categories, with length of hospital inpatient stay as the major 
contributory factor. 
For the cervical sample, 75,79,79 and 50 per cent of cancers at stages I 
through IV, respectively, were diagnosed on an inpatient basis, with average 
lengths of stay of 5,9,11 and 16 days, respectively. For the lung cancer sample 74 
per cent of the cancers were diagnosed as an inpatient episode, with an average 
length of stay of 12 days. All breast cancer diagnoses and staging investigations 
were carried out on an outpatient basis, irrespective of stage. 
With respect to radical radiotherapy, higher proportions of cervical cancer 
patients received such therapy: 62 per cent, in comparison with 42, and 4 per cent 
for breast cancer and lung cancer patients, respectively. Virtually all such 
radiotherapy was administered to breast and lung cancer patients on an outpatient 
basis: for example inpatient stays for radical radiotherapy accounted for 3 per cent 
of breast cancer patients (average length of stay of 40 days) and 1 per cent of lung 
cancer patients (average length of stay of 15 days). However, 45 per cent of 
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cervical cancer patients received radiotherapy as inpatients (average length of stay 
of 24 days). 
Inpatient palliative care was employed by 45 per cent of the lung cancer 
patients, with an average length of stay of 22 days. This is compared with 20-22 
per cent of breast and cervical cancer patients, with an average length of stay of 20 
and 30 days respectively. 
Although surgery represents the significant cost driver for breast cancer 
patients with 83 per cent of the breast cancer sample receiving surgery compared 
to 37 and 7 per cent of the cervical and lung cancer samples, the average length of' 
stay was 5 days for breast cancer patients. Thus, the resultant surgery costs for 
breast cancer are more than offset by the higher costs associated with diagnosis, 
radical radiotherapy and inpatient palliative care for the cervical and lung cancer 
patients. 
Table 7.10 Structure of total cost estimates within each cancer site 
Cervical Breast Lung____ 
Mean total cost (f UK, 2000) £12315.13 £5035.50 £7016.01 
CI 11,051.72- 4,442.38- 6,007.22- 
13,578.52 5,618.62 8,024.80 
of total cost: 
Diagnosis 23.1 1.4 47.7 
Surgery 9.3 39.6 6.0 
Radical radiotherapy 32.6 13.6 2.8 
Chemotherapy 2.1 2.7 1.8 
Hormone therapy 0.3 1.2 
- 
Palliative radiotherapy 4.1 5.7 3.8 
Inpatient palliative care 10.2 9.4 25.5 
Investigations and complications 12.1 4.9 9.2 
Follow up 6.1 21.3 3.3 
Other 
- 
0.1 
- 
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In conclusion, the comparison of the breast, cervical and lung cancer costs clearly 
indicates that the cost of cervical cancer is significantly higher than those incurred 
by lung and breast cancer patients, and in turn the hospital cost of lung cancer is 
significantly higher than that for breast cancer. The reason for the difference in 
cost appears to be as a direct result of a greater proportion of cervical and lung 
cancer patients undergoing longer inpatient lengths of stay compared with the 
breast cancer patients (see tables 5.6,6.7 and 7.6 in chapters 5,6 and 7). The 
second major finding of this empirical work highlights the implications for 
hospital costs by the progression of the disease through well defined stages, and 
how these costs differ between cancer sites. The hypothesis prior to the empirical 
work was that early stage disease by its nature would cost significantly less to 
diagnose and treat compared to late stage cancers. However, the work reported in 
chapters 5-7 show that by shifting the detection of the disease to the earliest 
invasive stage results in significant cost economies for cervical cancer, whereas 
the impact on overall cost for breast and colorectal cancer is minimal. 
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Appendix 7.1 
Diagnosis/staging algorithm for cervical cancer from the literature 
Physical examination Benign 
Chest x-ray 
Bronchoscopy or Malignant: Presentation Percutaneous needle biospy Lung function test 
Radioisotope scans 
ACT scans 
Treatment algorithm for breast cancer by stage from the literature. 
Surgery (thoracotomy) 
NSCLC 
Inoperable 
Malignant 
Pneumonectomy 
I. Lobectomy 
Chemotherapy 
Palliative radiotherapy + chemotherapy \Best 
supportive care 
Chemotherapy 
SCLC Palliative radiotherapy + chemotherapy 
Best supportive care 
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DIAGNOSIS FORM 
*tASIC INFO 
klign, 
ct Code: 
m 
Current Date: 
Study No: 
TIHSR ID: 
Abstracter: 
IIIII 
-ýý 
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If Smoker: No smoked per day: 
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< 10' / 10-192 / 20-293 / 30+4 / Lights / Medium6 / Heavy' / NR9 
No of years since started smoking: Q 
<51 / 5-92 / 10+ 3/ Long term4 / NR9 
If ex-smoker= No of years since stopped smoking: 
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<11/ 1-22/3-53/6-104/ >105/NR9 
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continued 
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Local spread (at diagnosis): Yes' / Noe / Not recorded9 
Site of local spread: (at diagnosis) 
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2 Pleural space 
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5 Other 
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Contralateral spread: 
(at diagnosis) 
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Date of surgery (d/m/y): ELITI -i 
Date discharged following surgery (d/m/y): [I JJI1] 
Ip1%0P2/DC3 
Type of surgery: 1 No removal (Thoracotomy) Q 
2 Lobectomy 
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5 Other 
9 Not specified 
If "other", please specify: 
Length of operation (hrs/mins): 
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Study No: 
TIHSR ID: ýI III F]-1 
TREATMENT OF NON-SMALL CELL CANCER (continued) 
> iotherapy: Yes' / Noe Q 
Radical' / Palliative2 Q 
Dow: Radiation dose (total dose cGy) 
No of fractions 
Duration of RT: Date started: 
Date finished: Q 
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Site: Chest' / Bone2 / Brain3 / Other4 Q 
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Further Radiotherapy: Yes' / Noe Q 
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IP'/OP2/DC3 Q 
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Study No: 
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TREATMENT OF NON-SMALL CELL CANCER (continued) 
Cbemotherapy: Yes' / Noe 
Single agent' / Combination2 
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5 Other 
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mcic/6.11.96 
Yes' / Noe / Not applicable' / Not recorded9 Q 
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Eevelopment of distant metastasis: Yes' / Noe / Not applicable' / Not recorded' 
(after diagnosis) 
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Date of first distant metastasis (d/m/y): 
(after first diagnosis) 
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(after first diagnosis) 
1 Liver 
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5 Brain 
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7 Other 
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if "fir", please specify: 
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Date admitted (d/m/y): 
Date discharged (oim/y): 
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Vital status: 
Dead' / Alive2 0 
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Page: I/1I 
Study No: 
TIHSR ID: 
NOTORY 
Vuration of history of symptoms (weeks): FM 
Mode of presentation: 1 Symptoms 
Q 
2 Routine chest X-ray 
3 Other investigations for other disease 
4 Other 
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If "fir", please specify: 
S13wy g history: Smoker' / Non-smoker2 / Ex-smoker3 / Not recorded' 
Q 
Type: Cigarette' / Cigar2 / Pipe3 / Roll-up4 / NA8 / NR9 Q 
If smoker: No smoked per day: 
Q 
< 101 / 10-192 / 20-293 / 30+4 / Lights / Medium6 / Heavy? / NR! 
No of years since started smoking: Q 
<5'/5-92/ 10+3/Long term4/NR9 
if ex-smoker: No of years since stopped smoking: 
Q 
<11/ 1-22/3-53/6-104/ >105/NR9 
Occupatich of patient: 
performance Status: Grade 0'/Grade 12/Grade 23/Grade 34/Grade 45/Not recorded9 Q 
Myocardial infarction: 
History of angina: 
Yes(<6mths)' / Yes(> 6mths)2 / No3 / Not recorded9 Q 
Yes' / No' / Not recorded9 0 
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Date of 
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pleural biopsy 
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continued 
....... 
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Study No: 
TIHSR ID: 
DIAGNOSIS (continued) 
J, esigations 1 Yes Date of 1 IP Date Date 
2 No 
9 Not recorded 
Investigation 2 OP 
3 DC 
Admitted Discharged 
Isotope bone scan 
other scan: 
C' scan: 
chest 
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QPM 
dosed 
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Diagnosis continued overleaf 
sck/6.11.96 Page: 4/11 
Study No: 
TIHSR ID: 
DIAGNOSIS (continued) 
Date of diagnosis (d/m/y): 
Local spread (at diagnosis): Yes' / Noe / Not recorded' 
Site of local spread: 
(at diagnosis) 
1 Mediastinum 
2 Pleural space 
3 Chest wall 
4 Lymphatic spread 
5 Other 
9 Not recorded 
0 
0 
jf *other", please specify: 
Contralateral spread: 
(at diagnosis) 
Yes' / Noe / Not recorded9 0 
Metastasis (at diagnosis): 
Site of metastasis: 
(at diagnosis) 
If "other", please specify: 
Yes' / Noe /Not recorded9 
1 Liver 
2 Adrenal 
3 Renal 
4 Abdominal node 
5 Brain 
6 Bone 
7 Other 
9 Not recorded 
El 
ED 
scic/6.11.96 Page: S/11 
Study No: 
TIHSR ID: 
MLSTOPATHOLOGY 
histology (attach copy of path report): 
Date of report (dimly): 
Report no: 
Type; 1 Squamous cell 
2 Small cell 
3 Adenocarcinoma 
4 Large cell 
5 Adenosquamous ca 
6 Carcinoid tumour 
7 Mesothelioma 
8 Other/Mixed type 
9 Not recorded 
If Mother/Mixed type", please specify: 
Grade: Well' / moderately2 / poorly differentiated' / not recorded9 
pathological size (cm): 
Side of tumour: 
Location of tumour: 
If "other", please specify: 
Left' / Right2 / Bilateral' 
1 Main bronchus 
2 Upper lobe 
3 Middle lobe 
4 Lower lobe 
5 Other 
9 Not recorded 
0 
ED 
. 
EID 
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Study No: 
TIHSR ID: ýýý 
STAGING OF SMALL CELL LUNG CANCER 
Specified in notes: Yes' / Noe Q 
Extent of disease: 1 Limited (confined to one side of thorax with or Q 
without enlarged supraclavicular nodes) 
2 Extensive (all other patients) 
-MATA ENT OF SMALL-CELL LUNG CANCER 
therapy; Yes' / Noe 
Single agent' / combination2 0 
Active Drugs Course/ Drug Dose Date Date 1 IP 
Cycle Code Started Finished 2 OP 
3DC 
ick/6.11.96 Page: 7/11 
Study No: 
TIHSR ID: 
TREATMENT OF SMALL CELL LUNG CANCER (continued) 
Radiotherapy: Yes' / Noe Q 
Radical' / Palliative 2 
Dose: Radiation dose (total dose cGy) 
No of fractions 
j)wation of RT: Date started: 
Date finished: 
IP' / OP2 / DC3 Q 
Site: Chest' / Bone2 / Brain3 / Other` Q 
If "other", please specify: 
Further Radiotherapy: Yes' / Noe Q 
Radical' / Palliative 2 
Dose: Radiation dose (total dose cGy) 
No of fractions 
Duration of RT: Date started: 
Date finished: 
IP' / OP2 / DC3 Q 
Site: Chest' / Bone 2/ Brain3 / Other4 Q 
If "other", please specify: 
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Study No: 
TIHSR ID: 
-MATMENT OF SMALL CELL LUNG CANCER (continued) 
may: Yes' / Noe 
Date admitted for surgery: 
Date of surgery: 
j)SW discharged following surgery: 
IP' / OP2 / DC3 
Type of surgery: 1 No removal (Thoracotomy) 
2 Lobectomy 
3 Segmentectomy 
4 Pneumonectomy 
5 Other 
9 Not specified 
If -ow", please specify: 
Length of operation (hrs/mins): 
Qlr-n 
Ell I -T 
,. 11.96 Page: 9/11 
Study No: 
TIHSR ID: 
FOLLOW UP/OUTCOME 
Frequency of Investigations per Year 
jºestigation 1993 1994 1995 1996 1997 
OF check up 
Chest X-ray 
Other X-ray 
CT scan 
Bone scan 
Uitrssound 
Blood count 
Transfusion 
LAIng function test 
Biochemistry 
F[senatology 
Microbiology 
Other 
Local recurrence, distant metastases, vital status 
Local recurrence: Yes' / Noe / Not applicable8 / Not recorded9 0 
Date of first local recurrence(d/m/y): 
Site of local recurrence: 1 Mediastinum 
2 Pleural space 
3 Chest wall 
4 Lymphatic spread 
5 Other 
9 Not recorded 
D 
If "other", please specify: 
Contralateral lung recurrence: 
Date of first contralateral 
lung recurrence (dimly): 
tclc/6.11.96 
Yes' / Noe / Not applicable" / Not recorded' Q 
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Study No: 
TIHSR ID: 
FOLLOW UP/OUTCOME (continued) 
Development of distant metastasis: Yes' / Noe / Not applicable' / Not recorded9 
(after diagnosis) 
0 
pate of first distant metastasis (d/m/y): 
(after first diagnosis) 
Site of first distant metastasis: 
(after first diagnosis) 
1 Liver 
2 Adrenal 
3 Renal 
4 Abdominal node 
5 Brain 
6 Bone 
7 Other 
9 Not recorded 
0 
if "other", please specify: 
palliative care: Yes(IP)' / Noe / Yes(GP)3 / Not applicable' / Not recorded9 
If inpatient: 
Date admitted (d/m/y): 
Date discharged (d/m/y): 
0 
Outcome: 
Vital status: Dead' / Alive2 0 
Date of death/date last seen: 
COMMENTS: 
sclc/6.11.96 Page: 11/11 
Appendix 7.3: Resource-use by cell type years 1-4 
- 
Lung Cancer 
YEAR 1 NSCLC SCLC 
Diagnosis 
chest X-ray 215 (94%) 26(100%) 
other X-ray 27 (12%) 2(8%) 
sputum cytology 67 (29%) 9 (35%) 
bronchoscopy 128 (56%) 18 (69%) 
percutaneous needle 15 (7%) 1 (4%) 
biopsy 
FNA 13 (6%) 
- 
lung biopsy 94(41%) 
- 
pleural biopsy 8 (4%) 1 (4%) 
lymph node biopsy 8 (4%) 4 (16%) 
pleural aspiration 19(8%) 3 (12%) 
bone marrow aspiration 2(1%) 1 (4%) 
blood count 205 (90%) 23 (89%) 
liver function test 143 (63%) 16(62%) 
lung function test 112 (49%) 7 (27%) 
ultrasound 43 (19%) 9 (5%) 
bone scan 21 (9%) 3 (12%) 
mediastinoscopy 4 (2%) 
- 
CT scan 97 (42%) 12 (47%) 
MRI scan 3(1%) 1 (4%) 
Treatment 
Surgery 17(8%) 
- 
thoracotomy 3(1%) 
lobectomy 8 (4%) 
- 
segmentectomy 1 (1%) 
- 
pneumonectomy 4 (2%) 
- 
Radical radiotherapy 9 (4%) 2 (8%) 
Secondary RRT 6 (3%) 
- 
Third RRT 1 (1 %) 
- 
Chemotherapy 4 (2%) 15 (58%) 
secondary chemotherapy - 1 (4%) 
Inpatient investigation 37 (16%) 6 (23%) 
second investigation 10 (4%) 3 (12%) 
third investigation 2(1%) 2 (8%) 
Palliative radiotherapy 79 (35%) 13(50%) 
secondary PRT 9(4%) 1 (4%) 
third PRT 2(1%) 
- 
fourth PRT 1 (1%) 
- 
Inpatient palliative care 92(41%) 10(38%) 
405 
Follow up (year 1) NSCLC S('1, (' 
outpatient visit 88 (39%) 13(50%) 
chest x-ray 82 (36%) 15 (57%) 
other x-ray 13 (6%) 7 (27%) 
CT scan 24(11%) 2 (8%) 
bone scan 18(9% 3 (12%) 
ultrasound 9 (4%) 3 (12%) 
lung function test 10(4%) 3 (12%) 
ECG 35 (15%) 6 (23%) 
bronchoscopy 4 (2%) 
- 
sputum cytology 1 (1 %) 
- 
biochemistry 70(31%) 12 (46%) 
blood count 77 (34%) 14 (54%) 
microbiology 17(7%) 4(15%) 
YEAR 2 
Treatment 
Inpatient investigation 4 (2% 
second investigation 4 (2%) 
- 
third investigation 1 (4%) 
second chemotherapy 
- 
1 (4%) 
secondary PRT 2(1%) 1 (15%) 
Inpatient palliative care 7(3%) 1 (15%) 
Follow up 
outpatient visit 25 (11%) 4 (4%) 
chest x-ray 16 (7%) 4 (4%) 
other x-ray 2(1%) 
- 
CT scan 5(2%) 1 (4%) 
bone scan 2(1%) 1 (4%) 
ultrasound 3 (1%) 1 (4%) 
lung function test 2(1%) 1 (4%) 
ECG 4 (2%) 
- 
bronchoscopy 2(1%) 
- 
sputum cytology 1 (1%) 
- 
biochemistry 9(4%) 1 (4%) 
blood count 8 (4%) 1 (4%) 
microbiology 4 (2%) 
- 
406 
YEAR3 NSCLC SCLC 
Treatment 
Inpatient investigation 3 (1%) 
_ 
second investigation 1 (1 %) 
- Palliative radiotherapy 3 (1%) 
- 
secondary PRT 1 (1%) 
- 
Inpatient palliative care 3 (1%) 
_ 
Follow up 
outpatient visit 14 (6%) 
- 
chest x-ray 8 (4%) 1 (4%) 
other x-ray 10%) 
- CT scan 2(1%) 
- bone scan 1 (1%) 
- 
ultrasound 4 (2%) 
- lung function test 2(1%) 
- 
ECG 4(2%) 
- bronchoscopy 
-- 
sputum cytology 1 (1%) 
- biochemistry 5 (2%) 
- blood count 7 (3%) 
- 
microbiology 6 (3%) 
- 
YEAR 4 
Treatment 
secondary investigation 1 (1 %) 
third investigation 1 (1 %) 
_ fourth investigation 1 (1 %) 
- 
Inpatient palliative care 2(1%) 
- 
Follow up 
outpatient visit 9 (4%) 
- 
chest x-ray 7 (3%) 1 (4%) 
other x-ray 
-- 
CT scan 3 (]%) 
_ 
bone scan 
-- 
ultrasound 
-- 
lung function test 
-- 
ECG 
-- 
bronchoscopy 3 (1%) 
- 
sputum cytology 
-- 
biochemistry 3 (]%) 
_ 
blood count 
-- 
microbiology 
-- 
407 
Chapter 8 
Appropriate statistical analysis of cost data 
8.1 Introduction 
In the previous three chapters (5,6 and 7) all the analysis of the cost data was 
undertaken using parametric tests such as the t-test and analysis of variance. 
parametric tests require the assumption of normality, however, due to its skewed 
nature, resource use and cost data pose problems for using these types of tests. Given 
the problems with the distributional nature of the data there has been a recent increase 
in the interest of how cost data for use in economic evaluations should be 
appropriately analysed(1-8). There are a number of proposed methods to overcome 
this problem including; removal of the outliers causing the data to be non-normal, 
transformation of data, use of `distribution free' methods such as non-parametric 
statistics and bootstrapping. The original data used in the previous three costing 
chapters are skewed, therefore the aim of this chapter is to firstly explore each of the 
proposed methods for analysing skewed data, and secondly to ascertain whether use of 
parametric tests led to the wrong conclusions being drawn in chapters 5-7. 
8.2 Skewed cost data 
The value of skew for a particular data set measures the asymmetry of its distribution. 
The expected value of skew for a symmetric distribution (i. e. the normal distribution) 
is zero. A distribution with a significant positive skew has a long right tail. A 
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distribution with a significant negative skewness has a long left tail. A skew value 
greater than 1 generally indicates a distribution that differs significantly from a normal 
distribution. 
Health care resource use and costs are typically positively skewed because(2,5,9): 
" It is impossible to have negative costs or counts of resource used 
" Invariably a few patients incur very high costs, for example due to long 
inpatient length of stays. 
In order to explore the distribution of the data, summary statistics such as the measure 
of central tendency i. e. the mean or median, the measure of dispersion i. e. standard 
deviation or quartiles and skew can be backed up by a graphic representation of the 
data in the form of a histogram. If the data are positively skewed it is certain that the 
mean value will be much higher than the median value. Other rules of thumb are that 
if the standard deviation is twice the value of the mean the data is likely to be 
skewed(10). Formal tests for skew exist (these are actually tests for normality of the 
data), the Shapiro-Wilk and Kolmogorov-Smirnov tests. With the Shapiro-Wilk test 
the test statistic gives a value from 0 to 1 with 1 indicating normality. The 
Kolmogorov-Smirnov test is used to test the hypothesis that a sample comes from a 
particular distribution (i. e. normal). The value of the Kolmogorov-Smirnov Z is based 
on the largest absolute difference between the observed and the theoretical cumulative 
distributions. 
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83 Methods for the appropriate analysis with skewed cost data 
An estimate of the average or arithmetic mean cost is paramount to any costing 
exercise. Decision-makers and planners in any health care system require knowledge 
of the total budget over a specified period of time (usually financial/budgetary year) 
that is necessary in order to provide a particular intervention or treatment to a group of 
patients. The average cost estimate multiplied by the patient numbers requiring the 
treatment or intervention produces such an estimate of total cost. Invariably, as health 
economists we require some formal comparison of the average per patient costs of one 
particular group of patients with the average per patient costs for another distinct 
group of patients, this cost difference is used as the numeraire for calculating cost- 
effectiveness ratios. However, there is concern over using standard parametric 
statistical techniques such as the t-test, analysis of variance and ordinary-least squares 
regression where the data used for the analysis are skewed (as in the case for cost 
data). The above techniques rely on the assumption of normality of the data. And 
although, these standard methods for analysing arithmetic means are known to be 
fairly robust to non-normality, the robustness depends on the sample size and the 
severity of the skew of the data, and no criteria exist for judging whether the analysis 
will be robust enough for a particular dataset. Therefore various standard textbook 
methods have been proposed as ways of analysing skewed data(11). 
8.3.1 Median 
In the presence of skewed data it is often common to report the median rather than the 
mean, however, although the median is useful to present alongside the mean, it is 
inappropriate to use in any cost or cost-effectiveness analysis. The reason is that we 
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are interested in the average per patient cost which provides information on the total 
cost of care to a particular patient group when combined with the total number of 
patients requiring that specified care. With positively skewed data the median value 
will be lower than the mean value, and using the product of the median value and the 
number of patients requiring the intervention will not give the total cost of the 
intervention for that group. 
8.3.2 Exclusion of outliers 
The exclusion of outliers is a method that is often used by statisticians and has been 
suggested for use with cost data(2). Once outliers are removed, a smoother 
distribution of costs is likely to be obtained, allowing statistical analysis of the 
differences in mean costs between specified groups using parametric statistical tests. 
However, one can argue that by excluding the outliers in a positively skewed dataset 
you are disposing of important information that will enable policy makers to 
determine the total budget involved with implementing one treatment compared to 
another. The excluded data in a cost dataset are likely to be for those patients 
incurring particularly high or low costs, hence using estimates from a restricted dataset 
will result in an under-estimate of the likely total budget required. However, in 
situations where a few patients have very low or high costs it may still be appropriate. 
s. 3.3 Transformation 
Another method used by statisticians when controlling for skewed data is to transform 
the data onto another scale. Transformation can have the effect of normalising the 
data and equalising the variance when comparing two datasets. Usual methods of 
transforming the data include taking the natural logarithm, reciprocal or square root. 
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The data are then analysed using parametric statistical tests such as the student t-test 
etc. However transformation can lead to problems of interpretation for the analysis of 
cost data. First, analyses using such transformed data are not addressing inferences 
about the arithmetic mean cost. It is not clear what the reported difference actually 
means on a transformed scale, the original scale (i. e., currency units), is required to 
enable proper interpretation. Therefore, second it is necessary to `back-transform' the 
point estimate of the difference in the mean value and the measure of variation or 
measure of precision of this mean value by taking the inverse function. This can only 
be done for transformations using the natural logarithm, by taking the exponential of 
the natural log value of the mean estimate. However, interpretation of this back- 
transformed value is still problematic, the value actually produced is the geometric 
mean and suffers the same problems as using the median. Back-transformation of the 
square root or reciprocal is completely meaningless. There is a nonparametric method 
proposed by Duan in 1983 to adjust the back-transformed data for any bias incurred 
after fitting a linear regression model on a transformed scale, this is known as the 
`smearing estimator'(14). Cost analysis using data on a transformed scale have been 
undertaken in a number of studies. A UK based study, report their cost data for 
patients with mental health problems to be highly variable and positively skewed(12). 
They transformed all their cost data to natural logarithms before undertaking further 
analyses. Adams Dudley and colleagues also transformed their cost data by taking the 
natural logarithm, which reduced the skew, but was not sufficient to produce a normal 
distribution of the costs or the residuals when undertaking an OLS regression of their 
cost data(13). Rutten van Molken and colleagues undertook a multivariate regression 
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analysis of longitudinal skewed cost data(1). They suggest a four-step procedure for 
the analysis of skewed data (1994: 339-342): 
1. Transformation 
-a simple logarithmic transformation 
2. Regression analysis 
- 
ordinary least squares regression 
3. Calculation of the standardized expected costs 
4. Retransformation 
- 
requires the expected costs on the untransformed scale. 
The authors argue that to obtain the expected costs on an untransformed scale (e. g. UK 
£ sterling) it is inappropriate to simply take the exponential function of the estimated 
mean of the transformed costs as the retransformed costs will be neither unbiased nor 
consistent, unless the transformation was linear. They therefore suggest using a non- 
parametric retransformation factor called a `smearing estimator'(14). 
The corresponding equations for the four-step procedure are outlined below, where 
Y; is the observed variable on the untransformed scale, X; is the vector of explanatory 
variables, ß is a column vector of unknown parameters to be estimated and s; is the 
residual error. 
1. Z; = Ln(Y; ) 
2. Z; =a+X; ß+E; 
3. ý; =ä +X1O 
4. E(Y; /X; ) _" exp(a + X; ß) 
Where is a retransformation factor that can be estimated by: 
= (E exp(s ; )/ N 
where s is defined as Z; -ä-X; ß (a smearing estimator) 
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8.3.4 Nonparametric tests 
Nonparametric statistics allow hypothesis testing even when certain classical 
assumptions such as normality of the data are violated. There are a number of tests 
that can be employed for the purpose of comparison of two or more independent 
groups; the Mann-Whitney test (for two independent samples) and the Kruskal-Wallis 
test (for three or more independent samples). The assumption underlying these tests is 
that the shape and variance of the distribution of the independent samples are the 
same, and the test relates to the difference in location of the two distributions. 
Unfortunately, this method runs into the problem of not providing information about 
the mean cost. 
8.3.5 Bootstrapping 
There is a nonparametric technique that allows for a comparison in the mean cost 
between two or more patient groups(5,9,15). Bootstrapping involves an extensive 
resampling procedure of an original sample to empirically provide an estimate of the 
statistics' sampling distribution. Given an original sample one takes a random re- 
sample with replacement8*' to yield a bootstrap sample of size ni and then the statistic 
of interest can be calculated. This process is repeated many times (1000 times by 
convention) to yield a vector of bootstrap estimates of the statistic of interest (in the 
case of costs; mean cost). Due to replacement the bootstrap sample of cost data may 
include the costs for some patients more than once while excluding the costs for other 
patients completely. The sampling with replacement allows for variation between the 
samples. The standard deviation of the bootstrap means is equivalent to the standard 
$. '
'Replacement' means that once a random value has been used for the bootstrap resample it is put 
back into the original sample. 
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error of the mean estimate using parametric statistics. Several approaches exist to 
estimate confidence intervals using the bootstrap estimate of the sampling 
distribution(15,16). However, the simplest method is the percentile method. The 
upper and lower CI are obtained using the (x/2)100 and (1-aº2)100 percentiles of the 
empirical sampling distribution. If using 1000 bootstrap re-samples the values for the 
95% confidence limits correspond to the 26th and 975th points in the rank ordered 
vector of bootstrap means. These points are chosen since this excludes 25 values, 
(25/1000 = 2.5%) at either end of the estimated distribution. 
The validity of the method rests on two assumptions. First, as the original sample 
size approaches the population size, the sample distribution will tend towards the 
population distribution, second, as the number of bootstrap replications increases the 
bootstrap estimate of the sampling distribution of the chosen statistic approaches the 
true sampling distribution. 
8.4 Empirical investigation of methods used for analysing cost data 
Recently there have been a number of commentaries on the appropriate methods for 
analysing cost data with no definite conclusions about the relative merits of each of 
these methods(1-8). Suggestions have included use of parametric tests on data with 
the outliers removed, or on transformed data, non-parametric tests, or more recently 
the non-parametric bootstrap method. Zhou (1997), and Thompson and Barber (2000) 
have independently of one another shown how results may change according to the 
method of analysis used, however the direction of the change cannot be predicted. 
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Thompson and Barber have concluded that in their experience, the results from the 
standard t-test are adequate for most comparative cost situations (8: 1199). 
With the aid of the data collected for the purpose of estimating the costs of breast, 
cervical and lung cancer I have investigated the use of the methods outlined above 
(section 8.2) for the univariate analysis of skewed cost data. Each cancer site has been 
explored in turn, with descriptions of and histograms displaying the data in terms of 
mean, median, standard deviation, 95 % confidence intervals and skew. The methods 
used include, parametric tests ignoring the issue of skewed data and then after the 
removal of outliers (removal of the five highest and five lowest values indicated by 
SPSS), and after transformation of the data (using three methods; the natural 
logarithm, the square root and the reciprocal), nonparametric tests and bootstrapping 
the data. 
8.4.1 Breast cancer 
The cost data and descriptive statistics for breast cancer by stage of disease are 
displayed in figures 8.1-8.6 for each of the methods explored. It is interesting to note 
that the distribution of the original cost data does not significantly differ from 
normality for stage IV cancers, whereas the distribution for stages I-III data do display 
a significant positive skew. The absolute value of the Shapiro-Wilk ranges from 0.56, 
0.87,0.85 and 0.87 (P = 0.03,0.05,0.01,0.28) for stages Ito IV respectively (where 
the absolute value ranges from 0-1, with 1 indicating normality) and similar results 
from the Kolmogorov Smirnov test (P =0.000,0.037,0.019,0.164, indicating that the 
cost distributions for stages I-III differ significantly from normality). Lack of stage IV 
patients meant that outliers could only be removed for stages I-III, however, the 
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original cost data for stage IV cancers did not appear to be skewed. This has the effect 
of reducing the skew (Kolmogorov Smirnov test P =0.017,0.070,0.200,0.164). 
Transforming the data using the natural logarithm and square root has the effect of 
reducing the skew, in fact changing from positive skew to negative skew using the 
Ln(cost), transforming the data also has the effect of equalising the variances between 
the stages. Transformation using the reciprocal worsens the skew for all four stages. 
Finally, figure 8.6 displays the histogram for the bootstrap estimate of the sampling 
distribution of the breast cost data. The bootstrap sampling distributions for each 
stage indicate that the sample size is sufficiently large that the assumption of normality 
for the use of parametric hypothesis testing is justified. 
In the previous chapters I was interested in the comparison of costs between 
stages of disease. Here I have chosen to explore the difference in costs between early 
stage and late stage disease. All cancers diagnosed at stage I represent early stage 
disease, whereas cancers diagnosed at stages 11-1V represent late stage disease( 17). 
Table 8.1 displays the results using the parametric t-test on the original cost data, after 
removal of outliers and after transforming the data, and the nonparametric Mann- 
Whitney test to explore the difference between early and late stage cancer costs. Only 
when the outliers are removed is there a reported significant cost difference between 
early and late stage cancers. The nonparametric Mann-Whitney results in no 
significant difference between early and late stage costs (P = 0.139). Finally, the 
bootstrap estimate of the sampling distribution of the mean cost difference was found 
to be £950 (equivalent to the median), with a standard deviation around this mean of 
600 (this standard deviation is equivalent to the standard error of the mean difference 
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using parametric statistics), and 95 % confidence intervals ranging from £-240-£2,142 
(see Figure 8.7). 
Table 8.1 Results of parametric and nonparametric analysis of difference in 
early stage and late stage costs - Breast cancer 
Data Stage N Mean SD Mean Test P Skew 
difference statistic value 
original Early 102 3,734 2,469 1,011 1.89 0.06 1.75 
Late 35 4,745 3,412 1.20 
Outliers Early 93 3,480 1,697 1,002 2.35 0.02 0.99 
removed Late 29 4,482 2,786 1.17 
Ln Early 102 7.99 0.78 2.06 1.35 0.18 
-1.54 
transformed Late 35 8.20 0.79 
-0.63 
Square root Early 102 0.0006 0.001 
-1.59 -0.84 0.40 0.45 
transformed Late 35 0.0004 0.0005 0.49 
Mann 0.14 
Whitney 
Figure 8.1 Histogram of original breast cancer cost data by stage 
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Figure 8.2 Histogram of breast cancer cost data with outliers removed 
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Figure 8.3 Histogram of Ln transformed breast cancer cost data 
Frequency 
25 
20 
15 
10 
5 
0 
4.0 
Stage I 
Mean = 7.99 
Median = 8.08 
SD = 0.78 
95% Cl = 7.84-8.14 
Skew = 
-1.54 
Stage II 
Mean = 8.26 
Median = 8.33 
Sn=n54 
  
Stage I 
  
Stage II 
Q Stages III & IV 
95% Cl = 7.93-8.58 
Skew = 
-0.07 
111 10 1Q 
4.8 5.5 6.3 7.0 7.8 8.5 
Stage III 
Mean = 8.04 
Median = 8.28 
SD = 0.93 
95% Cl = 7.55-8.53 
Skew 
= 
-0.73 
Stage IV 
Mean = 8.51 
Median = 8.53 
SID =. 088 
95% Cl = 7.59-9.43 
Skew = 
-0 14 
ID 9.3 
Ln (total cost) 
419 
Figure 8.4 Histogram of square root transformed breast cancer cost data 
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Figure 8.6 Histogram of the bootstrap estimate of the sampling distribution of 
the breast cancer cost data 
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Figure 8.7 Histogram of the bootstrap estimate of the sampling distribution of 
the difference in costs between early and late stage breast cancer. 
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&4.2 Cervical cancer 
The cost data and descriptive statistics for invasive cervical cancer by stage of disease 
are displayed in figures 8.8-8.13 for each of the methods explored. The distribution of 
the cost data for all stages apart from stage III differ significantly from normality, and 
are positively skewed. The Kolmogorov-Smirnov test gives P values of 0.000,0.000, 
0.14 and 0.056 for stages Ito IV respectively. The highest five and lowest five 
outliers were removed from the datasets for each of the four stages, this had the effect 
of reducing the skew for stages I-III and making the distribution of stage IV cancer 
negatively skewed, but not making any of the distributions for stage I-II and IV 
normal (Kolmogorov-smirnov test P=0.000,0.01,0.20,0.035). Transforming the 
data using the natural logarithm and square root also has the effect of reducing the 
skew, in fact changing from positive skew to negative skew using the Ln(cost), 
transforming the data also has the effect of equalising the variances between the 
stages. Transformation using the reciprocal worsens the skew for all four stages. 
Finally, figure 8.12 displays the histogram for the bootstrap estimate of the sampling 
distribution of the cervical cost data. The bootstrap sampling distributions for each 
stage indicate that the sample size is sufficiently large that the assumption of normality 
for the use of parametric hypothesis testing is justified. 
As with breast cancer I have explored the difference in cost associated with 
diagnosis at an early stage compared with a late stage diagnosis. All cancers 
diagnosed at stage I represent early stage disease, whereas cancers diagnosed at stages 
II-IV represent late stage disease(17). Table 8.2 displays the results using the 
parametric t-test on the original cost data, after removal of outliers and after 
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transforming the data, to explore the difference between early and late stage cancer. 
All methods suggest a significant difference in costs between cancers diagnosed at an 
early stage compared to those diagnosed at a later stage. The bootstrap estimate of the 
sampling distribution of the mean cost difference was found to be significant at 
£4,309, with a standard deviation around this mean of 843(this standard deviation is 
equivalent to the standard error of the mean difference using parametric statistics), and 
95 % confidence intervals ranging from £2,715-£5,97 1 (see Figure 8.14). 
Table 8.2 Results of parametric and nonparametric analysis of difference in 
early stage and late stage costs - Invasive cervical cancer 
Data Stage N Mean SD Mean Test P Skew 
difference statistic value 
Original Early 128 6,622 4,753 4,339 4.93 0.000 2.01 
Late 132 10,959 8,797 2.41 
Outliers Early 118 6,196 3,371 3,546 6.30 0.000 1.03 
removed Late 102 9,741 4,920 0.91 
Ln Early 128 8.56 0.77 0.42 3.99 0.00 
-1.78 
transformed Late 132 8.98 0.92 
-1.51 
Square root Early 128 77.04 26.28 20.52 5.04 0.00 0.84 
transformed Late 132 97.56 38.10 0.69 
Mann 0.000 
Whitney 
423 
Figure 8.8 
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Figure 8.9 Histogram of cervical cost data with outliers removed 
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Figure 8.10 Histogram of Ln transformed cervical cost data 
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Figure 8.11 Histogram of square root transformed cervical cost data 
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Figure 8.12 Histogram of reciprocal transformed cervical cost data 
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Figure 8.13 Histogram of the bootstrap estimate of the sampling distribution of 
the cervical cost data 
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Figure 8.14 Histogram of the bootstrap estimate of the sampling distribution of 
the difference in costs between early and late stage invasive cervical cancer 
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The cost data and descriptive statistics for lung cancer by cell type are displayed in 
figures 8.15-8.20 for each of the methods explored. The distribution of the cost data 
for both cell types differ significantly from normality, and are positively skewed. The 
Kolmogorov-Smirnov test gives P values of 0.000 and 0.04, for NSCLC and SCLC 
respectively i. e. the distribution of the data significantly differ from normality. The 
highest five and lowest five outliers were removed from the datasets for each of the 
four stages, hence reducing the skew, but only significantly for the SCLC data (P = 
0.200). Transforming the data using the square root also has the effect of reducing 
the skew, (P = 0.07 and 0.165 for NSCLC and SCLC respectively using the 
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Kolmogorov-Smirnov test). Whereas, transformation using the natural logarithm only 
reduced the skew for the SCLC data (P = 0.20), but not the NSCLC data (P = 0.000). 
Transformation using the reciprocal worsens the skew for both datasets (P = 0.000 and 
0.016 for NSCLC and SCLC respectively). Finally, figure 8.12 displays the histogram 
for the bootstrap estimate of the sampling distribution of the lung cancer cost data. 
The bootstrap sampling distributions for each cell type indicate that the sample size is 
sufficiently large that the assumption of normality for the use of parametric hypothesis 
testing is justified. 
The difference in cost associated with being diagnosed as SCLC compared 
with NSCLC is explored using the various methods of analysis. Table 8.3 displays the 
results using the parametric t-test on the original cost data, after removal of outliers 
and after transforming the data, and the nonparametric Mann-Whitney test to explore 
the difference between early and late stage cancer. All methods suggest no significant 
difference in costs between cancers diagnosed as being the non-small cell type 
compared with the small cell type. The bootstrap estimate of the sampling distribution 
of the mean cost difference of £475 was also found to be non-significant, with a 
standard deviation around this mean of 971(this standard deviation is equivalent to the 
standard error of the mean difference using parametric statistics), and 95 % confidence 
intervals ranging from £ -1,495-£2,299 (see Figure 8.21). 
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Table 8.3 Results of parametric analysis of difference in NSCLC and SCLC 
costs 
Data Stage N Mean SD Mean 
difference 
Test 
statistic 
P 
value 
Skew 
Original NSCLC 227 6,150 7,333 482 0.328 0.743 4.86 
SCLC 26 5,668 4,426 0.74 
Outliers NSCLC 217 5,563 4,738 704 0.586 0.559 1.13 
removed SCLC 16 4,858 2,919 1.26 
Ln NSCLC 227 8.10 1.34 0.20 0.745 0.457 
-1.25 
transformed SCLC 26 8.30 0.89 
-1.74 
Square root NSCLC 227 68.81 37.71 0.92 0.101 0.920 1.09 
transformed SCLC 26 69.58 29.32 0.37 
Mann 0.775 
Whitney 
Figure 8.15 Histogram of original cost data for lung cancer by cell type 
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Figure 8.16 Histogram of lung cost data with outliers removed 
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Figure 8.17 Histogram of Ln transformed lung cost data 
Frequency80 
70 NSCLC SCLC 
Mean = 8.10 Mean : 
60 Median = 8.33 Mediar SD=1.34 SD=C 
95% Cl = 7.93-8.28 95% C 
50 Skew = 
-1.25 Skew; 
40 
30 
20 
10 
1234 5 678 9 10 11 12 
Ln(totat cost) 
  NSCLC 
  
SCLC 
430 
Figure 8.18 Histogram of square root transformed lung cost data 
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Figure 8.19 Histogram of reciprocal transformed lung cost data 
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Figure 8.20 Histogram of the bootstrap estimate of the sampling distribution of 
the lung cost data 
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Figure 8.21 Histogram of the bootstrap estimate of the sampling distribution of 
the difference in costs between NSCLC and SCLC 
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8.5 Discussion 
It was found that by removing the outliers from or transforming the original data for 
all three cancers had the effect of reducing skew in the data. The reciprocal 
transformation appeared to worsen the skew and therefore was not used when 
exploring the difference in costs between early and late stage breast and cervical 
cancers and small cell and non-small cell lung cancers. 
For breast cancer there was found to be no significant difference in the costs of 
early disease compared with the costs of late disease when using parametric tests on 
the original and transformed data, non parametric tests and bootstrapping the data. 
Only when the outliers were removed were the costs found to significantly differ. For 
cervical and lung cancer consistent results were found across all methods used, for 
cervical cancer all methods suggested a significant difference between early and late 
stage costs, whereas for lung cancer all methods suggested no significant difference 
between the costs according to cell type. It would appear from the investigation of the 
different methods employed that the use of parametric tests for exploring cost 
differences in all three cancer sites are sufficiently robust. It is acknowledged that 
parametric tests are sufficiently robust to accommodate small deviations from the 
assumptions underlying them. 
These results confirm the conclusions of Thompson and Barber in that the 
results from the standard parametric tests are adequate for most comparative cost 
situations(8: 1199). 
The above examples use univariate analysis of cost data, however, increasing 
use of multivariate analysis of cost data is being undertaken. Potential multivariate 
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analysis includes ordinary least squares regression (OLS), and parametric and non- 
parametric survival (failure-time) models. Ordinary least squares regression has been 
used to predict costs while controlling for covariables such as disease severity, age, 
gender etc. Two UK studies exploring the costs of colorectal cancer and mental health 
used the OLS regression to determine whether health economists could predict ex-ante 
what cost-generating events have the greatest impact on cost and therefore should be 
collected(18,19). Whereas the underlying assumption of univariate analyses is that 
the data are normally distributed, the assumption underlying OLS is that the error 
terms from the predicted data are normally distributed. OLS regression on 
transformed data and non-parametric survival methods such as Kaplan-Meier survival 
analysis have been used where this assumption is violated. The Kaplan-Meier method 
also allows for analysis of costs where data are missing due to attrition (also known as 
drop-out or censoring) in longitudinal studies (the use of this method is explored in 
chapter 9). The relative merits of several multivariate methods for analysing cost data 
have been explored by a few researchers. However, as with the analysis of univariate 
cost data no firm conclusion as to the most appropriate method has been reached(1, 
13,20). 
8.6 Conclusions 
Given the requirement of health economists to compare patient groups in terms of the 
arithmetic mean costs, standard parametric approaches to hypothesis testing such as 
use of the t-test and one-way analysis of variance seem appropriate. However, the 
problem for health economists in using such tests lie in their assumptions of the 
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normality of the distribution of the data. Cost data are invariably positively skewed 
resulting in a violation of the assumption of normality and according to standard 
statistics restricting the use of parametric tests. This chapter has explored the use of 
alternative methods for the univariate analysis of cost data, although these have their 
own problems for use by health economists. Removal of outliers may well reduce the 
skew but also distorts any information on the total budget required for treating a 
particular group, by removing potentially important information. Use of transformed 
cost data also has the effect of reducing the skew of the data and additionally equalises 
the variances allowing the use of parametric tests, however there is a problem with 
interpretation of transformed means, standard deviations and confidence intervals. 
Health economists and policy makers require the information on the original scale, the 
cost scale. Back-transformation of the results from reciprocal and square root 
transformed data are meaningless, and although back-transformation using the 
exponential on natural logged cost data is possible, the process gives a geometric 
rather than arithmetic mean. Use of non-parametric tests also suffers from the lack of 
appropriate information to enable the calculation of a cost-effectiveness ratio. The 
bootstrap method is able to deal appropriately with skewed data, and can be used to 
report a measure of central tendency and confidence intervals around the mean. It can 
also be used as a check on the normality assumption of the sampling distribution of the 
data being analysed. 
From this chapter it can be concluded that: 
Reporting of the distributional form of the data being analysed is of paramount 
importance. This can be done using descriptive statistics such as the mean, 
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standard deviation and confidence intervals and a visual representation of the 
distribution using a histogram of costs or a scatter plot of cost and effect pairs. 
Reporting of the median and quartiles alongside the mean and standard 
devaition are useful when the distribution is skewed. 
9 The arithmetic mean value should always be reported, even where data are 
skewed, as this is the value health economists require to calculate cost- 
effectiveness ratios and is also a necessary requirement for the estimation of 
the total cost involved in providing packages of care or implementing 
treatments. 
9 Use of parametric hypothesis tests for exploring comparisons in arithmetic 
means are usually justified as long as the results are accompanied by 
descriptive information about the data. 
. 
Where skewed data are a problem the bootstrap method can be used to estimate 
confidence intervals around a mean estimate of the difference in sampling 
distributions. 
The bootstrap method can also be used as a check on the assumptions for using 
parametric methods. 
" 
It is acknowledged that parametric tests are sufficiently robust to accommodate 
small deviations from the assumptions underlying them. 
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Chapter 9 
Estimating costs with censored data 
9.1 Introduction 
The previous chapters have explored the costs involved with diagnosis, treatment and 
follow-up for breast, cervical and lung cancer patients. Observed counts of separate 
categories of patient-level resource use data were weighted by unit cost information 
and summed to provide an estimate of per patient total cost. This enabled 
comparisons of the average per patient costs according to disease severity (stage or 
cell type) to be made by dividing the total cost per patient by the total number of 
patients in each group. However, this method assumes that there is full cost 
information for all patients across all time periods in the study. Ideally, medical cost 
data should be available from diagnosis or implementation of an intervention until a 
specified time of follow up (or death if occurring before the specified period of follow 
up). This specified time of follow up should include all cost-generating events related 
to the disease or intervention being investigated i. e. all attributable costs. 
Figure 9.1 displays this idea graphically, the period beyond time t is the phase 
beyond which it becomes difficult to attribute costs to the specific disease or 
intervention as the patients are considered cured. The population on average incurs a 
baseline cost of medical care, as health economists we are interested in the additional 
cost incurred by the disease or intervention being examined. For certain diseases such 
439 
chronic degenerative diseases e. g. Alzheimer's disease, the appropriate time period 
might be from diagnosis until death, whereas for certain interventions such as hernia 
repair or appendectomy, shorter follow up periods are required as patients are likely to 
return to `normal' or `baseline cost' within twelve months. 
Unfortunately, medical cost data are rarely available for all patients over the 
whole specified length of follow up. Patients whose follow up is terminated prior to 
the study endpoint are said to be `right censored'. All that is known about their 
survival time (or time to specified event) is that it exceeds the time from diagnosis to 
last contact. Right censoring can occur in both prospective and retrospective data 
collection. In prospective studies, for example with the collection of resource use and 
unit cost data alongside a trial, censoring may arise due to the treatment continuing 
beyond the end of the trial period or more usually due to patient attrition (drop-out) 
before the end of the trial period. For retrospective studies patients may be right 
censored due to the choice of time horizon over which the data are extracted from the 
medical notes. 
Censoring is a particular problem for chronic diseases, where treatment costs 
are expected to continue over the patient's lifetime. Of course it is plausible to report 
within trial costs or costs per period of time (as were reported for the breast and 
cervical data in chapters 5 and 6). However, censoring will inevitably still exist within 
this defined period so there remains the problem of how to calculate unbiased costs. 
Although several techniques have been proposed in the published literature since 
1995(1-9), studies have continued to estimate mean costs by using the average total 
costs from all study subjects. This chapter explores the use of techniques to overcome 
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the bias from censored cost data using the breast and cervical cost datasets analyzed in 
Chapters 5 and 6. 
Figure 9.1 Follow up of patients cost-generating events 
Cost 
9.2 Comparison of methods 
- 
an empirical example 
In chapters 5 and 6, the average cost of breast and cervical cancer by stage were 
estimated using the sample mean of observed costs for all study patients over a 
respective four- and five-year period. However, where data were censored prior to the 
end of the full four and five years of follow up a monthly value was imputed based on 
the average monthly cost of the previous twelve months costs for that patient. This 
method is similar to the 'last value carried forward' method(I 1). 
For breast cancer costs, data were collected on 137 patients diagnosed with 
breast cancer in 1991. This permitted a resource audit for patients over a minimum 
period following diagnosis of 46 months and a maximum of 60 months. For cervical 
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cancer costs, data were collected on 260 patients diagnosed with cervical cancer in 
1990. This permitted a resource audit for patients over a minimum period following 
diagnosis of 59 months and a maximum of 77 months. Resource items included 
diagnostic, staging, treatment and follow up procedures already outlined in chapters 5 
and 6. Costs are presented in 1991 and 1990 UK pounds, discounted at 6% for breast 
and cervical cancer patients respectively. For the purpose of comparison with the 
results reported in chapters 5 and 6 the analysis is limited to 4- and 5-year cost 
estimates. The methods described in section 9.3 are applied to the breast and cervical 
cost data for the purpose of exploring the variation between the estimated average total 
costs. 
9.3 Outline of methods used 
There have been a number of papers proposing various methods to calculate average 
total costs in medical care. These include: 
" 
Ignoring the issue of censoring altogether (full-sample method), 
" 
Using all available cases (available case analysis)(10), 
" 
Imputation(11) 
" 
Prorating costs(9), 
" 
Discarding cases where data is censored (complete case analysisx 10), 
" 
Standard Kaplan Meier survival analysis techniques (where the variable `cost' 
is used in place of the variable `survival time' by attaching a censoring 
indicator to observed total costal, 2), 
" 
Use of the Kaplan Meier sample average approach(3,5-9). 
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9.3.1 Ignoring the issue of censoring 
This method of estimating average total costs completely ignores the issue of 
censoring (full-sample method; (Average cost = TC month 1+ TC month 2+ TC 
month 3 +..... TC month t)/number of cases). It effectively treats the censored 
individuals as if they have died or been discharged from care. The average total cost 
is therefore estimated using the sample mean of observed costs for all study patients. 
This method underestimates the true average total cost because any costs incurred 
after censoring are not accounted for. The degree of bias is dependent on the number 
of censored subjects in the sample, and is minimal if the number is small. 
9.3.2 Available case analysis (ACA) 
This method estimates the mean for the complete cases for each variable, then sums 
the means (total average cost rather than average total cost above). The major 
disadvantage is that different sample sizes are used across the analysis i. e. the sample 
base varies from one variable to another. Hence standard parametric statistical 
inference cannot be addressed. 
933 Imputation 
Imputation can be undertaken in a number of ways, two of the most popular forms are 
"mean imputation" and "last value carried forward". Mean imputation involves the 
calculation of the mean of the observed data for each variable and the substitution of 
this value into every case with a missing observation for that variable. However, by 
imputing the mean value in a number of cases the estimated variance or standard 
deviation for that variable will be underestimated (since the imputed values do not 
differ from the mean or each other). The last value carried forward method uses the 
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last observed value to fill in the missing values. This method only applies to data 
where repeated measures have been made on the variable inquestion. The advantages 
of this method are that it is easy to implement and understand and also allows for 
complete data methods to be employed. The disadvantage is that it will produce poor 
results where variables are expected to change over time. 
9.3.4 Prorated costs 
This method is simple to implement, but assumes a constant cost accumulation over 
time. The formula is: 
(mean cost/ mean follow-up time)*mean survival time 
Where mean survival time is based on the Kaplan-Meier survival method. 
9.3.5 Complete case analysis 
Complete case analysis (CCA) or listwise deletion of cases is the default method in 
most statistical software packages. It involves discarding all censored cases. The 
advantages of using this method are that it is easy to do and that the same set of data 
(albeit a reduced set) is used for all analyses. However, it is inefficient in that it 
excludes data that are potentially informative for the analysis. Furthermore, CCA will 
be biased if the uncensored cases systematically differ from the censored cases (e. g. if 
not missing at random). In practice, CCA is likely to be an acceptable method with 
small amounts of missing data (say where more than 90% of cases are completex 10). 
9.3.6 Survival analytic techniques 
Fenn and colleagues (1995,1996) have proposed the use of survival analytic 
techniques for the analysis of censored cost data(1,2). To introduce their method it is 
necessary to provide a brief summary of the Kaplan-Meier (K-M, also known as the 
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product limit) method for estimating survival. It is a non-parametric method and 
therefore requires no assumptions about the distribution of survival times. The only 
assumption made is that the survival times are independent of the censoring 
mechanism and that the individual survival times are independent of each other. An 
example of where this assumption may be violated is where those patients 
experiencing adverse reactions or poor health compared with the remainder of the 
sample are more likely to drop-out/ be censored. 
The estimator of the survival function is defined as follows: 
k n-d 
S(t) =11 '' ! =I nj 
Where nn denotes the number of people alive at time tk., and dj is the number of deaths 
at time tk. To illustrate this process, it can be seen in figure 9.2 that patients are 
followed up for a total time of = 12 months. Everyone is alive at the start of the 
period and in the first month no one dies or is censored so the probability of surviving 
for 1 month P1=1, At the start of the second month the number of patients at risk is 96 
(equivalent to the number at risk at the beginning of the first month minus the number 
of patients who died or who were censored within the first month), the conditional 
probability of surviving the second month having survived the first month p2= the 
number of patients followed for at least 1 month and who also survive month 2 
(equivalent to the inverse function of the hazard rate (Ht). The Kaplan-Meier survival 
estimate (St) for the 12-month period is the product of all the conditional survival 
probabilities up to t12 (Pti *Pt2*Pt3.... ti2).. A survival plot of the Kaplan-Meier 
probabilities can then be drawn as a step function (see Figure 9.3). It is possible to 
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determine the mean and median survival time by estimating the area under the curve 
(steps) and the point at which 50% of the study population are still alive, respectively. 
Figure 9.2 Kaplan-Meier example 
Time period No. at risk Deaths Censored Ht Pt St 
0 100 0 0 0 1 1.00 
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Fenn and colleagues apply this Kaplan-Meier technique employing cost as the metric 
in place of time. The average total cost is estimated by calculating the area under the 
curve. This method had previously been used by two separate US research teams; 
Adams-Dudley and colleagues and Rutten van Molken and colleagues for use in cost 
prediction(11,12). Fenn and colleagues also used alternative parametric survival 
analysis approaches such as Cox regression and Weibull functional forms to estimate 
average costs. However, the K-M method has the advantage in that it is a 
nonparametric method. Parametric techniques have recognized limitations due to the 
likely skew of cost data, and presence of a number of observations with zero costs. 
The use of the Kaplan-Meier technique when applied to the cost scale was later 
criticized in a paper by Hallstrom and Sullivan, who argued that this method could not 
be used as the assumption of independent censoring was violated(5). They use an 
example of two patients in a trial with equivalent survival times but with one patient 
incurring twice the cost of the other. When the Kaplan-Meier technique is applied to 
the cost scale the low-cost patient is censored earlier on the cost scale than the high 
cost patient (see figure 9.4a-c). This early censoring of the low cost patient results in 
an overestimate of the true cost. In response they suggest an unbiased estimator of 
average cost, obtained by dividing the time period of interest into a number of small 
intervals of equal length and then summing over all periods the product of the 
probability of survival and the mean cost of treatment in each defined period. This 
method known as the `Kaplan-Meier Sample Average' has been previously proposed 
by Lin and Etzioni(4). The authors also propose a similar technique for when the cost 
histories are not recorded(3). 
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When cost history available: YP(s) * E(cls), where P(s) is based on the K-M and E(cls) 
is the average cost during the interval conditional on being alive at the start of the 
interval. In other words, the mean cost at a given time period t given the probability of 
being alive at the start of time t is estimated using the cost data from subjects who 
survive to the start of the time interval t. The estimate is based on the subject costs 
during the time period t, this includes the cost of cases who survive to the start of time 
t, but who may die, be discharged or censored during the time period t. Therefore the 
costs related to death and discharge are included in the average cost estimates for each 
time period. 
These technical reports were later published as a technical paper(7) and an application 
paper using the techniques to estimate the average cost of ovarian cancer(6). 
448 
Figure 9.4 Transfer of real time costs to failure time scale and failure cost 
scale 
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9.4 Results 
Table 9.1 presents the number of patients with complete cost histories over the f'our- 
year period compared to the number with incomplete/censored cost information. Both 
data sets display considerable censoring, thirty-nine per cent of the breast cancer data 
(n=53) are censored, while fifteen per cent (n=40) of the cervical patients are 
censored. Figures 9.5 and 9.6 display when the censoring is incurred. For breast 
cancer the majority (52% of all censoring) is incurred in the fourth year following 
diagnosis. For cervical cancer although a smaller proportion of patients are censored 
compared with the breast cancer patients, similarly the majority (45%) of all censoring 
is incurred in the final year (the fifth year following diagnosis). 
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Table 9.1 Number of censored and complete cost histories for breast and 
cervical cancer 
Stage N Complete Censored 
1 102 55 47 
II 13 8 5 
Breast IIl 16 15 1 
IV 6 6 0 
All 137 84 53 
1 128 99 29 
11 76 70 6 Cervical 111 41 36 5 
IV 15 15 0 
All 260 220 40 
Figure 9.5 Year when censoring is incurred for breast cancer patients 
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Figure 9.6 Year when censoring is incurred for cervical cancer patients 
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The mean survival time for breast cancer patients over the four-year period was 38 
months, with total costs ranging from £ 119 to £ 16,668, and average total cost across 
all stages of £4,004 (sd 2,880). Patients who died or were discharged (i. e. had 
complete cost histories) during the study period incurred higher costs (not significant 
t=1.505 P=0.135) than patients who were censored (see table 9.2). Average total cost 
for censored patients was £3,540 (sd 2,5 17) and average total cost for those patients 
who had complete cost histories was £4,297 (sd 3,065). 
The mean survival time for the cervical cancer patients over the five-year period was 
42 months, with total costs ranging from £48 to £62,523, and average total cost across 
all stages of £8,749 (sd 7,404). Patients who had complete cost histories including 
those who died or were discharged during the study period incurred significantly 
higher costs (t=3.023 P=0.003) than patients who were censored (see table 9.2). 
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Average total cost for censored patients was £5,542 (sd 3,289) and average total cost 
for those patients who had complete cost histories was £9,332 (sd 7,791). 
The results of the various analyses to estimate average costs of breast and cervical 
cancer are reported in table 9.3. 
Table 9.2 Average cost by stage for complete and censored breast and 
cervical cancer patients 
Breast Cervical 
Stage Complete Censored Complete Censored 
Mean SD Mean SD Mean SD Mean SD 
3,910 2,659 3,487 2,511 6,920 4,993 5,267 3,382 
11 4,088 1,617 4,351 2,892 11,122 9,381 6,952 2,421 
III 4,900 3,894 1,945 
- 
11,571 7,175 5,453 3,814 
IV 6,613 4,920 
- - 
11,535 11,724 
- - 
All 4,297 3,065 3,540 2,517 9,332 7,791 5,543 3,289 
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Table 9.3 Average cost of breast and cervical cancer by method of estimation 
Method Stage Breast Cervical 
Mean 95% Cl Mean 95% Cl 
Impute I 3,734 3,248-4,217 6,623 5,789-7,452 
costs II 4,394 2,946-5,841 10,910 8,837-12,985 
I I1 4,331 2,481-6,179 10,838 8,590-13,085 
IV 6,613 1,450-11,776 11,535 5,042-18,027 
Full 1 3,715 3,207-4,224 6,546 5,721-7,371 
sample 11 4,189 2,932-5,447 10,793 8,716-12,870 
111 4,715 2,672-6,758 10,826 8,580-13,071 
IV 6,613 1,450-11,776 11,535 5,042-18,027 
ACA 1 4,055 
- 
6,945 
- 
II 4,470 
- 
12,318 
- 
III 6,314 
- 
15,027 
- 
IV 11,009 
- 
15,952 
- 
Prorated 1 4,040 
- 
7,165 
- 
II 4,577 
- 
11,094 
- 
III 4,860 
- 
11,978 
- 
IV 6,613 
- 
11,535 
- 
CCA 1 3,910 3,191-4,629 6,920 5,924-7,916 
11 4,088 2,737-5,440 11,122 8,885-13,359 
III 4,900 2,743-7,056 11,571 9,144-13,999 
IV 6,613 1,450-11,776 11,535 5,042-18,027 
K-M 1 5,438 4,461-6,415 7,807 6,696-8,917 
11 4,964 3,623-6,304 11,451 9,216-13,686 
111 4,991 3,035-6,946 11,917 9,602-14,233 
IV 6,613 2,676-10,550 11,535 5,588-17,450 
KMSA 1 3,877 
- 
6,716 
- 
11 4,244 
- 
10,822 
- 
111 4,801 
- 
11,482 
- 
IV 6,613 
- 
11,535 
- 
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9.5 Discussion 
The empirical example (table 9.3) using breast and cervical cancer cost data illustrates 
the variation in average cost estimates obtained by using different methods to calculate 
the average total medical costs. It has been argued that the full sample method results 
in average cost estimates that are biased downwards, as they take no account of costs 
following censoring(1,2,7). This argument appears to be borne out by the empirical 
results in table 9.3. 
Attempts to overcome this bias include using other naive methods such as 
available case analysis (ACA), complete case analysis (CCA) and prorated costs. All 
three methods result in higher cost estimates than the full sample method. ACA is not 
an ideal method for cost estimation for the purpose of economic evaluation as no 
measures of variance can be obtained from such an analysis. Cost estimates using 
CCA are inevitably biased towards the costs for patients with complete cost histories. 
In this example they reflect the costs of those patients who are discharged early, have 
full cost histories over the four- or five-year period or die from the disease. It is also 
an inefficient method as the estimates are based on 61 % and 84% of the total sample 
of breast and cervical patients respectively. The prorated method is likely to be a 
biased estimate as the basic assumption for using this method is a constant 
accumulation of cost over time. This is not the case with either the breast or cervical 
cancer costs (see figures 9.4 and 9.5). 
Use of the K-M method using costs in place of time as the metric for the 
survival analysis results in extreme overestimation of average costs. This 
overestimation has also been found in previous studies using this method proposed by 
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Fenn and colleagues(1,2,7,8), and is due to the early censoring of the low cost 
patients. 
The final method employs the Kaplan-Meier sample average to produce an 
unbiased estimator of average costs. This method allows for censoring by weighting 
the costs using the K-M survival estimates. For breast and cervical cancer, these cost 
estimates are higher than the full sample estimate and lower than the estimates 
produced by the CCA, prorated and K-M methods (except for stage IV cancer costs 
where cost histories are complete for all patients). Figures 9.4 and 9.5 display the 
cumulative cost functions for the KMSA method compared with the original cost data, 
it can be seen how the KMSA takes account of any censoring during each period, 
resulting in slightly higher costs than those for the full sample method. Of course if 
95% confidence intervals were to be calculated for the estimates produced by the 
different methods, it would appear from table 9.3 and figures 9.4 and 9.5 that variation 
in results produced by the alternative methods would probably not significantly differ 
from one another. 
There are drawbacks to using the KMSA method, in that it is recognized that 
smaller time intervals produce more efficient cost estimates. This requires resource 
use data to be collected, stored and analyzed in the database on a monthly interval 
basis. Compared with collecting, storing and analyzing data in an annual format this 
is a more time-consuming process. 
Another issue related to the length of the interval is the assumption that has to 
be made by the analyst as to whether censoring occurs at the start or end of the 
interval. In this example I have made the assumption that all censoring is incurred at 
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the end of the interval (see table 9.4), so that at the start of the analysis everyone is 
assumed to be alive thus the probability of survival S(tl) in the first month is 1. For 
stage III breast cancer patients this survival probability drops to 0.878 in the second 
month. If I was to assume that all censoring was incurred at the start of the period the 
average cost estimates would be lower than those reported in table 9.3. For example 
for stage I breast cancer costs the assumption of censoring at the start of the interval 
results in an average cost estimate of £3,858 compared with £3,877 when censoring is 
assumed to be incurred at the end of the period. Lin et al, (1997) point out that this 
assumption is the worst scenario as the censored patient has a zero observed cost in the 
censoring interval(7). They also mention that the amount of bias for this estimator 
depends on the amount and timing of censoring and diminishes as the intervals shrink. 
They suggest that monthly intervals are more than adequate. Intervals of an annual 
basis may be problematic, as cases censored during the year may significantly under- 
contribute to the sample mean cost for that year. 
As this is a relatively under-researched area, there are few studies available for 
comparative purposes. Using work reported by Lin and colleagues, it would seem 
that these results are consistent with what is expected. Lack of significant differences 
in cost estimates may be a result of smaller sample sizes being used in this analysis. 
It would appear from the results in table 9.3 that none of the techniques used 
actually change the conclusions made in chapters 5 and 6 concerning the cost-by-stage 
differences for breast and cervical cancer. Therefore use of the rather naive 
imputation method employed in chapters 5 and 6 appears to be a plausible method to 
apply. However, it is currently impossible to tell whether similar conclusions would 
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be reached for the analysis of censored cost data with respect to other diseases, or with 
the advantage of using larger datasets. It is apparent that the Kaplan-Meier method 
using cost rather than survival and the available case analysis 
9.6 Conclusions 
Unfortunately from the results reported in this chapter, and the limited empirical 
publications on the use of analytic methods for censored cost data, it is impossible to 
make any firm conclusions. The presence of censoring does present real 
methodological and practical problems for the estimation of mean total costs. 
However it is too early to tell whether, the methods proposed do actually make a 
difference to the results, moreover, it is currently unclear how to best judge between 
the techniques. The results obtained in this chapter are limited to a specific disease, it 
may well be that one would get different results from the analysis of censored cost 
data for different diseases or interventions. 
One important conclusion that can be drawn from this chapter is that, when 
undertaking any analysis of cost data, information on the number and proportion of 
patients with complete and censored costs should be routinely reported along with the 
method used to take account of the censoring. 
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Table 7.4 Assumption of censoring at end of period 
Month KM AC KMSA 
survival 
1 1 5917.72 5917.73 
2 0.878 2274.63 1997.13 
3 0.8028 426.57 342.45 
4 0.7777 401.05 311.90 
5 0.7526 187.06 140.79 
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Figure 9.7 Comparative cumulative breast cancer costs over the 4-year period 
with full sample method, available case analysis and KMSA. 
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Figure 9.8 Comparative cumulative cervical cancer costs over the 5-year 
period with full sample method, available case analysis and KMSA. 
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Chapter 10 
Discussion 
10.1 Introduction 
This chapter discusses the empirical findings of this thesis in relation to three 
important areas. 
The first topic for discussion is how the experience of costing in practice 
complies with the principles of costing set out in chapter 2. The literature review 
in chapter 3 has already alluded to the problems of costing in practice, and 
highlighted the divergence from how costs ought to be estimated in order to 
conform to economic principles. Section 10.2 explores the problems encountered 
when trying to adhere to the theory and guidelines, with reference to the empirical 
chapters 5-9. In particular it explores the issues of choice of perspective and the 
reality of using average costs in place of `true' opportunity costs or even marginal 
costs. 
Throughout this thesis an acknowledgment has been made of the 
considerable length of time required to collect the data and undertake such a 
costing exercise. Therefore the second subject for debate is whether the results 
could have been achieved using a less-time consuming method of estimation. For 
example, would length of stay have been a good enough predictor of costs 
463 
compared with those estimated by abstracting detailed information on all cost- 
generating events from patients' medical notes. 
The final area of discussion is centred on the policy implications of the 
results reported in chapters 5-7. The focus for this part of the discussion is on the 
potential users/audience of these results and how the findings might be used. 
10.2 Theory and practice of costing 
Chapter 2 outlined the principles of costing for the purpose of conducting an 
economic evaluation. However when actually conducting a costing exercise, as 
was undertaken for breast, cervical and lung cancers in chapters 5-7, it appears that 
there are two main divergences from the economic theory that underpins the 
principles of costing. Namely, the application of the societal perspective and the 
use of opportunity costs. 
The majority of existing economic evaluation guidelines argue that a 
societal perspective should be used for all analyses(1-4). The societal approach 
has been recommended as the standard perspective for costing, as it allows the 
analysis to be carried out on a number of viewpoints. In practice the societal 
perspective may be neither attainable nor of interest for the users of the results. 
For example, in costing the cancers for this thesis, a hospital-based perspective 
was taken. The reason for this choice of perspective is that Trent health authority, 
in defining what they wanted to know (i. e., the resources and costs used by the 
regions' hospitals in diagnosing and treating cancer), set the perspective. If the 
purpose of the costing exercise had been specifically for an economic evaluation 
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of an anti-cancer drug aimed at palliation in end-stage disease, the omission of 
other costs, such as informal care costs, could have been problematic. The drug 
may have had the effect of reducing the burden on informal carers, and if this cost 
had not been included the important effect would not have been quantified in the 
results. Therefore the choice of perspective and hence the costs to be estimated are 
dependent on the context and the question being asked. It should not be the case 
that all studies take the societal perspective, although, awareness of all the possible 
costs is important. 
The second issue of contention encountered while conducting the costing 
for this thesis was the use of average costs in place of opportunity costs. 
According to economic theory, the true cost in any economic analysis is the 
opportunity cost. It is measured as the benefits that would result from the next 
best alternative use of the foregone resources. Opportunity cost is difficult, perhaps 
impractical, to estimate precisely. In practice market prices are generally used and 
accepted as approximations to opportunity costs. Average costs rather than 
opportunity costs were used in this thesis. The choice in this case was felt to be 
justifiable on two counts. Firstly, it was felt that the use of average cost estimates 
were appropriate for the question being asked, `what is the current cost to our 
region of providing cancer'? Secondly, it was felt that any attempt at obtaining 
`true' opportunity costs or even marginal costs for all three cancer sites would 
require a significant amount of research time. From the experience of costing in 
practice I feel that obtaining `true' opportunity costs may in reality be impossible 
for any disease or intervention given the time and financial constraints. 
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Costing the cancers in this thesis required resource use information across a 
number of specialities (even, as in this case, when confined to estimating the 
hospital costs). Cancer treatment entails such specialities as surgery, 
chemotherapy, radiotherapy, diagnostic imaging, inpatient stays for complications 
to name a few. Invariably these interventions were conducted at different centres 
within the hospital or at different hospitals, with each department holding their 
own medical notes on the exact details of the treatment. For example the 
radiotherapy departments detail all the treatment planning and number of fractions 
of radiotherapy undertaken on a certain patient while the chemotherapy 
departments detail the drugs and doses used. Given the complexities of cancer 
care, obtaining accurate information on all the resources used for the care of 
breast, cervical and lung cancer patients and then placing a value that reflects the 
`true' opportunity cost on these resources would not be possible in practice. One 
would have to measure and value all the resources used in terms of foregone 
benefits. This would be conducted by asking an expert (clinical director, clinician, 
ward manager) to identify the marginal patient to be admitted to a ward or 
radiotherapy unit and suggest the benefits arising from not admitting this marginal 
patient, then one would have to place a value on these benefits that could be 
incorporated into an economic analysis. These estimates of `true' opportunity 
costs are unlikely. Even if the expert was able to identify the benefits arising from 
freeing up the resources from the marginal patient on the ward, trying to value this 
benefit in units that can be used in an economic evaluation is a complex task, and 
even if undertaken may still not reflect the true opportunity cost. The alternative 
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to `true' opportunity costing is the use of marginal costs. However, this is still 
reliant on obtaining (often subjective) information on the resource implications 
from not admitting the marginal patient, which include number of hours and 
minutes of staff time, consumables etc. and then valuing the resources at market 
prices. In this thesis conducting this task for all resource events (all diagnostic, 
surgical, radio-therapeutic, cytotoxic etc. ) would have been impractical, hence the 
use of average costs. Given the practical side of costing in this thesis, I would 
suggest a more useful way of presenting cost information is to provide separate 
information on resources used and released and then to attempt a valuation of them 
using market prices. Then even if the decision maker does not agree with the 
valuation aspect, s/he does have information on the basic resource use. 
10.3 Is it possible to reduce the research time required without jeopardising 
the findings? 
One criticism that can be levied against the costing method used for the purpose of 
this thesis is its time-consuming nature (even without estimating true opportunity 
costs). There are two possible alternatives available to reduce the amount of 
research time required. First, use of a smaller sample of patients, or a sample 
limited to one hospital. Second, use of length of stay as a proxy for total cost. 
The problems associated with using a smaller sample of patients for the 
cost estimation can be discussed using the breast cancer sample as a particular 
example. Only 82 per cent of the initial sample of 200 patients met with the 
inclusion criteria or could be traced, and of these only 137 were used to produce 
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meaningful cost estimates by stage of disease. It is not surprising to find that, 
because end stage disease is rarer than stage I cancer and because it was 
impossible to stratify and sample according to stage prior to obtaining the 
information from the medical notes, the number of stage IV cancers in the sample 
amounted to only 6 patients. Fortunately, the costs of these cancers were found to 
be significantly higher than the other disease stage costs despite the small sample 
size. Having an even smaller sample size might have jeopardized this finding. In 
fact one may question whether the results may have changed if a larger sample 
size had been used. 
An alternative to reducing the actual sample size is to reduce the number of 
centres/hospitals from which the resource use information was collected. It might 
be argued that collecting the data from a single hospital should be sufficient. 
However, this would have reduced the variability of the results. The cervical 
cancer cost data ranges from £6,300 in Barnsley to £11,700 in Bassetlaw yet do 
not vary significantly between the 12 districts (F = 1.277, P=0.237). The use of 
different hospitals in different districts in the Trent area also meant that the results 
are likely to be generalisable to other areas in England and Wales, as the region 
has a mix of urban and rural areas, ethnicity and teaching and non-teaching 
hospitals. 
The second possibility for conducting the research at lower cost is to use 
length of stay as a proxy for total care cost. Previous studies have shown that 
inpatient length of stay is a good predictor for total cost of care(5,6), therefore the 
product of average length of stay and the unit cost for an inpatient bed day could 
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be used as a proxy for total care costs. However, there are a number problems 
involved in estimating such a proxy and limitations associated with its use. 
In order to estimate the proxy measure of cost, information on inpatient 
length of stay is required. Routinely collected statistics on inpatient admissions 
and length of stay for patients in England and Wales can be obtained from the 
Hospital Episode Statistics (HESX7). This information is made available to the 
Office for National Statistics (ONS) by individual hospitals from their 
computerised patient administration systems (PAS). The data are limited in that 
the ONS only uses a 25% random sample of all inpatient episodes to inform the 
1-IES, neither patients nor hospitals are identified and individual episodes are not 
linked. Moreover the ONS acknowledge problems with the completeness of the 
PAS in recording resource events. The HES provide information on the number of 
inpatient days and mean length of stay in Trent for breast, lung and cervical cancer 
by ICD code. For England and Wales data are also provided on the number of 
inpatient episodes by type of procedure, although these categories are rather 
generalised, for example for breast cancer, the procedures are, `excision of the 
whole breast', `other excision' and `biopsy'. 
By combining the 3,5 and 10 days length of stay for Trent breast, cervical 
and lung cancers as reported by the HES with the unit cost estimates for an 
inpatient day used in chapters 5-7, the estimated average cost for breast, cervical 
and lung cancer amount to £542, £1,083 and £1,861 respectively. These average 
care costs are significantly lower than the results using the detailed costing 
methods. Moreover, use of inpatient length of stay information from the HES 
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would not enable an analysis of the costs by stage of disease or by other socio- 
demographic factors. Nor would the proxy measures allow for any statistical 
analysis of the cost data to provide information on the variability of the results, 
only a point estimate would be provided. The use of length of stay data would also 
limit any analysis of where the cost burden falls within the total care package. For 
example, with the breast cancer data a large proportion of the diagnostic and radio- 
therapeutic events were undertaken on an outpatient basis, and using any data on 
length of stay would mean these events would be excluded from the cost 
calculation. 
An alternative database to the HES exists for inpatient episodes in 
Scotland. These are the linked `Scottish Morbidity Records' (SMR). It is unique 
to the UK and suited to the work conducted in this thesis. It documents all hospital 
admissions from 1981, it is also possible to identify individual patients and 
hospitals, it covers the whole of the Scottish population and all episodes of care for 
the individual are linked. 
10.4 Policy implications and potential users of the findings from this thesis 
There are a number of potential users of the findings from the work conducted in 
this thesis. They include key decision makers such as health authorities, hospital 
trusts and the National Institute for Clinical Excellence (NICE) and are also likely 
to be employed by other researchers. 
Trent health authority used the findings to determine their current level of 
spending on specific cancers. Health authorities surprisingly have limited 
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knowledge of their current spending on specific disease areas, let alone the costs of 
specified treatment options within a disease area. The work conducted for this 
thesis therefore has not only provided information on the overall cost of breast, 
cervical and lung cancer in Trent, but has also highlighted the resource use and 
costs related to the diagnostic, therapeutic and maintenance events that in 
combination make up the total hospital care costs. Given the data were collected 
from various districts within the region and from patients with differing socio- 
demographic backgrounds, the results are felt to be generalisable to other regions 
in England and Wales. 
Another possible use for these results is in the commissioning of care for 
the region. At present, cancer services are commissioned by health authorities 
using a process of health needs assessment and the setting of service agreements 
(contracting). The health authority and trusts negotiate these service agreements 
based on finances and the number of outpatient, day case attendances and finished 
consultant episodes (FCEs). These are negotiated separately with different trusts, 
and acute and community service agreements are totally independent. With cancer 
services another problem is that the pharmacy budget is also negotiated separately. 
There are therefore a number of problems with the current process. It is 
fragmented; the process of commissioning cancer services with different trusts 
results in a discontinuity of care. It is inflexible; because the budgets are decided 
for each sector, (acute, community, pharmacy) separately, any savings generated 
in one budget cannot be used for another budget. It creates perverse incentives; 
there is no incentive for clinicians to make cost-effective changes to the way they 
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deliver their care, as it is likely that any savings made would be used for another 
speciality rather than to treat the same condition. There is therefore a need to 
change this current process of commissioning care. An alternative is to 
commission according to a care protocol or pathway, as developed in this thesis. 
The care pathways, with numbers of patients and resources used for each stage of 
the pathway could determine the cost of each stage, which in turn could inform the 
contract. By using the type of care pathways, resource use and costs developed in 
this thesis, commissioning could be undertaken on a `whole systems approach' 
that would eradicate the problems inflexibility and perverse incentives associated 
with the current method. The care pathways would be modified and monitored 
under clinical governance arrangements as part of audit, and would provide health 
authorities with information on the resources spent each year on specified disease 
areas or treatments. The only clear barrier to change is the present lack of linked 
databases on episodes of individual patient care. If England and Wales could 
adopt the system of the linked Scottish morbidity records, then commissioning 
according to the care pathways developed in this thesis would be feasible. 
The National Institute for Clinical Excellence (NICE) is another key 
decision-maker that could use the cost results reported in this thesis to determine 
the impact of their decisions on the total cost of breast, cervical and lung cancer. 
In summer 2001 they are due to announce whether specific anti-cancer drugs 
should be made available to cancer patients. For those drugs used to treat lung and 
breast cancer NICE could use the cost results reported here to inform health 
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authorities on how much the cost of implementing these drugs is likely to be as a 
proportion of their current total spending on those cancer sites. 
Other researchers are also potential users of the cost results. For example, 
the estimation of cervical cancer costs is extremely pertinent to the current 
research into HPV testing. Before such a programme can be introduced, the 
National Health Service requires evidence of its effectiveness and cost- 
effectiveness. Therefore there is potential for these UK based cervical cancer cost 
estimates by disease stage to be employed in such an analysis. Similarly the breast 
cancer cost results could be used to assess the impact of changes to the UK breast 
screening programme such as amendments to the screening interval or the age 
range. And the results from the lung cancer costing exercise could be used to 
assess the impact of any programme likely to reduce the numbers of lung cancers 
in the UK, such as smoking cessation or radon remediation(8). 
The key to the use of the cost data for all the above purposes is that it is 
UK based. No other detailed cost study of breast, cervical and lung cancer has 
been undertaken in the UK. Moreover, the method used for costing these cancers 
allows for a distinction to be made between disease characteristics or the socio- 
demographic background of the patients. 
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Chapter 11 
Conclusions 
11.1 Introduction 
The purpose of this thesis was to explore the theory, practice and application of 
costing with specific reference to cancer. In part it has reviewed the theory and 
guidelines related to costing methods including the recent focus on the analytical 
techniques used with cost data. In addition it has examined how these theories and 
guidelines are applied in practice, by reviewing the literature on costs and cancer. The 
empirical research in this thesis applied costing methods to three specific cancer sites; 
breast, cervix and lung. This analysis provided information on the total burden of 
these specified cancers in terms of cost to a typical health authority (Trent). It also 
explored the hypothesis highlighted in previous studies that the cost of cancer 
increases with the stage of the disease. The final area of contribution for the thesis is 
in the application of recently suggested analytical techniques for cost data to the 
breast, cervical and lung cancer data sets; it investigated a number of proposed 
techniques for the analysis of skewed cost data and methods for data with incomplete 
patient follow up. 
The aim of this final chapter is to pull together and summarise the main 
findings of thesis and to draw some broad conclusions about the methods and practice 
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of costing cancer. In doing so the contribution of the thesis to the area of costing and 
cancer is highlighted. Finally, this chapter indicates potential areas of further research. 
11.2 Findings and contribution of the thesis 
Chapter 2 introduced the concept of economic costing as used by health economists. 
The methods, recommendations and guidelines related to costing were explored by 
way of a literature review, with the aim of informing the empirical part of the thesis. 
The literature review, in providing answers to four key questions: 1) What are costs, 2) 
Why are we interested in costs? 3) How are costs estimated? and 4) How should costs 
be analysed?, has presented a descriptive outline of how the process of costing ought 
to be undertaken and how the issues related to costing be handled. The methods and 
guidelines were separated into three broad categories; current accepted conventions; 
debateable issues and; emerging techniques requiring further empirical research. It is 
interesting to note that approximately one-third of all methods and issues reviewed 
were deemed to fall under the heading of `current accepted conventions'. This is 
unsurprising given that costing by health economists has only been undertaken to any 
great degree throughout the past three decades. Therefore like other areas in health 
economics is an evolving discipline. 
Chapter 3 reported on a systematic review of the literature on costs and cancer. It 
was useful for the basis of the design of the empirical work in the thesis. The search 
resulted in 262 studies on cost and cancer, of which 50% were considered to be simply 
costing studies, 34% were cost-effectiveness analyses, 12% were cost-utility analyses, 
2% cost-minimisation studies and 2% cost benefit analyses. Forty eight per cent of the 
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studies were conducted in the US while 12% were UK based studies. It was 
unsurprising to find that most of the work had been conducted on cancer sites that 
display the highest incidence in the western world or are those amenable to early 
detection through screening, namely breast, colorectal, cervical, prostate and lung. In 
chapter 2 it was noted that there were some areas of accepted conventions in costing. 
However, the detailed review of forty published papers testified that in practice 
variation in the methods used exists even within a single disease classification such as 
cancer. 
Chapter 4 outlined the methods used in the core costing chapters. The key 
messages from this chapter are as follows: 
1. The time and effort involved with conducting a detailed retrospective cost analysis 
of this size is quite considerable. Economic evaluations are increasingly being 
conducted alongside trials. Although this enables resource use data to be collected 
prospectively, invariably researchers need to return to the patient medical notes to 
ascertain detailed patient specific resource use information. Investigating a disease 
such as cancer requires information on a number of interventions, chemotherapy 
drugs, radiotherapy planning and treatment, surgery, inpatient stays, diagnostic 
procedures and outpatient visits. This information, in such detail required for 
accurate costing, can only be obtained from patient medical notes. 
2. Even where databases exist, for example cancer registry data, the data have not 
been collected for the purpose of costing and are therefore of limited use. There 
may be problems with completeness and misclassification of cancers by the 
registry as was confirmed by the work undertaken in this thesis. 
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3. Access to and use of patients' medical notes represents a problem for researchers 
in a number of ways: 
a. It is becoming increasingly difficult to obtain permission to access 
information in patients' medical notes. Recent guidance, with the intention 
of protecting patients' confidentiality, from the General Medical 
Council(l) and the House of Commons in the Health and Social Care 
bill(2) prevents researchers gaining access to medical notes unless for the 
purpose of audit. This will present problems for health economists in 
obtaining detailed patient specific resource use information for future 
research. 
b. Even when given permission to access the notes there are often problems 
of legibility, missing information (details of treatments, pathology reports 
or in the case of cancer; stage is rarely documented), destroyed notes (notes 
for patients who have not been seen in the last eight years can be 
destroyed) or there may be a financial cost in accessing the notes of 
patients who have not been seen in the past eight years as they are 
invariably held off the hospital site in storage. 
Chapters 5-7 have reported on the results from the empirical estimation of the 
hospital costs of breast, cervical and lung cancer in the Trent region. The comparison 
of the cervical cancer management costs with those of lung and breast cancer clearly 
indicates not only that the former are significantly higher but that the implications of 
stage progression for management costs differ between cancer sites. 
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In all three cancer sites the standard deviations of the mean costs emerged as 
particularly high, indicating the wide variation in patient-specific resource use even 
within a given stage at diagnosis. 
Chapter 8 explored the appropriate statistical analysis to test for the difference in 
mean cost according to disease stage using the breast, cervical and lung cancer 
datasets. Cost data are invariably skewed and according to statistics textbooks, 
parametric tests should not be used in these circumstances. A number of proposed 
techniques have been suggested for the analysis of skewed cost data; removal of 
outliers, transformation of the original data, use of nonparametric tests and 
bootstrapping. However, the use of these methods made no difference to the results 
estimated using parametric one-way analysis of variance and t-tests. Following this 
finding this chapter resulted in a number of conclusions; 
1. The reporting of the distributional form of the data is of importance, this can be 
done using standard descriptive statistics or by displaying the data in a histogram. 
2. The arithmetic mean value of the cost data should always be reported, as this is the 
value health economists require when calculating cost-effectiveness ratios, and is 
also a necessary requirement for the estimation of the total cost of providing a 
package of care or intervention. 
3. It is acknowledged that parametric tests are sufficiently robust to accommodate 
deviations from the assumptions underpinning them. However, the bootstrap 
method can be used as a check for the use of such parametric tests. 
Chapter 9 explored the analysis of costs where data are censored. Censored 
cost data occurs where the end point of interest has not been observed for a particular 
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individual/patient. Several techniques have been proposed in the literature that aim to 
adjust for any censored data when estimating the average total cost. These range from 
ignoring the issue of censoring altogether to estimating costs based on only those with 
complete cost histories to using a combination of cost and Kaplan-Meier survival 
estimates that takes account of any censoring. The chapter reported on the results for 
the breast and cervical cancer data using the proposed techniques. Unfortunately from 
these results and the limited empirical publications on the use of analytic methods for 
censored cost data, it is impossible to make any firm conclusions at present. The 
existence of censoring does present real methodological and practical problems for the 
estimation of mean total costs. However it is too early to tell whether, the methods 
proposed do actually make a difference to the results, moreover, it is currently unclear 
how to best judge between the techniques. The results obtained in this chapter are 
limited to a specific disease, it may well be that one would get different results from 
the analysis of censored cost data for different diseases or interventions. 
One important conclusion that can be drawn from this chapter is that, when 
undertaking any analysis of cost data, information on the number and proportion of 
patients with complete and censored costs should be routinely reported along with the 
method used to take account of the censoring. 
Chapter 10 is a discussion chapter, where the empirical findings of the thesis are 
discussed in relation to three important areas. Firstly, how the experience of costing in 
practice complies with the principles of costing set out in the guidelines. Two areas of 
divergence were indicated and their strengths and limitations in relation to use in this 
thesis discussed; the use of a narrow hospital based perspective compared with the 
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recommended societal perspective and the use of average costs in place of true 
opportunity or marginal costs. The second discussion topic centred around the 
possibility of collecting the data for this thesis at a lower cost. The final area for 
discussion looked at the potential users and policy implications of the cost results. 
11.3 Future research 
The research in this thesis has highlighted a number of potential areas of future 
research: 
1. This thesis has limited its exploration of the cost datasets to univariate 
analysis, in particular how the cost of cancer varies according to the stage 
at diagnosis. However, the estimation is more complicated as variations in 
the cost of treatment are not only due to differences in stage at detection 
but may also be affected by other factors which cause the basis or 
prognosis of disease to differ between patients. Moreover, the estimate 
may be complicated by differing follow up times and incomplete data. 
Hence, there is a need to explore the cost datasets further using multivariate 
regression techniques that allow for longitudinal analysis with the presence 
of censored cost data. This analysis will also provide information on the 
main predictors of cost. This type of analysis has been undertaken for 
other disease area such as stroke(3). 
2. The second area of future research lies in estimating the impact that early 
detection programmes have on the total treatment costs of cancer. Two 
new screening programmes have been mooted; screening for lung cancer 
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using CT scanning and HPV screening. The lung and cervical cancer 
treatment probability and cost data estimated in chapters 7 and 6 could be 
used within a Markov model to provide estimates of the cost-effectiveness 
of such screening programmes. Preliminary work on a Markov model for 
lung cancer screening has recently been undertaken using Canadian 
data(4). 
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